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ABSTRACT 
 
The unfolded protein response (UPR) is a complex signalling pathway activated in response 
to endoplasmic reticulum stress.  In recent years, the UPR has been implicated in cancer and 
chemosensitivity, particularly in solid tumours.  This thesis investigated the potential value 
of targeting the UPR as a novel therapeutic approach in haematological malignancies using a 
panel of cell lines representing AML, lymphoma and myeloma.  The UPR was constitutively 
active in these haematological cancer cell lines, with differential activation of key UPR 
proteins both in the panel and between the panel, peripheral blood mononuclear cells and the 
colorectal cancer cell line HT-29.  A number of strategies were used to modulate the UPR 
and study chemosensitivity.  Minimally toxic concentrations of the ER stress inducer 
thapsigargin protected cells from cytotoxic agents, with a reduction in antiproliferative drug 
effect.  The activity of the novel small molecule versipelostatin, reported to downregulate the 
ER molecular chaperones GRP78 and GRP94, was also investigated, with the 
downregulation previously reported in solid tumour cell lines (Park et al. 2004) confirmed in 
HT-29 cells, but not observed in the haematological cell lines studied (although 
versipelostatin was an effective cytotoxic agent at low micromolar concentration).  
Combination experiments with the chemical chaperone 4-phenylbutyric acid (PBA) resulted 
in a small increase in apoptosis when PBA was combined with ER stress inducers.  
However, PBA also showed HDAC inhibitory activity at the concentrations used.  Finally, 
siRNA mediated silencing of GRP78 and GRP94 in THP1 (AML) and U266 (myeloma) 
cells resulted in a decrease in the targeted protein, but showed only minimal effects on 
chemosensitivity. In conclusion, the UPR is activated in these haematological cancer cell 
lines and plays a complex role in chemosensitivity.  In contrast to previous reports in solid 
tumour cells, modulating the UPR in these haematological malignancies had only a modest 
effect on chemosensitivity.  
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1.   Introduction 
 
1.1 Haematological malignancies 
 
1.1.1 – Classification of Haematological Malignancies 
  
Cancer or malignancy are terms used to describe many different diseases 
characterised by uncontrolled growth.  Similarly, the term haematological malignancies 
refers to a number of histologically and prognostically distinct types of cancer of the 
haematopoeitic system.  There are a number of classification systems that have been 
developed to describe the various haematological malignancies.  The main distinction 
between haematological cancer subtypes is based on whether the tumour is of myeloid or 
lymphoid origin.  The myeloid malignancies are commonly classified using the French 
American British (FAB) classification (Bennett et al., 1976b), whilst lymphoid malignancies 
are commonly classified using the Revised European American Lymphoma (REAL) 
classification (Harris et al., 1994).  More recently, the World Health Organisation has 
published the World Health Organization Classification of Neoplastic Diseases of the 
Hematopoietic and Lymphoid Tissues (Harris et al., 1999).  The WHO classification is based 
on both the FAB and REAL classifications with some significant differences, such as the 
incorporation of cytogenetic features in the classification of myeloid disorders.  
 
1.1.2 – Acute Myeloid Leukaemia 
 
The leukaemias are relatively rare, accounting for two percent of all cancers in the 
UK.  In 2007 there were just over 7000 new cases of leukaemia in the UK, with a five year 
survival of around 40 percent. Acute myeloid leukemia (AML) is the most common acute 
leukaemia in adults and incidence increases with age (CancerResearchUK, 2010a).  AML, 
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also known as acute myelogenous leukemia, is characterized by the rapid proliferation of 
myeloblasts (immature precursor myeloid cells) which accumulate in the bone marrow and 
interfere with the production of normal blood cells (Abeloff, 2004).  
 
 The FAB classification system divides AML into 8 subtypes, designated M0 to M7.  
based on morphologic and genetic factors (Bennett et al., 1976). The more recent WHO 
classification of AML aims to provide more clinically useful prognostic information than the 
FAB criteria (Harris et al., 1999).  The four subtypes of AML in the WHO classification 
system are: 
1. AML with characteristic genetic abnormalities  
2. AML with multilineage dysplasia  
3. AML and myelodysplastic syndromes (MDS), therapy-related 
4. AML not otherwise categorized  
 
 AML is typically detected as an abnormal result on a full blood count, which may 
show an increased level of abnormal white blood cells or the presence of leukaemic blasts.  
Bone marrow aspiration and biopsy are usually necessary for a definitive diagnosis.  If AML 
is left untreated most patients will die within a few months of diagnosis.   However, the 
disease is potentially curable, although the proportion of patients cured with current 
treatments is small.  Treatment consists of induction chemotherapy (aiming to induce disease 
remission) followed by consolidation chemotherapy (aiming to eliminate any minimal 
residual disease and maintain remission) (Abeloff, 2004).    
 
1.1.3 – Multiple Myeloma 
 
Multiple myeloma (MM) is a malignant disease of plasma cells, characterised by the 
production of abnormal intact monoclonal immunoglobulin (known as paraprotein or 
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monoclonal (M) protein) or monoclonal free light chains (known as Bence Jones Protein).  
The disease can have wide reaching effects, manifesting as bone lesions, fractures, 
myelosuppression, renal failure and other symptoms.  MM often develops from an 
asymptomatic premalignant stage of clonal plasma cell proliferation called monoclonal 
gammopathy of undetermined significance (MGUS) (Abeloff, 2004).  Myeloma accounts for 
approximately ten percent of all malignancies of the haematopoeitic system (Kyle and 
Rajkumar, 2008).  In the UK, MM is a relatively rare disease accounting for one percent of 
all cancers.  Incidence of the disease increases with advancing age and is extremely rare in 
people below the age of 30.  In 2007, just over 4000 new cases of multiple myeloma were 
registered and 5 year survival is currently less than 30 percent (CancerResearchUK, 2010b).   
  
The Durie-Salmon staging system for myeloma was introduced in 1975 (Durie and 
Salmon, 1975), however this system has now been superseded by the International Staging 
System (ISS) for MM published by the International Myeloma Working Group in 2005.  The 
ISS assigns three stages of disease: stage I (serum "2-microglobulin <3.5 mg/L, serum 
albumin #3.5 g/dL), stage II (disease that is neither stage I or stage III), and stage III (serum 
"2-microglobulin #5.5 mg/L) (Greipp et al., 2005). 
  
The first step in treatment of patients with symptomatic disease is combination 
chemotherapy.  The choice of regimen is primarily dependent on whether or not the patient 
is a candidate for haematopoeitic stem cell transplantation (Kyle and Rajkumar, 2008).     
 
1.1.4 – Non-Hodgkin Lymphoma 
  
Non-Hodgkin lymphoma (NHL), as the name suggests, is the name used to describe 
the many (and varied) malignant disorders of the lymphoid system other than Hodgkin 
lymphoma.  These diseases are often grouped in terms of whether they are aggressive (high 
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grade) tumours or less aggressive (low grade) tumours.  NHL is the fifth most common 
cancer in the UK, with over 10000 new cases in 2007.  Current five year survival rates are 
over 50 percent (CancerResearchUK, 2010c). 
 
As mentioned previously, lymphoid malignancies are classified according to the 
WHO Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues, 
which followed on from the earlier REAL classification system.  In the WHO classification 
system diffuse large B-cell lymphoma (DLBCL) is a subtype of B-cell neoplasms (Harris et 
al., 1999).  DLBCL is the most common lymphoid malignancy in adults and accounts for 
over 30 percent of all NHL cases (The Non-Hodgkin's Lymphoma Classification Project 
1997).  Other types of B-cell NHL include follicular lymphoma (the most prevalent indolent 
lymphoma, which transforms to DLBCL in 20 to 30 percent of patients, depending on age), 
Burkitt’s lymphoma (highly aggressive; c-myc translocation associated; common lymphoma 
in HIV patients), and mantle cell lymphoma (rare, aggressive tumour; characterised by 
translocation t(11:14); very poor prognosis) (Canellos et al., 2006).       
 
1.2. Endoplasmic Reticulum Stress 
 
1.2.1 – The Endoplasmic Reticulum 
 
The endoplasmic reticulum (ER) was first described by Porter and colleagues in 
1945, who used electron microscopy in order to visualise cellular structures that had not 
previously been seen (Porter et al. 1945).  The ER is an organelle consisting of an 
interconnected network of tubules, vesicles, and sacs that is present in all eukaryotic cells.   
This interconnected network forms a continuous phospholipid ER membrane around the 
cisternal space (known as the ER lumen) and functions to separate the ER lumen from the 
cytosol.  The ER has a number of functions, which include production of proteins and lipids, 
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protein folding and protein secretion.  The ER is the first compartment in the secretory 
pathway, to which proteins translocate for correct folding before delivery to the appropriate 
sites within the cell.  Proper functioning of the ER is essential for most cellular activities and 
survival.   
 
There are three types of endoplasmic reticulum: rough ER, smooth ER and 
sarcoplasmic reticulm (SR). The rough ER is covered with membrane bound ribosomes, 
which are the sites of protein synthesis.  Unlike rough ER, smooth ER does not have bound 
ribosomes.  Smooth ER contains exit sites, enabling transport vesicles carrying newly 
synthesised proteins and lipids to travel out of the ER and transfer to the Golgi apparatus.  
Sarcoplasmic reticulum is a specialised smooth ER responsible for pumping calcium into the 
ER lumen from the cytosol via a calcium-ATPase.  Both the amount of ER and the particular 
type of ER within an individual cell is determined by the specific cell type and functions to 
enable that cell type to carry out its specialised role and meet cellular demands.  For 
example, in comparison to other cell types, muscle cells contain an abundant sarcoplasmic 
reticulum which is necessary for the release and reuptake of calcium during the process of 
muscle contraction and relaxation (Alberts, 2002).  Another example of differences in ER 
between cell types is seen in plasma cells, which contain more ER than other cell types in 
order to carry out their functions as secretory cells (Yoshida, 2009). 
 
1.2.2 – Protein Folding in the Endoplasmic Reticulum 
 
The main stages involved in the production of proteins are transcription, translation 
and maturation.  Many proteins in the ER lumen are in transit to other sites, such as the golgi 
or mitochondria.  ER resident proteins contain an ER retention signal of 4 amino acids at 
their carboxyl terminus (Lys-Asp-Glu-Leu (KDEL)) that distinguishes them from proteins 
bound elsewhere and prevents their secretion (Munro and Pelham, 1987).  Selected proteins 
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from the cytosol are captured by the ER as they are being synthesised.  Secretory proteins 
(water soluble) translocate across the ER membrane and undergo folding in the ER lumen, 
whereas transmembrane proteins only partially pass through the ER membrane and remain 
attached to ribosomes on the cytosolic ER surface.  Folding of proteins can occur even as the 
protein is still being synthesised, i.e. it is a co-translational process (Alberts, 2002).  Protein 
folding in the ER is shown in figure 1.1. 
 
 
 
Figure 1.1.  Protein folding in the ER. 
Proteins enter the ER from the ribosome through the Sec61 complex,  
where ER chaperones and folding enymes (folding factors) facilitate  
correct folding.  The ER also contains escorts and guides that mediate  
transport downstream in the secretory pathway. COPI and COPII are  
coat protein complexes involved in protein transport.  
Terminally misfolded proteins are targeted for endoplasmic reticulum  
associated degradation (ERAD), with ERAD factors mediating transport  
to the proteasome for degradation.  
Reproduced from Sitia and Braakman (2003). 
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Translocation to the ER membrane is initiated by the binding of an ER signal 
sequence on the protein to a signal recognition particle (SRP) and a signal recognition 
particle receptor in the ER membrane.  The SRP and its receptor have been shown to be 
present in all cells and evolutionarily conserved (Keenan et al., 2001).  One end of the SRP 
binds to the ER signal sequence on the polypeptide chain as it emerges from the ribosome 
during synthesis, whilst the other end blocks the elongation factor binding site at the 
interface between the large and small ribosomal subunits.  It is thought that the resulting 
translational pause allows time for the ribosome to bind to the ER membrane ensuring that 
the protein is not released into the cytosol.  The SRP-ribosome complex then binds to the 
SRP receptor and reaches a protein translocator in the ER membrane.  The SRP and SRP 
receptor are released and the polypeptide chain transferred across the ER membrane through 
an aqueous pore in the translocator.  At the core of the translocator is the Sec61 complex, 
which is built from three units evolutionarily conserved from bacteria to eucaryotic cells.  
The translocation of proteins across the ER membrane is usually co-translational, however 
post-translational transport into the ER can also occur.  Once the protein has been released 
into the cytosol it binds to chaperone proteins (to prevent folding) and accessory proteins 
(associated with the Sec61 complex) that span the ER membrane and direct the ER 
chaperone protein GRP78 on to the polypeptide chain as it emerges from the pore into the 
ER lumen (Alberts, 2002, Keenan et al., 2001). 
 
During maturation, the unfolded protein undergoes conformational changes that 
enable it to achieve its most energetically favourable state (Ellgaard and Helenius, 2003).  
This folding of the protein is essential to enable the protein to reach its target site within the 
cell.  Studies on smaller proteins have shown that the interaction of a small number of amino 
acid residues on the polypeptide chain results in the formation of a folding nucleus and that 
the lowest energy overall structure then forms around this by means of trial and error (Fersht, 
2000).  In mammalian cells proteins are folded in the ER or the cytosol.  There are a number 
of differences between protein folding in the ER and the cytosol, for example, the ER is a 
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more oxidising environment than the cytosol and is also the main area of calcium storage 
(Schroder and Kaufman, 2005b).   
 
The ER also contains molecular chaperones and enzymes that function to aid correct 
protein folding.  There are several families of molecular chaperones and different family 
members function in different organelles, for example heat shock protein (HSP) 70 family 
chaperones bind to a string of hydrophobic amino acids before the protein has left the 
ribosome, whereas the cytosolic HSP60 family chaperones isolate proteins in a barrel-like 
structure that provides a favourable environment for correct folding (Alberts, 2002).  ER 
resident molecular chaperones include the HSP70 (e.g. GRP78) and HSP90 (e.g. GRP94) 
families, the lectins calnexin and calreticulin, and the HSP40 family of co-chaperones.  HSPs 
have an affinity for and bind to exposed hydrophobic patches on unfolded proteins that 
would ordinarily be buried in the interior of the structure, using hydrolysis of ATP to provide 
the energy required to carry out their chaperone function.  HSPs often require many cycles of 
ATP hydrolysis in order to fold a single polypeptide chain correctly (Ellgaard and Helenius, 
2003, Alberts, 2002, Ma and Hendershot, 2004a).  Folding enzymes include the thiol-
disulphide oxidoreductase family, one example of which is the enzyme protein disulphide 
isomerase (PDI).  PDI catalyses the formation of disulphide bonds in the ER via oxidation of 
free sulfhydryl (SH) groups on cysteines; this reaction is very rarely found in the cytosol due 
to its reducing environment (Ellgaard and Helenius, 2003, Braakman et al., 1992). 
 
Nascent polypeptide chains are subject to numerous post translational modifications 
in the ER, such as N-linked glycosylation, disulphide-bond formation, signal sequence 
cleavage and addition of glycosylphosphatidylinositol anchors.  These modifications are 
essential for correct protein folding and only occur in the ER (Ellgaard and Helenius, 2003).  
Two of the most important translational modifications in the ER are N-linked glycosylation 
and disulphide bond formation (catalysed by the enzyme PDI) (Schroder and Kaufman, 
2005b).  Both of these processes act to enable unfolded proteins to achieve their final folded 
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conformation.  Modifications such as these continue to take place in the ER until the final 
folded state of the protein has been reached, at which point the protein is marked for export 
from the ER. 
 
1.2.3 – Endoplasmic Reticulum Associated Degradation  
 
A large number of proteins fail to achieve their desired three-dimensional 
conformation due to the many intermediate stages involved in folding and the resulting 
opportunities for errors to occur.  Errors in the folding process may also occur for other 
reasons, such as genetic mutations and errors during transcription or translation.  It has been 
reported that as many as a third of all newly synthesised proteins are destroyed during, or 
within minutes of, their synthesis (Schubert et al., 2000).  The folding machinery can also be 
affected by the physiological conditions within the cell, for example, temperature, redox 
state or exposure to external toxins (Vembar and Brodsky, 2008).  In addition to affecting 
the production of new proteins, these cellular conditions can also cause mature proteins to 
become defective (Hirsch et al., 2009).  The resulting aberrant proteins must be dealt with in 
order to prevent build up of unfolded or misfolded proteins that may overwhelm the ER 
protein folding machinery and impair normal cellular function.  It is therefore imperative that 
the ER has a means of monitoring protein folding and dealing with any problems that may 
arise in the folding machinery.  This system is known as ER quality control and is mediated 
by the ER molecular chaperones.  This quality control mechanism detects unfolded or 
misfolded proteins and will either attempt to further facilitate correct folding or will target 
the protein for a process known as ER associated degradation (ERAD) (McCracken and 
Brodsky, 1996).   
  
 Work by the Klausner group in the late 1980s led to the discovery of the ERAD 
pathway (Lippincott-Schwartz et al., 1988).  Later work by Sommer and Jentsch linked 
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ERAD with the ubiquitin-proteasome pathway by showing that targeted ER proteins are 
degraded in the cytoplasm by the 26S proteasome (Sommer and Jentsch, 1993).   As 
illustrated in figure 1.2, there are five steps in the ERAD pathway: recognition of damaged 
or misfolded proteins by molecular chaperones such as PDI and HSP70 family members, 
targeting, retrotranslocation, ubiquitylation, and proteasomal degradation (Vembar and 
Brodsky, 2008).  In addition to targeting defective proteins, ERAD is also exploited by some 
pathogenic viruses and bacterial toxins in order to infect host cells (Meusser et al., 2005, 
Lord et al., 2005).  It has also been discovered that turnover of ER resident enzymes utilises 
ERAD, as illustrated by regulation of the sterol synthesis pathway.  When sterol production 
needs to be halted, the rate-limiting enzyme HMG-CoA reductase is targeted for regulated 
degradation via the ERAD pathway (Hampton, 2002). 
 
 
 
Figure 1.2.  The stages involved in endoplasmic reticulum associated degradation (ERAD). 
Reproduced from Vembar and Brodsky (2008). 
 
 
 
The exact mechanism of a misfolded protein being targeted as a substrate for ERAD 
is not known (although in recent years more details of this targeting mechanism have been 
elucidated for a very small number of individual substrates).  ER molecular chaperones 
recognise and bind to hydrophobic polypeptide motifs on misfolded proteins that would 
normally be buried within the folded protein structure and therefore not available for 
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chemical interaction.  One theory suggests that prolonged binding of a molecular chaperone 
to an ERAD substrate leads to recruitment of an E3 ubiquitin ligase and polyubiquitination 
of the substrate (Denic et al., 2006). 
 
In order to further understand the process of substrate recognition and targeting for 
ERAD, it is necessary to look in more detail at the way unfolded/misfolded proteins are 
processed in the ER and the role of N-linked glycosylation.  Glycosylation is one of the most 
important post translational modifications of proteins that occurs in the ER.  Glycosylation is 
the covalent addition of sugars to proteins and around half of all eucaryotic proteins are 
glycosylated.  Glycosylation is one of the major biosynthetic functions of the ER and most 
proteins synthesised in the ER are glycosylated, compared to very few proteins in the 
cytosol.  A preformed precursor oligosaccharide (glucose3-mannose9-N-acetylglucosamine2) 
is transferred to the side chain NH2 group of an asparagine amino acid of the protein in a 
process termed N-linked glycosylation.  The oligosaccharide transfer is catalysed by a 
membrane bound enzyme complex (an oligosaccharide transferase) which has its active site 
exposed on the luminal side of the ER membrane (this explains why cytosolic proteins are 
not glycosylated in this manner).  The original precursor oligosaccharide is later modified to 
form the mature glycoprotein.  Cycles of glucose trimming and glucose addition take place 
in the ER until the final folded state of the protein has been reached, at which point the 
protein is marked for exit from the ER.  The pattern of this N-linked glycosylation indicates 
the extent of protein folding and provides an indication of the amount of time a protein has 
been in the ER.  Glucose trimming by ER glucosidases I and II labels the protein as actively 
being folded and allows association of the chaperones calnexin and calreticulin to aid 
folding.  The folding process continues with further modifications, and where necessary 
glucose addition by UDP-glucose:glycoprotein glucosyl transferase (UGGT) allows re-
association of the protein with calnexin and calreticulin thereby facilitating further attempts 
at correct folding.  If correct protein conformation cannot be reached within a given time 
frame, ER mannosidase I and the mannosidase-like proteins EDEM1, EDEM2 and EDEM3 
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initiate mannose trimming and subsequent ERAD (Vembar and Brodsky, 2008, Alberts, 
2002, Hirsch et al., 2009, Buchberger et al., 2010, Helenius, 1994).  However, it should be 
noted that the exact mechanism of de-mannosylation and the initiation of ERAD in 
mammalian cells is still unclear, although a number of theories have been proposed and are 
currently being investigated (Aebi et al., 2010).   
 
The process discussed here relates to ERAD initiation for misfolded glycosylated 
proteins, although it should be mentioned that not all ER proteins are glycosylated.  
Therefore, it is logical to assume that a concurrent system exists to recognise and target 
misfolded non-glycosylated proteins for degradation.  It is thought that in this simpler system 
ERAD is initiated by binding and association of molecular chaperones and folding catalysts.  
To date, ERAD initiation for non-glycosylated proteins has not received much attention, as 
opposed to the extensive study of glycosylated protein systems (Buchberger et al., 2010). 
 
After an incorrectly folded protein has been recognised and targeted by molecular 
chaperones in the ER, it is exported back into the cytosol (retrotranslocation or dislocation) 
in a similar way to other modes of translocation, although the exact mechanism is unknown.  
Once in the cytosol the oligosaccharide chain is removed from glycoproteins by an N-
glycanase.  The protein is directed to membrane bound ligases on the cytosolic side of the 
ER membrane.  The protein is then ubiquitinated by an E3 ubiquitin ligase (a catalytic 
RING-finger protein).  A ligase complex then forms, consisting of an E3 ligase plus 
ubiquitin-conjugating enzymes (E2) and other co-factors.  The polyubiquitinated protein is 
then transported to the 26S proteasome for degradation.  Prior to proteasomal degradation, 
the ubiquitin chain is removed by deubiquitinating enzymes and the free ubiquitin released 
for reuse (Vembar and Brodsky, 2008, Hirsch et al., 2009). 
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1.2.4 – The Endoplasmic Reticulum Stress Response 
 
Correct folding of proteins is essential to maintain normal cellular function.  In the 
cytosol, accumulation of unfolded or misfolded proteins activates the heat shock response, 
leading to transcription of cytosolic chaperones in an attempt to further aid protein folding 
(Alberts, 2002).  A similar process occurs in the ER.  Various physiological stresses alter the 
ability of the ER to function normally and result in the accumulation of misfolded or 
unfolded proteins - a situation referred to as ER stress.  The term ER stress describes an 
imbalance between the demand on ER function and the ER capacity of the cell (Ron, 2002, 
Schroder and Kaufman, 2005b).  There are many factors that can provoke ER stress 
(Schroder and Kaufman, 2005a).   
 
Redox disturbances due to hypoxia, oxidising agents or reducing agents can interfere 
with the process of disulphide bond formation in the ER lumen leading to misfolded protein 
accumulation.  Similarly, conditions that interfere with N-linked glycosylation lead to ER 
stress, such as glucose deprivation.  Alterations in ER calcium homeostasis also cause ER 
stress and many of the ER resident molecular chaperones are calcium dependent (Schroder 
and Kaufman, 2005a).  These physiological stressors result in accumulation of unfolded or 
misfolded proteins thereby provoking an ER stress response and activation of a complex 
signalling pathway known as the unfolded protein response (Wu and Kaufman, 2006).   
 
1.2.5 Pharmacological Induction of Endoplasmic Reticulum Stress  
  
 In addition to normal cellular stresses, a number of pharmacological agents have 
been discovered to induce ER stress and trigger the ER stress response, thereby activating 
the unfolded protein response.  Some examples of ER stress inducing agents are discussed 
below. 
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Tunicamycin is a mixture of homologous antibiotics produced from the bacteria 
Streptomyces iysosuperficus.  Tunicamycin inhibits N-linked glycosylation by inhibiting the 
N-acetylglucosamine transferases, thereby preventing glycosylation of newly synthesised 
proteins.  This leads to accumulation of proteins in the ER and ER stress (Heifetz et al., 
1979).  Tunicamycin has been shown to cause apoptosis in both plant and mammalian cells 
by inducing ER stress (Crosti et al., 2001, Fujita et al., 2002).  It has been reported in the 
literature that induction of ER stress with tunicamycin can increase the activity of cytotoxic 
drugs in multidrug resistant cancer cell lines (Hiss et al., 1996, Hiss et al., 2007).  However, 
clinical relevance of these studies are limited by the high tunicamycin concentrations used, 
which would be expected to exhibit significant toxicity even as single agents.  Also, these 
studies only investigated the effect of simultaneous exposure to the two drugs.  Treatment 
with tunicamycin has been shown to enhance tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis of endometrial cells (Hasegawa et al., 2008) and 
to sensitise melanoma cells to TRAIL-induced apoptosis in vitro (Jiang et al., 2007a).  More 
recently, one study reported that treatment with tunicamycin induced resistance to the 
cytotoxic agents camptothecin and etoposide in hepatocellular carcinoma cells.  The authors 
suggested that this decreased cytotoxicity was due to both GRP78 induction and an 
independent arrest of the cell cycle in the G1 phase (Hsu et al., 2009).  Interestingly, these 
findings taken together suggest that the role of tunicamycin mediated ER stress may be more 
complex than initially thought. 
 
Thapsigargin is a sesquiterpene lactone extracted from the plant, Thapsia garganica.  
It is an effective inhibitor of sarcoplasmic endoplasmic reticulum calcium ATPases (known 
as SERCA pumps).  This inhibition leads to release of intracellular calcium, resulting in ER 
stress (Kijima et al., 1991).  Inhibition of the sarcoplasmic endoplasmic reticulum calcium 
ATPase by thapsigargin has been shown to occur at concentrations as low as 10-10M (Sagara 
and Inesi, 1991).  Along with tunicamycin, thapsigargin is commonly used by researchers to 
induce ER stress in order to study such stress and the resultant unfolded protein response.  
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Like tunicamycin, thapsigargin has been shown to sensitise melanoma cells to TRAIL-
induced apoptosis by inducing ER stress and the unfolded protein response (Chen et al., 
2007).  It has been reported that multidrug resistant cells deficient in the proapoptotic Bcl-2 
family members Bax and Bak are sensitive to ER stress mediated cell death (caspase 
independent) following treatment with thapsigargin (Janssen et al., 2009).  Another 
interesting area of research is the development of prodrugs of thapsigargin to inhibit SERCA 
pumps as a novel targeted treatment strategy in prostate cancer.  The thapsigargin prodrug 
(thapsigargin coupled to a targeting peptide) is activated by the proteolytic enzyme prostate 
specific antigen (PSA) and has been shown to be selectively toxic to prostate cancer cells in 
preclinical studies in vitro and in vivo (Christensen et al., 2009, Denmeade and Isaacs, 
2005).  If this approach proves succesful it would provide a solution to the important issue of 
thapsigargin cytotoxicity to normal cells and it may eventually be possible to apply this 
targeted strategy to other tumour types. 
 
Heat shock protein 90 (HSP90) inhibitors are a novel class of compound currently in 
development, with several compounds now in clinical trials.  These agents are being 
investigated for their anticancer activity (Neckers and Neckers, 2002).  HSP90 is a molecular 
chaperone involved in protein stabilisation, preventing protein aggregation, and in the 
trafficking and activation of many client proteins (Hartl and Hayer-Hartl, 2002).  In recent 
years there has been considerable focus on HSP90 inhibition as a novel treatment approach 
in cancer therapy.  HSP90 chaperones a number of oncoproteins that are degraded when 
HSP90 is inhibited (Goetz et al., 2003, Neckers, 2002).  Although early trials of HSP90 
inhibitors were hampered by a number of stability and toxicity issues, progress is being 
made, with new formulations and compounds now in clinical trials (Trepel et al., 2010).  It is 
thought that HSP90 as a therapeutic target may exhibit selectivity for cancer cells.  A high-
affinity activated form of HSP90 that forms a complex with high ATPase activity has been 
identified in tumours, whereas HSP90 in normal cells is in an uncomplexed (inactive) form 
that has low ATPase activity (Kamal et al., 2003).  HSP90 inhibitors have been shown to be 
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effective in both in vitro and in vivo models of multiple myeloma (Mitsiades et al., 2006).  
The HSP90 inhibitor 17-AAG (tanespimycin) has been shown to cause multiple myeloma 
cell death via a mechanism involving induction of ER stress and UPR pathways (Davenport 
et al., 2007).  It is now becoming clear this class of compound exert their anticancer activity 
in part by provoking ER stress and may also play a role in treatment of cancers not 
dependent on the main HSP90 client proteins (Mitsiades et al., 2006).  These findings 
provide a link between HSP90 inhibition, ER stress and the unfolded protein response in 
cancer therapeutics, highlighting the potential for future work in this area. 
 
Proteasome inhibitors have emerged over the last few years as a novel class of 
anticancer agent.  The first in class proteasome inhibitor bortezomib (Velcade®, Millenium 
Pharmaceuticals) is currently licensed in the UK for treatment of multiple myeloma, and is 
also licensed for the treatment of mantle cell lymphoma in the USA (Orlowski and Kuhn, 
2008).  Investigations are ongoing in other tumour types, including solid tumours, non-
hodgkin lymphoma and leukaemia (Richardson et al., 2006, Vink et al., 2006).  As discussed 
previously, the proteasome is involved in maintaining cellular homeostasis by degrading 
polyubiquitinated substrate proteins and is an integral component of the ERAD pathway 
(Sommer and Jentsch, 1993).  Inhibition of the proteasome has wide reaching effects on a 
number of pathways involved in cancer.  Mechanisms of action of this class of compound 
are thought to include inhibition of NF-$B signalling, induction of cell cycle arrest, and 
induction of apoptosis (Orlowski and Kuhn, 2008).  It has also been discovered that 
proteasome inhibition induces ER stress and activates the unfolded protein response in 
multple myeloma cells, and that this may be related to their function as secretory cells 
(Obeng et al., 2006).  More recently, it has been shown that bortezomib preferentially targets 
hypoxic tumour cells causing cell death and that this effect is due to ER stress and activation 
of the unfolded protein response in the hypoxic tumour cells (Fels et al., 2008).  Following 
on from bortezomib, second generation proteasome inhibitors are now in clinical 
development (Dick and Fleming, 2010).  Much like HSP90 inhibitors, ER stress induction 
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and unfolded protein response activation have now been implicated in the anticancer activity 
of proteasome inhibitors. 
 
1.3 The Unfolded Protein Response 
 
1.3.1 – Discovery of the Glucose Related Proteins 
 
The glucose related proteins (GRPs) were first identified in the 1970s.  The 
discovery of the proteins p78 and p94 by induction in RNA tumour virus transformed cells 
led to further work by Ira Pastan’s group at the National Cancer Institute, NIH, Maryland.  
Pastan’s group discovered that induction of the two proteins was not a direct result of cell 
transformation, but was in fact due to rapid depletion of glucose from the growth medium of 
transformed tumour cells.  Due to their relation with glucose these proteins were designated 
glucose related proteins; GRP78 and GRP94 (Shiu et al., 1977).  In addition to the discovery 
by the Pastan group, GRP78 was independently identified by another research group.  In 
1983, a group led by Haas identified an ER protein that bound to free immunoglobulin heavy 
chains and inhibited secretion in the absence of light chains.  They named the protein 
immunoglobulin heavy-chain binding protein, BiP (Haas and Wabl, 1983).  In a 1986 paper 
in the journal Cell, Munro and Pellam established that GRP78 and BiP were the same protein 
(Munro and Pelham, 1986).  It was later discovered that GRP78/BiP bound to various 
unfolded proteins in the ER and prevented their transport and secretion (Bole et al., 1986).  
Further studies on the regulatory mechanisms resulting in increased transcription of genes 
encoding the GRPs were carried out by Lee and colleagues (Lee, 1987).   
 
GRP78 and GRP94 are both molecular chaperones.  GRP78 is a member of the 
HSP70 family and GRP94 is member of the HSP90 family of heat shock proteins (Lee, 
2007).  GRP78 recognises hydrophobic residues on unfolded or misfolded proteins and binds 
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to them, thereby preventing their interaction with other molecules (Bole et al., 1986).  
GRP94 is the ER resident isoform of cytosolic HSP90, however in contrast to HSP90 (which 
has a very large number of client proteins), GRP94 appears to have a very limited number of 
client proteins.  GRP94 has been shown to be involved in B-cell differentiation and is also 
involved in the immune response (Ni and Lee, 2007, Liu and Li, 2008). 
 
1.3.2 – Discovery of the Unfolded Protein Response 
 
ER stress and the unfolded protein response (UPR) first came to light due to the 
work of two independent research groups in the late 1980s.  Randal Kaufman’s research 
group at the University of Michigan Medical Centre and Joseph Sambrook’s group at Cold 
Spring Harbour Laboratory, New York both observed that the accumulation of unfolded or 
misfolded proteins in the ER led to the induction of the GRPs, which were known to be 
involved in the folding of proteins (Dorner et al., 1987, Kozutsumi et al., 1988).  In a paper 
by Gething and Sambrook it was suggested that the induction of GRPs by unfolded proteins 
in the ER functioned to upregulate chaperone expression in an attempt to prevent 
accumulation of unfolded proteins and maintain normal ER function.  This signalling 
pathway then became known as the unfolded protein response (UPR) (Gething and 
Sambrook, 1992).  At this stage the link between unfolded proteins and the induction of 
molecular chaperones had been clearly established, however details of the signalling 
pathway involved remained unknown. 
 
In 1992, work in the Sambrook lab revealed a 22 bp cis-acting element in the yeast 
BiP promoter was sufficient to induce the yeast KAR2 (BiP) gene in response to the 
accumulation of unfolded proteins (Mori et al., 1992).  This crucial finding was utilised by 
both the Sambrook group, and the Walter group at the University of California, San 
Francisco, and led to the identification of IRE1 (inositol-requiring enzyme 1); a novel ER 
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serine/threonine kinase (Cox et al., 1993, Mori et al., 1993).  A further series of papers 
published by the Walter lab elucidated the UPR signalling pathway in yeast; the critical 
finding being the splicing of HAC1 mRNA mediated by IRE1 upon UPR activation, which 
produces a more active HAC transcription factor than the unspliced mRNA protein product 
(Kaufman, 1999).  It was discovered that whilst only three gene products are needed to 
provoke the UPR in yeast, almost 400 genes are subsequently affected to varying degrees 
(Patil and Walter, 2001).  In 1998, mammalian IRE1! and IRE1" were independently 
identified by the groups of Ron and Kaufman.  The IRE1! homolog was shown to be 
ubiquitously expressed, whereas the IRE1" homolog is only expressed in intestinal 
epithelium.  A number of features of the UPR were shown to have been conserved between 
yeast and mammals, although no mammalian homolog of the yeast HAC1 gene was found 
(Tirasophon et al., 1998, Wang et al., 1998).  
 
In 1999, a second mammalian UPR kinase was isolated in the ER by both the Ron 
group and the Wek group independently, designated PERK and PEK respectively.  
PERK/PEK is a member of the eIF2! family of kinases and when activated causes 
phosphorylation of eIF2! and subsequent inhibition of general protein translation (Shi et al., 
1998, Harding et al., 1999).  At around the same time the group led by Mori showed that 
ATF6 (a basic leucine zipper (bZIP) transcription factor previously identified by Prywes and 
colleagues) was the third ER stress sensor.  Upon activation of the UPR, ATF6 protein is 
transported to the Golgi apparatus where it is cleaved by site 1 and site 2 proteases.  Cleaved 
ATF6 then travels to the nucleus and activates transcription of UPR target genes (Yoshida et 
al., 1998, Ma and Hendershot, 2001).   
 
So by this point the PERK and ATF6 signalling branches of the UPR had been 
described, however, as no mammalian homolog of the HAC1 gene had been discovered there 
was no explanation as to why IRE1 had been evolutionarily conserved.  The final piece of 
the puzzle fell into place in 2001 when the Kaufman and Mori labs reported that XBP1 (an 
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X-box binding protein) undergoes IRE1 mediated mRNA splicing in a similar manner to 
HAC1 mRNA.  This unconventional splicing in C.elegans and mammals excises an XBP1 
mRNA fragment of 23 base pairs and 26 base pairs respectively, and the resulting protein 
product is a highly active transcription factor able to activate UPR target genes.  These 
experiments also provided a link, via XBP1, between the IRE1 and ATF6 signalling 
pathways (Shen et al., 2001, Yoshida et al., 2001).  This unconventional splicing of XBP1 
mRNA has recently been confirmed to occur in the cytoplasm, rather than conventional 
mRNA splicing which only occurs in the nucleus (Uemura et al., 2009, Yanagitani et al., 
2009). 
 
There has been a succession of discoveries over the last 20 years that have provided 
knowledge of the UPR, starting in yeast, progressing to C.elegans, followed by the 
characterisation of the mammalian UPR.  The three UPR signalling pathways and how they 
relate to one another are depicted in figure 1.3. 
 
  
 
Figure 1.3.  Comparison of the UPR signalling pathways in S.cerevisiae, C.elegans and 
mammals.  Broad lines represent the pathways dominant for UPR activation, narrow lines 
represent functional UPR pathways, and dotted lines represent pathways not required for 
activation of molecular chaperones during the UPR. 
Reproduced from Ma and Hendershot (2001). 
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1.3.3 – The Mammalian Unfolded Protein Response 
 
Under normal physiological conditions, GRP78 is bound to the three ER 
transmembrane stress sensors PERK, IRE1, and ATF6 thereby keeping them in an inactive 
form. During ER stress GRP78 dissociates from the receptors allowing their phosphorylation 
and activation of the three pathways of the UPR (Lee, 2001).  The UPR has a number of 
protective functions: to increase the folding capacity of the ER, reduce protein translation, 
increase the amount of ER within the cell, and promote degradation of misfolded proteins 
via ERAD pathways.  It is thought that these UPR functions are particularly relevant in the 
normal physiology of highly secretory cells, such as plasma cells, intestinal epithelial cells 
and pancreatic " cells where there is an increased ER workload.   In situations where ER 
stress is prolonged, or the UPR is unable to restore normal ER function, the UPR initiates 
apoptosis (programmed cell death).  Thus the UPR has complex and conflicting functions 
within the cell (Bernales et al., 2006).  The mammalian UPR is illustrated in Figure 1.4.  
Since 2006, when figure 1.2 was published, the importance of the ER molecular chaperone 
GRP94 in the UPR has become apparent and continues to be investigated.  The activation of 
each of the three branches of the UPR is discussed individually below.  
  
 
Figure 1.4.  The mammalian unfolded protein response. 
Reproduced from Szegezdi et al. (2006).   
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PERK:  Dissociation of GRP78 from PERK allows receptor dimerisation and 
autophosphorylation of the kinase domain of the receptor.  This activated PERK 
phosphorylates eIF2! which causes an inhibition of general protein translation, thereby 
reducing the protein load in the ER (Harding et al., 2000ba).  This inhibition of protein 
translation has been shown to occur immediately after the onset of ER stress, whereas UPR 
gene activation occurs one to two hours after stress onset (Harding et al., 2000ab, Harding et 
al., 2000ba).  Some proteins escape this translational block, such as activating transcription 
factor 4 (ATF4); a basic leucine zipper (bZIP) transcription factor.  ATF4 induces a number 
of genes with protective functions for the ER, however one of the genes induced by ATF4 is 
the pro-apoptotic transcription factor C/EPB homologous protein (CHOP, also called 
GADD153) (Harding et al., 2000ab).  The role of CHOP in apoptosis has been shown to 
occur in response to ER stress (Zinszner et al., 1998).  It has been discovered that a negative 
feedback loop exists that is mediated by GADD34 and leads to dephosphoryation of eIF2!.  
This dephosphorylation of eIF2! removes the block on general protein translation and is 
thought to promote recovery once the cellular stress has subsided (Novoa et al., 2001, Ma 
and Hendershot, 2003).  So it has been established that the PERK pathway has both 
protective effects (by decreasing general protein synthesis) and pro-apoptotic effects (via 
induction of CHOP).  
 
IRE1:  IRE1 is a transmembrane kinase/endoribonuclease and dissociation from 
GRP78 leads to autophosphorylation of the kinase domain and activation of the 
endoribonuclease domain, resulting in splicing of XBP1 mRNA.  This XBP1 splice variant 
encodes a highly active (and more efficient) transcription factor, which induces UPR target 
genes such as molecular chaperones.  It has been shown that activation of the kinase domain 
of IRE1 is required for its RNase activity and splicing of XBP1 in vivo, and that this 
autophosphorylation can be blocked by the use of ATP-competitive tyrosine kinase 
inhibitors (Ali et al., 2011, Korennykh et al., 2008).  XBP1 has been shown to be involved in 
B-cell differentiation and plasma cell development (Reimold et al., 2001, Gass et al., 2004, 
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Gass et al., 2008, Iwakoshi et al., 2003). Knockout mouse models have provided valuable 
insight into the role of IRE1 and XBP1 in B cell development.  IRE1! knockout mice exhibit 
embryonic lethality (Urano et al., 2000, Lee et al., 2002), as do XBP1 knockout mice 
(Reimold et al., 2001).  IRE1 (via its cytoplasmic domain) has been shown to be required in 
the first stage of B cell lymphopoiesis, and ire1!-/- B cells were unable to differentiate into 
antibody secreting plasma cells (Zhang et al., 2005).  XBP1 has also been shown to be 
necessary for the development of antibody secreting plasma cells, with xbp1-/- plasma cells 
unable to differentiate into antibody secreting plasma cells in vivo (Reimold et al., 2001).  
Microarray analysis of gene expression has revealed differential expression of XBP1 
between normal plasma cells, MGUS plasma cells, and myeloma plasma cells, as well as 
different expression ratios of spliced to unspliced XBP1 (Davies et al., 2003).  Another gene 
expression study in a patient with multiple myeloma and the patient’s identical twin reported 
an approximately 15-fold upregulation in XBP1 expression in the patient myeloma cells 
compared to the normal twin plasma cells (Munshi et al., 2004).  The XBP1 splice variant 
has also been shown to trigger ER expansion during the UPR (Sriburi et al., 2004).  Another 
target of spliced XBP1 is P58IPK.  P58IPK is a member of the HSP40 family and acts to inhibit 
PERK causing a negative feedback loop, which in turn removes the PERK induced block in 
protein translation (Yan et al., 2002, van Huizen et al., 2003).  This negative feedback loop 
is thought to be a late effect of PERK pathway activation, suggested to occur several hours 
after phosphorylation of eIF2! (Szegezdi et al., 2006).  It has also been reported that P58IPK 
is present in the ER lumen in association with GRP78 and functions as a cochaperone 
(Rutkowski et al., 2007).  Levels of spliced XBP1 have been reported to effect outcome in 
multiple myeloma patients, with increased overall survival in those patients with lower 
XBP1 spliced to XBP1 unspliced ratios and increased response to treatment with 
thalidomide containing therapy compared to conventional chemotherapy in these patients 
(Bagratuni et al., 2010).  This study suggests a role for spliced XBP1 as both a prognostic 
factor and a predictor of response to treatment in multiple myeloma.  In addition to its 
importance in plasma cells and myeloma, XBP1 is also of significance in other types of 
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secretory cells.  XBP1 deletion in intestinal epithelial cells resulted in intestinal 
inflammation in mouse models and was associated with human inflammatory bowel disease 
(Kaser et al., 2008).  The IRE1/XBP1 pathway has been shown to be involved in 
inflammatory responses in macrophages and in innate immunity under both stress and non-
stress conditions (Martinon and Glimcher, 2011, Martinon et al., 2010). Previously, it was 
thought that binding or dissociation of GRP78 to the three ER stress inducers was 
responsible for turning off or switching on the UPR.  However, a recent study has proposed 
that contrary to this idea of simply turning the UPR on or off, binding of GRP78 to inactive 
IRE1 receptor molecules is involved in preventing activation, stabilising and deactivating the 
UPR once favourable protein folding conditions have been reached (Pincus et al., 2010). 
 
ATF6:  ATF6 is a transmembrane protein that encodes a bZIP transcription factor in 
its cytosolic domain.  ATF6 exists as a 90kDa membrane bound isoform under normal 
physiological conditions.  Under ER stress conditions, GRP78 dissociates from the receptor 
and the cytoplasmic portion of ATF6 translocates to the Golgi apparatus where it is cleaved 
by site 1 and site 2 proteases to its 50kDa active form.  Cleaved (active) ATF6 then travels to 
the nucleus and induces target genes with an ER stress response element (ERSE) in their 
promoter, such as molecular chaperones, XBP1 and CHOP (Haze et al., 1999, Yoshida et 
al., 1998, Yoshida et al., 2001).  During the UPR, activated ATF6 has a critical role in ER 
expansion (a physical increase in the size of the ER), thereby allowing further capacity for 
the ER to correct the perturbations in the protein folding machinery.  It has been shown that 
this ER expansion occurs independently of any XBP1 mediated ER expansion 
(Bommiasamy et al., 2009).  It has been suggested that ATF6 is retained in the ER due to 
interaction of its oligosaccharide chain with the lectin chaperone calreticulin (Schroder and 
Kaufman, 2005b).  Work by Shen and colleagues has revealed that contrary to earlier theory, 
GRP78 binds to ATF6 in a stable manner and dissociation of GRP78 during the UPR is 
regulated rather than being due to competitive binding of GRP78 to unfolded proteins during 
such stress conditions (Shen et al., 2005).  There are two mammalian isoforms of ATF6; 
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ATF6! and ATF6".  Knockdown of ATF6! in mice has shown that whilst it is not required 
for development or basal chaperone expression, ATF6! function is required for recovery 
from acute and chronic cellular stress.  This is in spite of fully functioning PERK and IRE1 
branches of the UPR existing in these animals (Wu et al., 2007).  In another study, mice with 
a knockdown of either isoform of ATF6 were found to develop normally, however, dual 
knockdown of both ATF6 isoforms caused embryonic lethality.  The same study reported 
that ATF6! isoform was required for transcription of molecular chaperones during the UPR 
and that ATF6! forms a heterodimer with XBP1 leading to transcription of proteins 
involved in ERAD (Yamamoto et al., 2007).  More recently, it has been reported that ATF6 
is involved in the survival of dormant cancer cells.  In an in vivo study of squamous cell 
carcinoma, it was shown that ATF6 mediated the survival of dormant tumour cells via 
upregulation of Rheb and activation of mTOR in an AKT independent manner (Schewe and 
Aguirre-Ghiso, 2008).  This research suggests that the prosurvival functions of ATF6 
activation during the UPR can be exploited by cancer cells. 
 
 There are still a number of questions and controversies surrounding the activation of 
the UPR and the regulation of the conflicting pro-survival and pro-apoptotic signalling.  The 
debate surrounds how these complex signalling cascades interact with one another to 
determine the fate of the ER stressed cell.  Previously some authors suggested that the three 
UPR branches are activated in turn; PERK first, followed by ATF6, then finally IRE1 
(Szegezdi et al., 2006).  It has been shown that when IRE1 and PERK are individually 
activated in the absence of misfolded proteins for an equal duration of time, PERK activation 
results in decreased proliferation and cell death, whereas IRE1 activation increased cell 
proliferation resulting in cellular survival (Lin et al., 2009b).  Whilst these results are 
interesting in examining the individual roles of PERK and IRE1 activation, they deal with 
activation of one arm of the UPR in absence of the others.  This is unlikely to accurately 
reflect the complex situation under conditions of cellular stress, where the three branches of 
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the UPR interact with one another.  Another study discovered that when PERK function was 
suppressed, compensatory activation of the IRE1 and ATF6 pathways of the UPR occurred 
(Yamaguchi et al., 2008).  In a 2007 paper in the journal Science, the Walter lab has 
provided valuable insight into signalling and cell fate during the UPR.  The paper reports 
that in human cells exposed to persistent ER stress all three branches of the UPR were 
simultaneously activated, however there were considerable differences in the length of time 
each branch remained active after the onset of stress.  The researchers discovered that IRE1 
responses were attenuated within eight hours of stress onset, even in the presence of 
persistent stress.  ATF6 showed a delay in attenuation in comparison to IRE1, however the 
PERK pathway was found to be active as long as 30 hours after the initial onset of stress.  
These results are represented in figure 1.5.  The authors went on to show that this attenuation 
of IRE1 activity is an important factor in allowing cell death after UPR activation (Lin et al., 
2007).  A later study by the same research group confirmed that even under prolonged stress 
conditions, attenuation of IRE1 signalling occurs, as evidenced by dephosphorylation of the 
kinase domain and decreased RNase activity (Li et al., 2010).  This data provides an insight 
into how cells may make the decision to allow survival or initiate apoptosis when confronted 
with ER stress. 
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Figure 1.5.  Time course for activation of the three branches of the UPR. 
Reproduced from Lin et al. (2007). 
 
1.3.4 – Endoplasmic Reticulum Stress Induced Cell Death 
 
Some of the key mediators in ER stress induced cell death are shown in figure 1.4 
and discussed below.  Whilst it has been recognised for some time that if the UPR is unable 
to restore ER homeostasis it can trigger apoptotic cell death, it is now becoming clear that 
the UPR is also involved in other cell death pathways. 
 
Both the IRE1 and PERK branches of the UPR have been implicated in ER stress 
induced apoptosis.  In contrast, the ATF6 pathway appears to have only protective functions 
(Thuerauf et al., 2007, Szegezdi et al., 2006).  IRE1 is known to bind to TRAF2 (tumour 
necrosis factor receptor associated factor 2) leading to activation of ASK1 and JNK (Urano 
et al., 2000).  Interestingly, it has also been shown that IRE1! physically interacts with the 
pro-apoptotic BCL-2 family proteins BAX and BAK, providing a link between the UPR and 
the core apoptotic pathway (Hetz et al., 2006).  Another role for IRE1 in cell death comes 
via activation of caspase 12, an ER localised caspase activated exclusively during the UPR 
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(Nakagawa et al., 2000).  However, the majority of humans lack caspase 12 (due to a 
mutation in the coding region) and as a result, this pathway is unlikely to be of significance 
in man.  Caspase 4, a pro-inflammatory caspase, is one of the closest relations to rodent 
caspase 12 and it has been suggested that this caspase may be involved in ER stress induced 
apoptotic signalling in humans (Hitomi et al., 2004).  The PERK pathway is involved in ER 
stress induced apoptosis via induction of ATF4 and the resultant upregulation of CHOP as 
discussed previously. 
 
In addition to the accepted mechanism of UPR induced apoptosis, it has been shown 
that ER stress induced cell death can occur by differing mechanisms and involves both 
caspase dependent apoptosis and caspase independent cell death or necrosis (Egger et al., 
2003).  One such mechanism is alteration of ER calcium content, which is the mechanism of 
action of a number of pharmacological agents known to cause ER stress induced apoptosis.  
Anti-apoptotic BCL-2 and BCL-XL proteins have been shown to decrease calcium 
concentrations in the ER and pro-apoptotic BAX protein has been found to increase ER 
calcium concentrations (Foyouzi-Youssefi et al., 2000, Jones et al., 2007).  Another study 
reported that cells deficient in BAX and BAK were chemoresistant, however they were still 
sensitive to ER stress induced apoptosis mediated by thapsigargin treatment (Janssen et al., 
2009). 
 
Recently, an increasing role for autophagy in ER induced cell death has become 
apparent.  Autophagy (autophagocytosis) is a cellular process involving lysosomal 
degradation of cellular components.  ER stress has been found to induce autophagy, while 
the disturbance of autophagy makes cells more vulnerable to ER stress (Ogata et al., 2006).  
The PERK pathway has been implicated in autophagy in response to ER stress, although the 
significance of this remains to be determined (Kouroku et al., 2007).  Recently it has been 
reported that GRP78 is required for ER stress induced autophagy to occur (Abramson et al., 
2008).  Links have also been discovered between ER stress, the ubiquitin-proteasome system 
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and autophagy.  The ubiquitin-proteasome system has been shown to induce autophagy in 
response to ER stress and it is thought this may be a compensatory mechanism activated 
when the proteasome is overwhelmed by misfolded proteins (Ding et al., 2007). 
 
Another mechanism by which cells dispose of misfolded or unfolded 
polyubiquitinated proteins is the aggresome pathway (Garcia-Mata et al., 2002).  The 
incorrectly folded proteins coaggregate into a single aggresomal particle, which then 
migrates toward the microtubule organising centre (MTOC) and on to the aggresome.  These 
aggresomes recruit chaperones, proteasome subunits and ubiquitination enzymes in an 
attempt to dispose of the aggregated misfolded proteins.  Clearance of the aggresomes is 
thought to occur via autophagy.  Autophagosomes engulf the aggresomes and the proteins 
are then degraded by lysosomes (Rodriguez-Gonzalez et al., 2008).  The aggresome pathway 
has been implicated in cancer and identified as a possible therapeutic target, particularly in 
multiple myeloma (Hideshima et al., 2005).  
 
 
 
Figure 1.6.  The role of the unfolded protein response in cell death. 
Reproduced from Kim et al. (2008). 
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1.4 The Unfolded Protein Response and Disease 
 
1.4.1 – Classification of Diseases Caused by Impaired Endoplasmic Reticulum Function 
  
 ER stress and the UPR have been linked to a number of diverse clinical disorders, 
such as neurodegenerative diseases, diabetes, stroke, vascular injury, kidney disease, viral 
pathogenesis and cancer (Kaufman, 2002).  Based on the classification of ER storage 
diseases by Kim and Arvan, Schroder and Kaufman have classified diseases caused by 
impaired ER and UPR function (Schroder and Kaufman, 2005b). These ER related diseases 
are designated class I to class IV: 
o Class I diseases are caused by a mutation in secretory client proteins and alter folding of 
the affected protein.  Class I diseases include cystic fibrosis and diabetes. 
o Class II diseases are caused by mutations in the protein trafficking machinery and loss 
of function at the target site of the protein.  Class II diseases include the blood 
coagulation disorder combined coagulation factor V and VIII deficiency. 
o Class III diseases occur as a result of impaired UPR signalling.  Examples of class III 
diseases include IRE1/XBP1 related colitits and the infant diabetic syndrome Wollcott-
Rallison Syndrome, caused by mutations in the PERK kinase domain.  
o Class IV diseases are those diseases in which UPR signalling is functional, however the 
protective responses of the UPR are impaired.  This is seen in a number of 
neurodegenerative diseases, such as Huntington’s disease, where the proteasome is 
poisoned by cytosolic polyglutamine repeats. 
 
 Most cancers would fall into class III or class IV diseases, and the mechanisms 
underlying class III and IV diseases are utilised in the drug treatment of cancer (particularly 
diseases derived from secretory cells).  For example, proteasome inhibition as a therapeutic 
strategy in multiple myeloma (Schroder and Kaufman, 2005b). 
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1.4.2 – The Role of the Unfolded Protein Response in Disease 
 
While the UPR is now implicated in a number of diseases, the underlying 
mechanisms remain to be fully uncovered.  Also, it is not always clear whether the UPR is 
the primary cause in the pathogenesis of a particular disease, or a secondary response that 
may, for example, contribute to disease severity (Zhao and Ackerman, 2006).  Whilst a 
number of clinical disorders where the UPR is involved have now been identified, there is 
currently a distinct lack of treatments that utilise or target the UPR or UPR components.   
 
One group of disorders where the UPR is implicated in disease pathogenesis are the 
neurodegenerative diseases.  It has been reported that the neuronal loss in both inherited and 
sporadic forms of neurodegenerative diseases can occur alongside aggregation of misfolded 
or mutant proteins (Selkoe, 2003).  The UPR has been linked to both Alzheimer’s disease 
and Parkinson’s disease, as well as other neurodegenerative disorders such as Huntington’s 
disease and spongiform encephalopathy (Zhao and Ackerman, 2006).   
 
Gene mutations associated with Alzheimer’s disease (e.g. presenilin-1 mutations in 
familial Alzheimer’s and presenilin-2 in sporadic Alzheimer’s) have been reported to 
downregulate UPR signalling via IRE1, PERK and ATF6, thereby increasing vulnerability to 
ER stress (Katayama et al., 2001, Sato et al., 2001).  Downregulation of GRP78 has also 
been observed in the presence of these mutations in vitro, consistent with the finding that 
levels of the molecular chaperones GRP78 and GRP94 are decreased in the brains of 
Alzheimer’s patients compared with age-matched controls (Katayama et al., 1999).  In cells 
with amyloid beta peptides or overexpression of presenilin-1 mutations associated with 
Alzheimer’s disease, ER calcium homeostasis is impaired leading to neuronal toxicity and 
apoptosis (Mattson et al., 1993, Guo et al., 1997, Mattson et al., 2000).    
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Parkin is an E3 ubiquitin ligase involved in the degradation of unfolded or misfolded 
proteins.  Mutations in the parkin gene have been found to protect cells from UPR associated 
cell death and have been linked to Parkinson’s disease (Shimura et al., 2000, Imai et al., 
2000).  It has also been shown that transient cerebral ischaemia activates the UPR, as 
indicated by XBP1 mRNA splicing (Paschen et al., 2003), phosphorylation of PERK 
(Kumar et al., 2001) and expression of UPR genes (Paschen, 2004).    
 
ER stress and the UPR have also been linked to both type I and type II diabetes 
(Eizirik et al., 2008).  For example, a mutation in the EIF2AK3 gene (encoding human 
PEK/PERK) causes Wolcott-Rallison syndrome; a rare disease characterised by insulin 
dependent diabetes occurring in early infancy (with further symptoms such as osteoporosis, 
cardiovascular problems, mental and growth retardation occurring at a later age) (Delepine et 
al., 2000).  ER stress has also been found to play a role in the apoptosis of pancreatic islet "-
cells in type II diabetes (Laybutt et al., 2007).  Recently, it has been suggested that ER stress 
and the UPR may provide the link between obesity, insulin resistance, and the resulting type 
II diabetes (Ozcan et al., 2004, Boden et al., 2008). 
 
 Other diseases where the UPR is now known to have some sort of involvement 
include cardiovascular disease (Toth et al., 2007), kidney disorders (Kitamura, 2008) and 
musculoskeletal disorders (Acosta-Alvear et al., 2007). 
 
1.4.3 – The Unfolded Protein Response in Cancer 
 
 Cancer is one of the many diseases in which the UPR is proposed to be a factor.  The 
vast majority of work done to date on the role of the UPR in cancer is in the area of solid 
tumours, particularly in relation to tumour hypoxia.  As a tumour grows, increasing demands 
are placed on the microenvironment, eventually leading to glucose starvation, low pH, poor 
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vascular supply and hypoxia (Ma and Hendershot, 2004b).  Whilst the hypoxia-inducible 
factor (HIF) pathway in hypoxia has been known for some time, more recently a role for the 
UPR in relation to hypoxia has become apparent (Wouters and Koritzinsky, 2008).  
Koumenis and colleagues showed that both moderate and severe hypoxia were sufficient to 
activate the PERK branch of the UPR and that this activation was important for survival 
during hypoxia (Koumenis et al., 2002).  Tumour hypoxia has also been reported to activate 
the IRE1 branch of the UPR, indicated by XBP1 mRNA splicing, and again this activation 
was found to be necessary for survival during hypoxia and continued tumour growth 
(Romero-Ramirez et al., 2004).  Questions remain regarding the mechanisms underlying 
UPR activation by hypoxia, including whether there is any involvement of the ATF6 
pathway.  Further work is being done in this area to fully elucidate the interaction between 
tumour hypoxia and the UPR. 
 
Other areas of tumour development where the UPR has been implicated include 
tumour angiogenesis and metastasis.  Drogat and colleagues reported that activation of the 
IRE1 signalling pathway of the UPR in response to tumour hypoxia resulted in upregulation 
of vascular endothelial growth factor A (VEGF-A).  They also showed that in IRE1!-null 
mouse embryonic fibroblasts there was no upregulation of VEGF-A in response to either 
oxygen or glucose deprivation, and that this correlated with decreased tumor angiogenesis 
and growth in vivo (Drogat et al., 2007).  In a model of human glioma, it was shown that 
IRE1! inhibition led to a reduction in tumour angiogenesis, indicating a possible role for 
IRE1 in tumour invasiveness (Auf et al., 2010).  IRE1! has also been shown to be required 
for vascularisation and placental development in mice, with IRE1! deletion causing 
embryonic lethality (Iwawaki et al., 2009).  A study in human pancreatic adenocarcinomas 
found that XBP1 was required for angiogenesis during early tumour growth and that the 
proangiogenic effects of XBP1 occur independent of VEGF (Romero-Ramirez et al., 2009). 
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 Involvement of the UPR in a number of different solid tumour types has been 
shown.  In hepatocellular carcinoma GRP78 has been identified as a transformation 
associated gene, along with activation of the ATF6 and IRE1/XBP1 pathways (Shuda et al., 
2003).  In colon cancer, GRP78 has been shown to be upregulated in colon cancer tissue and 
increased cytoplasmic GRP78 expression was associated with the transformation from 
normal tissue to adenoma and then carcinoma (Xing et al., 2006).    GRP78 has also been 
shown to be overexpressed in malignant breast tumours, but there was no overexpression 
seen in benign breast tumours (Fernandez et al., 2000).  Both GRP78 and GRP94 have been 
shown to be overexpressed in lung cancer tissues (Wang et al., 2005), and GRP94 
overexpression has been reported in oesophageal adenocarcinomas (Chen et al., 2002).  
Activation of the UPR has also been shown in prostate cancer (Misra et al., 2006) and 
GRP78 has been linked to prostate cancer metastasis.  GRP78 has been shown to be weakly 
expressed in normal prostate tissue, however it is highly expressed in the bone metastases of 
prostate cancer patients (Mintz et al., 2003).  In another study in prostate cancer it was found 
that the intensity of GRP78 expression in prostate tissue was associated with survival and 
clinical recurrence (Daneshmand et al., 2007).  The antiapoptotic BCL-2 family protein 
MCL-1 has also been implicated in ER stress and cancer.  It has been reported that 
melanoma cells are resistant to ER stress induced apoptosis and that this increased survival is 
due to an upregulation of MCL-1 (Jiang et al., 2007b).  This finding suggests that inhibition 
of MCL-1 could be used as a therapeutic strategy to increase sensitivity to agents causing 
cell death via ER stress and the UPR.  Another finding of note from work in solid tumours is 
the discovery that alterations in genes encoding the sarcoplasmic endoplasmic reticulum 
calcium pumps have been found in squamous cell head and neck carcinoma (Korosec et al., 
2008).  This has interesting implications with respect to the modulation of ER calcium as a 
therapeutic strategy.   
 
 A large amount of work has been done on the UPR in solid tumours, however, 
comparatively little work has been done thus far on the role of the UPR in haematological 
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malignancies.  The work that has been done has focused primarily on activation of the UPR 
resulting from various therapeutic strategies in multiple myeloma, which will be discussed in 
further sections.    
  
1.5  The Unfolded Protein Response and Drug Resistance in Cancer 
 
A number of years before the elucidation of the mammalian UPR pathways and the 
vital role played by molecular chaperones such as GRP78, it was already known that the 
glucose related proteins were involved in resistance of tumours to treatment with traditional 
DNA-damaging chemotherapy drugs.  In 1987, it was shown that exposure of chinese 
hamster ovary (CHO) cells to conditions that induced GRPs (e.g. glucose deprivation and 
anoxia) induced resistance to the topoisomerase II poison doxorubicin (Shen et al., 1987).  
These researchers then went on to attempt to identify a mechanism for this resistance.  They 
found that following exposure of CHO cells to GRP inducing conditions (also including 
tunicamycin treatment) there was a rapid and selective depletion of topoisomerase II from 
the nucleus of these cells and associated cell cycle effects (Shen et al., 1989).   
 
Other investigators also reported that upregulation of GRP78 led to downregulation 
of topoisomerase II and resistance to topoisomerase II inhibitors, including etoposide (Yun 
et al., 1995, Gosky and Chatterjee, 2003).  However, further studies indicated that the 
downregulation of topoisomerase II and induction of drug resistance attributed solely to 
GRP78 in these early studies was actually due to UPR activation (Reddy et al., 2003, Gray et 
al., 2005).  It was shown that in the absence of ER stress inducers, overexpression of GRP78 
did not result in depletion of topoisomerase or arrest in G1 phase of the cell cycle (Reddy et 
al., 2003).  This was confirmed by a later study which reported that a cell line 
overexpressing GRP78, which was unable to activate the UPR, did not show topoisomerase 
II depletion or increased resistance to etoposide in response to stress conditions.  The authors 
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of this study attributed the decrease in topoisomerase II levels and the induction of resistance 
to topoisomerase II targeting drugs to activation of the UPR in general (including the 
resulting upregulation of GRP78), as opposed to it being a direct effect of GRP78 (Gray et 
al., 2005).  Another proposed mechanism for this drug resistance came from the 
identification of a sequence on topoisomerase II! that induces its proteasomal degradation in 
response to glucose deprivation and activates an UPR (Yun et al., 2004). 
 
In contrast to the relation between expression of GRP78 and resistance to 
topoisomerase II poisons, it has been shown that increased expression of GRP78 can actually 
sensitise tumours to other DNA damaging agents (Chatterjee et al., 1997).  Clonogenic assay 
experiments showed that overexpression of GRP78 was associated with an increased 
sensitivity to DNA cross-linking agents, including melphalan and cisplatin (Chatterjee et al., 
1997).  The authors concluded that overexpression of GRP78 decreased the ability of these 
cells to repair DNA cross-links, resulting in increased cytotoxicity (Chatterjee et al., 1997). 
 
The role of GRP78 in resistance of tumours to drug treatment is now being studied 
further.  Due to the vital role this molecular chaperone plays in UPR activation there is 
strong mechanistic rationale for targeting it.  This rationale was confirmed by Lee and 
colleagues in a 2006 study in breast cancer (Lee et al., 2006).  This retrospective cohort 
study analysed tumour specimens from 127 breast cancer patients and concluded that GRP78 
was a predictor of response to chemotherapy.  The authors reported that high GRP78 
expression was associated with a shorter time to disease recurrence after doxorubicin 
containing chemotherapy.  High tumour GRP78 expression was also associated with a 
shorter time to disease recurrence following mastectomy in this study (Lee et al., 2006).  
This was the first report to build on the earlier in vitro work and shed light on the role of 
GRP78 in patient tumours.  In parallel to this work, a study reporting immunohistochemistry 
results from prostate cancer patient samples revealed an association between GRP78 
expression and the development of castration resistance, which may have important 
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prognostic implications for prostate cancer patients (Pootrakul et al., 2006).  Building on this 
work in breast and prostate cancers, the Lee group focused on GRP78 in malignant gliomas; 
a tumour type known to have poor chemosensitivity.  It was shown that GRP78 is 
overexpressed in human malignant glioma cell lines compared to normal adult brain.  The 
expression of GRP78 was reported to correlate with the rate of tumour cell proliferation.  A 
small interfering RNA (siRNA) approach to down-regulating GRP78 decreased glioma cell 
proliferation and decreased resistance to the chemotherapeutic agent temozolomide used in 
this tumour type, whereas overexpression of GRP78 induced temozolomide resistance.  This 
siRNA mediated down-regulation of GRP78 also sensitised cells to the chemotherapetic 
agents fluorouracil and irinotecan (Pyrko et al., 2007b).  This study highlighted the 
possibility of targeting the UPR via GRP78 in order to increase sensitivity to current 
chemotherapy treatments and reported that overexpression of GRP78 appears to be 
associated with increased chemoresistance. 
 
A study by Zhang and colleagues provided a link between the UPR and the mitogen-
activated protein kinase (MAPK) pathway mediated by the IRE1 pathway.  The authors 
found that in gastric cancer cells GRP78 is a target of the MEK/ERK pathway and is 
responsible for protection against ER stress induced apoptosis (Zhang et al., 2008).  This 
study also suggested a role for GRP78 in decreasing chemosensitivity of tumours and 
highlighted the potential in targeting GRP78 as an adjunct to cancer chemotherapy. 
 
It has been reported that GRP78 is involved in resistance to the proteasome inhibitor 
bortezomib in solid tumours.  By studying a number of bortezomib resistant cell lines, it was 
discovered that these tumour cell lines were able to secrete GRP78 into the cell supernatant 
and that this was responsible for resistance to bortezomib treatment.  Interestingly, the 
investigators found that this effect was only seen in solid tumour cell lines and did not occur 
in multiple myeloma cell lines (Kern et al., 2009).  Another study in mantle cell lymphoma 
has linked upregulation of GRP78 to bortezomib resistance.  These investigators found that 
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downregulation of GRP78 either by knockdown or pretreatment with the HSP90 inhibitor 
IPI-504 lead to an increase in apoptosis following bortezomib treatment (Roue et al., 2011) 
 
Whilst there is some conflicting information on the role of GRP78 in drug sensitivity 
from the in vitro studies, the general consensus amongst investigators is that GRP78 has a 
protective effect in cancer cells and represents a valid therapeutic target in cancer. 
 
Although most of the work concerning the UPR and drug resistance in cancer has 
investigated the role of GRP78, other components of the UPR have also been shown to be 
involved.  It has been reported that activation of the phosphoinositide-3-kinase (PI3K) 
pathway and Akt, mediated by the XBP-1 (IRE1) pathway of the UPR, is implicated in the 
resistance of melanoma cells to the chemotherapy agents docetaxel and vincristine (Jiang et 
al., 2009).  PERK activation and the subsequent phosphorylation of eIF2! has been linked to 
control of the cell cycle by inhibiting translation of cyclin D1 and causing cell cycle arrest in 
G1 phase (Brewer and Diehl, 2000).  This PERK mediated cell cycle arrest has been 
implicated in the survival and drug resistance of dormant tumour cells (Ranganathan et al., 
2006, Ranganathan et al., 2008).  However, it has so far not been demonstrated that PERK is 
solely responsible for this effect and other eIF2! kinases, such as GCN2, also appear to be 
involved (Hamanaka et al., 2005).  One study has suggested that both PERK and PKR lead 
to cell cycle arrest by increasing proteasomal degradation of cyclin D1 in cells where eIF2! 
is phosphorylated (Raven et al., 2008).  These interesting results provide scope for future 
work in this area and may eventually lead to new drug targets, enabling successful treatment 
of dormant or slowly proliferating tumour cells and reversal of drug resistance. 
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1.6  The Unfolded Protein Response and Modulating Chemosensitivity in 
Cancer 
 
Due to the wide ranging involvement of the UPR reported in cancer, the role of the 
UPR in modulating chemosensitivity has recently begun to be investigated.  The rationale for 
this is that as cancer cells have been shown to have a constitutively active UPR (to varying 
extents) (Ma and Hendershot, 2004b), provoking further ER stress will result in increased 
cell death via the UPR machinery, while leaving normal (unstressed) cells able to adapt and 
therefore unaffected.   
 
Many drugs have been identified where the UPR is implicated in their mechanism of 
action to some extent.  In order to facilitate discussion of these agents and their effect on 
chemosensitivity of tumours, I have grouped them according to mechanism of action.  This 
approach results in the creation of four distinct groups: drugs that affect molecular 
chaperones involved in the UPR, drugs with direct effects on UPR transmembrane receptors 
and downstream signalling pathways, drugs that interfere with ERAD or cell death 
pathways, and drugs acting by other mechanisms. These groups of agents are discussed in 
detail below. 
 
1.6.1 – Drugs acting on UPR molecular chaperones 
 
 The two molecular chaperones with the most direct effect on UPR activation and 
UPR signalling are GRP78 and GRP94.  The role of these chaperones in the UPR has been 
discussed in detail in earlier sections.  However, there are also other molecular chaperones 
that are involved in the UPR which are being investigated in terms of their effect on 
sensitivity of tumours to chemotherapeutic agents.  It has been shown that the sensitivity of 
cells to apoptosis correlated with expression of HSP70 in AML cells in vitro (Chant et al., 
1996).  This may have implications for chemosensitivity of these leukaemic cells.  
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Interestingly, it has been reported that inhibition of protein sulphide isomerases with the PDI 
inhibitor bacitracin increased apoptosis in response to ER stress inducing treatment in 
melanoma cells.  This study provided very promising results and proof of principle in vitro, 
however the authors note that this strategy would be limited in vivo by the nephrotoxicity 
and low membrane permeability of bacitracin (Lovat et al., 2008).  The development of 
potent and specific small molecule inhibitors of PDI is eagerly awaited.       
 
 Based on earlier siRNA studies (Pyrko et al., 2007b) inhibition of GRP78 has 
emerged as another possible method of modulating the UPR in order to increase 
chemosensitivity of tumours.  The only small molecule inhibitor of GRP78 that has been 
described to date is versipelostatin; a natural product identified by a cell based screen for 
agents that would affect molecular chaperones (Park et al., 2002).  In a 2004 article Park and 
colleagues investigated the effect of this drug on UPR activation in response to glucose 
deprivation or other ER stress inducing agents.  They also investigated the antitumour 
activity of versipelostatin in vivo (Park et al., 2004).  Versipelostatin selectively inhibited 
expression of both GRP78 and GRP94 in response to ER stress induced by glucose 
deprivation (but not tumicamycin induced ER stress).  XBP1 splicing and ATF4 expression 
were both decreased by versipelostatin during glucose deprivation, indicating UPR 
suppression.  In a mouse xenograft model, the in vivo cytotoxic effect of versipelostatin was 
comparable to that of single agent cisplatin treatment, and the drug was well tolerated 
(Brough et al., 2008).  This work provided encouraging early results for this novel 
compound. 
 
Other strategies for targeting GRP78 are being explored, for example, the use of the 
cytokine interleukin-24 (IL-24 – also known as melanoma differentiation-associated gene-7 
or MDA-7); a member of the interleukin-10 family of cytokines (Jiang et al., 1995, Dent et 
al., 2005).  One of the effects of IL-24 is to cause ER stress through generation of reactive 
oxygen species.  IL-24 also directly interacts with GRP78 in the ER and has been shown to 
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suppress tumour growth, or cause apoptosis, in cell lines and mouse models of cancer (Gupta 
et al., 2006).  A recent study has shown that in prostate carcinoma cells, IL-24 causes 
apoptosis via inhibition of the antiapoptotic BCL-2 family protein MCL-1 (Dash et al., 
2010).  Another recent study reported that IL-24 treatment in AML cell lines resulted in ER 
stress induction and subsequent apoptosis (Rahmani et al., 2010).  Research is continuing 
into the use of this cytokine in cancer therapy, and has progressed into clinical trials (phase I 
and II).  IL-24 treatment is a gene therapy product and is delivered in vivo by recombinant 
MDA-7/IL-24 adenovirus.  Treatment with IL-24 has also been studied in glioma, leukaemia 
and ovarian cancers (Yacoub et al., 2010a, Yacoub et al., 2010b, Yang et al., 2010).  IL-24 
therapy was well tolerated in phase I clinical trials and evidence of efficacy has already been 
seen (Inoue et al., 2006, Lebedeva et al., 2007).   
 
Another group of drugs that have recently been linked with the ER chaperone 
proteins and UPR activation are histone deacetylase (HDAC) inhibitors.  HDAC inhibitors 
are novel anticancer agents, with the first in class inhibitor suberoylanilide hydroxamic acid 
(SAHA; vorinostat (Zolinza®)) approved by the FDA in the United States for the treatment 
of cutaneous T-cell lymphoma in 2006.  A second HDAC inhibitor romidepsin (Istodax®) 
was also approved by the United States FDA in 2009 for the treatment of cutaneous T-cell 
lymphoma.  Histone proteins are involved in the packing of DNA into nucleosomes.  
Epigenetic modifications of histone proteins, such as acetylation and methylation, are 
involved in a number of important processes, including gene regulation and DNA repair.  
HDACs and histone acetyl transferases (HATs) are together responsible for the modification 
of histones and regulation of target gene expression.  HATs mediate histone acetylation 
thereby facilitating gene expression, whilst HDACs mediate removal of acetyl groups 
(deacetylation) resulting in repression of transcription (Lane and Chabner, 2009, Bolden et 
al., 2006).  
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Eight classes of HDACs have been identified (based on homology with HDACs in 
yeast) and HDAC inhibitors can act on one or more of these classes.  The hydroxamic acid 
derived HDAC inhibitors, such as SAHA, are pan-HDAC inhibitors acting on class I, II and 
IV HDACs (Bolden et al., 2006, Lane and Chabner, 2009).  HDAC inhibitors have recently 
been linked to GRP78 and the UPR.  It has been known for some time that HSP90 is a non-
histone substrate of HDAC enzymes (Yu et al., 2002) and a 2009 recent study published in 
the journal Science has identified other chaperones that are non-histone HDAC substrates, 
including HSPA5 (GRP78) and HSP90B1 (GRP94).  It has been suggested that lysine 
acetylation on HSP90 may contribute to the anticancer activity of HDAC inhibitors, 
although recent knowledge of the roles of the ER molecular chaperones (GRP78 in 
particular) suggests an additional possible role for these proteins in mediating HDAC 
inhibitor activity (Choudhary et al., 2009).  Another study reported that the GRP78 promoter 
is repressed by HDAC1 and that HDAC inhibitors specifically induce GRP78 expression.  
These investigators also report that overexpression of GRP78 results in resistance to HDAC 
inhibitor induced apoptosis (in 293T renal epithelial cells), whilst GRP78 knockdown 
sensitised cells to HDAC inhibitor activity (in the colorectal HCT116 and melanoma MDA-
MB-435 cell lines) (Baumeister et al., 2009).  GRP78 and UPR activation have also been 
reported to contribute to the anticancer activity of SAHA.  Studies in a panel of glioblastoma 
and prostate cell lines showed that SAHA treatment resulted in GRP78 acetylation and 
subsequent activation of PERK (with eIF2! phosphorylation, ATF4 and CHOP expression), 
although the authors comment that this UPR activation was specific to certain cell lines.  
Knockdown of PERK using siRNA lead to an increase in cytotoxicity following SAHA 
treatment in the U251 glioblastoma cell line (Kahali et al., 2010).  Whilst these studies have 
reported an association between HDAC inhibition, GRP78 induction and UPR activation, a 
causal link has not yet been established. 
 
In recent years it has been discovered that a number of drugs widely used in clinical 
practice have other, previously unknown, off target effects linked to the unfolded protein 
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response.  For example, the antidiabetic drug metformin (belonging to the biguanide class) is 
one of the most common agents prescribed for the treatment of type 2 diabetes.  It acts by 
inhibiting glucose production in the liver, delaying intestinal glucose absorption and 
increasing insulin sensitivity in muscle.  It has been reported that metformin (and the other 
biguanide drugs buformin and phenformin) modulated the UPR under glucose deprivation 
conditions in a manner similar to that of versipelostatin (Saito et al., 2009).  Whilst a great 
deal more research is needed as regards metformin for cancer treatment, utilising drugs that 
are already in widespread clinical use for their UPR targeting effects is a particularly 
attractive treatment strategy.  A drug such as metformin that is taken orally, has been used 
for many years, is considered safe and has a well-known adverse effect profile would be an 
ideal therapeutic candidate.   
 
One of the limitations of the agents mentioned above in targeting molecular 
chaperones is the possible lack of total selectivity for a given chaperone.  However, these 
targets have only recently been identified and it is hoped that with continued research, agents 
with higher target selectivity (and therefore more potential to pass successfully through the 
drug development process and into the clinic) will be identified. 
 
1.6.2 – Drugs with direct effects on UPR receptors and downstream signalling 
 
The second group of drugs used to modulate the UPR in cancer treatment are those 
drugs with direct effects on UPR transmembrane receptors and downstream signalling 
pathways.  A number of different agents have now been linked directly to the UPR sensors 
PERK, IRE1 and ATF6 or their downstream signalling molecules and these agents are 
discussed below.   
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ER stress has been shown to be involved in apoptosis induced by treatment with the 
non-steroidal anti-inflammatory drug (NSAID) indometacin.  Increased GRP78 expression 
was seen, along with ATF6 and XBP1 activation, and expression of AFT4 and CHOP 
(Tsutsumi et al., 2004).  The cyclooxygenase-2 (COX-2) inhibitors, e.g. celecoxib, are also 
anti-inflammatory drugs.  They selectively inhibit COX-2 and therefore have less gastric 
adverse effects than traditional NSAIDs (Beers and Merck Research Laboratories., 2006).  
These drugs have also been found to cause ER stress mediated apoptosis, however in 
contrast to indometacin the mechanism of this apoptosis is due to effects on intracellular 
calcium and these drugs are therefore discussed in the next section.  
 
HSP90 inhibitors also interact directly with UPR signalling.  As early as 2002 it was 
shown that HSP90 physically interacts with the ER transmembrane receptors PERK and 
IRE1, by association with their cytoplasmic kinase domains.  In particular, HSP90 modulates 
the UPR through stabilisation of IRE1 (Marcu et al., 2002).  The activity of HSP90 
inhibitors in multiple myeloma was reported (Mitsiades et al., 2006) and further work 
published in 2007 showed that HSP90 inhibition with 17-AAG activated an UPR in multiple 
myeloma plasma cells, as evidenced by ATF6 activation, XBP1 splicing and induction of 
CHOP (Davenport et al., 2007).  The activity of another novel HSP90 inhibitor, IPI-504, has 
been shown in multiple myeloma cells, however, in contrast to the UPR activation seen with 
other HSP90 inhibitors, it has been reported that this agent blocks activation of the UPR 
(Patterson et al., 2008).  IPI-504 has been found to induce apoptosis in diffuse large B-cell 
lymphomas that are dependent on the HSP90 client protein AKT (Abramson et al., 2008), 
which may also be a factor in myeloma cytotoxicity.  As mentioned in the drug resistance 
section previously, IPI-504 has also been reported to overcome resistance to bortezomib 
occurring due to secretion of GRP78 by solid tumour cell lines (Roue et al., 2011).  It is 
worth mentioning that inhibitors of cytosolic HSP90, namely geldanamycin, also bind to 
both other mammalian isoforms of HSP90; its ER homologue GRP94, and its mitochondrial 
homologue TRAP1 (Felts et al., 2000, Chavany et al., 1996).  This binding is rarely 
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discussed in the context of HSP90 treatment and is not generally given much significance 
when considering the mechanism of action of these drugs.  It is probable that this is due to 
the large number of client proteins of HSP90 (many of which are key players in cancer) 
compared with the very few client proteins of GRP94, of which very little was known about 
until recently. 
 
Other agents exerting an anticancer effect via UPR receptors and signalling have 
recently been described.  The Ras inhibitor Salirasib (FTS) has been shown to cause ER 
stress induced apoptosis in cells overexpressing the Myc oncogene via increased GRP78, 
phosphorylation of PERK receptor and activation of downstream proapoptotic signalling 
(Yaari-Stark et al., 2010).  This finding has implications for potential cancer treatment as a 
number of different tumour types have been reported to have amplification of the Myc gene.  
Another compound that has recently been described to act via the UPR is the flavonoid 
xanthohumol.  A study in chronic lymphocytic leukaemia (CLL) found that treatment with 
xanthohumol induced the chaperones GRP78 and HSP70 as well as leading to sustained 
eIF2! phosphorylation and activation of proapoptotic UPR signalling (Lust et al., 2009).  
Other flavonoids have also been reported to act in this way, such as activation of the 
proapoptotic PERK pathway in leukaemic cell lines by tangeretin (Lust et al., 2010).  The 
natural plant phenol compound resveratrol has also been reported to exert an anticancer 
effect via PERK pathway mediated cell cycle arrest (Liu et al., 2010).  The tyrosine kinase 
inhibitor sorafenib used in renal cancer has been shown to induce cell death via ER stress 
and UPR activation in leukaemia cells (Rahmani et al., 2007). 
 
Research has been carried out over recent years to identify specific inhibitors of the 
UPR receptors, particularly the kinases (and in the case of IRE1, endoribonuclease) PERK 
and IRE1.  Earlier this year two separate research groups published studies of small 
molecule IRE1 inhibitors.  An article by Papandreou and colleagues in the journal Blood 
describes the novel small molecule compound STF-083010, an inhibitor of IRE1 
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endoribonuclease activity, after ER stress in both in vitro and in vivo models of multiple 
myeloma (Papandreou et al., 2011).  In the other paper by Volkmann and colleagues, the 
Salicylaldehyde analogs were reported to be specific inhibitors of the IRE1 
endoribonuclease.  These compounds have been shown to bind to IRE1 in a specific, 
reversible and dose dependent manner in both in vivo and in vitro models of ER stress 
(Volkmann et al., 2011).  While research is still at an extremely early stage, it is promising 
that compounds are being developed to target IRE1 and presents a good starting point for 
future drug development.  IRE1 inhibitor therapy has the potential to be particularly 
efficacious in cancers (or other disorders) where activation of the IRE1/XBP1 pathway has 
been implicated in disease pathology, for example, multiple myeloma. 
 
1.6.3 – Drugs that interfere with ERAD or cell death pathways 
 
The third group of drugs that modulate ER function act by interfering with ERAD or 
cell death pathways.  The main examples of drugs acting via this mechanism are proteasome 
inhibitors.  As previously discussed, the 26S proteasome is responsible for the degradation of 
polyubiquinated proteins and degradation of unfolded or misfolded polyubiquitinated 
proteins via the proteasome is the final stage in ERAD.  It is thought that by inhibiting the 
proteasome, therefore interfering with ERAD, other cell death/degradation pathways will be 
activated by the resulting ER stress and UPR activation.  Proteasome inhibition is already 
used in myeloma and some lymphomas, and is also being investigated in leukaemia 
(McConkey and Zhu, 2008, McConkey et al., 2005, Vink et al., 2006, Riccioni et al., 2007).  
The first in class proteasome inhibitor bortezomib has also been shown to increase the 
sensitivity of multiple myeloma cells to other chemotherapeutic agents (Ma et al., 2003).  
Experiments in pancreatic cancer cells showed that bortezomib sensitised the cells to ER 
stress mediated apoptosis (Nawrocki et al., 2005b).  The same researchers then reported that 
bortezomib inhibited PERK, but increased GRP78 and CHOP expression, and induced 
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apoptosis as a result of ER stress induction in pancreatic cancer cells (Nawrocki et al., 
2005a).  It was reported that in multiple myeloma cells bortezomib treatment activated 
unfolded protein response mediated apoptosis, via activation of the PERK pathway (Obeng 
et al., 2006).  It has also been shown that bortezomib is preferentially cytotoxic to hypoxic 
tumour cells due to an overactivation of ER stress.  Interestingly, whether cell death occurred 
via apoptosis or autophagy was found to depend on the cell type (Fels et al., 2008). 
 
A number of drugs used to treat HIV have recently been identified as potential 
anticancer agents, exerting their anticancer effects through ER stress.  The HIV protease 
inhibitors nelfinavir, atazanavir and ritonavir have all been discovered to have anticancer 
activity (Gills et al., 2007, Pyrko et al., 2007a, Kraus et al., 2008).  Ritonavir was shown to 
increase sensitivity to bortezomib in sarcoma (Kraus et al., 2008).  These agents have been 
found to decrease AKT and inhibit the proteasome, thereby activating the UPR and 
subsequent apoptosis (Gupta et al., 2007).  By inhibiting the proteasome these agents exert 
their anticancer effects by interfering with ERAD in the same way as bortezomib.  The use 
of these drugs to modulate the UPR has the advantage that they are established drugs used 
for many years in treatment of patients and their adverse effects are well known.  Also, these 
drugs are taken orally, which is a major advantage in terms of drug administration.  For these 
reasons, HIV protease inhibitor drugs have progressed quickly into clinical trials in cancer 
patients.  A phase I trial of nelfinavir in conjunction with chemoradiation in locally advanced 
pancreatic cancer has recently been completed, with acceptable toxicity and promising 
activity reported (Brunner et al., 2008).  
 
The sarcoplasmic endoplasmic reticulum is a specialised smooth ER responsible for 
pumping calcium into the ER lumen from the cytosol via a calcium-ATPase, (known as 
SERCA pumps), and inhibition of these pumps leads to leakage of intracellular calcium and 
ER induced cell death.  The pharmacological inducer of ER stress, thapsigargin, acts in this 
manner.  It therefore follows that other agents that disturb ER calcium homeostasis could be 
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used as potential anticancer agents via their induction of ER stress induced cell death.  The 
COX-2 inhibitors, e.g. celecoxib, are anti-inflammatory drugs used in the treatment of 
arthritis and pain.  They selectively inhibit COX-2 and therefore have less gastric adverse 
effects than traditional NSAIDs (Beers and Merck Research Laboratories., 2006).  Celecoxib 
has been shown to inhibit SERCA pumps in a similar way to thapsigargin, however it is 
much less potent.  It is thought that this effect on ER calcium may also be responsible for the 
cardiac adverse effects reported with long-term celecoxib treatment (Johnson et al., 2002).  
Recently it was discovered that celecoxib causes calcium dependent activation of the PERK-
eIF2!-ATF4-CHOP signalling branch of the UPR and an inhibition of general protein 
synthesis (Tsutsumi et al., 2006, Pyrko et al., 2008).  It was later found that this UPR 
activation was also induced by a non-COX-2 inhibiting analogue of celecoxib 
(dimethylcelecoxib), therefore the activity is mediated by a COX-2 independent mechanism 
(Pyrko et al., 2006).  Celecoxib or dimethylcelecoxib treatment has also shown increased 
cytotoxicity to glioblastoma cells when combined with the proteasome inhibitor bortezomib 
(Kardosh et al., 2008).  Celecoxib has been investigated as an adjunct to treatment with the 
HIV protease inhibitor nelfinavir in drug resistant breast cancer cell lines, resulting in 
increased ER stress induced toxicity (Cho et al., 2009). 
 
Mitochondrial inhibitors are another group of potential anticancer agents with a 
mechanism of action linked to ER stress induced cell death.  It has been reported that 
calcium leaked from the ER is delivered back to the mitochondria and it has therefore been 
suggested that in cells with an abundance of calcium the mitochondria will be of greater 
importance in calcium homeostasis.  Experiments in multiple myeloma cell lines showed 
that this increased calcium leakage to the mitochondria was present when compared to B-cell 
leukaemia cell lines.  The authors reported that this corresponded to an increased sensitivity 
to various mitochondrial inhibitors, such as carbonyl cyanide m-chloro phenyl hydrazone 
(CCCP), in the multiple myeloma cell lines (Kurtoglu et al., 2010).  This study suggests 
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another area of interest for cancer research, providing a potential strategy to target highly 
secretory cells with increased demands on ER function. 
 
Another clinically used drug that has recently been linked to ER stress induced cell 
death is the calcium channel blocker verapamil.  Verapamil is widely used clinically for the 
treatment of arrhythmias and hypertension.  Verapamil is also an inhibitor of the multidrug 
resistance gene product P-glycycoprotein (Pgp; a drug efflux pump).  It was found that the 
bortezomib mediated UPR activation in myeloma cells was enhanced by verapamil treatment 
leading to increased cytotoxicity (Meister et al., 2010). 
 
1.6.4 – Drugs acting via other mechanisms 
 
Lastly, there are a number of agents that act via other mechanisms to those discussed 
above.  It has been reported that insulin-like growth factor 1 (IGF-1) protects cells from ER 
stress induced apoptosis by increasing the adaptive capacity of the ER.  It does this by 
inducing expression of GRP78, stimulating translational recovery, and enhancing ER protein 
folding capacity (Novosyadlyy et al., 2008).  Another agent identified as targeting the ER is 
the lactone antibiotic brefeldin A.  Brefeldin A inhibits transport of proteins from the ER to 
the Golgi apparatus, resulting in disruption of normal ER protein trafficking and ER stress.  
In chronic lymphocytic leukaemia (CLL) cells brefeldin A treatment led to Golgi collapse, 
caspase activation, and cell death, even in cells resistant to the chemotherapeutic agent 
fludarabine commonly used to treat this disease (Carew et al., 2006).  Brefeldin A is 
currently being investigated further as a potential anticancer treatment.  Research has also 
been conducted into the use of chemical chaperones to modulate the UPR.  The chemical 
chaperone 4-phenylbutyric acid is a butyric acid derivative that has been reported to enhance 
the adaptive capacity of the ER and reduce the degree of UPR activation (de Almeida et al., 
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2007).  Therefore the use of chemical chaperones could present another potential anticancer 
strategy in tumours where UPR activation has been implicated.   
 
As can be seen from the many agents discussed above, modulating the UPR in 
cancer is a thriving research area and many compounds acting via this pathway are currently 
being investigated as anticancer agents.  Many of the drugs shown to have UPR mediated 
anticancer effects were previously known to have anticancer activity, however their UPR 
mechanism or involvement was only discovered at a later stage.  There is still much work to 
be done in order to establish druggable UPR targets and develop agents that exhibit high 
selectivity towards them.  Whilst the ultimate aim of such investigation is to identify novel 
targets for drug treatment in cancer patients, this area of research is complicated by the fact 
that the UPR is an incredibly complex signalling pathway involved in many cellular 
processes and under many physiological conditions.  As a consequence, modulating UPR 
components in an attempt to treat cancer may have unexpected consequences when carried 
out in vivo.  
 
 
In conclusion, the UPR is a complex signalling pathway activated in response to 
cellular stress that aims to restore normal ER function, or if this is not possible, initiates 
programmed cell death.  The UPR has been implicated in a number of diseases, including 
cancer, and modulating the UPR represents a potential strategy for novel anticancer drug 
development. 
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1.7  Project Aims 
 
This PhD project aims to investigate modulating the UPR as a novel therapeutic 
approach in haematological malignancies.  The role of the UPR in mediating the activity of 
both novel and established cytotoxic agents will be studied.  Various approaches will be 
utilised to investigate the UPR as a novel target in haematological malignancies.  The 
hypothesis being tested in this work is that modulating the UPR will affect chemosensitivity 
in haematological cancer cells, and represents a potential strategy for anticancer treatment.  
 
• The basal status of UPR activation in haematological cancers and relation to 
chemosensitivity will be investigated   
• The role of the UPR in mediating the activity of both novel and established cytotoxic 
agents in haematological malignancies will be studied 
• Underlying levels of ER stress, as well as provoking an ER stress response prior to 
cytotoxic treatment will be studied.   
• The effect of modulating the UPR on chemosensitivity will be investigated by gene 
silencing using RNA interference, as well as specific small molecule approaches. 
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2. Materials and Methods 
 
2.1  Cell Culture 
 
Ten haematological cancer cell lines were used in the initial panel.  Characteristics 
of each cell line can be found in table 2.1 below. 
 
Cell line Cancer type Origin 
 
Growth 
properties 
Morphology 
U937  
 
Histiocytic 
lymphoma  
Pleural effusion of 37 year 
old male with histiocytic 
lymphoma 
Suspension Monocyte 
HL60 
 
Acute 
myeloid 
leukaemia 
Peripheral blood leukocytes  
from 36 year old female with 
acute myeloid leukaemia 
(AML FAB M2) 
Suspension Myeloblastic 
THP1 
 
Acute 
monocytic 
leukaemia 
Peripheral blood of 1 year 
old male infant with acute 
monocytic leukaemia 
Suspension Monocyte 
RPMI-8226 
 
Multiple 
myeloma 
Peripheral blood of 61 year 
old male with multiple 
myeloma 
Semi-
adherent 
Lymphoblast 
U266 
 
Multiple 
myeloma 
Peripheral blood of 53 year 
old male with multiple 
myeloma 
Suspension Lymphoblast 
MM1.S 
 
Multiple 
myeloma 
Peripheral blood of patient 
with multiple myeloma 
Semi-
adherent 
Lymphoblast 
CRL-2261 
 
B cell 
lymphoma 
Ascites of 52 year old male 
patient with NHL 
Suspension Lymphoblast 
SUD4 
 
B cell 
lymphoma 
 Suspension Lymphoblast 
DOHH2 
 
B cell 
lymphoma 
Pleural effusion of a 60 year 
old male with 
centroblastic/centrocytic 
NHL that had transformed 
into an immunoblastic 
lymphoma 
Suspension Lymphoblast 
   Table 2.1. Characteristics of haematological cancer cell lines used in this project. 
 
HL60, THP1, RPMI-8226, U266, CRL-2261, SUD4 and DOHH2 cell lines were 
obtained from Cancer Research UK Cell Services.  MM1.S cell line was obtained from Dana 
Farber Cancer Institute.  The colorectal cancer cell line HT-29 was obtained from Cancer 
Research UK Cell Services.  All cell culture materials were procured from Sigma Aldrich, 
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UK unless otherwise specified.  All suspension cell lines were cultured in RPMI-1640 
medium supplemented with 10% foetal calf serum (FCS) and 1% penicillin-streptomycin.  
The adherent cell line HT-29 was cultured in McCoy’s 5A medium (Invitrogen, UK) 
supplemented with 10% foetal calf serum (FCS), 1% penicillin-streptomycin and 0.22g/L L-
glutamine. Cells were passaged every 3-4 days.  AML and lymphoma cell lines were set at a 
concentration of 2 x 105 cells/ml in culture and MM cell lines were set at a concentration of 5 
x 105 cells/ml.  All cell culture was performed under sterile conditions.  Cells were incubated 
at 37°C and 5% CO2 in a humidified atmosphere.   
 
 Cell number and viability was assessed by trypan blue exclusion.  Cells with a 
ruptured membrane (i.e. non-viable cells) take up the trypan dye and therefore appear blue 
when viewed under a microscope.  Cells were counted using a haemocytometer.  Cell 
suspensions were removed from culture flasks (MM1.S cells were first trypsinised or gently 
scraped), and centrifuged for 5 minutes at 150 x g.  The resulting supernatant was discarded 
and the cell pellet resuspended in fresh medium.  10µl of cell suspension was mixed with 
10µl of trypan blue (Sigma Aldrich, UK) and placed into the chamber of a haemocytometer.  
Cells were then counted using an inverted microscope.  The number and viability of cells 
contained in one of the large grids (16 small squares) on the outside of the haemocytometer 
were counted.  If cell number was below 35, then all four large outer grids were counted and 
the mean cell number and viability recorded.  From these values the percentage of viable 
cells and the number of viable cells per ml were calculated.   
 
2.2  Freezing Cells and Thawing from Liquid Nitrogen  
 
Cells were removed from culture flasks and counted as described in the previous 
section.  After centrifugation (5 minutes at 150 x g) the cell pellet was resuspended in 
freezing medium (70% RPMI-1640, 20% FCS and 10% DMSO) at a concentration of 2 to 4 
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x 106 cells/ml, dependent on the cell line.  One millilitre aliquots were placed into cryovials 
and frozen overnight at -80oC before transfer to liquid nitrogen (-196oC).   
 
To thaw cells, cryovials were placed directly into a water bath at 37oC.  Once 
defrosted, the cell suspension was transferred to a falcon tube containing 10 ml fresh culture 
medium.  After 5 minutes centrifugation at 150 x g, the supernatant was removed and the 
cell pellet resuspended in fresh medium before being placed into flasks for culture. 
 
2.3  Preparation of Drug Stocks 
 
Doxorubicin, cytarabine, etoposide, melphalan, tunicamycin, thapsigargin, 17-
allylaminogeldanamycin, and 4-phenylbutyric acid were obtained from Sigma Aldrich, UK.  
4-hydroperoxycyclophosphamide (the active metabolite of cyclophosphamide) was obtained 
from Squarix Biotechnology, Germany.  Bortezomib (Velcade®) was provided by Millenium 
Pharmaceuticals, Inc., USA.  KW-2478 was provided by Kyowa Hakko Kirin, Japan.  
Versipelostatin was kindly provided by Dr K Shin-ya, National Institute of Advanced 
Industrial Science and Technology, Japan.  SAHA was synthesised by Professor C Marson, 
UCL. 
 
All stock solutions were prepared in DMSO under sterile conditions unless 
otherwise specified.  Concentration of DMSO in culture was kept to a minimum and did not 
exceed 0.05%.  Aliquots of stock solutions were stored at 4°C or -20°C until use (dependent 
on drug stability).  All further dilutions of the stock solutions were prepared fresh in culture 
medium under sterile conditions immediately prior to use.  Doxorubicin, 2-deoxyglucose and  
4-hydroperoxycyclophosphamide stock solutions were prepared in purified water and used 
immediately. 17-allylaminogeldanamycin stocks were prepared in methanol.  
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2.4  Guava ViaCount Assay 
 
The Guava ViaCount assay (Guava Technologies Inc., USA) was used to determine 
total cell number (total cell number per millilitre) and cell viability (percentage viable cells 
and percentage dead cells) of each sample.  This assay uses the Guava PCA – 96 System 
allowing measurement of samples in 96 well microplates.  Cells are stained with the Guava 
ViaCount Flex Reagent and their fluorescence was analysed.  The assay distinguishes 
between viable and non-viable cells based on the differential permeabilities of two DNA-
binding dyes in the reagent. The nuclear dye stains all nucleated cells, while the viability dye 
stains only dead/dying cells. This enables the assay software to distinguish between viable, 
apoptotic, and dead cells. Debris is excluded from the analysis results based on negative 
staining with the nuclear dye.  The EasyFit analysis algorithm (Guava Technologies Inc., 
USA), providing 3-dimensional analysis for more accurate results, was used for all 
experiments. 
 
Cells in exponential growth phase were plated into 96 well plates (5000 cells per 
well) and incubated at 37°C and 5% CO2 in air.  Drug was added after 24 hours incubation, 
then on completion of the experimental incubation, plates were removed from the incubator 
and 100%l of diluted Guava ViaCount Flex Reagent was added to each well.  Plates were 
then analysed using the Guava PCA™ – 96 System.  All samples were run in triplicate and 
each experiment was repeated on three separate occasions to ensure reproducibility.  The 
mean values and standard deviations of each data set were then calculated and used in 
subsequent data analysis.  For concentration-effect modelling in GraphPad Prism, the mean 
values for each concentration in each experiment were used. 
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Figure 2.1.  Example dot plots generated from Guava Viacount assay.  Untreated U266 
cells (left) and U266 cells treated with 8nM bortezomib (right) for 48 hours.  Viable 
cells are shown in red, dead cells are shown in black and cellular debris is shown in 
green. 
 
 
 
 
Figure 2.2.  Example data from Guava Viacount assay.  The EasyFit analysis results can 
be used for subsequent data analysis (recommended by the manufacturer for more 
accurate results), or alternatively a gate can be placed around the population of interest 
manually.  EasyFit analysis was used throughout the experiments in this thesis.  
 
2.5  ATP Cytotoxicity Assay 
 
The effect of drug treatment on cell proliferation and viability was investigated using 
a plate based adenosine triphosphate (ATP) cytotoxicity assay.  Cells in exponential growth 
phase were plated into 96 well plates (5000 cells per well in 100%l medium) and incubated 
for 24 hours.  Varying concentrations of drug were diluted in culture medium and then added 
to each well to obtain the required final concentration.  Single agent treated wells, 
combination treated wells, and untreated control wells were present on each plate in the 
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combination experiments.  Control wells and single agent treatment wells were topped up 
with culture medium so that all wells of the plate contained a fixed volume of 120µl.  Plates 
were then incubated for 48 hours at 37°C and 5% CO2 in air. 
 
48 hours after addition of drug, plates were analysed using the ViaLight HS assay kit 
(Lonza Group Ltd, Switzerland) and read using a BMG Labtech Polarstar Optima microplate 
reader (BMG Labtech, Germany).  The ViaLight HS kit is a high sensitivity cell 
proliferation/cytotoxicity assay.  This assay uses a bioluminescence method to measure ATP 
content utilising the enzyme luciferase.  All mammalian cells require ATP to remain alive 
and functional and any kind of cell injury results in a rapid decrease in levels of ATP.  
Therefore, this assay is used as a measure of cell number and viability.  At the end of the 
incubation period 100%l of Nucleotide Releasing Reagent was added to each well of the 
plate to extract the ATP from the cells.  After 5 minutes 20%l of ATP Monitoring Reagent 
was added to each well to generate luminescence signal (automated injection using the 
microplate reader) and the plate was read. 
 
Experiments were repeated at least three times on separate occasions to ensure 
reproducibility.  Effect of drug treatment was calculated from the assay data (expressed as a 
percentage of the control value).  For each drug, the mean values and standard deviations of 
all experiments were determined for graphical representation.  For concentration-effect 
modelling in GraphPad Prism, the mean values for each concentration in each experiment 
were used. 
 
2.6  Calculation of EC50  values 
 
Drug activity data was fitted using sigmoidal concentration effect curves to derive 
EC50 values (effective concentration 50 – i.e. the concentration required to exert 50% of 
maximum effect) with 95% confidence intervals, using non linear regression in GraphPad 
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Prism software (GraphPad Software, San Diego, USA).  This was done for cell number and 
cell viability data.  Minimum and maximum values for effect of drug on cell number were 
set to zero and 100 percent (with respect to control).  For the effect of drug on cell viability 
the minimum effect was set to zero and the maximum was set to the control cell viability for 
each individual cell line.  However, for drugs where the observed effect plateaud above zero, 
and the correlation coefficient (R2, a measure of the goodness of fit from nonlinear 
regression) was less than 0.9, the minimum value was not set to zero and was fitted 
according to the model. 
 
The GraphPad Prism software fits data according to the following equation, 
Y = Bottom + (Top – Bottom) / (1 + 10 ^ ((logEC50 – X) . H) 
Where,  Y = effect 
X = log drug concentration 
Top = maximum effect 
 Bottom = minimum effect 
 H = hillslope  
 
This equation was rearranged algebraically in order to calculate any drug concentration 
required to give a particular effect (e.g. drug concentration required for an EC25 effect).  This 
method was used to calculate equipotent concentrations of drugs for use in subsequent 
experiments, using the model parameters (top, bottom, H) determined from the initial fits.  
 
2.7  Preparation of whole cell lysates 
 
 Whole cell lysates were prepared for use in western blotting experiments.  Two 
million cells were plated out into each well of six-well culture plates and incubated for 24 
hours at 37°C and 5% CO2 in air.  Where required, drug dilutions were prepared from stock 
solutions in fresh culture medium in order to obtain the required molar concentration per 
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well.  Drug dilutions were made in the smallest possible volume, and never to exceed five 
percent of the total well volume. Cells were then incubated for a further period as specified 
in each experiment, after which time the cells were harvested and the cell suspension 
centrifuged for five minutes at 150 x g.  The supernatant was then discarded and cell pellets 
were washed twice in Hanks Balanced Salt Solution (Sigma Aldrich, UK).  Cells were then 
centrifuged at 240 x g for ten minutes at 4°C and the supernatant was discarded.  Cell Lytic 
lysis buffer (Sigma Aldrich, UK) containing Complete protease inhibitor cocktail (Roche, 
UK) was added to the samples.  PhoStop phosphatase inhibitor cocktail (Roche, UK) was 
added to samples where phosphorylation status of proteins was to be investigated.  Samples 
were left on ice for 20-30 minutes to allow cell lysis to take place.  Cell lysates were then 
centrifuged for 10 minutes at 20800 x g and 4°C, the resulting supernatant harvested and the 
remaining pellet discarded.  The total protein content of each lysate was then measured using 
the BCA protein assay kit (Pierce, UK) according to the manufacturer’s protocol.  Samples 
were used immediately or placed into storage at -80°C until use.  
 
2.8  Western Blotting 
  
Protein samples were electrophoresed in 1 x NuPAGE MOPS SDS Running Buffer 
on SDS-polyacrylamide gels using the Novex mini/midi gel system (Invitrogen, UK) at 
200V for approximately one hour.   An equal amount of protein per sample was loaded into 
each lane of the gel (10%g - 40%g protein as necessary for the experiment).  Novex pre-
stained protein marker (Invitrogen, UK) was run alongside the samples as a reference for 
protein migration through the gel.  Proteins were transferred onto a PVDF membrane using 
the i-blot dry transfer system (Invitrogen, UK).  Membranes were then blocked with 5% non-
fat milk in Tris-buffered saline-Tween 20 (TBS-T) for one hour with gentle shaking (to 
prevent non-specific protein binding) then washed briefly in TBS-T before incubation with 
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the primary antibody.  5% bovine serum albumin (BSA) in TBS-T was used as blocking 
buffer when probing for phosphorylated proteins.   
 
Membranes were incubated with primary antibody either overnight at 4°C or for two 
hours at room temperature as per the manufacturer’s data sheet, then removed and followed 
by three washes of five minutes each in TBS-T.  Secondary antibody (horseradish peroxidase 
conjugated antibody) was then added for one hour, followed by a further three washes in 
TBS-T after antibody removal.  All primary and secondary antibodies were diluted in TBS-T 
immediately prior to incubation.  Preliminary experiments were carried out in order to 
optimise the concentration of both primary and secondary antibody for each experiment.  
Details of primary and secondary antibodies used are given in table 2.2.   
 
Antibody binding was detected using the enhanced chemiluminescence (ECL) 
detection system (Amersham, UK) and Hyperfilm ECL (Amersham, UK).  For experiments 
in chapters three to six inclusive, film developing was carried out using a manual tray 
developing method under darkroom conditions.  Processing chemicals consisted of film 
developer, stop bath and fixer used according to manufacturer’s instructions (Tetenal, 
Germany).  For experiments in chapters seven to nine inclusive, developing was carried out 
using a Fuji ImageQuant LAS 4000 camera (FujiFilm, Japan) used according to 
manufacturer’s instructions.  Membranes were stripped (Restore Plus Stripping Solution, 
Pierce, UK) and blocked before probing with new antibodies.    GAPDH antibody or !-
tubulin antibody were used as a loading control in each experiment.  
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Primary Antibody 
 
Dilution 
used 
Secondary 
Antibody 
Dilution 
used 
GRP78 
(sc-13539, Santa Cruz Biotechnology) 
1:1000 Anti-rat 1:3000 
GRP94  
(sc-32249, Santa Cruz Biotechnology) 
1:1000 Anti-rat 1:3000 
IRE1  
(#3294, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
IRE1 (phospho S724) 
(ab48187, Abcam) 
1:1000 Anti-rabbit 1:3000 
PERK 
(ab31373, Abcam) 
1:1000 Anti-rabbit 1:3000 
 p-PERK (Thr 981) 
(sc-32577, Santa Cruz Biotechnology) 
1:1000 Anti-mouse 1:3000 
ATF6  
(B50090, Stratagene) 
1:1000 Anti-mouse 1:3000 
ATF4 
(ab50983, Abcam) 
1:1000 Anti-mouse 1:3000 
GADD153 
(sc-7351, Santa Cruz Biotechnology) 
1:500 Anti-mouse 1:3000 
eIF2! 
(#9722, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
p-eIF2! (Ser51) 
(#9721, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
XBP1u 
(ab79724, Abcam) 
1:1000 Anti-rabbit 1:3000 
XBP1s 
(619502, Biolegend) 
1:1000 Anti-rabbit 1:3000 
HSP90 
(sc-69703, Santa Cruz Biotechnology)  
1:1000 Anti-mouse 1:3000 
HSP70 
(#4876, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
PDI 
(sc-30931, Santa Cruz Biotechnology) 
1:1000 Anti-goat 1:3000 
BCL2 
(M0887, Dako) 
1:1000 Anti-mouse 1:3000 
MCL1 
(sc-819, Santa Cruz Biotechnology) 
1:1000 Anti-rabbit 1:3000 
PARP 
(#9542, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
LC3B 
(#2775, Cell Signaling Technology)  
1:1000 Anti-rabbit 1:3000 
!-Tubulin 
(#2125, Cell Signaling Technology) 
1:1000 Anti-rabbit 1:3000 
GAPDH 
(ab9484, Abcam) 
1:1000 Anti-mouse 1:3000 
     Table 2.2.  Primary and secondary antibodies used for western blotting.  All secondary 
     antibodies were obtained from Dako Ltd., UK.   
 80 
2.9  Guava Nexin Assay 
 
The Guava Nexin assay (Guava Technologies Inc., USA) is a fluorescence based 
apoptosis assay using the Guava PCA – 96 System allowing measurement of samples in 96 
well microplates.  The assay utilises two dyes in order to detect cells undergoing apoptosis; 
Annexin V and 7-AAD.  Annexin V is a calcium-dependent phospholipid binding protein 
with high affinity for the membrane component phosphatidylserine.  Early in the apoptotic 
pathway, phosphatidylserine molecules are translocated to the outer surface of the cell 
membrane where Annexin V can bind to them.  The cell impermeant dye, 7-AAD, is also 
used as an indicator of cell membrane structural integrity.  7-AAD is excluded from live, 
healthy cells as well as early apoptotic cells.  Assay results were analysed using the Guava 
Nexin Analysis Software (Guava Technologies Inc., USA).  Results are obtained for four 
distinct cell populations present within the original sample: 
• Viable cells, not undergoing detectable apoptosis (Annexin V-PE (-) and 7-AAD (-)) 
• Early apoptotic cells (Annexin V(+) and 7-AAD(-)) 
• Late stage apoptotic and dead cells (Annexin V(+) and 7-AAD(+)) 
• Nuclear debris (Annexin V-PE (-) and 7-AAD (+)) 
 
Cells in exponential growth phase were plated into 96 well plates (10000 cells per 
well) and incubated at 37°C and 5% CO2 in air for 24 hours before addition of drug solution.  
The required amount of each drug was diluted in fresh culture medium and added to each 
well in order to achieve the desired molar concentration per well.  Control wells and single 
agent treatment wells were topped up with culture medium so that all wells of the plate 
contained a fixed volume of 120µl.  A positive control for apoptosis (doxorubicin 1µM) was 
included in all experiments.  Cells were then returned to the incubator for a further 48 hours.  
On completion of the 48 hour incubation with drug, plates were removed from the incubator 
and Guava Nexin Reagent was added to each well.  Plates were incubated in the dark at 
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room temperature for 20 minutes, then analysed using the Guava PCA – 96 System.  All 
samples were run in triplicate and mean values and standard deviations used in subsequent 
data analysis.   
 
2.10  Histone Deacetylase (HDAC) Activity Assay 
 
 Inhibition of histone deacetylases (HDAC) by drug was evaluated using an HDAC 
Fluorimetric Assay/Drug Discovery Kit (BIOMOL, Enzo Life Sciences, UK) as per 
manufacturer’s protocol.  The HeLa nuclear extract included in the kit is rich in HDAC 
activity and is used as the source of HDAC enzyme in the assay.  The potent HDAC 
inhibitor Trichostatin A was included as a positive control inhibitor.  Deacetylation of the 
substrate sensitises it to the developer, generating a fluorophore, which is excited with 
360nm light and the emmited light (460nm) detected using a fluorometric plate reader (BMG 
Labtech Polarstar Optima, BMG Labtech, Germany).  Trichostatin A or test inhibitor was 
diluted in assay buffer and plated into wells of a 96-well plate.  Diluted HeLa extract was 
added to all wells (except for no enzyme controls).  Fluor de Lys Substrate was then added to 
the wells initiating HDAC reactions.  After 30 minutes, Fluor de Lys Developer was added 
to stop the reactions and the plate was incubated in the dark at room temperature for 15 
minutes.  Samples were then read using a microplate reader (excitation wavelength 350 to 
380nm and emission 440 to 460nm). 
 
2.11  siRNA Transfection 
 
HP Validated siRNA and HiPerFect Transfection Reagent were obtained from 
Qiagen, UK.  The following siRNA duplexes were used: All Stars Negative Control siRNA 
Alexa Fluor 488 labelled (catalog no. 1027292), GRP78 siRNA (catalog no. SI02780554), 
GRP94 siRNA (catalog no. SI02663738), GFP siRNA (catalog no. 1022064) and the 
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positive control MAPK1 siRNA (catalog no. 1022564).  Sequences for the siRNA duplexes 
used are listed below.  GRP78 siRNA, sense GGGUGUGUGUUCACCUUCAdTdT, 
antisense UGAAGGUGAACACACACCCdTdA; GRP94 siRNA, sense 
GCCUCAGUUUGAACAUUGAdTdT, antisense UCAAUGUUCAAACUGAGGCdGdA; 
GFP siRNA, sense GCAAGCUGACCCUGAAGUUCAU, antisense 
GAACUUCAGGGUCAGCUUGCCG; MAPK1 siRNA, sense 
UGCUGACUCCAAAGCUCUGdTdT, antisense CAGAGCUUUGGAGUCAGCAdTdT. 
 
Transfection was carried out as per the manufacturer’s protocol for suspension cell 
lines.  The day before transfection cells in exponential growth phase were seeded in flasks at 
a density of 3 x 105 cells/ml in RPMI-1640 containing 10% foetal bovine serum and 1% 
penicillin streptomycin.  Cells were incubated under normal growth conditions for 24 hours 
before plating out at 2 x 105 cells per well of a 24-well plate in 100µl culture medium 
containing serum and antibiotics.  100µl of siRNA at a concentration of 200nM (diluted in 
serum free medium) was added to 3µl of HiPerFect transfection reagent (giving a siRNA to 
transfection reagent ratio of 500:1), mixed by vortexing and incubated at room temperature 
for 5 to 10 minutes to allow formation of transfection complexes.  The transfection 
complexes were then added drop-wise onto the cells and mixed by swirling the plate.  Cells 
were incubated under normal growth conditions for a further 6 hours before the addition of 
400µl culture medium containing serum and antibiotics.  Cells were then returned to the 
incubator until analysis of transfection efficiency at 24 hours post transfection.  Further 
culture medium was added as required.  Positive control siRNA, negative control siRNA, 
mock transfected (transfection reagent without siRNA) and untransfected controls were 
included in all experiments. 
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2.12  Flow Cytometry 
 
The uptake of siRNA into cells was monitored by observation of Alexa Fluor 488 
fluorescence after transfection with Alexa Fluor 488 labelled negative control siRNA 
(Qiagen, UK).  The percentage of cells transfected with siRNA from the total cell population 
(transfection efficiency) was determined at 24 hours post transfection.  Transfection was 
carried out as described in section 2.11, then aliquots of cell samples removed and analysed.  
Cells were washed twice with PBS, then resuspended in 500µl PBS and run immediately 
using a BD FacsCalibur flow cytometer with BD CellQuest software used for acquisition 
(BD Biosciences, UK).  Dot blots were created with x set to forward scatter (corresponding 
to cell size) and y set to side scatter (corresponding to cell granularity), with a gate then 
applied to include the cell population of interest (all viable cells).  Histogram plots were also 
created with the acquisition parameter being FL1 fluorescence.  Samples were run and set to 
acquire a minimum of 5000 events per sample, dependent on the cell line.  Data was 
analysed using WinMDI version 2.8.  Percent positive cells for fluorescence compared with 
mock transfected controls gave percentage uptake of siRNA, ie. transfection efficiency. 
 
2.13  Real Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
All reagents for real time reverse transcription polymerase chain reaction (RT-PCR) 
were obtained from Applied Biosystems, UK.  TaqMan Fast Cells-to-CT Kit was used to 
prepare samples for use in real time RT-PCR according to manufacturer’s protocol.  Pilot 
experiments were carried out using the TaqMan Fast Cells-to-CT Kit in conjunction with the 
TaqMan Cells-to-CT Control Kit in order to optimise the procedure and determine the cell 
number to be used for each cell line.  One x 105 cells were washed twice with cold PBS 
before being incubated with Lysis Solution (containing reagents to inactivate endogenous 
RNases and DNase I to degrade genomic DNA) at room temperature for 5 minutes.  After 
this time Stop Solution was added to inactivate the lysis reagents.  Lysates were then reverse 
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transcribed to cDNA using RT Enzyme Mix and buffer and run in a thermal cycler (37°C for 
60 minutes, then 95°C for 5 minutes to inactivate the RT).  Minus RT controls were included 
to demonstrate that the template for PCR was cDNA, not genomic DNA.  Completed RT 
reactions were either used immediately or stored at -20°C until use. 
 
 The cDNA was amplified by fast-cycling real time PCR using Taqman Fast 
Universal PCR Master Mix and Taqman Gene Expression Assay.  PCR Cocktail was added 
to cDNA samples and run in an Applied Biosystems 7900HD real time PCR instrument 
using fast settings (enzyme activation at 95°C for 20 seconds, PCR at 95°C for 1 second then 
60°C for 20 seconds x 40 cycles).  Gene expression assays were used for the target genes 
GRP78 (Assay ID: Hs00607129_gH) and GRP94 (Assay ID: Hs00427665_g1).  Assays 
were also used for the endogenous control gene actin (Assay ID: Hs03023880_g1) and the 
positive control gene MAPK1 (Assay ID: Hs00177066_m1).  Non-template control samples 
were included for each assay to ensure that any fluorescent signal generated in the assay was 
not due to DNA contamination. 
 
2.14  Colony Formation Assay 
 
 Cells were transfected as described in section 2.11.  Addition of drugs to cells was 
made at 48 hours post transfection and cells were incubated under normal growth conditions 
for a further 48 hours.  Medium containing drug was then removed and cells resuspended in 
fresh medium.  Cells were counted and viability determined and 500 cells per well were 
plated into 12-well plates in MethoCult methylcellulose-based media (StemCell 
Technologies, UK) according to the manufacturer’s instructions.  All plates contained wells 
with water only in order to maintain humidity and prevent the methylcellulose from drying 
out.  The cells were then incubated under normal growth conditions and allowed to form 
colonies for 10 to 14 days.  Each drug treated sample was grown in duplicate and each 
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experiment was performed on two separate occasions.  Colonies were visualised for counting 
using an inverted microscope fitted with a camera.  For each well, photographs were taken 
with the well viewed under 10x magnification from three different (randomly chosen) areas 
of the well. 
 
 
2.15  Statistical Analysis 
 
 Statistical analysis was performed using Microsoft Excel software, Microsoft 
Corporation, USA.  The data obtained from drug treatment experiments was used to 
determine mean and standard deviation values for each drug concentration.  These values 
were then used for graphical representation and subsequent statistical analysis.  Data was 
assumed to be normally distributed and parametric tests were therefore used throughout.  
Pairs were analysed using t-test and a p value of less than 0.05 was considered to be 
statistically significant.  A random sample of results from paired t-test obtained using 
Microsoft Excel were confirmed using the statistical package GraphPad InStat (GraphPad 
Software, San Diego, USA) to ensure accuracy. 
 
2.16  Drug Combination Analysis 
 
 The effect of two drugs used in combination was calculated using the fractional 
product method described by Webb (Webb, 1963) in order to determine if the combination 
effect was additive, supra additive, or antagonistic.  The fractional product method calculates 
the expected effect of a combination of two drugs according to the formula: 
 Fudrug1,drug2 = Fudrug1 x Fudrug2 
 where Fu is the fraction of cells unaffected following drug treatment. 
 
 86 
The ratio of the observed effect to the expected effect provides a measure of the 
interaction of two drugs used in a combination.  If the ratio of the combination effect is 1 
(i.e. the observed effect equals the expected effect), the combination is designated additive.  
If the ratio is less than 1 (i.e. the observed effect is greater than the expected effect), then the 
combination is considered to be supra-additive or synergistic.  If the ratio is more than 1 (i.e. 
the observed effect is less than the expected effect), then the combination is said to be 
antagonistic. 
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3.  Basal Expression of Unfolded Protein Response Proteins in a 
Panel of Haematological Cell Lines 
 
 
3.1  Introduction 
 
  
The UPR in solid tumours has been the focus of considerable research in recent 
years, however less is known about the role of the UPR in haematological malignancies.  
The focus of this thesis is the involvement of the UPR in the chemosensitivity of 
haematological malignancies, however, it is necessary to first understand the basal activity of 
the UPR in these cells.  As discussed in chapter 1, the UPR is a physiological mechanism 
that exists to protect organisms by maintaining protein homeostasis and preventing damage 
caused by unfolded or aggregated proteins.  This is initially a survival response, however if 
the damage to a cell becomes too severe then programmed cell death results in order to 
protect the organism as a whole.  Protein misfolding or aggregation has been shown to be 
involved in a number of diseases, including diabetes, neurodegenerative diseases and cancer 
(Schroder and Kaufman, 2005b).  The importance of the UPR in mediating the response to 
cytotoxic drug treatments (particularly for solid tumours) has been discussed in chapter 1, 
however the basal UPR in haematological malignancies has not been described.  For this 
reason, this chapter is concerned with determining the basal UPR activation status of a panel 
of haematological malignancy cell lines and establishing their sensitivity to treatment with a 
number of conventional and novel anticancer agents. 
 
 The three pathways of the mammalian UPR (PERK, IRE1 and ATF6) have been 
discussed in detail in Chapter 1.  Under normal physiological conditions the ER molecular 
chaperone GRP78 is bound to the three ER transmembrane stress sensors PERK, IRE1, and 
ATF6 thereby keeping them in an inactive form. During ER stress GRP78 dissociates from 
the receptors allowing activation of the three pathways of the UPR (Lee, 2001).  The UPR 
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has a number of protective functions within a cell.  It acts to increase the folding capacity of 
the ER, reduce protein translation, increase the amount of ER within the cell, and promote 
degradation of misfolded proteins via ERAD pathways.  It is thought that these UPR 
functions are particularly relevant in the normal physiology of highly secretory cells, such as 
plasma cells, intestinal epithelial cells and pancreatic " cells where there is an increased ER 
workload (Kim et al., 2008, Bernales et al., 2006).   In situations where ER stress is 
prolonged, or the UPR is unable to restore normal ER function, the UPR initiates apoptosis 
(Bernales et al., 2006). 
 
In order to further understand the significance of the basal physiological UPR in 
haematological cancer cells, the role of the UPR in unstressed cells should first be 
considered.  Unstressed (healthy) cells also experience some degree of ER stress and 
subsequent UPR activation, which is thought to adjust the folding capacity of the ER and 
regulate ER protein load in the manner classically attributed to the UPR and described above 
(Schroder and Kaufman, 2005b).  However, this physiological UPR has more recently been 
suggested to play other roles within healthy cells, such as control of nutrient sensing and 
differentiation mechanisms (Kaufman et al., 2002, Wellen and Thompson, 2010). 
 
In this chapter the basal status of a number of UPR markers were studied in order to 
establish the extent of the basal physiological UPR in a panel of haematological cancer cell 
lines.  As well as investigating basal protein expression of the three UPR receptors, other 
markers of the UPR were studied, such as the key ER molecular chaperones GRP78 and 
GRP94.  Based on the results of these initial western blotting experiments, cell lines 
representative of the basal expression of the UPR markers studied were selected for further 
study.  Prior to moving on to investigate the effect of chemotherapeutic agents commonly 
used in these cancer types on the UPR, it was necessary to establish the activity of these 
drugs in the panel of cell lines being studied.  Therefore, cytotoxicity experiments were 
carried out to discover the effect of drug treatment on cell viability and cell proliferation in 
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these cell lines, and if there was any correlation between chemosensitivity and basal UPR 
status.   
 
A number of both conventional and novel chemotherapy agents were used in these 
experiments.  Conventional cytotoxic agents used were doxorubicin, cyclophosphamide, 
melphalan, cytarabine and etoposide.  Novel agents used were the proteasome inhibitor 
bortezomib and the HSP90 inhibitor KW-2478.  Two agents known to pharmacologically 
induce the UPR, tunicamycin and thapsigargin, were also studied in all cell lines in the 
panel. 
 
Tunicamycin is an inhibitor of N-linked glycosylation that prevents glycosylation of 
newly synthesised proteins leading to accumulation of proteins in the ER and subsequent ER 
stress (Heifetz et al., 1979).  The activity of tunicamycin has been described in detail in 
chapter 1.2.5. 
 
Thapsigargin is an inhibitor of sarcoplasmic endoplasmic reticulum calcium 
ATPases (known as SERCA pumps).  This inhibition leads to release of intracellular 
calcium, resulting in ER stress (Kijima et al., 1991).  Thapsigargin is discussed in more 
detail in chapter 1.2.5. 
 
The first in class proteasome inhibitor bortezomib (Velcade®, Millenium 
Pharmaceuticals) is currently licensed in the UK for treatment of multiple myeloma.  
Bortezomib and proteasome inhibition have been discussed in more detail in chapter 1.2.5.  
 
Doxorubicin is an anthracycline antibiotic used in the treatment of a large number of 
different cancers, including both solid tumours and haematological malignancies.  It appears 
to act by a number of mechanisms, with the main one thought to be binding to and inhibition 
of the enzyme DNA topoisomerase II, thereby preventing replication (Tannock, 2005).  
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Both cyclophosphamide and melphalan are alkylating agents (derived from nitrogen 
mustard).  Cyclophosphamide is used to treat many different types of cancer, including 
haematological malignancies, while melphalan is predominantly used in the treatment of 
multiple myeloma.  They act by directly binding to DNA and forming crosslinks, which 
prevent cellular DNA replication.  The parent drug cyclophosphamide is an inert prodrug 
and is metabolised in the liver to the active form 4-hydroxycyclophosphamide (4-HC).  
Cyclophosphamide and melphalan can be clinically administered both orally and 
intravenously (Tannock, 2005). 
 
Cytarabine (cytosine arabinoside) is an antimetabolite drug used in the treatment of 
haematological malignancies, particularly leukaemias.  Cytarabine binds to the enzyme DNA 
polymerase and results in arrest of cells in the S-phase of the cell cycle (those actively 
undergoing DNA synthesis) (Tannock, 2005). 
 
Etoposide is a semi-synthetic plant alkaloid agent (epipodophyllotoxin) and 
topoisomerase II inhibitor.  It is used in the treatment of a number of cancers, such as breast 
cancer and leukaemia (Tannock, 2005). 
 
KW-2478 is a novel HSP90 inhibitor currently undergoing clinical trials in a number 
of cancers, including haematological malignancies.  HSP90 inhibitors have been discussed in 
chapter 1.2.5.  The ansamycin antibiotics geldanamycin and its derivatives (such as 17-AAG 
and 17-DMAG) represent the main HSP90 compounds investigated thus far, however the 
clinical development of these compounds has been complicated by their poor solubility and 
issues with hepatotoxicity (Neckers, 2002).  Other compounds with differing chemical 
structures are now also being studied.  One such compound is the novel HSP90 inhibitor 
KW-2478 (Kyowa Hakko Kirin, Japan).  KW-2478 is a non-ansamycin, non-purine analogue 
class of HSP90 inhibitor.  The chemical and biological activity of this compound has 
recently been reported, along with its activity in multiple myeloma (Nakashima et al., 2010).  
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The results of a first in man phase I clinical trial of KW-2478, as well as results from in vitro 
studies in B-cell malignancies carried out in the Cancer Pharmacology Lab, were presented 
at the American Society of Haematology conference in December 2008 (Cavenagh et al., 
2008, Juliger et al., 2008).  KW-2478 was therefore included in the drug treatments being 
investigated for activity in this haematological cancer cell line panel. 
 
The experiments described here provide valuable insight into areas of the UPR 
activated at a basal level and possible targets for modulating response to drug treatment in 
these haematological cancer cell lines.  The activity of novel and established anticancer 
agents has been determined, whilst also investigating if any correlation exists between 
chemosensitivity and basal UPR status in these haematological cell lines.  These results 
provide a foundation for future experiments investigating drug induced activation of the 
UPR, and targeting the UPR to modulate chemosensitivity. 
 
3.2  Materials and Methods 
 
Untreated cells in exponential growth phase were used to prepare whole cell lysates, 
as described in section 2.6.  Basal expression of UPR proteins was then studied using 
western blotting (see section 2.7 for details).  Equal amounts of protein (10µg or 20µg, 
dependent on experiment) were loaded per well for each experiment.  ER molecular 
chaperones, as well as markers from all three branches of the unfolded protein response were 
studied.  Three acute myeloid leukaemia (AML) cell lines, three multiple myeloma (MM) 
and three diffuse large B-cell lymphoma (DLBCL) cell lines were included in the initial 
panel studied.  AML cell lines used were U937, HL-60 and THP1.  MM cell lines used were 
RPMI-8226, U266 and MM1.S.  DLBCL cell lines used were CRL-2261, SUD4 and 
DoHH2.  The colorectal cancer cell line HT29 was used as an example of a solid tumour cell 
line (and was used in subsequent studies with versipelostatin).  Peripheral blood 
mononuclear cells from two healthy donors were used as an example of healthy 
 92 
haematological cells (kindly provided by Dr S Kassam, Cancer Pharmacology Lab).  Ethics 
committee approval for the use of blood from healthy volunteers for these studies was 
granted by the East London and City Research Ethics Committee 1 (ELCREC). 
 
Drug dilutions were made as described in section 2.3.  Cells in exponential growth 
phase were plated into 96 well plates (5000 cells per well) and incubated at 37°C and 5% 
CO2 in air for 24 hours before addition of drug solution.  The required amount of each drug 
was diluted in fresh culture medium and 10 %l of this solution was added to each well in 
order to achieve the desired molar concentration per well.  Untreated control cells had 10µl 
fresh medium alone added to the wells.  Cells were then returned to the incubator for a 
further 48 hours after which time 100%l of diluted Guava ViaCount Flex Reagent was added 
to each well and drug activity was measured using the plate based Guava Viacount® assay 
(see sections 2.3 and 2.4).  This assay provided total cell number and cell viability data after 
48 hours incubation with drug. 
 
HL-60 and THP1 cells were treated with doxorubicin, 4-HC (the active metabolite 
of cyclophosphamide), cytarabine and etoposide.  RPMI-8226 and U266 cells were treated 
with doxorubicin, 4-HC and melphalan.  DoHH2 and SUD4 cells were treated with 
doxorubicin and 4-HC.  All cell lines were also treated with the proteasome inhibitor 
bortezomib and the ER stress inducing drugs tunicamycin (TM; an inhibitor of N-linked 
glycosylation) and thapsigargin (TG; an inhibitor of sarcoplasmic-endoplasmic reticulum 
calcium pumps).  The AML cell lines were also treated with the novel HSP90 inhibitor KW-
2478, with data for the remaining cell lines provided from a separate experiment carried out 
in our lab by Dr S Juliger (using the same experimental conditions). 
 
Each drug concentration was tested in triplicate plate wells, and each experiment 
was carried out on three separate occasions.  Mean values and standard deviations were 
calculated for each experiment and used in subsequent data analysis.  Non-linear regression 
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using a sigmoidal concentration-effect curve was carried out and EC50, EC25 and EC5 values 
were calculated from these results using GraphPad Prism software (see section 2.5).  Whilst 
cell number data was also available from these experiments, the effect of drug on cell 
viability was considered the most important in the context of cancer chemotherapy; therefore 
EC25 and EC5 values for cell viability were calculated for use in further experiments. 
 
3.3  Results 
 
  
Western immunoblotting experiments were carried out in order to ascertain the basal 
expression of various UPR proteins in a panel of ten haematological cancer cell lines. The 
results of these western blotting experiments are shown in figure 3.1.  This experiment was 
repeated for low expression proteins, loading 20µg per sample (shown in figure 3.2). 
 
These experiments have revealed a number of differences in UPR protein expression 
both between, and within, the three haematological tumour types.   
 
The MM cell lines all show higher expression of IRE1 receptor than the other 
tumour types.  The AML cell lines do express IRE1, albeit to a lesser extent, however IRE1 
receptor expression was completely absent in the lymphoma cell lines CRL-2261, SUD4 and 
DOHH2.   
 
The MM cell lines also exhibited the highest expression of the molecular chaperone 
GRP94, followed by the AML cell lines, then the lymphoma cell lines SUD4 and DHL4.  
The lymphoma cell lines CRL-2261 and DOHH2 showed considerably lower expression of 
GRP94 compared with all other cell lines studied.   
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The AML cell lines U937 and HL-60 were found to have lower levels of PERK 
receptor than the other cell lines.   
 
The 50kDa isoform of ATF6, only present during ER stress, was visible in all cell 
lines, but more prominent in some of the AML and MM lines.  The 90kDa isoform of ATF6, 
corresponding to the membrane bound form of the protein, was also present in all cell lines, 
though at a lower level.   
 
All cell lines expressed the molecular chaperone GRP78.  ATF4 protein was 
expressed in all cell lines to a similar degree.  Expression of eIF2! was seen in all cell lines, 
with the phosphorylated eIF2! protein seen as a very faint band present in all cell lines. 
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Figure 3.1.  Western blotting experiments to show basal expression  
of UPR markers in a panel of haematological cancer cell lines.  
GAPDH included as a loading control.  10µg of protein loaded. 
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Figure 3.2.  Western blotting experiments to show basal expression  
of UPR markers in a panel of haematological cancer cell lines.  
GAPDH included as a loading control.  20µg of protein loaded. 
 
 
 Further basal UPR experiments were conducted with the 9 cell line haematological 
cancer cell line panel, plus the colorectal cancer cell line HT-29 and two samples of 
peripheral blood mononuclear cells (PBMC) from healthy donors. 
 
 The cancer cell lines typically showed increased expression of the molecular 
chaperone GRP78 compared with the two PBMC samples. 
 
 As reported earlier, the AML and MM cell lines showed increased expression of the 
molecular chaperone GRP94 compared with the lymphoma cell lines.  Interestingly, it was 
found that the level of GRP94 expression in the two PBMC samples was similar to that of 
the higher expressing AML and MM lines.  The solid tumour cell line HT-29 also showed 
clear GRP78 and GRP94 expression. 
U
93
7 
 H
L-
60
 
 TH
P-
1 
 R
PM
I-
82
26
 
 U
26
6 
 M
M
1.
S 
 C
R
L-
22
61
 
 SU
D
-4
 
 D
oH
H
2 
 D
H
L-
4 
 
 
 97 
 Three levels of IRE1 receptor expression were seen in the panel studied.  IRE1 was 
highly expressed in the MM cell lines.  AML cell lines, HT-29 and the PBMC samples 
expressed IRE1 at a low level.  IRE1 receptor expression was not seen in the lymphoma cell 
lines. 
 
 PERK receptor was expressed in all the cancer cell lines, with higher expression 
seen in U266 and DOHH2 cell lines.  PERK receptor expression was not seen in the PBMC 
samples. 
 
 The 90kDa isoform of ATF6 was expressed in all cell lines, with a higher level in 
the PBMC samples and HT-29.  The 50kDa cleaved form of ATF6 was also observed in all 
cancer cell lines, with higher levels in U266, CRL and SUD4 cells.  The 50 kDa cleaved 
form was not observed in the two PBMC samples. 
 
 A faint band for phosphorylated eIF2! was seen in all cell lines, with total eIF2! 
protein expressed in all cancer cell lines.  By comparison, total and phosphorylated eIF2! 
were very low in the two PBMC samples. 
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Figure 3.3. Western blotting experiments to show basal expression of UPR markers in  
a panel of haematological cancer cell lines. GAPDH included as a loading control.   
Two peripheral blood mononuclear cell (PBMC) samples were included as an example  
of healthy haematological cells.  The colorectal cancer cell line HT29 was included as  
an example of a solid tumour cell line.   
 
 
The next experiments in this chapter were conducted in order to establish the activity 
of a number of conventional and novel anticancer agents in the cell line panel.   Tables 3.1 
and 3.2 show the results obtained for a single drug (doxorubicin) in a single cell line (HL-60) 
and illustrated in figure 3.4.  This was done for all drugs in each cell line (data tables are 
shown in appendix 1).  The concentration effect plots obtained for the effect of drug on cell 
number and viability are shown in figures 3.5 to 3.13.  The EC50 values for cell number and 
cell viability are also shown, along with EC5 and EC25 values for cell viability.   
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Cell no. (% of control) Cell line Conc. 
Set 1 Set 2 Set 3 
Average SD 
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 1nM 83.7 88.3 85.8 85.9 2.3 
HL-60 10nM 79.5 81.4 76.5 79.1 2.5 
HL-60 100nM 47.2 34.7 41.2 41.0 6.3 
HL-60 300nM 45.2 37.0 38.8 40.3 4.3 
HL-60 1!M 42.7 34.1 33.7 36.8 5.1 
 
Table 3.1.  Effect of treatment with increasing concentrations of doxorubicin for 48  
hours on cell number in the AML cell line HL60  
 
 
Cell viability (%) Cell line Conc. 
Set 1 Set 2 Set 3 
Average SD 
HL-60 0 94.0 90.2 85.6 89.9 4.2 
HL-60 1nM 80.1 86.3 89.9 85.4 5.0 
HL-60 10nM 86.4 85.0 91.2 87.5 3.3 
HL-60 100nM 77.0 72.1 67.6 72.2 4.7 
HL-60 300nM 11.1 24.6 32.7 22.8 10.9 
HL-60 1!M 0.0 8.6 0.0 2.9 5.0 
 
Table 3.2.  Effect of treatment with increasing concentrations of doxorubicin for 48  
hours on cell viability in the AML cell line HL60  
 
 
 
 
Figure 3.4.  Effect of treatment with increasing concentrations of doxorubicin for 48 hours  
on cell number and viability in the AML cell line HL60.  Error bars show mean ± standard  
deviation (SD)  
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Figure 3.5.  Effect of tunicamycin (TM) treatment on cell number and viability of six 
haematological cancer cell lines.  A – Total cell number against log TM concentration (error 
bars show mean ± SD).  B - Viable cell number against log TM concentration (error bars 
show mean ± SD).  C - EC50 (cell number and viability), EC25 and EC5 (cell viability) values 
calculated from GraphPad Prism fitted parameters. 
Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
TM HL-60 1.2%M 251.8nM 97.9nM 20.0nM 
 THP-1 22.6nM 220.9nM 38.8nM 2.1nM 
 RPMI8226 3.9%M 1.7%M 378.5nM 31.1nM 
 U266 84.1%M 85.8%M 20.8%M 1.9%M 
 DOHH2 198.4nM 116.4nM 88.2nM 55.4nM 
 SUD4 122.6nM 4.9%M 399.9nM 6.0nM 
A 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
TG HL-60 0.8nM 2.1nM 0.1nM 0.001nM 
 THP-1 7.7nM 947.0nM 94.8nM 1.1nM 
 RPMI8226 1.2nM 15.3nM 4.8nM 0.6nM 
 U266 4.2nM 28.7%M 3.0%M 364.0nM 
 DOHH2 1.3nM 3.1nM 1.6nM 0.6nM 
 SUD4 4.9nM 1.6%M 272.5nM 14.3nM 
 
 
Figure 3.6.  Effect of thapsigargin (TG) treatment on cell number and viability of six 
haematological cancer cell lines.  A - Total cell number against log TG concentration (error 
bars show mean ± SD).  B - Viable cell number against log TG concentration (error bars 
show mean ± SD).  C - EC50 (cell number and viability), EC25 and EC5 (cell viability) values 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
Doxorubicin HL-60 16.5nM 176.2nM 114.6nM 48.4nM 
 THP-1 14.0nM 158.0nM 134.0nM 98.3nM 
 RPMI8226 4.6nM 115.3nM 105.0nM 89.6nM 
 U266 9.6nM 1.1%M 736.0nM 399.2nM 
 DOHH2 5.7nM 51.5nM 12.8nM 0.9nM 
 SUD4 2.3nM 422.3nM 277.7nM 138.2nM 
 
 
Figure 3.7.  Effect of doxorubicin treatment on cell number and viability of six 
haematological cancer cell lines.  A - Total cell number against log doxorubicin 
concentration (error bars show mean ± SD).  B - Viable cell number against log doxorubicin 
concentration (error bars show mean ± SD). C - EC50 (cell number and viability), EC25 and 
EC5 (cell viability) values 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
Bortezomib HL-60 1.8nM 5.5nM 3.3nM 1.4nM 
 THP-1 3.1nM 6.2nM 4.1nM 2.0nM 
 RPMI8226 1.2nM 6.1nM 3.0nM 1.0nM 
 U266 1.2nM 6.0nM 1.6nM 0.2nM 
 DOHH2 4.3nM 4.7nM 4.0nM 2.9nM 
 SUD4 3.9nM 6.1nM 4.7nM 3.1nM 
 
Figure 3.8.  Effect of bortezomib treatment on cell number and viability of six 
haematological cancer cell lines.  A - Total cell number against log bortezomib concentration 
(error bars show mean ± SD).  B - Viable cell number against log bortezomib concentration 
(error bars show mean ± SD).  C - EC50 (cell number and viability), EC25 and EC5 (cell 
viability) values 
A 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
4-HC HL-60 3.2%M 5.4%M 1.5%M 393.6nM 
 THP-1 2.7%M 7.2%M 4.9%M 2.5%M 
 RPMI8226 1.4%M 12.4%M 2.4%M 257.9nM 
 U266 1.1%M 18.4%M 5.2%M 635.4nM 
 DOHH2 276.4nM 594.1nM 163.7nM 16.5nM 
 SUD4 1.7%M 11.0%M 3.3%M 1.4%M 
 
 
Figure 3.9.  Effect of 4-hydroperoxycyclophosphamide (4-HC) treatment on cell number 
and viability of six haematological cancer cell lines.  A - Total cell number against log 4-HC 
concentration (error bars show mean ± SD).  B - Viable cell number against log 4-HC 
concentration (error bars show mean ± SD).  C - EC50 (cell number and viability), EC25 and 
EC5 (cell viability) values  
A 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
Cytarabine HL-60 16.3nM 396.9nM 171.9nM 42.1nM 
 THP-1 62nM 5.6%M 2.7%M 801.1nM 
 
 
Figure 3.10.  Effect of cytarabine treatment on cell number and viability of AML cell lines.  
A - Total cell number against log cytarabine concentration (error bars show mean ± SD).  B - 
Viable cell number against log cytarabine concentration (error bars show mean ± SD).  C - 
EC50 (cell number and viability), EC25 and EC5 (cell viability) values 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
Etoposide HL-60 88.2nM 555.8nM 262.4nM 74.3nM 
 THP-1 66.1nM 982.2nM 457.3nM 126.7nM 
 
 
Figure 3.11.  Effect of etoposide treatment on cell number and viability of AML cell lines.  
A - Total cell number against log etoposide concentration (error bars show mean ± SD).  B - 
Viable cell number against log etoposide concentration (error bars show mean ± SD).  C - 
EC50 (cell number and viability), EC25 and EC5 (cell viability) values 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
Melphalan RPMI8226 515.1nM 46.2%M 15.9%M 2.6%M 
 U266 1.5%M 107.4%M 18.0%M 888.5nM 
 
 
Figure 3.12.  Effect of melphalan treatment on cell number and viability of MM cell lines.  
A - Total cell number against log melphalan concentration (error bars show mean ± SD).  B - 
Viable cell number against log melphalan concentration (error bars show mean ± SD).  C - 
EC50 (cell number and viability), EC25 and EC5 (cell viability) values 
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Drug Cell line EC50 cell 
number 
EC50 cell 
viability 
EC25 cell 
viability 
EC5 cell 
viability 
KW-2478 HL-60 588.9nM 2.0%M 1.2%M 504.4nM 
 THP-1 361.1nM 1.2%M 768.6nM 387.1nM 
 RPMI8226* 250.0nM 145.0nM 30.0nM 2.1nM 
 U266* 257.0nM 473.0nM 330.6nM 118.5nM 
 DOHH2* 251.0nM 350.0nM 175.3nM 54.7nM 
 SUD4* 101.0nM 94.1nM 33.0nM 5.7nM 
 
Figure 3.13.  Effect of KW-2478 treatment on cell number and viability of AML cell lines.  
A - Total cell number against log KW-2478 concentration (error bars show mean ± SD).  B - 
Viable cell number against log KW-2478 concentration (error bars show mean ± SD). C - 
EC50 (cell number and viability), EC25 and EC5 (cell viability) values. 
* Values calculated from a separate experiment carried out within our lab by Dr S Juliger 
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The individual cell lines showed differing sensitivities to the drugs studied.  The 
widest range in drug effect was seen when the cells were treated with the two ER stress 
inducing drugs.  Large differences in sensitivity were seen between cell lines, for example, 
the EC50 values for thapsigargin effect on cell viability range from approximately 1nM to 
10µM (see figure 3.6).  This large difference in sensitivity was seen both within the same 
tumour type and between tumour types.  The DOHH2 cell line proved to be most sensitive 
cell line to ER stress induction with both tunicamycin and thapsigargin in the panel tested.  
Whilst the effect of tunicamycin on cell proliferation followed the same pattern in all six cell 
lines, the effect on viability did not follow the same pattern.  In the two AML cell lines 
viability decreased in a concentration dependent manner initially, however the effect then 
plateaued just above 60% cell viability.   
 
The conventional cytotoxic agents doxorubicin, 4-HC, cytarabine, etoposide and 
melphalan all decreased cell proliferation and viability, as would be expected.  There were, 
however, a number of differences in sensitivity to the drugs in the cell line panel studied.  
The U266 cell line was less sensitive to treatment with doxorubicin in terms of effect on cell 
viability.  DOHH2 cells proved considerably more sensitive to the effect of doxorubicin on 
cell viability than the other cell lines, whilst the SUD4 cell line was the most sensitive to the 
anti-proliferative effect of doxorubicin.  The DOHH2 cell line also proved to be the most 
sensitive cell line to treatment with 4-HC.  The THP1 cell line was less sensitive to the effect 
of cytarabine than the HL-60 cell line, however both showed very similar sensitivity to 
etoposide.   
 
The U266 cell line was less sensitive to treatment with bortezomib and doxorubicin 
in terms of the effect on cell viability, although sensitivity to melphalan was comparable to 
that of the other myeloma cell line studied RPMI-8226.   
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The HSP90 inhibitor KW-2478 inhibited cell proliferation as expected in both AML 
cell lines, however it did not show a marked effect on the viability of THP-1 cell line, with 
viability remaining above 75% for the concentration range studied. 
 
3.4  Discussion 
 
The expression of UPR proteins in untreated cells was investigated, using a limited 
antibody panel, in order to provide an indication of the basal level of UPR activation across 
the panel of haematological cancer cell lines.  The aim of these initial experiments was to 
establish the full spectrum of UPR activation in the cell line panel.  This in turn would allow 
the selection of representative cell lines for further detailed study. 
 
The first set of experiments, as seen in figure 3.1, provided a number of interesting 
findings.  Whilst all cell lines in the panel exhibited GRP78 protein expression to a similar 
extent, there were considerable differences in the expression of GRP94 protein.  This pattern 
of GRP94 protein expression mirrored the expression of IRE1 protein seen in the cell line 
panel, suggesting a potential link between the two.  It is thought that IRE1 activity and 
subsequent spliced XBP1 activity is of particular importance in highly secretory cells (Gass 
et al., 2004, Kaser et al., 2008), such as myeloma cells.  The results observed here also 
suggest that GRP94 is of increased importance in myeloma cells (and potentially other types 
of secretory cells).  Multiple myeloma cell lines showed the highest expression of both IRE1 
receptor and GRP94 proteins, followed by AML cell lines, with the lowest expression in the 
lymphoma cell lines.  These results were confirmed by the further experiments shown in 
figure 3.2.  Another interesting result seen was the level of activated (cleaved) ATF6 protein 
in the AML and MM cell lines.  This result is of note as it shows a degree of basal activation 
of the ATF6 branch of the UPR in these cell lines.  The results in figure 3.1 show that PERK 
receptor protein expression is higher in the lymphoma cell lines, compared to the other 
tumour types, suggesting a potential importance of the PERK branch of the UPR in 
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lymphoma.  However, when a larger amount of protein was loaded (see figure 3.2), this 
pattern was less clear. 
 
The next set of experiments went on to look at the haematological malignancy cell 
line panel whilst also including a solid tumour sample and two PBMC samples for 
comparison purposes.  The colorectal cancer cell line HT-29 was chosen as it is a widely 
used and well categorised cell line for in vitro research purposes, and will be used in 
subsequent experiments.  Two PBMC samples were obtained from healthy donors and 
included in the experiments in order to provide a reference for the basal UPR protein 
expression of healthy haematological cells.  This was chosen to be the best approach 
following previous issues with the proliferation of the NC-NC normal B-cell line.  Whilst it 
would also have been valuable to include a number of primary samples from patients with 
these tumour types, these samples are limited and in great demand and were therefore not 
available for these experiments. 
 
As seen in figure 3.3, these experiments both confirmed and expanded upon the 
results of the previous experiments.  They also highlighted a number of key differences in 
the basal expression of UPR proteins in the haematological cancer cell lines compared to the 
solid tumour cell line and the healthy haematological cell (PBMC) samples.  Whilst all cell 
lines exhibited GRP78 protein expression, this expression was lower in the PBMC samples.  
In contrast to this, GRP94 expression was lowest in the lymphoma cell lines, whilst the 
PBMC samples contained increased GRP94 expression at a level similar to that seen in the 
other cancer cell lines.  This interesting finding suggests GRP94 may be more important in 
the function of normal healthy cells than previously thought.  Another interesting result was 
the expression of IRE1 receptor protein.  As reported in the earlier experiments, IRE1 
receptor was highly expressed in the myeloma cell lines, yet expression was undetectable 
under these experimental conditions in any of the lymphoma cell lines.  The solid tumour 
cell line and PBMC samples showed expression of IRE1 protein at a lower level than the 
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myeloma cell lines, comparable to the expression seen in the AML cell lines.  These results 
confirm the importance of the IRE1 receptor in myeloma cells, and suggests IRE1 is of little 
importance in lymphoma cell line basal UPR. 
 
Differences were also seen in the level of ATF6 protein across the samples studied 
as seen in figure 3.3.  The 50kDa active (cleaved) ATF6 protein was present in all the cancer 
cell lines, with lower levels in the solid tumour HT-29 cell line and the semi-adherent 
myeloma cell line MM1S.  However, it was observed that the two PBMC samples did not 
express this activated ATF6 protein, indicative of an active UPR.  As may be expected, the 
highest expression of full length ATF6 protein was also seen in these two samples.  In line 
with current knowledge of the UPR, these results suggest that UPR mediated activation of 
ATF6 is not seen in these healthy haematological cells and that the ATF6 protein in these 
samples is expressed as the 90kDa membrane bound form.   
 
In terms of PERK pathway proteins, there were also differences seen in PERK 
receptor protein as well as phosphorylated eIF2! (p-eIF2!) and total eIF2! (a downstream 
target of PERK receptor).  PERK receptor protein expression was seen to some degree in all 
the cancer cell lines, however protein expression was undetectable under these experimental 
conditions in the two PBMC samples.  PERK protein expression was considerably higher in 
the U266 myeloma cell line and the DOHH2 lymphoma cell line than in the other cancer cell 
lines.  Similarly, phosphorylated eIF2! expression was seen at the protein level in all cancer 
cell lines, however it was also expressed at a low level in the PBMC samples.  Total eIF2! 
protein was highly expressed to a similar degree in all cancer cell lines in contrast to the two 
PBMC samples, which had a low expression of eIF2! compared to the cancer cell lines.  
Again, these results highlight the clear differences seen in UPR protein expression between 
unstressed healthy cells and cancer cells in these experiments. 
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One of the key findings from these experiments of basal UPR protein expression is 
the difference that was observed in the basal expression of the three UPR receptors IRE1, 
PERK and ATF6 across the cell line panel studied.  Whilst it should be noted that the IRE 
and PERK results are somewhat limited by the fact that they refer to total receptor protein 
expression and not specifically phosphorylated protein, a number of notable observations 
have been reported here.  In some cell lines in the panel, expression of these UPR receptors 
was not detectable in these experiments.  This is not to suggest that receptor expression is 
not present in these cells, but reflects that expression is present at a much lower level than 
the comparison cell lines in the panel, and as such longer exposure times (and increased 
protein load) are needed to detect expression using Western blotting.  The lack of expression 
of PERK protein or the activated (cleaved) form of ATF6 protein in the PBMC samples 
indicate the lack of any basal activation of these pathways of the UPR in healthy cells.  
However, activation of both these pathways is seen at the protein level in all the cancer cell 
lines, albeit to differing extents.  Another finding of note is the pattern of expression of IRE1 
protein.  IRE1 protein levels were highly expressed in the myeloma cell lines and expression 
was also seen in the AML cell lines, solid tumour cell line and both PBMC samples.  
However, IRE1 protein levels were undetectable in the lymphoma cell lines in these 
experiments, indicating a possible lack of importance of this pathway in the basal UPR of 
lymphoma cells.  This observation suggests an interesting difference in activation of the 
fundamental UPR branches between tumour types that has not been reported to date.    
 
In conjunction with the determination of basal UPR activation in these cells lines, it 
was also important to establish sensitivity to cytotoxic agents across the haematological cell 
line panel, and any relationship between the two.  There are a number of established 
experimental methods used to investigate the cytotoxicity of a drug in vitro.  These methods 
include plate based cytotoxicity assays (such as the widely used MTT assay), clonogenic 
assay, the study of apoptosis by other methods (such as flow cytometry or TUNEL staining), 
or the traditional method of trypan blue exlusion.  For the experiments in this chapter it was 
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decided to use the plate based Guava Viacount assay as this assay offered a number of 
advantages over other methods available (see chapter 2.4 for assay details).  This assay was 
microplate based which was more convenient when studying several drugs across a panel of 
cell lines.  In addition, this assay has the advantage over other methods such as MTT that it 
provides individual data on both the effect of a drug on cell proliferation and the effect on 
cell viability.  This was considered particularly useful in the study of the novel anticancer 
agents, where anticancer effects may be due to a cytostatic effect and not only the traditional 
cytotoxic action seen with conventional chemotherapy drugs. 
 
A number of both conventional and novel chemotherapy agents were used in these 
experiments.  Some drugs are clinically used in only one particular tumour type, for example 
cytarabine and etoposide in AML or melphalan treatment in myeloma, and as a result their 
use was also limited to that particular tumour type in these experiments.  Other drugs, such 
as doxorubicin and cyclophosphamide have a role clinically in the treatment of patients with 
all three tumour types and were therefore used in all cell lines.  Novel agents used were the 
proteasome inhibitor bortezomib and the HSP90 inhibitor KW-2478.  Whilst bortezomib is 
currently only licensed for the treatment of multiple myeloma in the UK, it has recently been 
linked to the unfolded protein response and was therefore also used in all cell lines being 
studied.  The novel HSP90 inhibitor KW-2478 is currently progressing through clinical trials 
and is now entered into a phase I/II trial as combination therapy with bortezomib (Clinical 
Trials.gov identifier: NCT01063907). 
 
As would be expected, there were a number of differences in drug activity across the 
cell line panel.  These differences were seen both within, and between, tumour types.  Whilst 
this in itself is not surprising, there were a number of notable results seen, particularly in 
response to treatment with the two ER stress inducing agents.  Whilst all the conventional 
cytotoxic drugs exhibited activity in the cell lines studied, the pattern of sensitivity depended 
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on the drug being used and not the cell line itself.  Anti-proliferative effects were seen at 
lower concentrations than cytotoxic effects, as would be expected with these drugs. 
 
In terms of the novel anticancer drugs used, it was observed that the non-myeloma 
cell lines were particularly sensitive to the effects of bortezomib, although this drug is only 
used clinically for the treatment of myeloma.  The KW-2478 compound was an effective 
anti-proliferative agent, whilst it only proved cytotoxic in one of the two leukaemia cell lines 
studied.  Previous work in our lab has established a similar pattern in other cell lines, such as 
myeloma and mantle cell lymphoma (Juliger, S., personal communication). 
 
The largest difference in drug activity and sensitivity was seen with the two ER 
stress inducing agents.  Interestingly, the response to pharmacological ER stress induction 
did not appear to be related to either tumour type or sensitivity to other types of anticancer 
agent.  In addition, the cell lines most sensitive to stress induction with tunicamycin were not 
necessarily the most sensitive to treatment with thapsigargin.  This may represent the 
different mechanisms by which these compounds cause ER stress, or may be due to other as 
yet undetermined factors.  Thapsigargin, in particular, showed a very large range in potency 
across the cell line panel studied.   
 
Drug sensitivity did not appear to be related to basal UPR activation in the 
haematological cell line panel studied.  The pattern of basal activation of UPR proteins in the 
cell line panel did not correspond to chemosensitivity.  For example, the DLBCL cell lines 
DOHH2 and SUD4 exhibited similar basal activation of UPR proteins, however sensitivity 
to drug treatment was varied. 
 
In conclusion, basal expression of UPR proteins across cell lines and tumour types 
has not previously been described and these studies have provided novel insights into basal 
UPR activity in the haematological cancer cell line panel.  The activity of a number of both 
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conventional and novel cytotoxic agents were established in these cell lines; characterising 
the effect on both proliferation and cell viability.  This information will be used in 
investigating the UPR in response to treatment with these agents in the haematological 
cancer cell lines being studied. 
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4.  Treatment with Minimally Toxic and Cytotoxic Drug 
Concentrations and Study of Unfolded Protein Response 
Activation in vitro 
 
 
4.1  Introduction 
 
 There have been a number of reports over the years that have linked the 
UPR, or its individual components, to the response to drug treatment.  However, published 
studies have focused on the change in drug treatment that results after modulating the UPR 
in some way, for example, overexpression of GRP78 and the subsequent change in activity 
of a particular drug compared to cells without such forced overexpression.  The results of 
these types of experiments were discussed in chapter 1.  The activation of UPR markers in 
response to drug treatment in a panel of haematological cell lines has not previously been 
described.  This chapter is concerned with determining the extent of UPR activation 
following treatment with various conventional and novel anticancer agents in the 
haematological cell line panel being studied. 
 
 The mammalian UPR is represented in figure 1.4 (Szegezdi et al., 2006).  This 
figure illustrates the three pathways of the UPR (IRE1, PERK and ATF6), whilst also 
highlighting key downstream components activated during the UPR.  The role of the ER 
resident molecular chaperone GRP78 in binding to and stabilising the three transmembrane 
receptors is shown.  Another key ER molecular chaperone involved in the UPR, GRP94, is 
not specifically mentioned, but is one of the chaperones whose transcription is induced upon 
UPR activation. 
 
 The experiments in this chapter aim to establish the extent of UPR activation (if any) 
in these haematological cancer cells after treatment with a number of established 
chemotherapy drugs and also novel anticancer agents.  The choice of drug treatment used 
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reflects the clinical treatment of these cancer types, and varies accordingly between the 
AML, myeloma and DLBCL cell lines studied.  The two ER stress inducing agents used in 
previous experiments have also been included here to establish their effect on individual 
components of the UPR.  Experiments in this chapter will focus on changes in the UPR 
observed at the translational level, as this was considered to be most relevant to the clinical 
use of these agents. 
 
4.2 Materials and Methods 
 
Based on the drug activity experiments described in chapter 3, equipotent 
concentrations (a minimally toxic concentration (EC5) and cytotoxic concentrations (EC25 
and EC50)) were calculated for each drug used in each cell line (as described in chapter 2.7).  
The concentrations used are listed in chapter 3.3.  Whilst KW-2478 was shown to affect cell 
number, it did not show a marked effect on cell viability in the majority of cell lines studied.  
Where this was the case, the maximal effect of the drug as fitted by the model used appeared 
small, with a correspondingly small EC50 value.  For this reason it was decided to include a 
third concentration in the western blotting experiments; the concentration of KW-2478 that 
resulted in an actual 25% decrease in cell viability from the control viability. 
 
Cells in exponential growth phase were plated into 6-well plates and incubated under 
normal growth conditions for 24 hours.  After this time, drug solutions were prepared for use 
in fresh culture medium from drug stocks (see section 2.3) and were added to the plates.  
Cells were incubated with drug for either 6 hours or 24 hours (untreated controls were also 
included in each experiment) and whole cell lysates prepared, as described in section 2.6.  
Levels of various UPR markers at the protein level were then studied by western blotting (as 
described in section 2.7) in order to establish the effect of drug treatments on the UPR.  20µg 
of protein lysate was loaded into each gel well unless otherwise specified.  Considerable 
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preliminary work was carried out in order to optimise the experimental conditions used, such 
as amount of lysate, antibody concentrations and antibody incubation times for each cell line 
being studied.  Visualisation of western blots was achieved using chemiluminescence and 
manual film developing.  The manual developing process was first optimised in order to 
establish optimum conditions.  This consisted of developing the film for 2 minutes, 
immersion into stop solution to inactivate the developer for 30 seconds, immersion in fixer 
solution for 5 minutes, then a final rinse before allowing the film to air dry.  The amount of 
time the film was placed onto the chemiluminescent membrane was optimised for each 
individual antibody used in each individual cell line.  Experiments were carried out at least 
once, with experiments repeated to confirm key results. 
 
4.3  Results 
 
Figures 4.1 to 4.4 show protein levels of the UPR markers studied in the AML cell 
lines after treatment with EC5 and EC25 concentrations of drugs for 6 and 24 hours.  Where 
clear changes in the activation of UPR proteins were seen, relative to the untreated control, 
such changes are described below.  A number of UPR proteins were studied in addition to 
those shown here, but were not detectable under the experimental conditions used.   
 
Figure 4.1 shows that in the HL-60 cell line, 6 hour exposure to the study drugs 
resulted in clear changes only in the level of GRP78 protein (relative to control), with an 
increase seen with all drug treatments except tunicamycin (even allowing for small 
differences in the intensity of the GAPDH band).  GRP78 remained elevated in this cell line 
after 24 hours of treatment with bortezomib (EC25) and KW-2478 at all concentrations (see 
figure 4.2).  GRP94 protein levels were also increased following 24 hours of drug treatment 
with tunicamycin (EC5 and EC25) and thapsigargin (EC25). 
 
 120 
 
In the THP1 cell line, GRP78 protein was increased in response to 6 hours of drug 
treatment with EC25 concentrations of tunicamycin and thapsigargin, as well as with KW-
2478 at all concentrations, as shown in figure 4.3.  With tunicamycin and thapsigargin (EC25) 
this was associated with a small increase in GRP94 protein.  In addition, an increased level 
of phosphorylated eIF2! protein can be seen following 6 hours treatment with KW-2478 at 
the concentration resulting in 25% cell death.  After 24 hours of drug treatment, GRP78 
protein levels were increased in the bortezomib (EC25 only), cytarabine and KW-2478 
treated samples, whilst GRP94 protein levels were increased in the thapsigargin (EC25 only), 
cytarabine, etoposide and KW-2478 treated samples (see figure 4.4). 
 
 
 
  HL-60 6 HOURS 
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Figure 4.1.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the AML cell line HL-60 after 6 hours of drug treatment.  GAPDH is 
included as a loading control.   
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  HL-60 24 HOURS 
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Figure 4.2.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the AML cell line HL-60 after 24 hours of drug treatment.  GAPDH is 
included as a loading control.  
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  THP-1 6 HOURS 
 
 
 
 
 
 
 
 
 
 
 
 
       #          #          #    #     #  
  GRP78   
 
  GRP94   
              #  
  p-eIF2!   
 
  eIF2!    
 
  GAPDH   
 
 
 
Figure 4.3.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the AML cell line THP1 after 6 hours of drug treatment.  GAPDH is 
included as a loading control.  
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  THP-1 24 HOURS 
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Figure 4.4.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the AML cell line THP1 after 24 hours of drug treatment.  GAPDH is 
included as a loading control.   
 
 
Figures 4.5 to 4.8 show expression of the UPR markers studied in the multiple 
myeloma cell lines after treatment with EC5 and EC25 concentrations of drugs for 6 and 24 
hours.  After both 6 hours and 24 hours of drug treatment in the RPMI-8226 cell line, 
GRP78 protein was increased only in the highest KW-2478 concentration treated sample, 
with a marked increase after 24 hours (see figures 4.5 and 4.6 respectively).  At 24 hours in 
this cell line, GRP94 protein levels were increased in the sample treated with the EC25 
concentration of thapsigargin (see figure 4.6).  Phosphorylated eIF2! expression was 
increased in the samples treated with EC25 concentrations of tunicamycin, thapsigargin, 
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bortezomib and KW-2478 for 6 hours (see figure 4.5).  It was also increased in the samples 
treated with EC5 concentrations of tunicamycin and thapsigargin for 24 hours, however a 
decrease in phosphorylation was seen following treatment with the highest KW-2478 
concentration (see figure 4.6).  Total IRE1 receptor protein levels were seen in all samples 
(including controls) to the same extent at 6 hours in RPMI-8226 cells (see figure 4.5).  Total 
IRE1 protein was also visible in all samples at 24 hours, with increased levels seen in the 
EC25 tunicamycin and thapsigargin treated samples (see figure 4.6).  Phosphorylated IRE1 
protein was only visible in the EC25 tunicamycin and thapsigargin treated samples at both the 
6 and 24 hour time points (figure 4.5 and 4.6 respectively). 
 
In the U266 cell line, GRP78 protein was increased in the sample treated with the 
highest KW-2478 concentration, as shown in figure 4.7.  In the 24 hour treated samples 
GRP78 protein levels were increased in the bortezomib (EC25) and KW-2478 (at the two 
higher concentrations) treated samples (see figure 4.8).  No changes were seen in the level of 
GRP94 protein after drug treatment in U266 cells at either time point.  Phosphorylated eIF2! 
expression was increased in the thapsigargin (EC5 and EC25) treated samples after 6 hours 
treatment.  At 24 hours phosphorylated eIF2! was increased in the samples treated with 
tunicamycin, thapsigargin and doxorubicin, whilst in the samples treated with the highest 
concentrations of bortezomib and KW-2478 there was a marked decrease in phosphorylated 
eIF2!, due mainly to a decrease in total eIF2! protein.  GAPDH protein, used as a loading 
control, was present in both these samples.  Total IRE1 protein was visible in all samples 
(including controls) after both 6 and 24 hours of drug treatment in U266 cells, but showed a 
clear increase with thapsigargin and KW-2478 (EC5) treatment at 24 hours (see figure 4.7 
and 4.8 respectively).  Notably, total IRE1 protein decreased markedly after 24 hours 
treatment with the highest bortezomib and KW-2478 concentrations used (GAPDH was still 
present).  The level of phosphorylated IRE1 protein in the EC25 treated bortezomib sample 
was very low in comparison to all other samples (see figure 4.8).  As shown in both figures 
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4.7 and 4.8, no increase in the spliced isoform of XBP1 was seen at the protein level in 
response to any of the drug treatments used in the U266 cell line. 
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Figure 4.5.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the myeloma cell line RPMI-8226 after 6 hours of drug treatment.   
GAPDH is included as a loading control. 
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  RPMI-8226 24 HOURS 
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Figure 4.6.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the myeloma cell line RPMI-8226 after 24 hours of drug treatment.  
GAPDH is included as a loading control.  
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Figure 4.7.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the myeloma cell line U266 after 6 hours of drug treatment.  GAPDH is 
included as a loading control.  
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Figure 4.8.  Western blotting experiments to investigate activation of unfolded protein  
response markers in the myeloma cell line U266 after 24 hours of drug treatment.  GAPDH  
is included as a loading control. 
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 Figures 4.9 to 4.12 show protein levels of the UPR markers studied in the lymphoma 
cell lines after treatment with EC5 and EC25 concentrations of drugs for 6 and 24 hours.  In 
the DOHH2 cell line, no changes were seen in the level of GRP78 or GRP94 following drug 
treatments for 6 hours (see figure 4.9).  After 24 hours treatment with the two higher 
concentrations of KW-2478, GRP78 protein levels were shown to increase, however no 
changes were seen in GRP94 protein levels compared to the untreated control (see figure 
4.10).  In the DOHH2 cell line, no changes were found in phosphorylated eIF2! protein 
levels following drug treatments for 6 hours (see figure 4.9).  After 6 hours of treatment, 
total eIF2! protein levels were increased with EC25 thapsigargin treatment, but decreased 
with all concentrations of KW-2478 studied, and remained decreased (relative to control) 
after 24 hours treatment with KW-2478 at the highest concentration studied (see figure 4.9 
and 4.10 respectively).  Phosphorylated eIF2! protein levels were also decreased following 
24 hours treatment with KW-2478 at the highest concentration.  Phosphorylated PERK 
receptor protein was increased in the sample treated with EC25 thapsigargin, but decreased in 
the samples treated with KW-2478, for 6 hours (see figure 4.9).  At the 24 hour time point, 
both phosphorylated and total PERK receptor protein levels were decreased samples treated 
with KW-2478 at the highest concentration studied (see figure 4.10). 
 
 In the SUD4 cell line, GRP78 protein was shown to increase following both 6 hours 
and 24 hours of treatment with the highest concentration of KW-2478 used (figures 4.11 and 
4.12 respectively).  It was also shown that the level of GRP94 protein in this cell line was 
increased in all drug treated samples at 6 hours (see figure 4.11).  Phosphorylated eIF2! 
protein was increased following 6 hours of treatment with tunicamycin, thapsigargin, 4-HC 
and KW-2478 EC5 and EC25, however a decrease was seen in the highest KW-2478 
concentration treated sample (see figure 4.11).  At the 24 hour time point, phosphorylated 
eIF2! protein was decreased in all KW-2478 treated samples (see figure 4.12).  
Phosphorylated PERK receptor protein was increased following 6 hours of treatment with 
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KW-2478 at the highest concentration studied (see figure 4.11).  Blots for phosphorylated 
PERK protein at the 24 hour time point were quite faint when developed and any changes 
occurring following drug treatment were therefore hard to discern (see figure 4.12). 
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Figure 4.9.  Western blotting experiments to investigate activation of unfolded  
protein response markers in the lymphoma cell line DOHH2  after 6 hours of drug  
treatment.  GAPDH is included as a loading control. 
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Figure 4.10.  Western blotting experiments to investigate activation of unfolded  
protein response markers in the lymphoma cell line DOHH2 after 24 hours of drug  
treatment.  GAPDH is included as a loading control.  
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  SUD4  6 HOURS 
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Figure 4.11.  Western blotting experiments to investigate activation of unfolded  
protein response markers in the lymphoma cell line SUD4 after 6 hours of drug  
treatment.  GAPDH is included as a loading control. 
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Figure 4.12.  Western blotting experiments to investigate activation of unfolded  
protein response markers in the lymphoma cell line SUD4 after 24 hours of drug  
treatment.  GAPDH is included as a loading control. 
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are as listed in chapter 3.3.  Figures 4.13 to 4.18 shows the effect of treatment with EC50 
drug concentrations on protein levels of various UPR markers in the haematological cell line 
panel studied.  Clear changes observed in activation status of the UPR markers studied 
compared to untreated control cells are described below.  Figure 4.13 shows the effect of 
treatment with EC50 drug concentrations for 6 and 24 hours on protein levels of UPR 
markers in the AML cell line HL60.  GRP78 levels were only seen to increase in the KW-
2478 treated sample at 24 hours.  GRP94 protein levels showed a slight increase after 24 
hours treatment with thapsigargin and a marked increase after 24 hours treatment with 
tunicamycin.  A decrease in phosphorylated eIF2! protein was seen after 6 hours treatment 
with thapsigargin.  It should be noted that a difference was also seen in eIF2! protein levels 
in the untreated control samples.  At 6 hours there was low expression of eIF2! protein, 
however an increased protein level was seen in the 24 hour control sample.   
 
In the THP1 cell line (see figure 4.14), a slight increase in GRP78 protein was seen 
after 24 hours treatment with both tunicamycin and thapsigargin, with a marked increase 
seen after 24 hours treatment with KW-2478.  A slight increase in GRP94 protein was also 
seen following 24 hours of treatment with both tunicamycin and thapsigargin.  Changes were 
seen in the levels of phosphorylated eIF2! protein between the two control samples, with a 
lower level seen at 6 hours compared with 24 hours.  However, no corresponding changes 
were seen in the levels of total eIF2! protein.  An increase in phosphorylated eIF2! protein 
was seen after treatment with tunicamycin and thapsigargin for 6 hours. 
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Figure 4.13.  Western blotting experiments to investigate activation of unfolded protein 
response markers after treatment with EC50 concentrations of drug for 6 and 24 hours in  
the AML cell line HL-60.  GAPDH is included as a loading control. 
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Figure 4.14.  Western blotting experiments to investigate activation of unfolded protein 
response markers after treatment with EC50 concentrations of drug for 6 and 24 hours in  
the AML cell line THP1.  GAPDH is included as a loading control.
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 In the RPMI-8226 cell line, the only changes in UPR activation seen after treatment 
with EC50 drug concentrations were in the levels of the ER molecular chaperone proteins 
(see figure 4.15).  A clear increase in GRP78 protein levels were seen following treatment 
with tunicamycin and thapsigargin for 24 hours, and a marked increase seen following KW-
2478 treatment at both 6 and 24 hours.  An increase in the level of GRP94 protein was seen 
in the samples treated with tunicamycin and thapsigargin for 24 hours. 
 
 Figure 4.16 shows the effect of EC50 drug treatment on UPR protein levels in the 
U266 cell line.  Again, the only changes seen following drug treatment were in the levels of 
the molecular chaperone proteins GRP78 and GRP94.  GRP78 protein increased after 
treatment with thapsigargin, melphalan and bortezomib for 24 hours, with a marked increase 
seen after treatment with KW-2478 for 24 hours.  GRP94 protein was observed to increase 
following treatment with thapsigargin, bortezomib and melphalan for 24 hours. 
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Figure 4.15.  Western blotting experiments to investigate activation of unfolded  
protein response markers after treatment with EC50 concentrations of drug for 6 and  
24 hours in the myeloma cell line RPMI-8226.  GAPDH is included as a loading  
control.
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Figure 4.16.  Western blotting experiments to investigate activation of  
unfolded protein response markers after treatment with EC50 concentrations  
of drug for 6 and 24 hours in the myeloma cell line U266.  GAPDH is  
included as a loading control. The TM treated samples could not be included  
as the protein content of the samples was insufficient for western blotting. 
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 Figures 4.17 and 4.18 show the effect of treatment with EC50 drug concentrations on 
protein levels of various UPR markers in the diffuse large B-cell lymphoma cell lines 
DOHH2 and SUD4 respectively.  In the DOHH2 cell line, a clear increase in GRP78 protein 
was seen following KW-2478 treatment for 24 hours, relative to control (see figure 4.17).  
Treatment with KW-2478 for 24 hours led to a decrease in phosphorylated eIF2! protein 
levels.  Western blots for PARP protein were also carried out in order to study the effect of 
drug treatment on apoptosis.  In the DOHH2 cells, PARP cleavage was seen following 
treatment with tunicamycin (6 hours), doxorubicin (24 hours) and KW-2478 (24 hours).  
 
 Figure 4.18 shows that in the SUD4 cell line, GRP78 protein was increased 
following treatment with tunicamycin and KW-2478 at both time points.  GRP94 protein 
levels were increased after treatment with tunicamycin and thapsigargin for 24 hours.  
Differences were also seen in activation of the PERK pathway of the unfolded protein 
response in this cell line.  An increase in phosphorylated PERK was seen following 6 hours 
of treatment with tunicamycin.  Phosphorylated eIF2! protein levels were shown to increase 
after 6 hours treatment with tunicamycin, whilst a decrease was seen with KW-2478 at both 
time points.  An increase was also seen in the levels of eIF2! protein and the pro-apoptotic 
ATF4 protein after 6 hours treatment with tunicamycin.  PARP cleavage was present after 
treatment with tunicamycin for both 6 and 24 hours (notably, there was no PARP cleavage 
visible after treatment with KW-2478 in this cell line). 
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Figure 4.17.  Western blotting experiments to investigate activation of  
unfolded protein response markers after treatment with EC50  
concentrations of drug for 6 and 24 hours in the lymphoma cell line  
DOHH2.  GAPDH is included as a loading control.  The TM 24 hour  
treated sample could not be included as the protein content of the sample  
was insufficient for western blotting. 
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Figure 4.18.  Western blotting experiments to investigate activation of  
unfolded protein response markers after treatment with EC50 concentrations  
of drug for 6 and 24 hours in the lymphoma cell line SUD4.  GAPDH is  
included as a loading control. 
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proteins studied in each cell line.  Figures 4.19 and 4.20 summarise the data for the two ER 
stress inducing agents tunicamycin and thapsigargin.  Figure 4.19 illustrates that tunicamycin 
treatment caused some increases in the protein levels of both molecular chaperones GRP78 
and GRP94.  Some increases in expression of PERK pathway proteins were also seen.  At 
the EC25 concentration an increase in phosphorylated and total IRE1 protein was seen in the 
RPMI-8226 cell line compared to untreated control, but not in the U266 cell line. 
 
 Figure 4.20 shows that thapsigargin treatment caused some increases in the protein 
levels of the molecular chaperones GRP78 and GRP94.  At minimally toxic concentrations 
the only increases in molecular chaperone protein levels were in the HL60 cell line (GRP78) 
and SUD4 cell line (GRP94).  Phosphorylated eIF2! protein levels were increased in the 
myeloma cell lines.  In the multiple myeloma cell lines there was no change in 
phosphorylated IRE1 protein at the minimally toxic thapsigargin concentration, however an 
increase was seen with the cytotoxic concentration in the RPMI-8226 cell line.  An increase 
in total IRE1 receptor protein levels was seen in the U266 cell line at both minimally toxic 
and cytotoxic thapsigargin concentrations following 24 hours of treatment. 
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Figure 4.19.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of tunicamycin (TM) for 6 and 24 
hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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Figure 4.20.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of thapsigargin (TG) for 6 and 24 
hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 Figures 4.21 to 4.24 summarise the western blot data for the effect of doxorubicin, 
bortezomib, 4-HC and KW-2478 respectively on the activation of UPR marker proteins.  
These drugs were tested in all cell lines in the panel.   
 
 Few changes were observed in the UPR proteins studied following treatment with 
doxorubicin (see figure 4.25).  Increases were seen in the molecular chaperone GRP78 in the 
AML cell line HL60, and GRP94 protein in the lymphoma cell line SUD4 after 6 hours.  An 
increase in phosphorylated eIF2! was seen after treatment with the EC5 and EC25 
concentrations of doxorubicin for 24 hours in the U266 cell line.  In the myeloma cell lines, 
no changes were seen in phosphorylated or total IRE1 receptor activation after doxorubicin 
treatment with minimally toxic or cytotoxic concentrations for 6 or 24 hours. 
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Figure 4.21.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of doxorubicin (dox) for 6 and 24 
hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 The effects of bortezomib treatment on UPR activation are summarised in figure 
4.22.  Some changes in levels of both GRP78 and GRP94 proteins were observed after 
bortezomib treatment.  Increases were observed in the level of GRP78 protein in the AML 
cell lines, HL60 and THP1, and the myeloma cell line U266.  In the SUD4 cell line, GRP94 
protein levels increased after treatment with the minimally toxic and cytotoxic EC25 
concentrations for 6 hours.  The U266 myeloma cell line showed a decrease in the level of 
phosphorylated and total IRE1 protein after treatment with the cytotoxic EC25 bortezomib 
concentration for 24 hours, with no changes seen in the RPMI-8226 cell line. 
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Figure 4.22.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of bortezomib (bort) for 6 and 24 
hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 Similarly to doxorubicin, drug treatment with 4-HC did not result in UPR activation 
to the same extent as some of the other drugs tested.  An increase in GRP78 protein was seen 
in the HL60 cell line after 6 hours of treatment with both the minimally toxic and EC25 
cytotoxic concentrations.  Changes in the level of GRP94 protein was only seen in the SUD4 
cell line, with an increase in GRP94 protein was observed after treatment with the EC5 and 
EC25 concentrations of 4-HC for 6 hours.  
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Figure 4.23.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of 4-HC for 6 and 24 hours,  
where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 A number of changes in UPR proteins were seen following treatment with the novel 
HSP90 inhibitor KW-2478 in the cell line panel studied, with the molecular chaperone 
protein GRP78 being particularly affected (see figure 4.24).  Increases were seen in GRP78 
protein following KW-2478 treatment in all cell lines.  Marked increases in GRP78 protein 
levels were also seen at a number of KW-2478 concentrations and time points.  The AML 
cell lines were most affected by HSP90 inhibitor treatment in terms of GRP78 changes, 
however, no changes were seen in GRP94 protein levels in these cell lines.  In the HL60 and 
THP1 cell lines, GRP78 protein increased following all treatments except the EC50 
concentration for 6 hours, with a marked increase observed after 24 hours treatment.  
Increased GRP78 protein was also seen in the RPMI-8226 myeloma cell line at the higher 
two concentrations, with a marked increase with 24 hours treatment with the 25% cell death 
concentration and the EC50 concentration at both 6 and 24 hours.  In the U266 myeloma cell 
line, increased GRP78 protein was observed following treatment with the EC25 concentration 
for 24 hours, the 25% cell death concentration at both time points (marked increase after 24 
hours) and a marked increase with 24 hours EC50 concentration treatment.  DOHH2 cells 
treated KW-2478 for 24 hours resulted in increased GRP78 protein (with the exception of 
the EC25 concentration).  The SUD4 cell line showed an increase in GRP78 protein at the 
two higher concentrations at both 6 and 24 hours, with a marked increase following the EC50 
concentration for 24 hours.  The only changes observed in GRP94 protein levels were in the 
SUD4 cell line, with an increase in the level of GRP94 protein after treatment with the three 
lower concentrations of KW-2478 at 6 hours, although no change was observed with the 
highest drug concentration studied. 
 
 Whilst there were some increases observed in phosphorylated eIF2!, there was a 
general trend towards decreased levels of this protein following KW-2478 treatment in the 
affected cell lines.  There was also a difference in the effect of KW-2478 treatment on 
phosphorylated PERK protein levels between the lymphoma cell lines.  In the DOHH2 cell 
line, there was no change at the minimally toxic concentration, a decrease in protein at the 
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EC25 concentration, a marked decrease in protein at the 25% cell death concentration.  After 
treatment with the 25% cell death concentration of KW-2478 in the SUD4 cell line, there 
was an increase in phosphorylated PERK protein at 6 hours.  There were no changes 
observed in the level of phosphorylated IRE1 protein in the myeloma cell lines.  There was 
an increase in total IRE1 protein after treatment with the minimally toxic EC5 concentration 
for 24 hours in the U266 cell line, with a decrease in IRE1 protein seen following treatment 
with the concentration resulting in 25% cell death at 6 and 24 hours. 
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Figure 4.24.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25, EC25% cell death and EC50) concentrations of KW-2478 (KW)  
for 6 and 24 hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 Figure 4.25 summarises the western blot data for the effect of cytarabine and 
etoposide respectively on the activation of UPR marker proteins.  These drugs were tested in 
the AML cell lines HL60 and THP1.  As with doxorubicin and 4-HC, few changes in UPR 
proteins were observed following cytarabine and etoposide treatment.  Some increases were 
seen in the levels of the chaperone proteins GRP78 and GRP94 with both drugs at the 
minimally toxic and EC25 cytotoxic concentrations, although no such increases were seen 
with EC50 concentrations of either drug.  No changes were seen in phosphorylated or total 
eIF2! protein levels in either cell line. 
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Figure 4.25.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of cytarabine (cyt - top) and  
etoposide (etop - bottom) for 6 and 24 hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
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 Figure 4.26 summarises the western blot data for the effect of melphalan on the 
activation of UPR marker proteins.  These drugs were tested in the myeloma cell lines 
RPMI-8226 and U266.  As can be seen from the figure, fewer changes were seen on UPR 
protein levels after melphalan treatment compared to the other agents investigated.  At the 
highest concentration following 24 hours treatment, there was an increase in the levels of 
GRP78 and GRP94 proteins in the U266 cell line.   
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Figure 4.26.  Summary of protein levels of key UPR markers after treatment with minimally 
toxic (EC5) and cytotoxic (EC25 and EC50) concentrations of melphalan (mel) for 6 and 24 
hours, where: 
 
Increase in protein compared to untreated control 
No change in protein compared to untreated control 
Decrease in protein compared to untreated control 
 
 
 
4.4  Discussion 
 
 The experiments described here established the extent of UPR activation in this 
haematological cell line panel as a result of treatment with a number of drugs. These 
experiments focus only on UPR activation occurring at the translational level, as opposed to 
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the transcriptional level (i.e. mRNA).  This was in order to confirm that any changes in UPR 
markers observed were not just occurring at the transcriptional level, but were actually 
resulting in changes to protein translation.  These translational changes were considered to 
be more relevant clinically, particularly in terms of chemosensitivity.  
 
 Due to the large scope of the work undertaken in this chapter, it was not possible to 
repeat every experiment multiple times, however, experiments with notable results were 
repeated, such as IRE1 activation in the myeloma cell lines.  As a consequence, these 
experiments do not provide absolute or quantitative results, they do however provide a 
global snapshot of UPR activation in response to drug treatment at the time points studied.  
This overall view of the UPR as a whole was considered to be the most valuable to obtain, 
rather than looking in detail at only specific UPR components in isolation, hence the 
decision to approach the experiments in the manner described. Further experiments using 
densitometry software to analyse the results from three independent drug treatment and 
western blotting experiments would provide quantitative results and enable formal statistical 
analysis.  This would provide a more robust analysis of UPR protein activation and allow for 
subsequent comparison and interpretation of the results obtained. 
 
 As in the previous chapter, it was decided to use a panel of anticancer drugs to study 
their effects on key UPR proteins, which included conventional cytotoxic drugs used in these 
tumour types, in addition to novel anticancer agents and ER stress inducing agents.  Whilst 
there was some evidence of UPR activation after treatment with the conventional cytotoxic 
agents at the concentrations and time points studied, a far greater degree of UPR activation at 
the protein level was seen with the ER stress inducing drugs and novel anticancer agents.  
This finding suggests that the unfolded protein response is less significant with regard to 
treatment with conventional cytotoxic chemotherapy.  This is also interesting as it suggests 
that in response to agents with a mechanism of action that differs from the conventional 
DNA damaging cytotoxicity, the unfolded protein response may play a greater role.  For 
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example, the HSP90 inhibitor KW-2478 had little effect on cell viability in the majority of 
cell lines studied, with this compound appearing to exert its anticancer effect via its 
significant antiproliferative activity (see chapter 3).  As a result of the experiments described 
in this chapter, it can be seen that UPR changes at the translational level in response to 
treatment with KW-2478 was more pronounced than with any of the other agents tested.   In 
the case of the molecular chaperone GRP78, the increases seen were more marked 
(occurring even at minimally toxic concentrations in some cell lines) than with both ER 
stress inducing agents.  This finding may be related to the action of this agent in binding to 
and inhibiting HSP90 (and its ER homologue GRP94) and suggests the possibility of a 
resulting compensatory increase in the key ER chaperone (and HSP70 family member) 
GRP78.  This increase may be activated in an attempt to maintain ER protein homeostasis. 
 
 A number of other notable changes in UPR proteins were detected in response to 
drug treatment.  One such change was activation of IRE1 receptor in response to drug 
treatment.  It was described in chapter 3 that the multiple myeloma cell lines expressed 
higher levels of IRE1 protein than the leukaemia or lymphoma cell lines studied.  In the drug 
activity studies described here, changes were observed in IRE1 protein levels in response to 
treatment.  Differences were also seen between the multiple myeloma cell lines in their 
response to drug treatment.  In the RPMI-8226 cell line, there was no phosphorylated 
(activated) IRE1 receptor protein visible in the untreated control samples, although total 
IRE1 protein was present.  Phosphorylated IRE1 protein was only seen following treatment 
with EC25 concentrations of tunicamycin and thapsigargin (at both 6 and 24 hours) in this 
cell line.  In contrast, phosphorylated IRE1 protein was observed in all U266 cell line 
samples, including the untreated control samples (at both time points).  Experiments were 
carried out to look for IRE1 protein phosphorylation in the AML and DLBCL cell lines, but 
were unable to detect any protein under these experimental conditions.  Experiments were 
also undertaken to detect the protein product of spliced XBP1 mRNA (this splicing of XBP1 
mRNA occurs downstream of IRE activation).  Spliced XBP1 protein product was detected 
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only in the myeloma cell lines, as evidenced by a faint band.  However, no change in the 
protein was detected following treatment with any of the drug concentrations tested.  Even in 
the presence of confirmed IRE1 receptor activation (phosphorylation), evidence of increased 
XBP1s protein levels was not seen in these experiments.  This is most likely due to a 
problem with the antibody used, and further experiments using RT-PCR to detect XBP1s 
mRNA would therefore be valuable. 
 
 Some UPR proteins studied showed a mixed response to drug treatment, for example 
eIF2! protein.  Phosphorylated and total eIF2! protein showed both increases and decreases 
in protein levels in response to drug treatment, although in general, there appeared to be a 
trend towards either increased protein levels, no change, or decreased protein levels 
following treatment with a particular drug, for example, after KW-2478 there was a pattern 
of decreased phosphorylated eIF2! protein. 
 
 In conclusion, it can be seen that KW-2478 treatment had the greatest effect on the 
activation of the UPR proteins studied, followed by the ER stress inducing agents and 
bortezomib.  The conventional chemotherapy agents doxorubicin, 4-HC, cytarabine, 
etoposide and melphalan all had a minimal effect on the activation of the UPR proteins 
investigated here.  
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5.  Treatment with Minimally Toxic Concentrations of ER Stress 
Inducing Agent and Effect on Chemosensitivity in vitro 
 
 
5.1  Introduction 
 
 In addition to normal cellular stresses, a number of pharmacological agents have 
been shown to induce ER stress and trigger the ER stress response, thereby activating the 
unfolded protein response.  One such agent is thapsigargin; a sesquiterpene lactone extracted 
from the plant, Thapsia garganica.  It is an effective inhibitor of sarcoplasmic endoplasmic 
reticulum calcium ATPases (known as SERCA pumps).  This inhibition leads to leakage of 
ER calcium, resulting in ER stress (Kijima et al., 1991).  Thapsigargin is a potent inducer of 
ER stress, with inhibition of the SERCA pumps at concentrations as low as 10-10M (Sagara 
and Inesi, 1991).  Along with tunicamycin, thapsigargin is commonly used by researchers to 
induce ER stress in order to study such stress and the resultant unfolded protein response.   
 
 Published research investigating the role of thapsigargin in modulating 
chemosensitivity have reported mixed results, with some studies describing sensitisation and 
others reporting resistance.  Like tunicamycin, thapsigargin has been shown to sensitise 
melanoma cells to TRAIL-induced apoptosis by inducing ER stress and the unfolded protein 
response (Chen et al., 2007).  It has been reported that multidrug resistant cells deficient in 
the proapoptotic Bcl-2 family members Bax and Bak are sensitive to ER stress mediated cell 
death (caspase independent) following treatment with thapsigargin (Janssen et al., 2009).  
Thapsigargin treatment was also shown to sensitise prostate cancer cells to the taxane 
chemotherapy agents paclitaxel and docetaxel (Wu et al., 2009).  However, thapsigargin has 
also been associated with chemoresistance.  A study in rats revealed that thapsigargin 
treatment enhanced P-gp expression and transport function in liver cancer cells, known to be 
involved in the development of drug resistance.  This effect was mediated by the 
endoplasmic reticulum stress response and involved MDR transcriptional induction through 
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c-Jun activation (Ledoux et al., 2003).  ER stress induction with tunicamycin has also been 
reported to lead to activation of p38 (via GRP78 upregulation and PERK activation) thereby 
protecting dormant tumor cells from chemotherapy and other stressors (Ranganathan et al., 
2006). 
 
 Another interesting area of research is the development of prodrugs of thapsigargin 
to inhibit SERCA pumps as a novel targeted treatment strategy in prostate cancer.  The 
thapsigargin prodrug (thapsigargin coupled to a targeting peptide) is activated by the 
proteolytic enzyme prostate specific antigen (PSA) and has been shown to be selectively 
toxic to prostate cancer cells in preclinical studies in vitro and in vivo (Christensen et al., 
2009, Denmeade and Isaacs, 2005).  If this approach proves succesful it would provide a 
solution to the important issue of thapsigargin cytotoxicity to normal cells and it may 
eventually be possible to apply this targeted strategy to other tumour types. 
 
 In this chapter, the effect of combining minimally toxic concentrations of the ER 
stress inducer thapsigargin on the activity of anticancer agents in haematological cell lines in 
vitro has been studied.  Thapsigargin was chosen over tunicamycin as an ER stress inducing 
agent due to the high concentrations of tunicamycin necessary for ER stress induction and its 
associated toxicity.  In contrast to other studies, minimally toxic concentrations of 
thapsigargin were used in an attempt to increase the relevance to clinical use of these agents, 
where treatment aims to minimise the potential toxicity to non-cancerous cells that would 
occur with higher concentrations.  Two schedules of thapsigargin combinations were 
investigated; simultaneous treatment with thapsigargin and drug for 48 hours, and 6 hours of 
thapsigargin pretreatment followed by the addition of drugs for 48 hours.  Previous 
experiments in this thesis have established that the UPR is activated in these cell lines 
following minimally toxic thapsigargin concentrations, with 6 hours of thapsigargin 
treatment sufficient to show UPR activation. 
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5.2 Materials and Methods 
 
5.2.1  Cytotoxicity Studies 
 
 The effect of drug treatment on cell viability was investigated using a plate based 
adenosine triphosphate (ATP) cytotoxicity assay (see chapter 2.5).  Cells in exponential 
growth phase were plated into 96 well plates (5000 cells per well in 100%l medium) and 
incubated for 24 hours.  Cells were treated with thapsigargin (at two minimally toxic 
concentrations; approximate EC5 and approximate EC15 based on previous cell viability 
experiments), and 2 concentrations each of doxorubicin (dox), bortezomib (bort), 17-AAG, 
and SAHA (approximate EC20 and EC50).  The concentrations of thapsigargin used in each 
cell line are shown in table 5.1 below.  
  
Cell line Approximate EC5 Approximate EC15 
HL60 0.05nM 0.5nM 
THP1 1nM 5nM 
RPMI-8226 0.5nM 5nM 
U266 1nM 5nM 
DOHH2 0.05nM 0.5nM 
SUD4 2nM (simultaneous) 
1nM (pretreatment) 
10nM 
 
     Table 5.1.  Approximate EC5 and EC15 concentrations of thapsigargin  
     used in cytotoxicity studies. 
 
 The effects of both simultaneous drug treatment and pre-treatment for 6 hours with 
thapsigargin were investigated.  Varying concentrations of drug were diluted in culture 
medium and then added to each well to obtain the required final concentration.  Single agent 
treated wells, combination treated wells, and untreated control wells were present on each 
plate in the combination experiments.  Control wells and single agent treatment wells were 
topped up with culture medium so that all wells of the plate contained a fixed volume of 
120µl.  Plates were then incubated for 48 hours at 37°C and 5% CO2 in air, before analysis 
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using the ViaLight HS assay kit (Lonza Group Ltd, Switzerland) in conjunction with a BMG 
Labtech Polarstar Optima microplate reader (BMG Labtech, Germany). 
 
 Simultaneous treatment experiments were carried out in a cell line panel consisting 
of 2 AML cell lines (HL-60, THP1), 2 MM cell lines (RPMI-8226, U266) and 2 DLBCL cell 
lines (DOHH2, SUD4).  Pretreatment experiments were carried out in 1 AML cell line 
(THP1), 1 MM cell line (U266) and 1 DLBCL cell line (SUD4).  Experiments were repeated 
at least three times on separate occasions to ensure reproducibility, with the exception of the 
DOHH2 cell line where experiments were repeated twice.  The effect of thapsigargin on the 
response to drug treatment was calculated using the fractional product method described by 
Webb (Webb, 1963) in order to determine if the effect of thapsigargin addition to drug 
treatment was additive, supra additive, or antagonistic. The ratio of the observed effect to the 
expected effect provides a measure of the interaction of two drugs used in a combination.  If 
the ratio of the combination effect is 1 (i.e. the observed effect equals the expected effect), 
the combination is designated additive.  If the ratio is less than 1 (i.e. the observed effect is 
greater than the expected effect), then the combination is considered to be supra-additive or 
synergistic.  If the ratio is more than 1 (i.e. the observed effect is less than the expected 
effect), then the combination is said to be antagonistic. 
 
5.2.2  Protein Analysis 
 
 
 Whole cell lysates were also prepared following drug treatments for use in western 
blotting experiments (see chapter 2.7).  Western blotting was carried out as described in 
chapter 2.8, with 20µg of protein loaded in each lane of the gel.  Blots were visualised using 
ECL (Amersham, UK) and a Fuji ImageQuant LAS 4000 camera (FujiFilm, Japan) used 
according to manufacturer’s instructions.   
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5.2.3  Apoptosis Assay 
 
 
  The Guava Nexin assay (Guava Technologies Inc., USA) is a fluorescence 
based microplate apoptosis assay.  Cells in exponential growth phase were plated into 96 
well plates (10000 cells per well) and incubated at 37°C and 5% CO2 in air for 24 hours 
before addition of drug solution.  Cells were either pretreated with thapsigargin for 6 hours 
prior to the addition of drug, or treated only with drug for 48 hours.  Cells were treated with 
the higher of the thapsigargin and drug concentrations used in the ATP cytotoxicity 
experiments in order to ensure detectable levels of apoptosis.  The required amount of each 
drug was diluted in fresh culture medium and added to each well in order to achieve the 
desired molar concentration per well.  Control wells and single agent treatment wells were 
topped up with culture medium so that all wells of the plate contained a fixed volume of 
120µl.  A positive control for apoptosis (doxorubicin 1µM) was included in all experiments.  
Cells were then returned to the incubator for a further 48 hours before addition of Guava 
Nexin Reagent to each plate well.  Plates were incubated in the dark at room temperature for 
20 minutes, then analysed using the Guava PCA – 96 System.  All samples were run in 
triplicate and mean values and standard deviations used in subsequent data analysis.  Data 
was presented as the percentage of cells per sample in each of the four cell populations.  
Total and viable cell number were also calculated for drug alone and drug with thapsigargin 
pretreatment (each normalised to its own control).  As the concentrations of thapsigargin 
used were minimally toxic, the effect of thapsigargin pretreatment on chemosensitivity was 
also investigated using apoptosis assay at both higher thapsigargin and higher drug 
concentrations. 
 
5.2.4  Statistical Analysis 
 
 
 Statistical analysis was performed using Microsoft Excel software, Microsoft 
Corporation, USA.  The data obtained from the apoptosis assay was used to determine mean 
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and standard deviation values for each drug concentration.  These values were then used for 
graphical representation and subsequent statistical analysis.  Data was assumed to be 
normally distributed and parametric tests were therefore used throughout.  Drug treatments 
were compared using a paired t-test, with a p value of less than 0.05 considered to be 
statistically significant. 
 
5.3  Results 
 
  Cytotoxicity assay (ATP) results revealed a clear pattern of effect across all cell 
lines in the panel.  The simultaneous administration of minimally toxic thapsigargin 
concentrations and chemotherapy resulted in additive to antagonistic effects in these 
haematological cancer cell lines.  This effect was observed with both concentrations of 
thapsigargin used (i.e. EC5 and EC15), as seen in figures 5.1 to 5.4.  Results are shown for the 
AML cell line THP1, myeloma cell line U266 and DLBCL cell line SUD4 (experimental 
data tables in appendix 2).  These results are representative of all cell lines studied, with the 
results for the remaining cell lines given in appendix 2. 
 166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  Effect of simultaneous treatment with EC5 (top) and EC15  
(bottom) thapsigargin (TG) concentrations and doxorubicin (Dox) for  
48 hours on viable cell number (ATP content) in three haematological  
cancer cell lines.  The combination effect compares the observed effect of  
the combination with the expected effect calculated using the fractional  
product method.  Values % 1 indicate an additive effect, values < 1 indicate  
synergy and values > 1 indicate antagonism.  Results shown are from three  
separate experiments. 
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Figure 5.2.  Effect of simultaneous treatment with EC5 (top) and EC15  
(bottom) thapsigargin (TG) concentrations and bortezomib (Bort) for  
48 hours on viable cell number (ATP content) in three haematological  
cancer cell lines.  The combination effect compares the observed effect of  
the combination with the expected effect calculated using the fractional  
product method.  Values % 1 indicate an additive effect, values < 1 indicate  
synergy and values > 1 indicate antagonism.  Results shown are from three  
separate experiments. 
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Figure 5.3.  Effect of simultaneous treatment with EC5 (top) and EC15  
(bottom) thapsigargin (TG) concentrations and 17-AAG for 48 hours  
on viable cell number (ATP content) in three haematological cancer cell  
lines.  The combination effect compares the observed effect of the  
combination with the expected effect calculated using the fractional  
product method.  Values % 1 indicate an additive effect, values < 1 indicate  
synergy and values > 1 indicate antagonism.  Results shown are from three  
separate experiments. 
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Figure 5.4.  Effect of simultaneous treatment with EC5 (top) and EC15  
(bottom) thapsigargin (TG) concentrations and SAHA for 48 hours on  
viable cell number (ATP content) in three haematological cancer cell  
lines.  The combination effect compares the observed effect of the  
combination with the expected effect calculated using the fractional product  
method.  Values % 1 indicate an additive effect, values < 1 indicate synergy  
and values > 1 indicate antagonism.  Results shown are from three separate  
experiments. 
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 The effect of pre-exposure, with minimally toxic concentrations of thapsigargin, was 
then investigated.  As the pattern seen with simultaneous treatment was consistent across all 
cell lines in the panel, pre-exposure experiments were conducted in one cell line of each 
tumour type, namely THP1, U266 and SUD4.  Figures 5.5 to 5.8 show the effect of 6 hours 
pretreatment with thapsigargin, followed by 48 hours further treatment with drug.  Pre-
exposure with minimally toxic thapsigargin concentrations resulted in chemoprotection, with 
antagonism of the effects of doxorubicin, bortezomib, 17-AAG and SAHA.  Again, this 
effect was seen with both concentrations of thapsigargin, and in all cell lines studied. 
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Figure 5.5.  Effect of pretreatment with EC5 (top) and EC15 (bottom)  
thapsigargin (TG) concentrations for 6 hours and doxorubicin (Dox)  
for a further 48 hours on viable cell number (ATP content) in three  
haematological cancer cell lines.  The combination effect compares the  
observed effect of the combination with the expected effect calculated using  
the fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.  Results  
shown are from three separate experiments. 
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Figure 5.6.  Effect of pretreatment with EC5 (top) and EC15 (bottom)  
thapsigargin (TG) concentrations for 6 hours and bortezomib (Bort)  
for a further 48 hours on viable cell number (ATP content) in three  
haematological cancer cell lines.  The combination effect compares the  
observed effect of the combination with the expected effect calculated using  
the fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.  Results  
shown are from three separate experiments. 
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Figure 5.7.  Effect of pretreatment with EC5 (top) and EC15 (bottom)  
thapsigargin (TG) concentrations for 6 hours and 17-AAG for a  
further 48 hours on viable cell number (ATP content) in three  
haematological cancer cell lines.  The combination effect compares the  
observed effect of the combination with the expected effect calculated using  
the fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.  Results  
shown are from three separate experiments. 
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Figure 5.8.  Effect of pretreatment with EC5 (top) and EC15 (bottom)  
thapsigargin (TG) concentrations for 6 hours and SAHA for a further  
48 hours on viable cell number (ATP content) in three haematological  
cancer cell lines.  The combination effect compares the observed effect  
of the combination with the expected effect calculated using the fractional  
product method.  Values % 1 indicate an additive effect, values < 1 indicate  
synergy and values > 1 indicate antagonism.  Results shown are from three  
separate experiments. 
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 The next set of experiments were conducted to determine if this antagonism of drug 
was due to a decrease in apoptosis with the addition of thapsigargin to anticancer drug 
treatment in these cell lines.  Apoptosis experiments were therefore carried out in the THP1, 
U266 and SUD4 cell lines after 6 hours pretreatment with the higher concentration of 
thapsigargin and 48 hours of further treatment with drug.  The results are shown in figures 
5.9 to 5.15.  It can be seen that thapsigargin as a single agent at the minimally toxic 
concentrations used did not cause any increase in apoptosis compared to the untreated 
control in any of the cell lines studied.  The proportion of THP1 cells that were apoptotic 
(early and late apoptosis) following TG pretreatment and 48 hour drug treatments can be 
seen in figure 5.9.  At these concentrations the only samples with a large proportion of 
apoptotic cells were the doxorubicin treated THP1 cells.  There was a small, but statistically 
significant, increase in apoptotic cells in the TG pretreated bortezomib sample (p<0.05). No 
antagonism of the proportion of apoptotic cells in each sample with TG pretreatment was 
observed. 
 
 
 
Figure 5.9.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 6 hours pretreatment with TG 5nM followed by addition of drug for a further 48  
hours in the THP1 cell line.  Error bars show mean ± SD. * denotes statistically significant 
increase in total apoptosis (p < 0.05) with TG pretreatment, compared to drug alone. 
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 The apoptosis assay also provided data for total and viable cell number, which can 
be seen in figure 5.10.  Thapsigargin treatment alone at this concentration was found to have 
an inhibitory effect on proliferation (data tables in appendix 2).  Analysis of this data 
revealed a statistically significant protective effect on THP1 total cell proliferation when 
thapsigargin pretreatment was added to 48 hours of doxorubicin or SAHA treatment (p<0.05 
and p<0.01 respectively).  A statistically significant increase in viable cell number was also 
seen with the thapsigargin pretreated SAHA combination (p<0.01). 
 
 
 
 
Figure 5.10.  Cell number (top) and viable cell number (bottom) after 48 hours  
treatment with drug, with or without 6 hours of pretreatment with TG 5nM in THP1  
cells (each value normalised to its own control).  * or ** denotes statistically  
significant difference (p < 0.05 or p<0.01 respectively) between drug alone and drug  
with TG pretreatment. 
 
    & 
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 Apoptosis assay results for the U266 cell line are shown in figures 5.11 and 5.12.  
As with the THP1 cell line, the addition of thapsigargin pretreatment to 48 hour drug 
incubation had little effect on the proportion of apoptotic cells, with no statistically 
significant differences seen (see figure 5.11).  
 
 
Figure 5.11.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 6 hours pretreatment with TG 5nM followed by addition of drug for a further 48  
hours in the U266 cell line.  Error bars show mean ± SD.  
 
 
 Some decreases in the antiproliferative effects of drugs were seen when combined 
with thapsigargin in the U266 cell line, as shown in figure 5.12.  A small, but statistically 
significant, increase in total cell number was observed in the thapsigargin pretreated 
bortezomib sample (p<0.01), although an increase in viable cell number was not observed.  
A decrease in viable cell number was seen in the thapsigargin and doxorubicin combination 
sample (p<0.05).  The increases in viable cell number observed in the bortezomib and SAHA 
combination treated samples were not statistically significant. 
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Figure 5.12.  Cell number (top) and viable cell number (bottom) after 48 hours  
treatment with drug, with or without 6 hours of pretreatment with TG 5nM in U266  
cells (each value normalised to its own control). * or ** denotes statistically  
significant difference (p < 0.05 or p<0.01 respectively) between drug alone and drug  
with TG pretreatment. 
 
 
 
 
 Apoptosis assay results for the SUD4 cell line are shown in figure 5.13.  The 
addition of thapsigargin pretreatment to 48 hour drug incubation had little effect on the 
proportion of apoptotic cells, however a very small, but statistically significant, increase in 
apoptotic cells was seen in both the pretreated doxorubicin and SAHA samples (p<0.05 and 
p<0.01 respectively). 
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Figure 5.13.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 6 hours pretreatment with TG 10nM followed by addition of drug for a further 48  
hours in the SUD4 cell line.  Error bars show mean ± SD. * or ** denotes statistically  
significant difference (p < 0.05 or p<0.01 respectively) in total apoptosis with TG 
pretreatment,. compared to drug alone. 
 
 
 
 
 
 In the SUD4 cell line, some decreases in the antiproliferative effects of drugs were 
seen when combined with thapsigargin, with a trend towards increased viable and total cell 
number in the thapsigargin pretreated samples (see figure 5.14).  Pretreatment with 
thapsigargin resulted in a statistically significant increase in total cell number after 17-AAG 
treatment (p<0.01), and this increase corresponded to a statistically significant increase in the 
number of viable cells in this sample (p<0.05). 
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 Figure 5.14.  Cell number (top) and viable cell number (bottom) after 48 hours  
treatment with drug, with or without 6 hours of pretreatment with TG 10nM in SUD4  
cells (each value normalised to its own control). * or ** denotes statistically  
significant difference (p < 0.05 or p<0.01 respectively) between drug alone and drug  
with TG pretreatment. 
 
 
 The apoptosis experiments were then repeated in the SUD4 cell line, in order to 
establish if the effect of TG pretreatment differed at higher cytotoxic drug concentrations.  
The proportion of apoptotic cells in the sample treated with this higher concentration of 
thapsigargin alone was not found to be statistically significant from that of the control 
sample.  It can be seen from figure 5.15 that higher concentrations resulted in an increase in 
the proportion of apoptotic cells seen; specifically an increase in late apoptosis.  There was a 
pattern of increased proportion of apoptotic cells observed when thapsigargin pretreatment 
was combined with all drugs studied compared to drug alone, and these increases were 
&& 
& 
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statistically significant in the doxorubicin, bortezomib and 17-AAG treated samples 
(p<0.05).  At these concentrations, no antagonism of the antiproliferative drug effects were 
seen following thapsigargin pretreatment, with no statistically significant changes observed 
in either total or viable cell number (data not shown). 
 
 
 
 
Figure 5.15.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 6 hours pretreatment with TG 100nM followed by addition of drug for a further  
48 hours in the SUD4 cell line.  Error bars show mean ± SD. * denotes statistically  
significant increase in total apoptosis (p < 0.05) with TG pretreatment, compared to drug 
alone. 
 
   
 
 
 In an attempt to further elucidate the mechanism of the antagonism observed when 
combining minimally toxic concentrations of thapsigargin and anticancer agents, western 
blotting was carried out to determine changes occurring at the protein level after 6 hours of 
thapsigargin pretreatment and a further 24 hours of drug treatment.  In the THP1 cell line 
(see figure 5.16), a clear increase in GRP78 protein was seen following treatment with 17-
AAG (with or without thapsigargin), however no other changes in the molecular chaperone 
proteins GRP78 and GRP94 were seen.  LC3B protein cleavage is used as a marker of 
autophagy, and was visible at a low level in all samples.  There appeared to be a subtle 
 
  *         *    * 
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increase in LC3B in the thapsigargin pretreated bortezomib sample, compared to bortezomib 
alone (indicating a possible increase in autophagy) and a decrease in the thapsigargin 
pretreated 17-AAG sample (indicating a possible reduction in autophagy).  No clear 
difference was seen in the levels of the antiapoptotic protein BCL-2 or apoptosis mediated 
cleavage of PARP protein in this cell line, when comparing drug treatment alone with drug 
plus thapsigargin pretreatment. 
 
 
 
 
 
 
 
 
 
 
  GRP78  
 
  GRP94    
 
  LC3B               
 
  BCL2    
 
  PARP    
 
  GAPDH    
 
 
Figure 5.16.  Western blotting experiments to investigate the effect of  
pretreatment with TG on chemosensitivity in THP1 cells.  Markers of  
the unfolded protein response, autophagy and apoptosis were studied.    
GAPDH is included as a loading control. 
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 In the U266 cell line (see figure 5.17), no clear changes in the levels of the 
molecular chaperone proteins GRP78 and GRP94 were observed when thapsigargin 
pretreatment was combined with chemotherapy.  LC3B protein cleavage was clearly present 
in all samples, including untreated control, consistent with the basal level of autophagy 
reported to occur in this myeloma cell line.  A decrease in LC3B protein cleavage was seen 
in the thapsigargin pretreated doxorubicin sample, compared to doxorubicin treatment alone, 
indicating a possible reduction in autophagy.  No clear changes were observed in the levels 
of BCL2 and MCL1 proteins, or in the amount of parp cleavage seen, in the thapsigargin 
pretreated samples compared to chemotherapy drug alone. 
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Figure 5.17.  Western blotting experiments to investigate the effect of  
pretreatment with TG on chemosensitivity in U266 cells.  Markers of  
the unfolded protein response, autophagy and apoptosis were studied.    
GAPDH is included as a loading control. 
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 Western blotting results for the SUD4 cell line are shown in figure 5.18.  Levels of 
the molecular chaperone proteins GRP78 and GRP94 did not appear to change following 
thapsigargin pretreatment prior to chemotherapy in the SUD4 cell line.  The basal level of 
autophagy in the SUD4 cells was very low (as indicated by a very faint band representing 
LC3B cleavage on western blot).  A small increase was seen in the level of LC3B protein 
cleavage in the thapsigargin pretreated doxorubicin sample, compared to doxorubicin alone 
and LC3B cleavage was present (but unchanged) in the bortezomib, 17-AAG and SAHA 
single agents and combinations.  No clear changes were seen in BCL2 protein levels, 
although some changes were observed in the levels of MCL1 protein, with an increase seen 
in the thapsigargin single agent sample.  The level of this antiapoptotic protein was seen to 
decrease in the thapsigargin pretreated doxorubicin and SAHA samples compared to each 
drug alone.  This result is consistent with the statistically significant increase in apoptosis 
seen in the thapsigargin pretreated doxorubicin and SAHA samples compared to either drug 
alone in the apoptosis assay results (see figure 5.21).  No changes in PARP cleavage were 
observed between the single agent and combination samples.  
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Figure 5.18. Western blotting experiments to investigate the effect of  
pretreatment with TG on chemosensitivity in SUD4 cells.  Markers of  
the unfolded protein response, autophagy and apoptosis were studied.    
GAPDH is included as a loading control. 
 
 
5.4  Discussion 
 
 Attempts to sensitise cancer cells to chemotherapy by inducing ER stress and 
activation of the unfolded protein response have been reported in the literature, with mixed 
results.  It appears that whether such ER stress induction sensitises or protects cells from the 
effects of anticancer agents is dependent not only on the cell line and tumour type, but also 
on the particular anticancer agent used and the concentration of the ER stressor. 
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 The results described in this chapter raise a number of important questions regarding 
the strategy of using ER stress induction to sensitise cancer cells to chemotherapy.  
Minimally toxic concentrations of thapsigargin were used here as an attempt to make these 
studies more relevant to anticancer treatment in vivo.  It has long been known that 
compounds such as thapsigargin (and tunicamycin) are highly toxic to normal cells, as well 
as cancerous cells, due to their mechanism of action.  Earlier experiments in this project have 
shown that ER stress and unfolded protein response activation does in fact occur with 
minimally toxic concentrations of ER stress inducing agents (see chapter 4) and experiments 
described here focused on investigating if this low level of ER stress and UPR activation was 
sufficient to affect the response of cancer cells to chemotherapeutic agents in vitro.   
 
 Cytotoxicity (ATP) assay results revealed a clear pattern of chemoprotection when 
minimally toxic thapsigargin pre-exposure was combined with the chemotherapy agents 
doxorubicin, bortezomib, 17-AAG or SAHA across all concentration ranges studied in these 
haematological cell lines.  Whilst the effects of simultaneous administration for 48 hours had 
an additive to antagonistic effect in the cell lines studied, clear antagonism of the cytotoxic 
effects of the chemotherapeutic agents studied occurred following 6 hours pretreatment with 
thapsigargin prior to addition of drug treatment for a further 48 hours.  Apoptosis assay data 
revealed that this protective effect did not occur as a result of a decrease in apoptosis on 
addition of thapsigargin treatment to chemotherapy, in contrast apoptosis actually increased 
in some combinations.  However, analysis of cell proliferation suggested an increase in cell 
number and more importantly, the number of viable cells in thapsigargin pretreated samples.  
Western blotting experiments were conducted to investigate any changes occurring 
following the addition of thapsigargin pretreatment in these cells lines.  Due to published 
reports suggesting an involvement of autophagy on myeloma cell cytotoxicity (Hoang et al., 
2009), determination of LC3B protein cleavage (a marker of autophagy) was also carried 
out.  These experiments confirmed a basal level of autophagy was present in the myeloma 
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cell line U266, and to a lesser extent in the AML cell line THP1 (only very low protein 
levels were detectable in the DLBCL cell line SUD4).   
 
 No changes were seen in the protein levels of the molecular chaperones GRP78 and 
GRP94 in the thapsigargin pretreated samples compared to chemotherapy alone in any of the 
cell lines studied.  Other markers of UPR activation were investigated, but protein levels 
were not detectable in these samples.  This raises the possibility that the antagonism of 
chemotherapeutic drug effects seen following the addition of thapsigargin is not ER stress or 
UPR mediated, and is caused by another mechanism specific to the action of thapsigargin.  
Based on the experiments described in this chapter, it is possible that thapsigargin 
antagonises chemotherapy through effects on cell proliferation.  Thapsigargin has been 
reported to induce growth arrest in prostate cancer cells due to an increase in intracellular 
calcium (occurring as a result of influx of extracellular calcium following depletion of ER 
calcium pools) (Lin et al., 1997).  Induction of growth arrest by low thapsigargin 
concentrations may decrease the effectiveness of chemotherapeutic agents and could explain 
why viable cell number is unaffected in the thapsigargin pretreated samples.  Further 
experiments investigating cell cycle effects and intracellular calcium concentrations of 
thapsigargin combination treated cells and chemotherapy alone treated cells would determine 
if this calcium induced growth arrest is responsible for the antagonism observed.          
 
 As discussed in the introduction to this chapter, the development of thapsigargin 
prodrugs is another interesting area of cancer research.  A thapsigargin prodrug (thapsigargin 
coupled to a targeting peptide) has now moved into a phase I clinical trial in solid tumours 
(clinical trials number: NCT01056029) (Ghantous et al., 2010).  Whilst this is an exciting 
development, the experiments described here would suggest a cautious approach to the 
combination of this thapsigargin prodrug with existing chemotherapy agents.  The toxicity of 
such an agent to normal cells also remains to be determined. 
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6.  Attenuation of the Unfolded Protein Response Using the 
 Chemical Chaperone 4-Phenyl Butyric Acid and Effect on 
 Chemosensitivity in vitro 
 
 
6.1  Introduction 
 
 The small molecule compound 4-phenylbutyric acid (4-PBA) has been reported to 
act as a chemical chaperone, thereby relieving ER stress.  4-PBA is a simple molecule with a 
relative molecular mass of 164.2, and a chemical structure as shown in figure 6.1.  4-PBA is 
a short chain fatty acid derived from the first generation histone deacetylase (HDAC) 
inhibitor butyric acid.  HDAC inhibitors have been discussed previously in chapter 1.  4-
PBA has been reported to have weak HDAC inhibitory activity in addition to its action as a 
chemical chaperone (Lin et al., 2009a).   
 
 
 
Figure 6.1.  The chemical structure of 4-phenylbutyric acid (4-PBA) 
 
 
 4-PBA, as the sodium salt sodium phenylbutyrate, is clinically used for the treatment 
of urea cycle disorders, and is approved for use in both the USA and Europe.  It is available 
as both oral and intravenous dosage forms and is well tolerated.  It is oxidised in vivo to 
phenylacetic acid, which is conjugated with glutamine and excreted in the urine as 
phenylacetylglutamine.  This results in the loss of two molecules of nitrogen for each 
molecule of PBA and is therefore effective in treating the hyperammonaemia seen in urea 
cycle disorders (Iannitti and Palmieri, 2011).   
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 4-PBA has been used as a chemical chaperone in a number of studies.  The function 
of a chemical chaperone is to reduce ER stress, both by stabilising protein conformation and 
by improving the folding capacity of the ER (Welch and Brown, 1996).  It has been reported 
that pretreatment of liver cells with 4-PBA decreased PERK and eIF2! phosphorylation and 
JNK activation following tunicamycin treatment both in cell line and animal models.  The 
authors also report that tunicamycin mediated XBP-1 mRNA splicing was reduced.  This 
study found that 4-PBA was able to decrease ER stress and restore glucose homeostasis in a 
mouse diabetes model (Ozcan et al., 2006).  In a short term phase I/II clinical study, 4-PBA 
was shown to modulate heat shock protein expression and restore maturation of the F508 
CTFR mutant protein in cystic fibrosis patients (Zeitlin et al., 2002) and this has also been 
shown in a number of in vitro studies (Rubenstein et al., 1997, Brown et al., 1996).  Other 
chemical chaperone functions reported for 4-PBA include correction of temperature sensitive 
protein folding defects (Brown et al., 1997) and enabling secretion of functionally active, but 
misfolded, mutant !1-antitrypsin protein, thereby providing a potential pharmacological 
strategy for prevention of liver injury and emphysema in !1-antitrypsin deficiency (Burrows 
et al., 2000).  The studies reported thus far using 4-PBA as a chemical chaperone support a 
role for the drug in reducing ER stress by preventing protein aggregation and increasing 
overall ER function, although 4-PBA has not been shown to alter the conformation of 
misfolded proteins themselves.  These considerable effects are all the more surprising 
considering the simple chemical structure of 4-PBA. 
 
 The haematological cancer cell lines in this study have been shown to have an 
underlying degree of ER stress and a constitutively active UPR.  The effect of the reported 
chemical chaperone 4-PBA on chemosensitivity has therefore been investigated in these cell 
lines in order to determine whether attenuation of ER stress by 4-PBA would alter the 
sensitivity of these cell lines to anticancer drugs and ER stress inducing agents.  
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6.2 Materials and Methods 
 
6.2.1  Cytotoxicity Studies 
 
 Cytotoxicity experiments were carried out as described in chapter 2 (sections 2.4 to 
2.6 inclusive).  The effect of 4-PBA treatment on cell proliferation and viability was 
investigated using a plate based adenosine triphosphate (ATP) cytotoxicity assay.  Four 
cancer cell lines were studied; three haematological cancer cell lines (THP1, U266 and 
DOHH2) and the colorectal cancer cell line HT-29 as an example of a solid tumour cell line.  
Cells in exponential growth phase were plated into 96 well plates (5000 cells per well in 
100%l medium) and incubated for 24 hours.  Varying concentrations of drug were diluted in 
culture medium and then added to each well to obtain the required final concentration (all 
drug additions were made in a fixed volume of 10µl per well).  Control wells were topped up 
with culture medium so that all wells of the plate contained a fixed volume of 110µl.  Plates 
were then incubated for 48 hours at 37°C and 5% CO2 in air.  48 hours after addition of drug, 
plates were analysed using the ViaLight HS assay kit (Lonza Group Ltd, Switzerland) and 
read using a BMG Labtech Polarstar Optima microplate reader (BMG Labtech, Germany). 
 
 Each drug treatment was investigated in triplicate wells and experiments were 
repeated on three separate occasions.  Effect of drug treatment was calculated from the assay 
data (expressed as a percentage of the control value).  For each drug, the mean values and 
standard deviations of all experiments were determined for graphical representation.  For 
concentration-effect modelling in GraphPad Prism, the mean values for each concentration 
in each experiment were used.  Drug activity data was fitted using sigmoidal concentration 
effect curves to derive EC50 values (effective concentration 50 – i.e. the concentration 
required to exert 50% of maximum effect) with 95% confidence intervals, using non linear 
regression in GraphPad Prism software (GraphPad Software, San Diego, USA). 
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 In the three haematological cancer cell lines, it was also possible to use the Guava 
ViaCount assay (Guava Technologies Inc., USA) to determine total cell number (total cell 
number per millilitre) and cell viability (percentage viable cells and percentage dead cells) of 
each sample (this assay is not suitable for use with adherent cell lines, such as the HT-29 cell 
line).  Cells in exponential growth phase were plated into 96 well plates (5000 cells per well 
in 100%l medium) and incubated at 37°C and 5% CO2 in air for 24 hours.  Drug dilutions and 
addition to cells were as described for ATP assay above.  Following 48 hours of incubation 
with drug, plates were analysed using the Guava PCA™ – 96 System, as described in chapter 
2.4.  All samples were run in triplicate and each experiment was repeated on three separate 
occasions to ensure reproducibility.  The mean values and standard deviations of each data 
set were then calculated and used in subsequent data analysis.  For concentration-effect 
modelling in GraphPad Prism, the mean values for each concentration in each experiment 
were used. 
 
 The effect of 4-PBA treatment combined with ER stress inducing agents and 
anticancer agents on cell proliferation and viability was investigated using ATP cytotoxicity 
assay as described above (see also chapter 2.5).  Based on the results of initial experiments, 
cells were treated with 4-PBA 0.5mM and two concentrations each of tunicamycin (TM), 
thapsigargin (TG), doxorubicin (dox), bortezomib (bort), 17-AAG, and SAHA.  The effects 
of both simultaneous drug treatment and pre-treatment for 24 hours with 4-PBA were 
investigated.  Varying concentrations of drug were diluted in culture medium and then added 
to each well to obtain the required final concentration.  Single agent treated wells, 
combination treated wells, and untreated control wells were present on each plate in the 
combination experiments.  Control wells and single agent treatment wells were topped up 
with culture medium so that all wells of the plate contained a fixed volume of 120µl.  Plates 
were then incubated for 48 hours at 37°C and 5% CO2 in air, before analysis using the 
ViaLight HS assay kit (Lonza Group Ltd, Switzerland) in conjunction with a BMG Labtech 
Polarstar Optima microplate reader (BMG Labtech, Germany).   
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 Each drug treatment was studied in triplicate and experiments were repeated three 
times on separate occasions.  In the combination experiments, the effect of 4-PBA on the 
response to drug treatment was calculated using the fractional product method described by 
Webb (Webb, 1963). The ratio of the observed effect to the expected effect provides a 
measure of the interaction of two drugs used in a combination.  If the ratio of the 
combination effect is 1 (i.e. the observed effect equals the expected effect), the combination 
is designated additive.  If the ratio is less than 1 (i.e. the observed effect is greater than the 
expected effect), then the combination considered to be supra-additive or synergistic.  If the 
ratio is more than 1 (i.e. the observed effect is less than the expected effect), then the 
combination is said to be antagonistic. 
 
6.2.2  Apoptosis Assay 
 
 As the concentration of 4-PBA used in the ATP assay was minimally toxic, the 
effect of 4-PBA pretreatment on chemosensitivity was investigated using an apoptosis assay 
at the higher drug concentrations used in the cytotoxicity experiments.  The Guava Nexin 
assay (Guava Technologies Inc., USA) is a fluorescence based microplate apoptosis assay 
(see chapter 2.9).  Cells in exponential growth phase were plated into 96 well plates (10000 
cells per well) and incubated at 37°C and 5% CO2 in air for 24 hours before addition of drug 
solution.  Cells were either pretreated with 4-PBA for 24 hours prior to the addition of drug 
for a further 48 hours, or treated only with drug for 48 hours.  Control wells and single agent 
treatment wells were topped up with culture medium so that all wells of the plate contained a 
fixed volume of 120µl.  All drug treatments were investigated in triplicate, with mean values 
and standard deviations used in subsequent data analysis.  Data was presented as the 
percentage of cells per sample in each of the four cell populations.  Total and viable cell 
number were also calculated for drug alone and drug with 4-PBA pretreatment (each 
normalised to its own control).   
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6.2.3  Protein Analysis 
 
 Whole cell lysates were also prepared following drug treatments for use in western 
blotting experiments (see chapter 2.7).  Western blotting was carried out as described in 
chapter 2.8, with 20µg of protein loaded in each lane of the gel.  Blots were visualised using 
ECL (Amersham, UK) and a Fuji ImageQuant LAS 4000 camera (FujiFilm, Japan) used 
according to manufacturer’s instructions.   
 
6.2.4  HDAC Activity 
 
 Inhibition of histone deacetylases (HDAC) by 4-PBA was evaluated using a HDAC 
Fluorimetric Assay/Drug Discovery Kit (BIOMOL, Enzo Life Sciences, UK) as per 
manufacturer’s protocol (see chapter 2.10).  Trichostatin A or test inhibitor was diluted in 
assay buffer and plated into wells of a 96-well plate.  Diluted HeLa extract was added to all 
wells (except for no enzyme controls).  Fluor de Lys Substrate was then added to the wells 
initiating HDAC reactions.  The addition of Fluor de Lys Developer was used to stop the 
reactions and the plate was incubated in the dark at room temperature for 15 minutes.  
Samples were then read using a microplate reader (excitation wavelength 350 to 380nm and 
emission 440 to 460nm).  Each sample was studied in duplicate, with the experiment 
performed on three separate occasions to ensure reproducibility.  Values were expressed as 
percentage of control HDAC activity. 
 
6.2.5  Statistical Analysis 
 
 Statistical analysis was performed using Microsoft Excel software, Microsoft 
Corporation, USA.  The data obtained from the apoptosis assay was used to determine mean 
and standard deviation values for each drug concentration.  These values were then used for 
graphical representation and subsequent statistical analysis.  Data was assumed to be 
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normally distributed and parametric tests were therefore used throughout.  Group means 
were analysed using a paired t-test, with a p value of less than 0.05 considered to be 
statistically significant. 
 
 
6.3  Results 
 
 The reported chemical chaperone 4-PBA was found to have a cytotoxic effect in the 
cancer cell lines studied, with EC50 values in the low milimolar range following 48 hours of 
treatment (see figure 6.2).  The lymphoma cell line DOHH2 was the most sensitive to the 
cytotoxic effects of 4-PBA, whilst the colorectal cancer cell line HT-29 was found to be the 
least sensitive.  The AML cell line THP1 and the myeloma cell line U266 showed similar 
sensitivities to 4-PBA treatment. 
 
 
 
Drug Cell line EC50 95% CI 
4-PBA THP-1 1.91mM 1.65mM to 2.20mM 
 U266 1.70mM 1.52mM to 1.89mM 
 DOHH2 0.83mM 0.61mM to 1.12mM 
 HT-29 2.99mM 2.27mM to 3.92mM 
 
 
Figure 6.2.  Effect of treatment with 4-PBA for 48 hours on cell viability (ATP  
content) in three haematological cancer cell lines and the colorectal cancer cell  
line HT29 (error bars show mean ± SD).  EC50 values, with 95% confidence intervals,  
for 4-PBA treatment are shown. 
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 For the three haematological cancer (suspension) cell lines, the effect of 4-PBA on 
cell proliferation and cell viability was also determined.  As illustrated in figure 6.3 A, 
treatment with 4-PBA had an antiproliferative effect across the concentration range studied, 
with the THP1 cell line being more sensitive to this antiproliferative effect, whilst the U266 
and DOHH2 cell lines had similar sensitivities.  It can be seen from figure 6.3 B that the 
cytotoxic effects of 4-PBA were observed at higher drug concentrations than the 
antiproliferative effects (as is often the case with anticancer agents).  The DOHH2 cell line 
was found to be considerably more sensitive to the effect of 4-PBA in reducing cell viability, 
with the THP1 and U266 cell lines exhibiting similar sensitivities. 
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Drug Cell line EC50 95% CI 
4-PBA THP-1 0.55mM 0.31mM to 1.00mM 
 U266 4.98mM 2.52mM to 9.84mM 
 DOHH2 5.92mM 3.71mM to 9.44mM 
 
 
 
Drug Cell line EC50 95% CI 
4-PBA THP-1 6.96mM 5.68mM to 8.54mM 
 U266 5.70mM 5.21mM to 6.23mM 
 DOHH2 0.52mM 0.09mM to 3.19mM 
 
Figure 6.3. A - Effect of treatment with 4-PBA for 48 hours on cell number  
in three cancer cell lines (error bars show mean ± SD).  EC50 values, with 95%  
confidence intervals, for 4-PBA treatment on cell number are shown.  B - Effect of  
treatment with 4-PBA for 48 hours on cell viability in three cancer cell lines  
(error bars show mean ± SD).  EC50 values, with 95% confidence intervals, for  
4-PBA treatment on cell viability are shown 
A 
B 
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 The effect of increasing concentrations of 4-PBA on UPR markers in the three 
haematological cancer cell lines was studied by western blotting, in an attempt to detect 
protein changes that may reflect its reported chemical chaperone activity (see figure 6.4).  
Levels of the antiapoptotic proteins BCL2 and MCL1 were also examined.  A concentration 
dependent decrease in GRP78 was observed in the DOHH2 cell line following 4-PBA 
treatment, although this effect was subtle.  No other changes in GRP78 or GRP94 protein 
levels were seen.  No changes in either GADD153 protein or the spliced XBP1 protein 
product were detectable following 4-PBA treatment in this experiment.  A concentration 
dependent decrease in the level of BCL2 protein was seen following treatment with 
increasing concentrations of 4-PBA in the THP1 and U266 cell lines, whilst no change was 
seen in the DOHH2 cell line.  In the U266 cell line, a concentration dependent decrease in 
MCL1 protein was also observed after treatment with increasing 4-PBA concentrations.  The 
THP1 and DOHH2 cell lines had lower basal expression of MCL1 protein than the U266 cell 
line.  In these cell lines, treatment with lower concentrations of 4-PBA (0.5%M and 1%M) 
resulted in an increase in MCL1 protein, whilst treatment with the higher concentration 
(5mM) resulted in a decrease in MCL1 protein (this effect was more subtle in the THP1 cell 
line where a possible small decrease was seen at the higher concentration).  GAPDH protein 
was included as a loading control, with equal protein loading seen within each cell line 
studied.  
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Figure 6.4. Western blotting experiments to investigate the effect of  
increasing concentrations of 4-PBA on markers of the unfolded protein  
response and apoptosis in three haematological cancer cell lines.   
GAPDH is included as a loading control. 
 
 
 Experiments next focused on establishing the effect of combining 4-PBA with other 
agents.  Based on the results of the initial experiments described above, 4-PBA at a 
concentration of 0.5mM was chosen for use in further studies, as higher concentrations 
appeared too toxic in these haematological cell lines (particularly DOHH2).  The effect of 
simultaneous treatment and pretreatment with 4-PBA on the cytotoxic effects of the ER 
stressors tunicamycin and thapsigargin, plus the anticancer agents doxorubicin, bortezomib, 
17-AAG and SAHA were investigated in the three haematological cancer cell lines THP1, 
U266 and DOHH2.  These experiments were also carried out in the colorectal cancer cell 
line HT-29, in order to determine if the effect of this chemical chaperone compound differed 
between the solid tumour cells and haematological cell lines. 
0    0.5   1    5     0   0.5   1    5     0   0.5   1     5 
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 Simultaneous treatment with 4-PBA had mixed effects in this cell line panel as 
shown in figures 6.5 to 6.8.  Simultaneous treatment with 4-PBA and drugs for 48 hours in 
the THP1 cell line had a broadly additive effect, although a synergistic effect was seen with 
the combination of 4-PBA and tunicamycin 1µM (see figure 6.5).     
 
 
 
Figure 6.5.  Effect of simultaneous treatment with 4-PBA 0.5mM  
and drug for 48 hours on viable cell number (ATP content) in  
THP1 cells.  The combination effect compares the observed effect  
of the combination with the expected effect calculated using the  
fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
  
 
 
 200 
Figure 6.6 shows the result of simultaneous treatment with 4-PBA 0.5mM and drugs 
for 48 hours in the U266 cell line.  In this cell line, concurrent treatment with 4-PBA and 
drugs was also broadly additive, although a synergistic effect was again seen with the 
combination of 4-PBA 0.5mM and tunicamycin at the 1µM concentration, and an 
antagonistic effect seen with 4-PBA combined with the higher concentrations of bortezomib 
and 17-AAG studied.  
 
 
 
 
Figure 6.6.  Effect of simultaneous treatment with 4-PBA 0.5mM  
and drug for 48 hours on viable cell number (ATP content) in  
U266 cells.  The combination effect compares the observed effect of  
the combination with the expected effect calculated using the  
fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
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 In the DOHH2 cell line, mixed effects were seen when 4-PBA was combined with 
drug treatment for 48 hours (see figure 6.7).  The combination of 4-PBA and the ER stress 
inducing drugs tunicamycin and thapsigargin was found to be broadly additive, whilst the 
combination of 4-PBA with anticancer agents was additive to antagonistic. 
 
 
 
 
Figure 6.7.  Effect of simultaneous treatment with 4-PBA 0.5mM  
and drug for 48 hours on viable cell number (ATP content) in  
DOHH2 cells.  The combination effect compares the observed effect  
of the combination with the expected effect calculated using the  
fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
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 Figure 6.8 shows that in the colorectal cancer cell line HT29, the effect of 
simultaneous treatment with 4-PBA and drugs for 48 hours was broadly additive (additive to 
antagonistic). 
 
 
 
 
Figure 6.8.  Effect of simultaneous treatment with 4-PBA 0.5mM  
and drug for 48 hours on viable cell number (ATP content) in  
HT29 cells.  The combination effect compares the observed effect  
of the combination with the expected effect calculated using the  
fractional product method.  Values % 1 indicate an additive effect,  
values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
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 The effect of pre-treatment with 4-PBA 0.5mM for 24 hours followed by addition of 
drug for a further 48 hours was also investigated (see figures 6.9 to 6.12).  Results were 
broadly additive in all four cancer cell lines studied.  The additive effect of 4-PBA 
pretreatment in the THP1 cell line can be seen in figure 6.9.  
 
 
 
 
 
Figure 6.9.  Effect of pretreatment with 4-PBA 0.5mM for 24  
hours and drug for a further 48 hours on viable cell number  
(ATP content) in THP1 cells.  The combination effect compares the  
observed effect of the combination with the expected effect calculated  
using the fractional product method.  Values % 1 indicate an additive  
effect, values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
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 In the U266 cell line (see figure 6.10), 4-PBA pretreatment also appeared to have a 
broadly additive effect when combined with all drugs studied, although a supra-additive 
effect was seen in the 4-PBA pretreated cells after 48 hours of treatment with thapsigargin 
10nM. 
 
 
 
 
 
Figure 6.10.  Effect of pretreatment with 4-PBA 0.5mM for 24  
hours and drug for a further 48 hours on viable cell number  
(ATP content) in U266 cells.  The combination effect compares the  
observed effect of the combination with the expected effect calculated  
using the fractional product method.  Values % 1 indicate an additive  
effect, values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
 
 
 
 
 
 
 
 
 205 
 Pretreatment with 0.5mM 4-PBA for 24 hours prior to the addition of drugs was 
found to have an additive to antagonistic effect in the DOHH2 cell line, as shown in figure 
6.11. 
 
 
 
 
 
Figure 6.11.  Effect of pretreatment with 4-PBA 0.5mM for 24  
hours and drug for a further 48 hours on viable cell number  
(ATP content) in DOHH2 cells.  The combination effect compares  
the observed effect of the combination with the expected effect  
calculated using the fractional product method.  Values % 1 indicate  
an additive effect, values < 1 indicate synergy and values > 1 indicate  
antagonism.  Results shown are from three separate experiments. 
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 Pretreatment with 4-PBA for 24 hours prior to drug treatment had a broadly additive 
effect in the colorectal cancer cell line HT29, as shown in figure 6.12. 
 
 
 
 
Figure 6.12.  Effect of pretreatment with 4-PBA 0.5mM for 24  
hours and drug for a further 48 hours on viable cell number  
(ATP content) in HT29 cells.  The combination effect compares the  
observed effect of the combination with the expected effect calculated  
using the fractional product method.  Values % 1 indicate an additive  
effect, values < 1 indicate synergy and values > 1 indicate antagonism.   
Results shown are from three separate experiments. 
 
 
 
 
 
 
 Whilst the addition of 4-PBA to drug treatment appeared broadly additive using 
ATP cytotoxicity assay, the assay was not able to differentiate between cytotoxic and 
cytostatic effects that may be occurring as a result of 4-PBA addition to drug treatment.  As a 
result, an apoptosis assay was carried out in order to investigate if 4-PBA pretreatment 
affected the level of apoptosis seen following treatment with the ER stress inducing agents 
tunicamycin and thapsigargin in the haematological cancer cell lines THP1 and U266. It was 
thought that use of this chemical chaperone might modulate the response to pharmacological 
ER stress inducers in these cell lines that have been shown in this thesis to have a 
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constitutively active UPR (as suggested by the supra-additive combination effects observed 
following treatment with 4-PBA tunicamycin and thapsigargin). 
 
 As can be seen from figure 6.13, a statistically significant increase in apoptotic cells 
was seen in the 4-PBA pretreated 1%M tunicamycin sample (p<0.05) and both thapsigargin 
samples (p<0.01) in the THP1 cell line, compared to samples treated with drug alone.  This 
increase in apoptosis was manifested as both an increase in early apoptotic cells and an 
increase in late apoptotic (dead) cells. 
 
 
 
Figure 6.13.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 24 hours pretreatment with 4-PBA 0.5mM followed by addition of drug for a 
further 48 hours in the THP1 cell line.  Error bars show mean ± SD. * or ** denotes 
statistically significant increase in total apoptosis (p < 0.05 or p<0.01 respectively) with  
4-PBA pretreatment, compared to drug alone. 
 
 
 
 
 In addition to the percentage of apoptotic cells in each sample, this assay also 
provided counts of both total and viable cell number.  It can be seen from figure 6.14 and 
6.15 that there was little effect on cell proliferation in the tunicamycin treated samples, 
 *            ** 
 
      ** 
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however a statistically significant decrease in the number of viable cells was observed with 
4-PBA pretreatment in the thapsigargin treated THP1 cells (p<0.05). 
 
 
 
Figure 6.14.  Cell number after 48 hours treatment with drug, with or without  
24 hours of pretreatment with 4-PBA 0.5mM in THP1 cells (each value  
normalised to its own control).  Error bars show mean ± SD.  * denotes  
statistically significant difference (p < 0.05) between drug alone and drug with  
4-PBA pretreatment. 
 
 
 
Figure 6.15.  Viable cell number after 48 hours treatment with drug, with or  
without 24 hours of pretreatment with 4-PBA 0.5mM in THP1 cells (each value  
normalised to its own control).  Error bars show mean ± SD.  * denotes  
statistically significant difference (p < 0.05) between drug alone and drug with  
4-PBA pretreatment. 
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 Figure 6.16 shows the results of the apoptosis assay in the U266 cell line, where a 
statistically significant increase in apoptotic cells was seen in the 4-PBA pretreated 
thapsigargin samples, compared to samples treated with thapsigargin alone (10nM, p<0.01 
and 100nM, p<0.05 respectively).  This increase in apoptosis was manifested as both an 
increase in early apoptotic cells and an increase in late apoptotic (dead) cells.  However, no 
significant differences were seen in the tunicamycin treated samples when 4-PBA 
pretreatment was added. 
 
 
Figure 6.16.  Percentage of cells in each category after treatment with drug alone for 48  
hours, or 24 hours pretreatment with 4-PBA 0.5mM followed by addition of drug for a 
further 48 hours in the U266 cell line. Error bars show mean ± SD. * or * denotes 
statistically significant increase in total apoptosis (p < 0.05 or p<0.01 respectively) with  
4-PBA pretreatment, compared to drug alone. 
 
 
 
 
 
 It can be seen from figures 6.17 and 6,18, that whilst there were no significant 
differences in total cell number with the addition of 4-PBA pretreatment, a statistically 
significant decrease in viable cell number was observed in the 4-PBA pretreated thapsigargin 
treated U266 cells (p<0.05). 
 
            * 
 
     ** 
 210 
 
Figure 6.17.  Cell number after 48 hours treatment with drug, with or without  
24 hours of pretreatment with 4-PBA 0.5mM in U266 cells (each value  
normalised to its own control).  Error bars show mean ± SD.  
 
 
 
Figure 6.18.  Viable cell number after 48 hours treatment with drug, with or  
without 24 hours of pretreatment with 4-PBA 0.5mM in U266 cells (each value  
normalised to its own control).  Error bars show mean ± SD.  * denotes  
statistically significant difference (p < 0.05) between drug alone and drug with  
4-PBA pretreatment. 
 
 
 
 
 4-PBA has been reported to have weak HDAC inhibitory activity, as well as 
chaperone activity, therefore a HDAC activity assay was used to determine the extent of 
HDAC inhibition by 4-PBA.  The results are shown in figures 6.19 to 6.21 and table 6.5.  
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Trichostatin A is the positive control HDAC inhibitor included in the assay kit, and figure 
6.19 shows effective inhibition of HDAC activity by Trichostatin A with increasing 
concentration.  The known HDAC inhibitor SAHA was also included in the assay as it had 
been used as an anticancer agent in these experiments, therefore comparison of its HDAC 
inhibitory activity at the concentrations used here would provide useful insight.  Figure 6.20 
shows that SAHA at a concentration of 0.5µM (500nM), which has been used in cytotoxicity 
experiments in this chapter, resulted in a decrease in HDAC activity of over 70 percent.  This 
assay confirmed that 4-PBA does have HDAC inhibitory activity (see figure 6.21).  At the 
concentration used in this experiment (0.5mM) 4-PBA inhibited HDAC activity by almost 
25 percent, with around 70 percent inhibition seen at the 5mM concentration. 
 
 
 
 
Figure 6.19.  Trichostatin A inhibition of substrate deacetylation  
by HeLa nuclear extract.  Error bars show mean ± SD 
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Figure 6.20.  SAHA inhibition of substrate deacetylation by HeLa  
nuclear extract.  Error bars show mean ± SD 
 
 
 
 
Figure 6.21.  4-PBA inhibition of substrate deacetylation by HeLa nuclear  
extract.  Error bars show mean ± SD 
 
 
 
 Western blotting experiments were carried out to study the levels of various 
chaperone proteins and UPR markers following treatment with the ER stress inducing drugs 
tunicamycin and thapsigargin for 24 hours, with or without 4-PBA pretreatment for 24 
hours.  Experiments were conducted in the AML cell line THP1 and myeloma cell line U266 
(figures 6.22 and 6.23 respectively).  No clear changes in protein levels were seen between 
the 4-PBA pretreated samples and those treated with drug alone.  Other UPR proteins were 
studied, but were undetectable under these experimental conditions. 
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Figure 6.22.  Western blotting experiments to investigate the effect  
of pretreatment with 4-PBA on chemosensitivity in THP1 cells.  
Tubulin is included as a loading control. 
 
 
 
 
 
 214 
 
C
on
tro
l 
 PB
A
 0
.5
m
M
 
 TM
 1
00
nM
 
 TM
 1
0µ
M
 
 PB
A
 +
 T
M
 1
00
nM
  
 PB
A
 +
 T
M
 1
0µ
M
 
 TG
 1
0n
M
 
 TG
 1
00
nM
 
 PB
A
 +
 T
G
 1
0n
M
 
 PB
A
 +
 T
G
 1
00
nM
 
    
 
 
 
 
 
 
 
 
 
 
 
 
  GRP78  
 
  GRP94  
 
  HSP90  
 
  HSP70  
 
  PDI   
 
  BCL2   
 
  Tubulin  
 
 
 
Figure 6.23.  Western blotting experiments to investigate the effect  
of pretreatment with 4-PBA on chemosensitivity in U266 cells.  
Tubulin is included as a loading control. 
 
 
 
 
6.4  Discussion 
 
 4-PBA is a small molecule that has been reported to act as a chemical chaperone.  
The experiments described here focused on the effect of this compound on the 
chemosensitivity of haematological cancer cell lines.  The colorectal cancer cell line HT29 
was used in the cytotoxicity studies as an example of a commonly used solid tumour cell 
line, in order to detect if any differences occurred between the solid tumour cell line and the 
haematological cancer cell lines, which have been shown in earlier experiments to have a 
constitutively active UPR. 
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 The cytotoxic activity of 4-PBA as a single agent was confirmed, with EC50 values 
in the low milimolar range (the HT-29 cell line proved the least sensitive to 4-PBA treatment 
with an approximate 3-fold increase in EC50 compared to the most sensitive cell line 
DOHH2).  Based on these initial cytotoxicity experiments, it was decided to use a 
concentration of 0.5mM in combination studies, as higher concentrations would prove too 
toxic in these cell lines.  Other investigators have reported that 0.1mM and 2mM 
concentrations of 4-PBA are clinically relevant concentrations (Brusilow et al. 1991).  In 
addition, two phase I clinical trials of sodium phenylbutyrate in refractory solid tumours 
have been conducted. These studies reported that the molecular effects of 4-PBA were noted 
at concentrations above 0.5mM, and that these concentrations were readily achievable in 
vivo.  The recommended phase II doses (both intravenous and oral) from these trials aimed 
for plasma concentrations above this 0.5mM level (Carducci et al., 2001, Gilbert et al., 
2001).   
 
While mixed effects on drug sensitivity were observed following simultaneous 
administration of 4-PBA and drug for 48 hours in this study, the effect was broadly additive.  
This additive effect was confirmed in experiments using a 24 hour 4-PBA pretreatment, prior 
to the addition of drug for a further 48 hours.   
 
 An apoptosis assay was utilised to investigate the effect of 4-PBA pretreatment for 
24 hours on the level of apoptosis seen following 48 hours of treatment with the 
pharmacological ER stress inducers tunicamycin and thapsigargin.  These experiments were 
undertaken in the THP1 and U266 cell lines due to the supra-additive effects seen with these 
combinations using the ATP cytotoxicity in these cell lines.  This assay revealed a 
statistically significant increase in apoptotic cells with both thapsigargin concentrations used 
following pretreatment with 0.5mM 4-PBA for 24 hours in the THP1 and U266 cell line.  A 
statistically significant increase in apoptotic cells was also seen following tunicamycin 
treatment at the higher concentration in the 4-PBA pretreated THP1 cells.  Interestingly, 
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these results suggest that pretreatment with 4-PBA sensitises these haematological cell lines 
to ER stress mediated apoptosis.  The potential interaction with other anticancer agents 
remains to be determined.  The apoptosis assay described here was the result of one 
experiment conducted in triplicate and as a result further confirmatory experiments would be 
needed before definite conclusions could be drawn from these results.  
 
 This study also investigated the mechanism of action of 4-PBA in these 
haematological cancer cell lines.  At the protein level, decreases in the antiapoptotic proteins 
BCL2 and MCL1 were seen following 24 hours of treatment with the 5mM 4-PBA 
concentration, however no changes were detected in the UPR proteins studied.  Whilst it is 
possible that the attenuation of ER stress is not visible at the protein level under these 
experimental conditions, it is also a possibility that the effect of 4-PBA is mediated by 
another mechanism, for example HDAC inhibition.  Down regulation of antiapoptotic BCL2 
family proteins is consistent with the mechanism of action of HDAC inhibitors (Zhang et al., 
2004).   
 
 4-PBA is a derivative of the first generation HDAC inhibitor butyric acid, and whilst 
investigators who have reported the chemical chaperone function of 4-PBA have generally 
overlooked its HDAC inhibitory activity, it may be significant in this context.  The HDAC 
activity assay revealed that 4-PBA at the 0.5mM concentration used in this study did exhibit 
some HDAC inhibitory activity.  At the 5mM concentration, this HDAC inhibitory activity 
was comparable to that of the clinically used HDAC inhibitor SAHA at the 0.5%M 
concentration used in these in vitro studies.  It is therefore worth considering the HDAC 
inhibitory activity of this 4-PBA when discussing its other reported function as a chemical 
chaperone. 
 
 One other important issue relating to the use of 4-PBA as a chemical chaperone is 
the concentration of 4-PBA used.  The studies of 4-PBA reported to date (see the 
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introduction to this chapter) routinely use concentrations 10 to 20-fold higher than those 
used in this experiment to show amelioration of ER stress and the UPR.  No mention is made 
of the cytotoxicity of 4-PBA alone at this concentration in the experimental models used.  
For example, in the 2006 report in the journal Science by Ozcan and colleagues, 4-PBA 
concentrations of 10mM and 20mM were used in the in vitro studies (Ozcan et al., 2006).  In 
the experiments conducted as part of this project, 4-PBA proved extremely cytotoxic at these 
concentrations, hence the use of the lower 0.5mM concentration.  In addition, 4-PBA at these 
higher concentrations has been shown in this project to be an effective HDAC inhibitor, 
which is important when considering the effects that have been ascribed to 4-PBA treatment.  
The lack of an ER stress relieving effect at lower concentrations observed in this project has 
been confirmed by other investigators, for example Basseri and colleagues showed a 
decrease in GRP78 and GRP94 protein levels following administration of 10mM 4-PBA, but 
no change compared to the control levels after treatment with 1mM 4-PBA (Basseri et al., 
2009).  Taken together, these results suggest that 4-PBA is not acting as a chemical 
chaperone at these lower concentrations and the effects observed are mediated by other 
mechanisms (for example, HDAC inhibition). 
 
 Further experiments are needed to fully establish the relationship between 4-PBA 
treatment and increased sensitivity to the cytotoxic effects of ER stress inducing agents.  
Experiments investigating the effect of 4-PBA on cell cycle distribution (HDAC inhibitors 
are known to cause cell cycle arrest in G1/G2) and histone acetylation would further 
determine the importance of HDAC inhibition in the action of 4-PBA at the concentrations 
studied. 
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7.  Downregulation of ER Resident Molecular Chaperones Using 
the Novel Small Molecule Compound Versipelostatin and the 
Effect on Chemosensitivity in vitro 
 
 
7.1  Introduction 
 
 Molecular chaperones facilitate the correct folding of proteins, with the ER 
containing a number of resident molecular chaperones, such as the heat shock protein (HSP) 
70 and HSP90 families, the lectins calnexin and calreticulin, and the HSP40 family of co-
chaperones.  HSPs have an affinity for, and bind to, exposed hydrophobic sites on unfolded 
proteins that would ordinarily be buried in the interior of the structure, using hydrolysis of 
ATP to provide the energy required to carry out their chaperone function.  HSPs often 
require many cycles of ATP hydrolysis in order to fold a single polypeptide chain correctly 
(Ellgaard and Helenius, 2003, Alberts, 2002, Ma and Hendershot, 2004a).   
 
Targeting molecular chaperones has been suggested as a therapeutic strategy in a 
number of different diseases and anticancer agents inhibiting the chaperone protein HSP90 
have now progressed to clinical trials (Smith and Workman, 2007).  The two molecular 
chaperones with the most direct effect on UPR activation and UPR signalling are GRP78 and 
GRP94.  GRP78 is a member of the HSP70 family and GRP94 is a member of the HSP90 
family of heat shock proteins (Lee, 2007).  GRP78 recognises hydrophobic residues on 
unfolded or misfolded proteins and binds to them, thereby preventing their interaction with 
other molecules (Bole et al., 1986).  GRP94 is the ER resident isoform of cytosolic HSP90, 
however in contrast to HSP90 (which has a very large number of client proteins, a number of 
which are oncogenic), GRP94 appears to have a very limited number of client proteins.  
GRP94 has been shown to be involved in B-cell differentiation and is also involved in the 
immune response (Ni and Lee, 2007, Liu and Li, 2008).  GRP78 is a vital mediator of the 
response to ER stress, being the main ER stress sensor whose dissociation from the three 
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transmembrane UPR receptors results in activation of the UPR.  The role of this key ER 
molecular chaperone in the UPR and chemosensitivity have been described in detail in 
Chapter 1; brief highlights from the literature describing the importance of these ER 
molecular chaperones in cancer are discussed below. 
 
 Involvement of GRP78 (and to a lesser extent GRP94) in a number of different solid 
tumour types has been shown.  In hepatocellular carcinoma GRP78 has been identified as a 
transformation associated gene, along with activation of the ATF6 and IRE1/XBP1 pathways 
(Shuda et al., 2003).  In colon cancer, GRP78 has been shown to be upregulated in colon 
cancer tissue and increased cytoplasmic GRP78 expression was associated with the 
transformation from normal tissue to adenoma and then carcinoma (Xing et al., 2006).    
GRP78 has also been shown to be overexpressed in malignant breast tumours, but there was 
no overexpression seen in benign breast tumours (Fernandez et al., 2000).  Both GRP78 and 
GRP94 have been shown to be overexpressed in lung cancer tissues (Wang et al., 2005), and 
GRP94 overexpression has been reported in oesophageal adenocarcinomas (Chen et al., 
2002).  Activation of the UPR has also been shown in prostate cancer (Misra et al., 2006) 
and GRP78 has been linked to prostate cancer metastasis.  GRP78 has been shown to be 
weakly expressed in normal prostate tissue, however it is highly expressed in the bone 
metastases of prostate cancer patients (Mintz et al., 2003).  In another study in prostate 
cancer it was found that the intensity of GRP78 expression in prostate tissue was associated 
with survival and clinical recurrence (Daneshmand et al., 2007).   
 
A number of years before the elucidation of the mammalian UPR pathways and the 
vital role played by molecular chaperones such as GRP78, it was already known that the 
glucose related proteins were involved in resistance of tumours to treatment with traditional 
DNA-damaging chemotherapy drugs.  In 1987, it was shown that exposure of chinese 
hamster ovary (CHO) cells to conditions that induced GRPs (e.g. glucose deprivation and 
anoxia) induced resistance to the topoisomerase II poison doxorubicin (Shen et al., 1987).  
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These researchers then went on to attempt to identify a mechanism for this resistance.  They 
found that following exposure of CHO cells to GRP inducing conditions (also including 
tunicamycin treatment) there was a rapid and selective depletion of topoisomeraase II from 
the nucleus of these cells and associated cell cycle effects (Shen et al., 1989).  GRP78 and 
drug resistance is discussed in more detail in chapter 1.5.   
   
In light of the importance of these ER resident molecular chaperones in cancer, 
modulating the UPR by targeting these chaperones has been proposed as a novel anticancer 
strategy.  Research has focused on modulating GRP78 (also known as BiP) function.  
However, work conducted in this area to date has consisted almost exclusively of studies in 
solid tumours, the vast majority of which have involved utilisation of molecular biology 
techniques such as gene silencing or overexpression in order to modulate GRP78 function 
(Kardosh et al., 2008, Pyrko et al., 2007b, Lee et al., 2008).  The search for more clinically 
viable strategies to target GRP78 is therefore ongoing.  Strategies for targeting GRP78 
currently being explored include the use of the cytokine interleukin-24 (IL-24 – also known 
as melanoma differentiation-associated gene-7 or MDA-7), a member of the interleukin-10 
family of cytokines (Jiang et al., 1995, Dent et al., 2005).   
 
One emerging therapeutic strategy to modulate GRP78 function is the use of the 
novel small molecule Versipelostatin (VST).  This compound was discovered by Dr Shin-ya 
and colleagues at the National Institute of Advanced Industrial Science and Technology 
(AIST) in Japan, as a result of a screen for compounds with the potential to affect molecular 
chaperones.  These researchers utilised a luciferase reporter gene assay to detect activation of 
the GRP78 promoter in their screen for inhibitors of GRP78 expression.  Versipelostatin was 
isolated from the culture broth of Streptomyces versipellis 4083-SVS6.  Its molecular 
formula was determined as C61H94O17 and study of the NMR spectra revealed its structure to 
be a macrocyclic compound consisting of an !-acyltetronic acid and sugar moieties.  
 221 
Versipelostatin has a relative molecular mass of 1099 (chemical structure is shown in figure 
7.1) (Park et al., 2002).  
 
 
 
Figure 7.1.  The structure of versipelostatin. 
Reproduced from Park et al. (2002). 
  
 
In the initial publication detailing the discovery and structure of versipelostatin, it 
was reported that the compound exhibited limited cytotoxicity alone in vitro, yet was able to 
inhibit the expression of GRP78 induced by ER stressors such as tunicamycin treatment or 
hypoglycaemic insult in the HeLa cell line (Park et al., 2002).  Research published by this 
group in 2004 further elucidated the mechanism of action of versipelostatin and its potential 
as an anticancer agent (Park et al., 2004).  This work confirmed that versipelostatin inhibited 
GRP78 expression in response to ER stress due to glucose deprivation, but not GRP78 
expression resulting from ER stress induction with tunicamycin.  At this time it was also 
reported that in addition to inhibiting GRP78 expression occurring as a result of glucose 
deprivation mediated ER stress, versipelostatin inhibited the expression of GRP94 under 
glucose deprivation conditions (Park et al., 2004). 
 
Versipelostatin is the only compound described to date that acts specifically to 
reduce the expression of the ER molecular chaperones GRP78 and GRP94 induced after ER 
stress.  In order to test the specificity of versipelostatin for UPR molecular chaperones, the 
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authors examined the effect of versipelostatin on HSP70 mRNA expression and discovered 
that VST was unable to inhibit HSP70 gene expression under all experimental conditions 
studied.  The authors propose that versipelostatin selectively inhibits the transcription of 
genes containing the endoplasmic reticulum stress response element (ERSE) in their 
promoter during glucose deprivation conditions.  XBP1 splicing and ATF4 expression were 
both decreased by versipelostatin treatment during glucose deprivation, indicating UPR 
suppression, however no decrease in ATF6 cleavage (activation) was seen (Park et al., 
2004). 
 
This study also examined the effect of versipelostatin treatment on cell viability.  
After 24 hours drug treatment in the colorectal cancer cell line HT-29, versipelostatin was 
found to have only a weak cytotoxic effect alone, but had a profound cytotoxic effect under 
glucose deprivation conditions with an approximately 30-fold lower IC50.  The growth 
inhibitory effect of versipelostatin was characterised in a panel of 39 solid tumour cancer cell 
lines, with growth inhibition seen in the majority of cell lines following 48 hours treatment 
under normal growth conditions.  The authors report that there was little apoptosis in the cell 
line panel under normal growth conditions, whilst extensive apoptosis was seen under 
glucose deprivation conditions (Park et al., 2004).  In a mouse xenograft model, the in vivo 
cytotoxic effect of versipelostatin was comparable to that of single agent cisplatin treatment, 
and the drug was well tolerated (Park et al., 2004).  These studies provided encouraging 
early results for this novel compound, however further research is required to fully elucidate 
the mechanism of versipelostatin downregulation of GRP78 and GRP94. 
 
 Differences in glucose metabolism between tumour cells and normal non-malignant 
cells have been known for many years.  In a February 1956 issue of the journal Science, the 
nobel laureate Otto Warburg published his work “On the origin of cancer cells”, which 
outlined his observation that the increased glycolysis seen in cancer cells was due to a 
fundamental injury in cellular respiration.  This metabolic shift from oxidative 
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phosphorylation for energy production in normal cells, to the less efficient aerobic glycolysis 
in tumour cells is known as the Warburg effect (Warburg, 1956).  Whilst it has still not been 
definitively established whether this metabolic shift is the cause of cancer (as proposed by 
Warburg) or a by-product of tumour growth, the Warburg effect does highlight a potential 
difference between normal and cancer cells that may be exploited as a therapeutic target.  
 
 ER stress and the unfolded protein response can be provoked in a number of 
different ways; one example of which is glucose deprivation.  As a tumour grows, increasing 
demands are placed on the microenvironment, eventually leading to glucose deprivation, low 
pH, poor vascular supply and hypoxia (Ma and Hendershot, 2004b).  Aerobic glycolysis and 
increased glucose metabolism by tumours is the rationale behind the use of 
18fluorodeoxyglucose positron emission tomography (18FDG-PET) imaging in the diagnosis 
of tumours (Gatenby and Gillies, 2004, Lopez-Lazaro, 2010).  Similar to research on the 
UPR in cancer, research into targeting glycolysis in cancer cells has focused only on solid 
tumours.  However, a recent review has highlighted that with 18FDG-PET being utilised as a 
diagnostic tool in some haematological malignancies, targeting glycolysis does therefore 
represent a valid therapeutic approach in these haematological cancers (Shanmugam et al., 
2009).  In the versipelostatin studies by the Shin-ya research group, glucose deprivation 
conditions were achieved either through the replacement of normal (glucose-containing) 
culture medium with glucose free medium, or the addition of 2-deoxyglucose (2-deoxy-D-
glucose, 2-DG) to glucose-containing culture medium.  2-DG is an antimetabolite compound 
that is almost identical in structure to glucose.  2-DG is therefore imported into cells via 
glucose transporters and is phosphorylated by the enzyme hexokinase to 2-deoxyglucose-6-
phosphate, which accumulates intracellularly, but importantly inhibits the activity of 
hexokinase, thereby inhibiting the metabolism of glucose.  2-DG treatment has been reported 
to potentiate the cytotoxic effects of both chemotherapy and radiotherapy in a number of 
tumour types (Yamada et al., 1999, Maschek et al., 2004, Hernlund et al., 2008, Simons et 
al., 2007).  2-DG has also been investigated as an anticancer agent in its own right and has 
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shown potency in vitro, however, after progressing to phase I clinical trials development 
appears to have been halted due to lack of efficacy in the clinic, with the dose administered 
limited by unacceptable toxicity at the concentrations required for activity (Shanmugam et 
al., 2009). 
 
 In this chapter, the activity of the novel compound versipelostatin is established in 
haematological cancer cell lines, and its ability to downregulate the ER molecular 
chaperones GRP78 and GRP94 determined.  The activity of versipelostatin and its effect on 
the UPR has not previously been reported in haematological cancer cells. 
 
7.2  Materials and Methods 
 
 Versipelostatin (VST) was kindly provided by Dr K Shin-ya, National Institute of 
Advanced Industrial Science and Technology, Japan.  VST stock solution was prepared in 
DMSO and stored at -20°C until use.  2-deoxyglucose (2-DG) was obtained from Sigma 
Aldrich, UK.  Stock solution of 2-DG was prepared in purified water and stored at -20°C 
until use.  All further dilutions of the stock solutions were prepared fresh in culture medium 
under sterile conditions immediately prior to use.  The haematological cancer cell lines 
THP1, U266 and SUD4 were used for experiments in this chapter, along with the adherent 
colorectal cancer cell line HT-29 (the activity of versipelostatin in this solid tumour cell line 
has previously been reported (Park et al., 2004)).  Cell culture materials and conditions were 
as described in chapter 2. 
 
Cytotoxicity experiments were carried out as described in chapter 2 (sections 2.4 to 
2.6 inclusive).  The effect of drug treatment on cell proliferation and viability was 
investigated using a plate based adenosine triphosphate (ATP) cytotoxicity assay.  Cells in 
exponential growth phase were plated into 96 well plates (5000 cells per well in 100%l 
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medium) and incubated for 24 hours.  Varying concentrations of drug were diluted in culture 
medium and then added to each well to obtain the required final concentration (all drug 
additions were made in a fixed volume of 10µl per well).  Control wells were topped up with 
culture medium so that all wells of the plate contained a fixed volume of 110µl.  Plates were 
then incubated for 48 hours at 37°C and 5% CO2, before analysis using the ViaLight HS 
assay kit (Lonza Group Ltd, Switzerland) and a BMG Labtech Polarstar Optima microplate 
reader (BMG Labtech, Germany).  
 
The effect of VST concentration was studied in triplicate wells with biological 
replicates studied on three separate occasions (expressed as a percentage of the control 
value).  For each drug, the mean values and standard deviations of all experiments were 
determined for graphical representation.  For concentration-effect modelling in GraphPad 
Prism, the mean values for each concentration in each experiment were used. 
 
Further studies in two cell lines used the Guava ViaCount assay (Guava 
Technologies Inc., USA) to determine total cell number (total cell number per millilitre) and 
cell viability (percentage viable cells and percentage dead cells) of each sample. Cells were 
plated out and drug additions made as described above.  48 hours after addition of drug, 
plates were removed from the incubator and 100%l of diluted Guava ViaCount Flex Reagent 
was added to each well.  Plates were then analysed using the Guava PCA™ – 96 System.  All 
samples were run in triplicate and each experiment was repeated on two separate occasions.  
The mean values and standard deviations of each data set were then calculated and used in 
subsequent data analysis.  For concentration-effect modelling in GraphPad Prism, the mean 
values for each concentration in each experiment were used. 
 
Drug activity data was fitted using sigmoidal concentration effect curves to derive 
EC50 values (effective concentration 50 – i.e. the concentration required to exert 50% of 
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maximum effect) with 95% confidence intervals, using non linear regression in GraphPad 
Prism software (GraphPad Software, San Diego, USA) as described in chapter 2.6 
 
 For western blotting experiments, two million cells were plated out into each well of 
six-well culture plates and incubated for 24 hours at 37°C and 5% CO2 in air.  Drug dilutions 
were made as described in chapter 2.7.  Cells were then incubated for a further 24 hours, 
after which time the cells were harvested and whole cell lysates prepared as described in 
chapter 2.7.  All antibodies, reagents and experimental conditions for western blotting were 
as described in chapter 2.8.  For some experiments, drug incubations were carried out in the 
absence of glucose.  In these cases, glucose free RPMI-1640 medium was used, 
supplemented with 10% dialysed heat-inactivated foetal calf serum (FCS) and 1% penicillin-
streptomycin.  All western blotting experiments were repeated to ensure reproducibility. 
 
 In conjunction with the western blotting experiments, cytotoxicity experiments were 
carried out in order to establish the effect of versipelostatin treatment in combination with 2-
DG treatment.  The Guava ViaCount assay (Guava Technologies Inc., USA) was used to 
determine total cell number (total cell number per millilitre) and cell viability (percentage 
viable cells and percentage dead cells) of each sample as described above.  Single agent 
treated wells, combination treated wells, and untreated control wells were present on each 
plate in the combination experiments.  Control wells and single agent treatment wells were 
topped up with culture medium so that all wells of the plate contained a fixed volume.  Plates 
were then incubated for 24 hours at 37°C and 5% CO2 in air, before analysis.  Each 
concentration was studied in duplicate, with mean values and standard deviations determined 
for graphical representation.  
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7.3  Results 
 
 The activity of versipelostatin has not previously been reported in haematological 
cancer cell lines.  It was therefore necessary to initially determine the effect of this novel 
small molecule compound under normal cell culture conditions in these cell lines.  The solid 
tumour cell line HT-29 was also included as a reference cell line in which the activity of 
versipelostatin has previously been reported.  Figure 7.2 below shows an example of the data 
generated in these experiments.  Cells were treated for 48 hours with increasing 
concentrations of versipelostatin and the effect on cell proliferation and viability was then 
assessed using an ATP cytotoxicity assay.  This data was then used to plot concentration-
effect curves and calculate EC50 values (see figure 7.3).  The same was also done for 2-DG 
treatment in these cell lines (see figure 7.4). 
 
 
Figure 7.2.  Effect of treatment with increasing concentrations of  
VST for 48 hours on viable cell number (ATP content) in the AML  
cell line THP1.  Error bars show mean ± standard deviation (SD). 
 
 
Figure 7.3 shows the cytotoxicity of versipelostatin in the three haematological 
cancer cell lines and the colorectal cancer cell line being studied.  The haematological cancer 
cell lines were more sensitive to versipelostatin treatment than the solid tumour cell line.  
The AML cell line THP1 and the DLBCL cell line DOHH2 proved significantly more 
sensitive to versipelostatin treatment, with EC50 values of 2.9%M and 2.5%M respectively.  
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The U266 cell line was the least sensitive of the haematological cancer cell lines, with an 
EC50 of 7.5%M.  The colorectal cancer cell line HT-29 was the least sensitive cell line overall 
to versipelostatin, with an EC50 of 19.0%M. 
 
 
 
Drug Cell line EC50 95% CI 
VST THP-1 2.9µM 2.4µM to 3.6µM 
 U266 7.5µM 4.8µM to 11.6µM 
 DOHH2 2.5µM 2.0µM to 3.1µM 
 HT29 19.0µM 11.7µM to 30.7µM 
 
 
Figure 7.3.  A – Effect of treatment with VST for 48 hours on viable cell number  
(ATP content) in three haematological cancer cell lines and the colorectal cancer  
cell line HT29 (error bars show mean ± SD).  B – EC50 values, with 95%  
confidence intervals, for VST treatment. 
  
 
 In order to further investigate the cytotoxicity of versipelostatin, experiments were 
conducted in the THP1 (AML) and U266 (MM) cell lines to determine the differential 
effects of this compound on cell proliferation and cell viability.  Versipelostatin decreased 
cell proliferation in a concentration dependent manner in both cell lines studied after 48 
hours of treatment.  Cell viability data revealed that viability decreased with 48 hours of 
versipelostatin treatment, also in a concentration dependent manner.  Similar sensitivity to 
versipelostatin was seen with both cell lines, with similar EC50 values. 
A 
B 
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Drug Cell line EC50 95% CI 
VST THP-1 2.7µM 1.8µM to 4.1µM 
 U266 3.8µM 2.1µM to 7.2µM 
 
 
 
Drug Cell line EC50 95% CI 
VST THP-1 16.6µM 15.3µM to 18.0µM 
 U266 16.9µM 13.8µM to 20.8µM 
 
Figure 7.5.  A – Effect of treatment with VST for 48 hours on cell number in  
three cancer cell lines (error bars show mean ± SD).  B – EC50 values, with  
95% confidence intervals, for VST treatment on cell number.  C - Effect of  
treatment with VST for 48 hours on cell viability in three cancer cell lines (error  
bars show standard deviation).  D – EC50 values, with 95% confidence intervals,  
for VST treatment on cell viability 
 
B 
A 
 
C 
D 
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 In order to induce hypoglycaemic (glucose deprivation) conditions in vitro, 
investigators commonly use the glycolysis inhibitor 2-DG.  In higher concentrations, this 
compound can exert a cytotoxic effect in its own right, therefore in order to optimise its use 
in these cell lines, initial experiments were undertaken to study the cytotoxicity of increasing 
concentrations of 2-DG for 48 hours in these cell lines (see figure 7.4).  It can be seen that in 
the milimolar range, 2-DG did in fact exhibit a concentration-dependent cytotoxic effect.  
The DOHH2 cell line appeared most sensitive to 2-DG treatment across the concentration 
range studied, followed by the THP1 and U266 cell lines.  The colorectal cancer cell line 
HT-29 was least sensitive to treatment with 2-DG at the concentrations studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4.  A – Effect of treatment with 2-DG for 48 hours on viable cell number  
(ATP content) three haematological cancer cell lines and the colorectal cancer cell  
line HT29 (error bars show standard deviation).  B – EC50 values, with 95%  
confidence intervals, for 2-DG treatment 
 
Drug Cell line EC50 95% CI 
2-DG THP-1 2.2mM 1.6mM to 3.2mM 
 U266 3.0mM 1.6mM to 5.6mM 
 DOHH2 0.57mM 0.32mM to 1.0mM 
 HT29 3.6mM 3.0mM to 4.4mM 
A 
 
B 
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 As with versipelostatin treatment, experiments were carried out using the THP1 and 
U266 cell lines to determine the effects of 48 hours of 2-DG treatment on cell proliferation 
and cell viability.  A similar pattern of sensitivity to that occurring with versipelostatin 
treatment was seen in each of the haematological cancer cell lines.  2-DG treatment was 
found to decrease cell proliferation in both cell lines studied after 48 hours of treatment.  As 
with versipelostatin treatment, the antiproliferative effect seen was concentration dependent.  
Cell viability also decreased after 48 hours of 2-DG treatment in a concentration dependent 
manner in these cell lines. 
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Drug Cell line EC50 95% CI 
2-DG THP-1 5.5mM 2.5mM to 11.9mM 
 U266 9.8mM 4.5mM to 21.5mM 
 
 
 
 
Drug Cell line EC50 95% CI 
2-DG THP-1 24.1mM 19.3mM to 30.0mM 
 U266 23.0mM 15.4mM to 34.4mM 
 
 
Figure 7.6. A – Effect of treatment with 2-DG for 48 hours on cell number in  
three cancer cell lines (error bars show standard deviation).  B – EC50 values, with  
95% confidence intervals, for 2-DG treatment on cell number.  C – Effect of  
treatment with 2-DG for 48 hours on cell viability in three cancer cell lines (error  
bars show standard deviation).  D – EC50 values, with 95% confidence intervals,  
for 2-DG treatment on cell viability 
A 
 
B 
C 
 
D 
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The next set of experiments were carried out to investigate the effect of 
versipelostatin treatment under glucose deprivation conditions on ER molecular chaperone 
protein levels in the haematological cell lines THP1 and U266.  The glycolysis inhibitor 2-
DG was used to induce glucose deprivation conditions in vitro.  As a result, the DOHH2 cell 
line was not used due to its extreme sensitivity to 2-DG treatment at concentrations required 
for glycolysis inhibition, as determined in the previous experiments.  In conjunction with the 
western blotting experiments, cytotoxicity experiments were carried out to establish the 
effect of versipelostatin treatment in combination with 2-DG treatment on cell number and 
viability.  Treatments with increasing concentrations of versipelostatin were carried out, 
alone or in the presence of 2-DG, for 24 hours before analysis. 
 
 After 24 hours of treatment, neither versipelostatin alone nor 2-DG alone exhibited 
any major effects on cell number in either the THP1 or U266 cell lines (see figures 7.7 and 
7.9 respectively).  The inhibition of cell proliferation seen with the combination of 
versipelostatin treatment and glucose deprivation conditions (mediated by 2-DG treatment) 
appeared to be broadly additive in both cell lines.  In the THP1 cell line, only the 0.3%M 
versipelostatin concentration showing a statistically significant decrease in cell number with 
glucose deprivation compared with versipelostatin alone under normal growth conditions.  In 
the U266 cell line, treatment with the highest versipelostatin concentration under glucose 
deprivation conditions led to a statistically significant increase in cell number compared to 
treatment under normal glucose conditions. 
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Figure 7.7.  Effect of treatment with VST alone, or in combination with 2-DG, for 24  
hours on cell number in THP1 cells.  Error bars show standard deviation.  * denotes  
statistically significant difference (p < 0.05) between treatment with VST alone and  
VST in combination with 2DG at that concentration. 
 
 
 
 
Figure 7.8. Effect of treatment with VST alone, or in combination with 2-DG, for 24  
hours on cell number in U266 cells.  Error bars show standard deviation.  * denotes  
statistically significant difference (p < 0.05) between treatment with VST alone and  
VST in combination with 2DG at that concentration. 
  
 
 
 
 
 &  
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 Following 24 hours of treatment, 2-DG had a minimal effect on cell viability in 
either the THP1 or U266 cell lines at the concentration studied (see figure 7.9 and 7.10 
respectively), with the U266 cell line being slightly more sensitive.  In the THP1 cell line, 
treatment with versipelostatin alone proved minimally toxic at all concentrations tested, as 
shown in figure 7.9.  However, when cells were treated with versipelostatin together with 2-
DG, there was a greater than additive decrease in cell viability compared to versipelostatin 
alone at all concentrations studied.  This increased cytotoxicity of versipelostatin combined 
with 2-DG proved statistically significant at the highest versipelostatin concentration used 
(10µM).  In the U266 cell line, versipelostatin treatment alone also had little effect on cell 
viability, with the highest concentration resulting in only a 13 percent decrease in viability 
compared to the untreated control (see figure 7.10).  It can also be seen that the combination 
of versipelostatin and 2-DG for 24 hours whilst having an additive effect at the lowest 
versipelostatin concentration, caused a greater than additive decrease in viability compared 
with versipelostatin alone at the three higher versipelostatin concentrations studied.  As with 
the THP1 cell line, this increased cytotoxic effect on U266 cell viability was statistically 
significant at the highest concentration studied. 
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Figure 7.9. Effect of treatment with VST alone, or in combination with 2-DG, for 24  
hours on cell viability in THP1 cells.  Error bars show standard deviation.  * denotes  
statistically significant difference (p < 0.05) between treatment with VST alone and  
VST in combination with 2DG at that concentration. 
 
 
 
 
Figure 7.10. Effect of treatment with VST alone, or in combination with 2-DG, for 24  
hours on cell viability in U266 cells.  Error bars show standard deviation.  * denotes  
statistically significant difference (p < 0.05) between treatment with VST alone and  
VST in combination with 2DG at that concentration. 
 
 
 
 
    &  
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 By this point, experiments had established the cytotoxic effect of versipelostatin as a 
single agent and confirmed an increased cytotoxic effect when versipelostatin treatment 
occurred under 2-DG mediated glucose deprivation conditions.  The next set of experiments 
were undertaken to investigate the ability of versipelostatin to downregulate GRP78 and 
GRP94 expression, both under normal cell culture conditions and glucose deprivation 
conditions.  It was decided to use a 10mM concentration of 2-DG, as this concentration has 
been used for glycolysis inhibition by other researchers, and yet is not unduly toxic in the 
haematological cancer cell lines being studied.  However, studies in solid tumours have used 
the higher concentration of 20mM 2-DG(Park et al., 2004).  A range of versipelostatin 
concentrations was then studied, as shown in figure 7.11, in order to identify any changes in 
protein levels of the molecular chaperones GRP78 and GRP94 after 24 hours treatment.  In 
both the AML cell line THP1 and the myeloma cell line U266, versipelostatin treatment 
alone had no effect on the protein levels of GRP78 and GRP94 compared to the untreated 
control.  There was a slight increase in both GRP78 and GRP94 protein levels with 2-DG 
treatment, although the effect was subtle, and the addition of versipelostatin to 2-DG 
treatment did not result in any change to the levels of these proteins.  No downregulation of 
GRP78 or GRP94 protein levels with versipelostatin under 2-DG mediated glucose 
deprivation conditions was seen in either haematological cell line studied. 
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Figure 7.11.  Effect of VST treatment, alone or in combination with  
2-DG, for 24 hours on GRP78 and GRP94 protein expression in  
THP1 cells (top panel) and U266 cells (bottom panel).  
GAPDH included as a loading control. 
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 Due to the inability of versipelostatin to downregulate GRP78 and GRP94 protein 
expression under glucose deprivation conditions in the haematological cell lines tested, the 
same experimental conditions were investigated in the colorectal cancer cell line HT-29, in 
which such downregulation has previously been reported in published studies.  
Versipelostatin treatment alone for 24 hours appeared to have little, if any, effect on the 
levels of the chaperone proteins studied.  However, when combined with 2-DG treatment, a 
downregulation of GRP78 protein levels was seen with versipelostatin at the 1, 3 and 10%M 
concentrations.  Effects on GRP94 protein were more subtle, although there did appear to be 
a decrease in protein with the 1%M versipelostatin concentration. 
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Figure 7.12. Effect of VST treatment alone, or VST in combination with  
2-DG, for 24 hours on GRP78 and GRP94 protein expression in HT29 cells.  
GAPDH is included as a loading control. 
 
 
 
 
7.4  Discussion 
 
The two molecular chaperones with the most direct effect on UPR activation and 
UPR signalling are GRP78 and GRP94.  Versipelostatin is a novel small molecule 
compound proposed to act via downregulation of GRP78 and GRP94 levels in glucose 
deprived cells (this glucose deprivation leads to ER stress and activation of the UPR).  
Studies of versipelostatin so far have been exclusively in solid tumours, and the activity of 
 240 
this novel compound in haematological malignancies has not previously been reported.  This 
is in line with other research concerning glycolysis and the Warburg effect in cancer, which 
has historically focused almost exclusively on solid tumours (Gatenby and Gillies, 2004).  
Whilst encouraging early studies of versipelostatin action have been reported, the detailed 
molecular mechanism underlying the effect of versipelostatin remains to be fully elucidated.  
The research group responsible for the initial discovery of versipelostatin have now 
synthesised a number of labelled derivatives of versipelostatin, with a view to developing a 
chemical biological method in order to identify the precise molecular target of this 
compound (Shin-Ya, 2005). 
 
Versipelostatin has been reported to downregulate GRP78 and GRP94 only in 
response to glucose deprivation mediated ER stress, and not to UPR activation mediated 
through other known pharmacological inducers, such as tunicamycin.  Therefore, it follows 
that this compound may have anticancer activity in tumours where hypoglycaemia is known 
to occur as a consequence of tumour growth (as is the case in a number of solid tumours).  In 
theory, treatment with versipelostatin may offer a tumour selective anticancer effect, 
resulting in decreased toxicity to normal (unstressed, non-glucose deprived) cells.  The 
glycolysis inhibitor 2-DG has long been used to induce glucose deprivation conditions in 
vitro, as has been done in the experiments in this chapter.  2-DG has also been investigated 
as an anticancer agent in its own right.  After promising pre-clinical findings, 2-DG 
progressed to a phase I clinical trial in solid tumours (Raez et al., 2006), however it has since 
been reported that development of 2-DG as a cancer therapeutic agent has been halted by the 
pharmaceutical company involved.  This was apparently a consequence of unacceptable 
toxicities reported at concentrations that are required for glycolysis inhibition in vivo 
(Gatenby and Gillies, 2004).  In the experiments described in this chapter, the effect of 
versipelostatin in downregulating ER molecular chaperone expression under glucose 
deprivation conditions was not observed in the haematological cancer cell lines studied.  
However, this downregulation was confirmed to occur when the same experiments were 
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carried out using the adherent solid tumour (colorectal cancer) cell line HT-29.  This 
observation supports the hypothesis that glucose deprivation, though a phenomenon 
associated with the growth of solid tumours, may be of less significance in haematological 
malignancies. 
 
It is also of note that the haematological cell lines proved more sensitive to the 
cytotoxic effects of versipelostatin treatment as a single agent than either the HT-29 cell line 
used in these experiments, or the solid tumour cell lines reported in other versipelostatin 
studies.  Versipelostatin was cytotoxic in these leukaemia, lymphoma and myeloma cell lines 
at low micromolar concentrations, indicating a potency in vitro comparable to that of 
clinically used cytotoxic agents such as 4-HC (the active metabolite of cyclophosphamide) 
or melphalan in these cell lines.  Further investigation may reveal that the increased potency 
of versipelostatin in these haematological cancers in vitro is mediated by a previously 
undescribed mechanism. 
 
In recent years it has been reported that a number of drugs widely used in clinical 
practice have other, previously unknown, off target effects linked to the unfolded protein 
response.  For example, the antidiabetic drug metformin (belonging to the biguanide class) is 
one of the most comment agents prescribed for the treatment of type 2 diabetes.  It acts by 
inhibiting glucose production in the liver, delaying intestinal glucose absorption and 
increasing insulin sensitivity in muscle.  It has been reported that metformin (and the other 
biguanide drugs buformin and phenformin) modulated the UPR under glucose deprivation 
conditions in a manner similar to that of versipelostatin (Saito et al., 2009).  Whilst a great 
deal more research is needed as regards metformin for cancer treatment, utilising drugs that 
are already in widespread clinical use for their UPR targeting effects is a particularly 
attractive treatment strategy.  A drug such as metformin that is taken orally, has been used 
for many years, is considered safe and has a well known adverse effect profile would be an 
ideal therapeutic candidate, particularly in light of the toxicity associated with administration 
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of 2-DG at clinically relevant concentrations for glycolysis inhibition(Gatenby and Gillies, 
2004).  However, it may well prove to be the case that the activity of agents such as 
metformin that have been described to modulate the UPR in the same manner as 
versipelostatin are only clinically relevant in glucose deprived solid tumours, as the 
experiments described in this chapter with versipelostatin suggest. 
 
One of the limitations of the agents mentioned above in targeting molecular 
chaperones is the possible lack of total selectivity for a given chaperone.  However, these 
therapeutic targets and anticancer agents have only recently been identified and it is hoped 
that with continued research, agents with higher target selectivity (and therefore more 
potential to pass successfully through the drug development process and into the clinic) will 
be identified. 
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8.  siRNA Mediated Gene Silencing of ER Resident Molecular 
Chaperones and the Effect on Chemosensitivity in vitro 
 
 
8.1  Introduction 
 
 Molecular chaperones facilitate the correct folding of proteins, with the ER 
containing a number of resident molecular chaperones, such as the heat shock protein (HSP) 
70 and HSP90 families, the lectins calnexin and calreticulin, and the HSP40 family of co-
chaperones (Ellgaard and Helenius, 2003, Alberts, 2002, Ma and Hendershot, 2004a).  The 
two molecular chaperones with the most direct effect on UPR activation and UPR signalling 
are the glucose related proteins (GRPs) GRP78 and GRP94.  Molecular chaperones have 
been discussed extensively in chapters 1 and 7. 
 
 GRP94 is the most abundant glycoprotein found in the ER and regulation of GRP94 
at the transcriptional level is linked to that of GRP78, as evidenced by conservation of 
elements of the regulatory promoter (Fu and Lee, 2006, Yang and Li, 2005).  GRP94 is the 
ER resident isoform of the cytosolic chaperone protein HSP90 and is a member of the 
HSP90 family of heat shock proteins.  Anticancer agents inhibiting HSP90 have now 
progressed to clinical trials (Smith and Workman, 2007).   In contrast to HSP90 (which has a 
very large number of client proteins, many of which are oncogenic), GRP94 appears to have 
a very limited number of client proteins.  The main roles of GRP94 described to date include 
involvement in B-cell differentiation and the immune response (Ni and Lee, 2007, Liu and 
Li, 2008).  Oncogenic client proteins of GRP94 identified to date are limited to ErbB1 and 
ErbB2 (also designated EGFR and HER2 respectively).  More recently it has been reported 
that insulin-like growth factor (IGF) 1 and 2 are also clients of GRP94.  This has 
implications for cancer research as IGF-1 signalling activates AKT, whose activation is a 
feature of numerous cancers.  
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 GRP78 is a member of the HSP70 family (Lee, 2007).  GRP78 recognises 
hydrophobic residues on unfolded or misfolded proteins and binds to them, thereby 
preventing their interaction with other molecules (Bole et al., 1986).  GRP78 is a vital 
mediator of the response to ER stress; it is the main ER stress sensor and dissociation of 
GRP78 from the three transmembrane UPR receptors is necessary for activation of the UPR. 
GRP78 has also been implicated in resistance to anticancer agents, which is discussed in 
more detail in chapter 1.5. 
 
The role of these key ER molecular chaperones in the UPR and chemosensitivity has 
been described in chapters 1 and 7.  In light of the importance of these ER resident molecular 
chaperones in cancer, modulating the UPR by targeting these chaperones has been proposed 
as a novel anticancer strategy.  Attempts to therapeutically target GRP78 and GRP94 in this 
project using small molecule approaches have not succeeded thus far.  In light of the positive 
results published by groups that have targeted GRP78 using gene silencing in vitro in solid 
tumours, it was decided to adopt this approach in the haematological cell lines being studied.  
This would establish whether the lack of any chemosensitising effect was due to lack of 
target efficacy of the small molecules tested in these experiments, or the absence of such a 
chemosensitising effect occurring in these haematological cancer cell lines following 
downregulation of these ER chaperone proteins.  Gene silencing, using small interfering 
RNA (siRNA) targeting GRP78 and GRP94 was therefore carried out and the resultant effect 
on chemosensitivity was determined using cytotoxicity assays and clonogenic assay. 
 
 
8.2  Materials and Methods 
 
8.2.1  siRNA Transfection 
 
 Experimental techniques used for transfection of small interfering RNA (siRNA) 
were as described in chapter 2.11.  HP Validated siRNA and HiPerFect Transfection 
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Reagent were obtained from Qiagen, UK.  The following siRNA duplexes were used: All 
Stars Negative Control siRNA Alexa Fluor 488 labelled (catalog no. 1027292), GRP78 
siRNA (catalog no. SI02780554), GRP94 siRNA (catalog no. SI02663738), GFP siRNA 
(catalog no. 1022064) and the positive control MAPK1 siRNA (catalog no. 1022564).  
Sequences for the siRNA duplexes used are given in chapter 2.11.  Positive control siRNA, 
negative control siRNA, mock transfected (transfection reagent without siRNA) and 
untransfected controls were included in all experiments. 
 
 Transfection was carried out as per the manufacturer’s protocol for suspension cell 
lines.  The day before transfection cells in exponential growth phase were seeded in flasks at 
a density of 3 x 105 cells/ml in RPMI-1640 containing 10% foetal bovine serum and 1% 
penicillin streptomycin.  Cells were incubated under normal growth conditions for 24 hours 
before plating out at 2 x 105 cells per well of a 24-well plate in 100µl culture medium 
containing serum and antibiotics.  100µl of siRNA at a concentration of 200nM (diluted in 
serum free medium) was added to 3µl of HiPerFect transfection reagent (giving a siRNA to 
transfection reagent ratio of 500:1), mixed by vortexing and incubated at room temperature 
for 5 to 10 minutes to allow formation of transfection complexes.  The transfection 
complexes were then added drop-wise onto the cells and mixed by swirling the plate.  Cells 
were incubated under normal growth conditions for a further 6 hours before the addition of 
400µl culture medium containing serum and antibiotics.  Cells were then returned to the 
incubator until analysis of transfection efficiency (and toxicity) at 24 hours post transfection.  
Further culture medium was added as required. 
 
8.2.2  Transfection Efficiency 
 
 The uptake of siRNA into cells was monitored by observation of Alexa Fluor 488 
fluorescence after transfection with Alexa Fluor 488 labelled negative control siRNA 
(Qiagen, UK).  The percentage of cells transfected with siRNA from the total cell population 
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(transfection efficiency) was determined at 24 hours post transfection for each siRNA 
transfection experiment.  Transfection was carried out as previously described, after which 
aliquots of cell samples were removed and analysed by flow cytometry (see chapter 2.12).  
Cells were washed twice with PBS, then resuspended in 500µl PBS and run immediately 
using a BD FacsCalibur flow cytometer with BD CellQuest software used for acquisition 
(BD Biosciences, UK).  Percent positive cells for fluorescence compared with mock 
transfected controls gave percentage uptake of siRNA, ie. transfection efficiency.  In 
conjunction with the transfection efficiency experiments, an aliquot of cells was also 
removed at this time for analysis of the cytotoxicity of the transfection process.  Cell number 
and viability was assessed using the Guava Viacount assay (methodology described in 
chapter 2.4). 
 
 A series of initial experiments were conducted to determine the optimum 
experimental conditions for transfection in the haematological cancer cell lines being 
studied, (i.e. effective delivery of siRNA into cells, with limited associated toxicity).  
Transfection reagents were tested using a range of siRNA concentrations, along with a range 
of dilution ratios of siRNA to transfection reagent.  Transfection efficiency was determined 
at 24 hours post transfection and, in conjunction with cytotoxicity data, used to determine the 
final siRNA concentration and ratio of siRNA to transfection reagent to be used in 
subsequent experiments.  All six cell lines in the haematological cell line panel (2 AML, 2 
MM, and 2 DLBCL) were used in initial experiments, before the THP1 (AML) and U266 
(MM) cell lines were chosen for further experiments. 
 
8.2.3  Knockdown Efficiency 
 
 Knockdown efficiency following siRNA transfection was determined at 48 and 72 
hours post transfection using reverse transcription real time polymerase chain reaction (RT-
PCR) as described in chapter 2.13.  All reagents for reverse transcription and real time RT-
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PCR were obtained from Applied Biosystems, UK.  TaqMan Fast Cells-to-CT Kit was used 
to prepare samples for use in real time (RT-PCR) according to manufacturer’s protocol.  
Pilot experiments were carried out using the TaqMan Fast Cells-to-CT Kit in conjunction 
with the TaqMan Cells-to-CT Control Kit in order to optimise the procedure and determine 
the cell number to be used for each cell line.  The prepared cell lysates were then reverse 
transcribed to cDNA using RT Enzyme Mix and buffer and run in a thermal cycler (37°C for 
60 minutes, then 95°C for 5 minutes to inactivate the RT).  Minus RT controls were included 
to demonstrate that the template for PCR was cDNA, not genomic DNA.  Completed RT 
reactions were either used immediately or stored at -20°C until use. 
 
 The cDNA was amplified by fast-cycling real time PCR using Taqman Fast 
Universal PCR Master Mix and Taqman Gene Expression Assay.  PCR Cocktail was added 
to cDNA samples and run in an Applied Biosystems 7900HD real time PCR instrument 
using fast settings (enzyme activation at 95°C for 20 seconds, PCR at 95°C for 1 second then 
60°C for 20 seconds x 40 cycles).  Gene expression assays were used for the target genes 
GRP78 (Assay ID: Hs00607129_gH) and GRP94 (Assay ID: Hs00427665_g1).  Assays 
were also used for the endogenous control gene actin (Assay ID: Hs03023880_g1) and the 
positive control gene MAPK1 (Assay ID: Hs00177066_m1).  Non-template control samples 
were included for each assay to ensure that any fluorescent signal generated in the assay was 
not due to DNA contamination. 
 
 Quantitative real-time PCR uses cycle threshold (CT) values to quantify the amount 
of starting template.  Knockdown of target mRNA following siRNA transfection was 
calculated using the delta delta CT (&&CT) method for relative quantitation as per the 
manufacturer’s protocol. &CT is the normalised expression value for the gene of interest, 
calculated as the difference in the CT value of the targeted mRNA vs. the CT of the 
endogenous control mRNA (any gene whose mRNA values do not change under the 
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experimental conditions).  This &CT value for the gene of interest is then compared to the 
&CT value for the negative control siRNA transfected sample.  Calculation of percentage 
knockdown was carried out as follows: 
• Mean CT and standard deviation of experimental replicates calculated 
• &CT (sample CT – endogenous control CT) for target siRNA transfected and control 
siRNA transfected samples calculated 
• &&CT calculated (&&CT = &CT target siRNA transfected sample – &CT negative 
control siRNA transfected sample) 
• Percentage knockdown (%KD) calculated using the formula  
%KD = (1–2–&&CT x 100)    
 
8.2.4  Cytotoxicity Studies 
 
 For chemosensitivity experiments, cells were transfected with target siRNA (grp78 
or grp94 siRNA) or control (non-targeting) siRNA (GFP siRNA).  Addition of drugs to cells 
was made at 48 hours post transfection and cells were incubated under normal growth 
conditions for a further 48 hours.  Cytotoxicity experiments were carried out at this time 
using the Guava Viacount assay, as described in section 2.4.  In the cytotoxicity experiments, 
each drug treatment was studied in triplicate and experiments were carried out on three 
separate occasions (following three independent siRNA transfection experiments). 
 
 Colony formation assay was carried out as described in chapter 2.14.  Cells were 
transfected with either target siRNA (grp78 or grp94 siRNA) or control siRNA (GFP 
siRNA) as described above.  At 48 hours post transfection, drugs were added to the cells (at 
the higher concentrations used in the cytotoxicity assays) and incubated for a further 48 
hours before medium containing drug was removed and cells resuspended in fresh medium.  
Cells were counted and viability determined before 500 cells per well were plated into 12-
well plates in MethoCult methylcellulose-based media (StemCell Technologies, UK) 
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according to the manufacturer’s instructions.  All plates contained wells with water only, in 
order to maintain humidity and prevent the methylcellulose from drying out.  The cells were 
then incubated under normal growth conditions and allowed to form colonies for 10 days.  
Each drug treated sample was grown in duplicate and each experiment was performed on 
two separate occasions (following two independent siRNA transfection experiments).  
Colonies were visualised for counting using an inverted microscope fitted with a camera.  
For each well, photographs were taken with the well viewed under 10x magnification from 
three different (randomly chosen) areas of the well.  Representative photographs of each 
sample were shown for illustration purposes. 
 
8.2.5  Statistical Analysis 
 
Statistical analysis was performed using Microsoft Excel software, Microsoft 
Corporation, USA.  The data obtained from cytotoxicity experiments and apoptosis assay 
was used to determine mean and standard deviation values for each drug concentration.  
These values were then used for graphical representation and subsequent statistical analysis.  
Data was assumed to be normally distributed and parametric tests were therefore used 
throughout.  Group means were analysed using a paired t-test, with a p value of less than 
0.05 considered to be statistically significant. 
 
8.3  Results 
 
 The AML cell line THP1 and multiple myeloma cell line U266 were chosen from 
initial transfection experiments to be used for further study.  For each transfection 
experiment, evaluation of transfection efficiency (percentage of transfected cells from the 
total cell population) and cytotoxicity and antiproliferative effects of the transfection process 
was determined at 24 hours post transfection.  Untransfected cells, mock transfected 
(transfection reagent only), along with samples containing siRNA without transfection 
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reagent were subject to the same experimental conditions as the siRNA transfected sample 
and used as an experimental controls. The effect of the transfection process on cell number 
and viability is given in figure 8.1 below.  It can be seen that the siRNA transfection process 
was not toxic to either the THP1 or U266 cell lines.  A small antiproliferative effect was seen 
in the transfected samples in both cell lines.  
 
 
 
 Figure 8.1.  Cell viability and cell number of transfected cells at 24 hours post  
 transfection in the THP1 and U266 cell lines.  Values shown are mean ± SD of  
 three separate experiments 
 
 
 Transfection efficiency was determined by uptake of fluorescently labelled siRNA 
using flow cytometry, the results are shown in figures 8.2 (THP1) and 8.3 (U266).  
Evaluation of transfection efficiency was carried out for each of the three transfection 
experiments in both cell lines studied.  Transfection efficiency was highest in the THP1 cell 
line, followed by the U266 cell line.  Representative histogram plots from the flow 
cytometry experiments are shown in figures 8.2 (THP1) and 8.3 (U266).  In both cell lines, 
an increase in fluorescence, along with the characteristic change in peak shape can be 
observed in the siRNA transfected samples compared to controls. 
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 Figure 8.2.  Transfection efficiency (percentage of transfected  
 cells from the total cell population) for the THP1 cell line as  
 determined by flow cytometry.   
 Top panel: Results from three separate transfection experiments 
 Bottom panel: Flow cytometry histogram plot of one transfection  
 efficiency experiment. 
 KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
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 Figure 8.3.  Transfection efficiency (percentage of transfected  
 cells from the total cell population) for the U266 cell line as  
 determined by flow cytometry.   
 Top panel: Results from three separate transfection experiments 
 Bottom panel: Flow cytometry histogram plot of one transfection  
 efficiency experiment. 
 KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
 
 
 
 Once successful uptake of siRNA by transfected cells was established, the next step 
in the gene silencing experiments was to evaluate the effect of siRNA transfection on the 
expression of the target (i.e. knockdown efficiency).  Knockdown of the target gene was 
determined at both the transcriptional (mRNA) and translational (protein) levels at both 48 
and 72 hours post transfection.  Percentage GRP78 mRNA knockdown, as determined by 
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real time RT-PCR, is shown in table 8.1.  Experiments to determine GRP94 mRNA 
knockdown could not be optimised in the time available.  Knockdown of GRP78 and GRP94 
at the protein level, determined by western blotting, is shown in figure 8.2 (blots shown are 
representative of three separate experiments).  It can be seen that when siRNA targeting 
GRP78 was used, there appeared to be some upregulation of GRP94 at the protein level.  
This increase in GRP94 protein was most visible in the U266 cell line. 
 
 
Cell line siRNA Knockdown (%) 
at 48 hours 
Knockdown (%) 
at 72 hours 
THP1 GRP78 63.1 96.8 
U266 GRP78 72.5 71.9 
 
        Table 8.1.  Knockdown efficiency as determined by real time  
        RT-PCR in cells transfected with siRNA targeting GRP78 at 48 
        and 72 hours post transfection. 
 
 
 
 
      THP1      U266 
 
    
 
 
 
 
 
 
 
   GRP78   
 
   GRP94  
 
Figure 8.4.  Westerns to show GRP78 and GRP94 protein expression in  
untransfected cells, mock transfected cells, and cells transfected with  
siRNA targeting GRP78, GRP94 or GFP at 72 hours post transfection. 
 
 
 
 After knockdown of the target gene had been achieved, the transfected cells were 
then used for further study.  Chemosensitivity was investigated 48 hours after transfection 
with siRNA targeting GRP78 or GRP94.  Cells transfected with siRNA targeting GFP were 
used as a control in the chemosensitivity experiments.  At 48 hours post transfection, 
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assessment of cell number and viability was carried out prior to experimental set up, in order 
to confirm no excessive toxicity was observed from the transfection process.  This was done 
for three separate transfection experiments and the mean values with standard deviations are 
shown in figure 8.5.  It can be seen that the results at 48 hours post transfection do not reveal 
any excessive toxicity when compared to the results obtained 24 hours following 
transfection, but a small antiproliferative effect was apparent, particularly in U266 cells. 
 
 
 Figure 8.5.  Cell viability and cell number of transfected cells at 48 hours post  
 transfection in the THP1 and U266 cell lines.  Values shown are mean ± SD of  
 three separate experiments 
 
 
 Transfected cells were then treated with drugs for a further 48 hours, before analysis 
of the effect of GRP78 or GRP94 knockdown on chemosensitivity.  This was done either by 
analysis of cell proliferation and viability using plate based cytotoxicity assays, or by 
washing the cells and plating out for colony formation assay to determine their ability to 
recover and form colonies in longer term culture.  The results of the cell viability and 
proliferation experiments are shown in figures 8.6 to 8.9. 
 
 The effect of GRP78 and GRP94 knockdown on chemosensitivity was not marked, 
but overall there was a trend toward increased chemosensitivity in the THP1 cell line.  
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Following 48 hours of drug treatment, with all drugs at all concentrations studied, there was 
a decrease in cell number in the GRP78 and GRP94 knockdown cells compared to the 
control GFP siRNA transfected cells (see figure 8.6).  This decrease in cell number 
following drug treatment with the GRP94 knockdown was statistically significant at the two 
higher tunicamycin concentrations (1µM, p<0.001 and 10µM, p<0.05) and the two lower 
thapsigargin concentrations (10nM, p<0.05 and 100nM, p<0.05).  Although the effect was 
modest, GRP94 knockdown appeared to sensitise cells to a greater extent than GRP78 
knockdown (exceptions being thapsigargin and SAHA at the highest concentration used).   
 
 This pattern was less apparent in the effect of GRP78 and GRP94 knockdown on 
cell viability in the THP1 cell line (see figure 8.7).  With the majority of drugs and 
concentrations investigated, cell viability following 48 hours of drug treatment was not 
changed by GRP78 or GRP94 siRNA transfection. However, there was a statistically 
significant decrease in cell viability compared to control siRNA in the cells with GRP78 
knockdown following treatment with tunicamycin 1µM and bortezomib 1nM for 48 hours 
(p<0.05 for both).  The decreased viability in the GRP78 knockdown cells following 
bortezomib treatment, although statistically significant, was small and therefore unlikely to 
be of any clinical significance.  The reduction in cell viability observed after drug treatment 
in the GRP94 knockdown cells was also statistically significant with the 10µM concentration 
of tunicamycin (p<0.01). 
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Figure 8.6.  Effect of drug treatment for 48 hours on cell number in THP1 cells transfected with siRNA targeting GRP78, GRP94 and the control 
siRNA targeting GFP.  Error bars show mean ± standard error of three separate experiments.  * or ** denotes statistically significant difference  
between GRP94 siRNA and GFP control siRNA (p<0.05 and p<0.01 respectively). 
 
 
 
 
      **      *       *       * 
     ___   ___   ___   ___ 
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Figure 8.7.  Effect of drug treatment for 48 hours on cell viability in THP1 cells transfected with siRNA targeting GRP78, GRP94 and the control 
siRNA targeting GFP.  Error bars show mean ± standard error of three separate experiments. # denotes statistically significant difference  
between GRP78 siRNA and GFP control siRNA (p<0.05). ** denotes statistically significant difference between GRP94 siRNA and GFP  
control siRNA (p<0.01). 
 
 
 #         
__      ** 
         ___ 
      
    #            
   __       
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 Figure 8.8 shows the effect of transfection with siRNA targeting GRP78, GRP94 or 
the control GFP, on cell number following 48 hours of drug treatment in the U266 cell line.  
There was little effect of GRP78 and GRP94 knockdown on chemosensitivity in U266 cells.  
There was a trend towards decreased cell number following 48 hours of drug treatment in the 
GRP94 knockdown cells compared to cells transfected with the control siRNA targeting 
GFP, however this was only statistically significant at the 3µM thapsigargin concentration 
(p<0.01).  No statistically significant changes in cell number after drug treatment was 
observed in the GRP78 transfected cells compared to GFP transfected control. 
 
 The effect of transfection with siRNA targeting GRP78, GRP94 or the control GFP 
on cell viability following 48 hours drug treatment in the U266 cell line can be seen in figure 
8.9. The only statistically significant changes in the target knockdown cells compared to the 
control were observed in the samples treated with 17-AAG.  A statistically significant 
decrease in cell viability was seen following 17-AAG treatment in the GRP78 knockdown 
cells at the 3µM concentration and in the GRP94 knockdown cells at the 1µM concentration 
compared to cells transfected with non-targeting siRNA (p<0.05 for both).  
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Figure 8.8.  Effect of drug treatment for 48 hours on cell number in U266 cells transfected with siRNA targeting GRP78, GRP94 and the  
control siRNA targeting GFP.  Error bars show mean ± standard error of three separate experiments.  ** denotes statistically significant  
difference between GRP94 siRNA and GFP control siRNA (p<0.01) 
 
    ** 
   ___ 
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Figure 8.9.  Effect of drug treatment for 48 hours on cell viability in U266 cells transfected with siRNA targeting GRP78, GRP94 and the control 
siRNA targeting GFP.  Error bars show mean ± standard error of three separate experiments.  # denotes statistically significant difference  
between GRP78 siRNA and GFP control siRNA (p<0.05). * denotes statistically significant difference between GRP94 siRNA and GFP  
control siRNA (p<0.05). 
 
       * 
    ____  # 
  __ 
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 In addition to the cytotoxicity experiments with 48 hours of drug treatment in the 
cells transfected with target or control siRNA, colony formation assay was also conducted to 
determine the ability of these drug treated transfected cells to recover and grow as colonies 
in longer term culture conditions.  In both the THP1 cell line and U266 cell line, colony 
growth in the non-drug treated GRP78 and GRP94 knockdown cells was comparable to that 
of the untreated GFP siRNA transfected cells as well as non-drug treated untransfected cells 
(see figures 8.8 and 8.9 respectively).  Photographs of colonies formed in the THP1 and 
U266 transfected cells following drug treatment are shown in figures 8.10 and 8.11 
respectively. 
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     Untransfected control       THP1 
          
    
     GFP siRNA    GRP78 siRNA           GRP94 siRNA 
         
 
 
Figure 8.8.  Colony formation assay in untransfected and siRNA transfected THP1 cells.  
Representative photographs are shown for each sample. 
 
 
 
     Untransfected control       U266 
         
 
     GFP siRNA   GRP78 siRNA         GRP94 siRNA 
       
 
 
Figure 8.9.  Colony formation assay in untransfected and siRNA transfected U266 cells. 
Representative photographs are shown for each sample. 
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 In the THP1 cell line (see figure 8.10), transfection with siRNA targeting GRP78 or 
GRP94 rendered cells unable to recover and form colonies to the same extent as the cells 
transfected with control GFP siRNA following treatment with tunicamycin, doxorubicin, 
bortezomib and SAHA.  Neither GRP78 nor GRP94 knockdown affected the colony growth 
observed following treatment with 17-AAG in this cell line.  No colony growth was seen 
following thapsigargin treatment in either the cells transfected with target siRNA or control 
siRNA in the THP1 cell line. 
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     GFP siRNA  + TM   GRP78 siRNA TM          GRP94 siRNA TM 
         
 
     GFP siRNA Dox  GRP78 siRNA Dox          GRP94 siRNA Dox  
         
 
     GFP siRNA Bort  GRP78 siRNA Bort          GRP94 siRNA Bort 
          
 
     GFP siRNA 17-AAG GRP78 siRNA 17-AAG          GRP94 siRNA 17-AAG  
         
  
     GFP siRNA SAHA  GRP78 siRNA SAHA          GRP94 siRNA SAHA 
         
  
Figure 8.10.  Colony formation assay following 48 hours of drug treatment in the THP1 cell  
line.  Representative photographs are shown for each sample. 
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 In the U266 cell line (see figure 8.11), transfection with either GRP78 or GRP94 
siRNA led to a reduction in colony growth compared to the GFP transfected cells following 
treatment with SAHA.  There also appeared to be a small decrease in colony growth 
following thapsigargin treatment.  A reduction in colony formation was observed in the 
GRP78 siRNA transfected cells after treatment with 17-AAG, but not in the GRP94 siRNA 
transfected U266 cells.  No colony growth was seen in either the control or target siRNA 
transfected cells following treatment with tunicamycin, doxorubicin or bortezomib in the 
U266 cell line. 
 
 
 
 
     GFP siRNA TG  GRP78 siRNA TG        GRP94 siRNA TG 
       
 
     GFP siRNA 17-AAG GRP78 siRNA 17-AAG        GRP94 siRNA 17-AAG 
       
 
     GFP siRNA SAHA  GRP78 siRNA SAHA        GRP94 siRNA SAHA 
       
 
Figure 8.11.  Colony formation assay following 48 hours of drug treatment in the U266 cell  
line.  Representative photographs are shown for each sample. 
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8.4  Discussion 
 
 Previous studies conducted in solid tumours have reported that knockdown of 
GRP78 increases chemosensitivity (Pyrko et al., 2007b, Dong et al., 2005, Lee et al., 2008).  
The experiments conducted here suggest that the role of ER molecular chaperone 
knockdown in chemosensitivity is less clear-cut in these haematological cell lines.  However, 
it should also be noted that the transfection system used in these experiments did not result in 
a complete knockdown of the targeted protein, and further experiments using a lentiviral 
vector system to deliver short hairpin RNA (shRNA), resulting in stable transfection, could 
be utilised to achieve this and further investigate the effect of knockdown on 
chemosensitivity. 
 
 Results of cytotoxicity assay in cells with siRNA mediated GRP78 and GRP94 gene 
silencing revealed only a modest effect on chemosensitivity in these haematological cancer 
cell lines.  In both cell lines, statistically significant sensitisation to the anticancer agents 
used occurred with only a minority of drug treatments studied.  Sensitisation was more 
apparent in the THP1 cell line, in comparison with the U266 cell line.  In the AML cell line 
THP1, knockdown of GRP94 sensitised cells to the antiproliferative effects of the two ER 
stress inducing agents tunicamycin and thapsigargin, although the effect was small.  In the 
U266 cell line, GRP78 knockdown resulted in a decrease in sensitivity to the cytotoxic effect 
of treatment with 17-AAG, a HSP90 inhibitor.   No consistent pattern was seen in the effect 
of knockdown on chemosensitivity in these cell lines, neither in terms of cell number, nor 
viability. 
 
 Other investigators have reported that knockdown of GRP78 in mouse models led to 
an increase in the levels of both GRP94 mRNA and protein (Luo et al., 2006), and that this 
increase is a consequence of a novel compensatory feedback mechanism (Fu and Lee, 2006).  
Western blotting experiments in described in this chapter also suggest that when GRP78 is 
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silenced using a siRNA approach in the U266 cell line, an increase in GRP94 protein can be 
observed.  It is possible that this is a compensatory mechanism, designed to protect ER 
molecular chaperone function and may influence the response to drug treatment after GRP78 
knockdown.  Interestingly, in the THP1 cell line the GRP78 knockdown resulted in a 
decrease in sensitivity to the cytotoxic effect of treatment with 17-AAG, an inhibitor of 
cytosolic HSP90, which has also been shown to bind to GRP94.  Further investigation may 
reveal whether this antagonism is related to this possible compensatory feedback mechanism 
for these ER molecular chaperones. 
 
 When designing the colony formation experiments, it was intended that each well 
would be photographed (i.e. one picture of the entire well) enabling counting of the total 
number of colonies per well.  Replicate wells could then be averaged and the mean of the 
two separate experiments could be calculated, along with standard deviation, with this data 
illustrated graphically.  However, due to a fault with the microscope, the required objective 
was unavailable and this was unfortunately not possible.  Therefore, representative 
photographs from each set of replicates are shown for illustration purposes.  Further 
experiments conducted according to the originally planned methodology would provide 
quantitative results for the effect of chaperone knockdown on colony formation post drug 
treatment in these haematological cell lines. 
 
 The results of colony formation assay in the THP1 cell line confirmed the trend seen 
after the 48 hour cytotoxicity assay, with GRP78 or GRP94 knockdown enhancing the 
cytotoxic effects of drug treatment as shown by a decrease in the ability of these cells to 
recover and form colonies in longer term culture.  The only exception to this was following 
treatment with 17-AAG in this cell line, where neither GRP78 nor GRP94 knockdown had 
any effect on colony formation.  This may be related to the compensatory feedback loop 
suggested above, and further experiments would be needed to determine if this was in fact 
the case.  In this cell line, no colony growth was seen following treatment with thapsigargin 
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in either the target or control (non-targeting) siRNA transfected cells.  This may indicate that 
the THP1 cell line is particularly susceptible to ER stress induced cell death, mediated via 
SERCA inhibition, with cells being unable to recover upon removal of drug. 
 
 Whilst the cytotoxicity assay results in the U266 cell line showed limited effects of 
chaperone knockdown on chemosensitivity, colony formation assay did show a 
chemosensitising effect of molecular chaperone knockdown to treatment with SAHA, and to 
a lesser extent, thapsigargin.  Chemosensitisation to 17-AAG treatment was only seen in the 
GRP78 knockdown cells, and further experiments would be required to establish the 
mechanism behind the differing responses seen with GRP78 or GRP94 knockdown cells 
following 17-AAG treatment.  U266 cells proved particularly susceptible to the longer term 
effects of treatment with tunicamycin, doxorubicin and bortezomib, with no colony growth 
observed in any of the samples, including the transfection control samples.  
 
 In conclusion, some chemosensitisation effects were seen in these haematological 
cell lines, particularly in the AML cell line THP1.  However, the chemosensitisation 
observed was modest and not present to same extent as that previously reported in solid 
tumours. 
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9. Discussion and Conclusions 
 
 
 At the time work began on this PhD project, ER stress and the unfolded protein 
response were generating a great deal of interest and excitement amongst cancer researchers.  
A considerable amount of research had already been published on the UPR and its role in 
cancer, however work in this emerging field almost exclusively related to solid tumours.  
This focus on solid tumours was understandable given that a number of the physiological 
conditions known to cause ER stress were more applicable to solid tumours, such as glucose 
deprivation or hypoxia.  Very little research had been done at this point looking at the UPR 
in haematological malignancies, with the few studies that had been done looking at multiple 
myeloma.  During the few years spent working on this project, the UPR has continued to be 
an area of intense study.  More work has now been published on the UPR and 
haematological cancers, with a number of studies looking at the role of the UPR in drug 
treatment of cancers also being reported.  The work presented in this thesis further 
contributes to the knowledge of this exciting area of cancer therapeutics. 
 
Whilst there has been considerable progress in understanding the mammalian UPR 
in recent years, a number of important issues remain outstanding.  One of the key issues is 
whether a therapeutic window exists in which modulating the UPR can be used as a 
therapeutic strategy in cancer and other diseases.  As outlined in the introduction to this 
thesis, the UPR is a complex signalling pathway, initiated in response to a number of 
perturbations in ER homeostasis, with far reaching consequences for the cell (and the 
organism as a whole).  Promising early results of modulating the UPR in solid tumours, such 
as glioblastoma, have been published (Pyrko et al., 2007b, Dong et al., 2005, Lee et al., 
2008).  The work contained in this thesis focused on the potential of modulating the UPR in 
haematological malignancies.  Research in this area is still in its infancy in comparison to the 
body of work published in solid tumours, and much remains to be determined.  The data 
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presented here adds to the current knowledge of the UPR in haematological malignancies 
and the potential for targeting the UPR as a novel therapeutic strategy in vitro. 
 
 The first stage in this thesis was to establish the basal level of UPR activation in 
haematological cancer cells.  This work was done in a panel of commonly used and well-
characterised haematological cancer cell lines.  Three cell lines were chosen, each 
representing one of three major types of haematological malignancy; AML, multiple 
myeloma and DLBCL.  Basal activation of the UPR in cancer cell lines has not been 
described in this manner previously and novel insights into the role of the basal 
(physiological) UPR have been elucidated.  It was observed that these haematological cell 
lines had a constitutively active UPR.  It was particularly interesting to note the differences 
in protein expression of proteins in the three branches of UPR signalling; PERK, IRE1 and 
ATF6.  Whilst small differences were seen between individual tumour types, in general, 
similar UPR protein activation was observed according to the tumour type studied, with the 
myeloma (and AML) cell lines exhibiting higher expression of IRE1 protein and the 
lymphoma cell lines showing higher expression of PERK pathway proteins.  These findings 
suggest that different cell types have differences in their basal UPR activation.  This agrees 
with established thought on the UPR, where it is believed that for certain types of cell, such 
as highly secretory cells, the UPR plays a more important role in maintaining protein 
homeostasis and normal cellular function (Glimcher and Hetz, 2008, Obeng et al., 2006).  
 
 Interesting differences were also seen when basal UPR activation in the 
haematological cell line panel was compared with the solid tumour cell line HT29 and two 
samples of peripheral blood mononuclear cells (PBMC) from healthy donors.  Increased 
expression of GRP78 was seen in the cancer cell lines compared to the healthy 
haematological cell PBMC samples.  Although the number of normal samples was small, 
this finding highlights the potential value in targeting GRP78 as a cancer cell selective 
therapeutic strategy in these haematological malignancies. 
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The search for clinically meaningful in vitro models of haematological malignancies 
is ongoing, in an attempt to more closely reflect the complex tumour microenvironment of 
malignancies such as multiple myeloma.  Whilst it would therefore have been preferable to 
confirm these cell line findings in primary tumour samples, the high demand and scarcity of 
supply of these patient tumour samples meant that this was not possible.  Further 
experiments using a panel of primary tumour samples would be valuable in confirming 
whether UPR activation (and the differential pattern of activation seen across the various 
haematological cancer types studied) is also present in patient tumours ex vivo.  
 
 Analysis of cell proliferation and cell viability following drug treatment did not 
discover a direct relationship between basal UPR activation status and sensitivity to 
anticancer agents.  However, these experiments did reveal that sensitivity to pharmacological 
ER stress inducers differed widely amongst the haematological cell lines studied, and 
sensitivity was dependent on the ER stressor used.  This suggests that the sensitivity of 
cancer cells to ER stress inducing agents is specific to the mechanism of ER stress induction, 
and not as a result of general exposure to ER stress.  This finding has implications for 
anticancer agents whose mechanism of action is related to ER stress induction, raising the 
possibility that efficacy may be cancer type specific.  These experiments also established that 
novel anticancer agents and ER stress inducers did not always produce the characteristic 
cytotoxic effect expected from traditional cancer chemotherapy, with only antiproliferative 
effects seen in some of the cell lines studied. 
 
 Once basal UPR activation had been established, activation of the UPR following 
drug treatment was then studied.  A number of potential approaches were available to 
undertake such studies, with the main strategies being either a detailed study of a limited 
number of UPR markers, or a snapshot of global UPR activation.  It was decided to adopt the 
latter strategy, as this would identify potential areas of interest in these haematological cell 
lines that could then be studied in further detail.  The UPR has not previously been 
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characterised in this way in haematological malignancies, so this was considered a suitable 
starting point for further investigation on the role of the UPR in chemosensitivity in these 
cell lines.  Consequently, the results presented in chapter 4 represent a snapshot of global 
UPR activation following drug treatment for the purposes of highlighting potential areas of 
interest, and should not be viewed as quantitative or definitive results.  With that in mind, 
whilst it was not possible to repeat all experiments presented due to the scope of the work 
undertaken, experiments were repeated to confirm notable results observed.  In addition, 
only clear changes in protein levels were highlighted in the results observed.  These changes 
are summarised in figures 4.19 to 4.26 inclusive.  In general, it appeared that UPR activation 
was limited following treatment with conventional DNA damaging chemotherapy agents, 
with a greater degree of UPR activation seen after treatment with both the novel anticancer 
agents (bortezomib and KW-2478) and ER stress inducing agents (tunicamycin and 
thapsigargin) studied.  The increase in UPR activation seen with the novel HSP90 inhibitor 
KW-2478 was more pronounced than any of the other agents studied, including the ER stress 
inducers tunicamycin and thapsigargin.  These results support previous studies which have 
shown that treatment with the HSP90 inhibitior 17-AAG and the proteasome inhibitor 
bortezomib are associated with induction of ER stress and UPR activation in multiple 
myeloma cells (Davenport et al., 2007; Obeng et al., 2006).  Future experiments providing 
more information on the functional significance of HSP90 inhibitors binding to the ER 
homologue of HSP90, GRP94, in vivo would further the current knowledge on the 
relationship between HSP90 inhibition and activation of the UPR. 
 
 The experiments presented in chapters 3 and 4 of this thesis provided some novel 
findings on basal UPR activation status in this haematological cancer cell line panel, 
sensitivity of these cell lines to both conventional and novel anticancer agents, as well as ER 
stress inducing agents, and UPR activation in response to treatment with these drugs.  A 
number of potential strategies for targeting the UPR and studying chemosensitivity were 
identified, such as modulating the IRE1 pathway in AML and myeloma cell lines, or 
 273 
targeting the PERK pathway in the lymphoma cell lines.  It was observed that the key ER 
molecular chaperones GRP78 and GRP94 were implicated in all haematological cancer cell 
lines studied, with these chaperone proteins therefore considered good candidates for further 
study of the relationship between the UPR and chemosensitivity in these cell lines.   
 
These haematological cancer cell lines had been shown in earlier experiments in this 
thesis to have a constitutively active UPR (see chapter 3), with evidence of UPR activation 
seen following even minimally toxic concentrations of ER stress inducing agents in some 
cell lines (see chapter 4).  The effect of treatment with minimally toxic concentrations of an 
ER stress inducing agent on chemosensitivity was therefore investigated in the cell line 
panel.  The rationale for adopting this approach was to investigate whether minimally toxic 
concentrations of ER stressors were sufficient to increase the apoptosis seen following 
anticancer drug treatment in these cells with a constitutively active UPR.  If successful, this 
strategy would have the advantage of using much lower concentrations of ER stress inducing 
agents, which due to their mechanism of action are known to be highly toxic to normal cells, 
as well as cancer cells.  Thapsigargin was chosen for these experiments as it is a much more 
potent inducer of ER stress than tunicamycin.  The earlier drug activity experiments in 
chapter 3 had used the Guava Viacount assay to analyse both cell number and cell viability 
effects.  However, the equipment being in high demand, combined with the sheer number of 
experiments to be undertaken meant that an alternative method of analysing cytotoxicity had 
to be used.  A high sensitivity ATP cytotoxicity assay was therefore utilised for the 
experiments in chapters 5 and 6 of this thesis.  Concentrations used with the ATP assay were 
lower than those used to see an effect on viability in the Guava Viacount assay, due to the 
cells beginning to lose ATP before there is loss of membrane permeability, therefore the 
ATP assay is more sensitive to changes in viability (with lower concentrations needed to see 
an effect). 
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There are a number of established methods of investigating and analysing the effect 
of combinations of drugs.  Two of the most commonly used methods are to compare the 
combination effect with the single agent effect of either drug alone, or to compare the 
combination effect with an expected combination effect, based on the addition of the single 
agent effects of both drugs.  Another widely used method is the combination index method 
of Chou and Talalay (Chou and Talalay, 1984).  This method is particularly effective for 
analysis of combinations across a wide range of concentrations, where a constant ratio is 
maintained between the agents being studied, and for the study of more than two inhibitors. 
However, the purpose of these experiments was to act as an initial screen of only two 
concentrations used in combination, and if any synergy was seen the plan was to then carry 
out a more detailed set of experiments (for example, using the combination index method 
across a larger concentration range using constant ratios).  For this reason, it was decided to 
use the fractional product method of Webb (Webb, 1963) to study the combination effect.  
As with the other combination analysis methods available the fractional product method also 
has its limitations.  Whilst widely used by investigators, this method is considered most valid 
where the inhibitors obey first order kinetics, and where the inhibitors being tested have 
independent mechanisms of action.  Whilst this method may not be ideal, it was considered 
the most appropriate in this case.  In any event, treatment with minimally toxic thapsigargin 
concentrations was not found to have any synergistic effect with chemotherapy, with an 
antagonistic effect seen after pre-treatment with thapsigargin for 6 hours.  This effect was 
consistent across all cell lines in the panel, and has interesting implications for the use of 
thapsigargin clinically.  While experiments presented here suggest that the protective effect 
seen was due to changes in cell proliferation, further experiments are needed to fully 
elucidate the nature of this interaction and whether it occurs as a result of ER stress induction 
or rather as a result of thapsigargin mediated changes in intracellular calcium, or another as 
yet unidentified mechanism. 
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 Another strategy utilised to modulate the UPR in these haematological cancer cell 
lines, was the use of the chemical chaperone 4-penylbutyric acid.  This compound has been 
reported to act as a chemical chaperone, thereby reducing ER stress mediated cellular 
dysfunction (Welch and Brown, 1996).  It was therefore hypothesised that if 4-PBA could 
reduce the levels of ER stress in these haematological cells where the UPR is constitutively 
active, then this may make the cells more sensitive to treatment with anticancer agents 
(particularly those known to induce ER stress).  The apoptosis assay data for the 
combination of 4-PBA pre-treatment for 24 hours with the ER stressors tunicamycin and 
thapsigargin appears to support this hypothesis, although western blotting did not reveal any 
changes in the UPR proteins studied at these concentrations.  However, analysis of HDAC 
activity showed that at the 0.5mM concentration used in these experiments, 4-PBA did 
possess weak HDAC inhibitory activity, with further experiments needed to determine if the 
results seen were due to chemical chaperone or HDAC inhibitory effects. 
 
 The activity of the novel small molecule versipelostatin was also studied.  This 
promising small molecule is an inhibitor of both ER molecular chaperones GRP78 and 
GRP94.  Inhibition occurs under glucose deprivation conditions, and although the previously 
published downregulation of these chaperones reported in solid tumours (Park et al., 2004) 
was confirmed in these experiments, downregulation was not observed in the haematological 
cell lines studied.  This raises the possibility that glucose deprivation conditions have a more 
pronounced effect on solid tumour cells than haematological cells in vitro, and that 
versipelostatin may be of more value in the treatment of glucose starved solid tumours than 
haematological malignancies.  However, versipelostatin is an anticancer agent in its own 
right with potency in the low micromolar range, and the haematological cell lines studied 
appearing more sensitive than the widely used solid tumour cell line HT-29.  In addition, 
increased cytotoxicity was observed when versipelostatin was combined with 2-DG, 
compared to single agent versipelostatin treatment.  Further investigation is needed to 
determine whether versipelostatin also acts via other, as yet undetermined, mechanisms. 
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 With attempts to target the UPR in order to modulate chemosensitivity in this thesis 
using small molecules having had minimal success, siRNA mediated silencing of GRP78 
and GRP94 was investigated to provide proof of concept that the UPR (and ER molecular 
chaperones in particular) are a valid therapeutic target in these haematological cancer cell 
lines.  Earlier experiments in this thesis had shown that the molecular chaperones GRP78 
and GRP94 were highly expressed in these haematological cell lines, and protein levels were 
seen to increase following treatment with ER stress inducing agents and novel anticancer 
agents.  Other investigators have previously shown the potential benefit of GRP78 
knockdown on chemosensitivity (Pyrko et al., 2007b, Dong et al., 2005, Lee et al., 2008) 
and due to the high basal levels of GRP94 seen in these haematological cancer cells, GRP94 
knockdown was also studied.  Cytotoxicity experiments revealed minimal effects of GRP78 
or GRP94 knockdown on chemosensitivity in the AML cell line THP1 and myeloma cell 
line U266.  Whilst some decrease in proliferation was seen on the colony formation assay, 
this experiment did not provide quantitative data and further experiments would therefore be 
needed to confirm this effect.  Previous reports in glioblastoma cell lines have shown that 
whilst transfection with siRNA targeting GRP78 is sufficient to decrease basal GRP78 
levels, it does not prevent the induction of GRP78 protein seen upon induction of ER stress 
(Kardosh et al., 2008), suggesting the possibility that GRP78 induction following drug 
treatment may act to restore the silenced GRP78 function.  Further experiments investigating 
the effect of GRP78 and GRP94 knockdown on chemosensitivity in these haematological 
malignancies are required to probe such an effect.     
 
 This thesis adds to the current knowledge of the UPR in haematological 
malignancies, an area that is continuing to provide novel discoveries and areas for further 
development in the search for new cancer treatments.  One such area is the development of 
small molecule IRE inhibitors (Papandreou et al., 2011), which is of particular significance 
in multiple myeloma.  Other important research areas include the discovery that GRP78 is 
found outside the ER, in locations including the nucleus, cytoplasm and mitochondria, and 
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what significance this may have on the viability of GRP78 as a therapeutic target (Ni et al., 
2011, Pfaffenbach and Lee, 2010, Zhang et al., 2010).  Studies also continue with 
versipelostatin and its derivatives.  Recently, data on another GRP78 targeting compound 
NKP-1339 (developed by Niiki Pharma) was presented at the American Society of Clinical 
Oncology Annual Meeting 2011, with a phase I clinical trial of this agent in patients with 
metastatic solid tumours resistant to standard therapies initiated in the United States 
(ClinicalTrials.gov identifier: NCT01415297) (Dickson et al., 2011).  The UPR remains a 
promising area of cancer research, and the arrival of the first UPR targeted therapy to reach 
the clinic is eagerly awaited. 
 
 In conclusion, the UPR is activated in these haematological cancer cell lines and 
plays a complex role in chemosensitivity.  In contrast to previous reports in solid tumour 
cells, modulating the UPR in these haematological malignancies had only a modest effect on 
chemosensitivity. 
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11. Appendices 
 
Appendix 1 
 
Additional data for chapter 3: 
 
Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 10nM 80.2 85.6 85.7 83.8 3.1 
HL-60 100nM 84.4 87.7 80.8 84.3 3.5 
HL-60 1!M 48.7 51.0 46.3 48.7 2.4 
HL-60 10!M 49.2 47.0 44.4 46.9 2.4 
HL-60 100!M 23.6 20.8 31.7 25.4 5.7 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 10nM 66.2 80.2 88.6 78.3 11.3 
THP-1 100nM 43.8 53.9 58.3 52.0 7.4 
THP-1 1!M 42.8 50.4 42.8 45.3 4.4 
THP-1 10!M 49.4 44.7 40.4 44.8 4.5 
THP-1 100!M 31.3 33.1 30.2 31.5 1.5 
       
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 10nM 97.9 94.8 91.1 94.6 3.4 
RPMI-8226 100nM 95.5 77.5 93.7 88.9 9.9 
RPMI-8226 1!M 75.9 61.9 62.3 66.7 8.0 
RPMI-8226 10!M 62.8 54.8 59.8 59.1 4.0 
RPMI-8226 100!M 40.4 31.4 44.7 38.8 6.8 
       
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 10nM 87.0 91.8 93.0 90.6 3.2 
U266 100nM 86.3 85.9 89.6 87.3 2.0 
U266 1!M 71.0 78.7 76.8 75.5 4.0 
U266 10!M 63.6 62.2 68.0 64.6 3.0 
U266 100!M 38.1 47.4 60.0 48.5 11.0 
       
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 10nM 99.9 100.5 95.6 98.7 2.7 
DOHH2 100nM 75.8 79.3 79.1 78.1 2.0 
DOHH2 1!M 50.2 43.4 40.0 44.5 5.2 
DOHH2 10!M 44.7 34.8 38.3 39.3 5.0 
DOHH2 100!M 31.0 32.1 31.0 31.4 0.6 
       
SUD4 0 100.0 100.0 100.0 100.0 0.0 
SUD4 10nM 93.3 70.4 84.8 82.8 11.6 
SUD4 100nM 61.0 56.4 56.1 57.8 2.7 
SUD4 1!M 50.9 43.9 31.4 42.1 9.9 
SUD4 10!M 33.3 46.4 31.9 37.2 8.0 
SUD4 100!M 18.7 21.5 20.2 20.1 1.4 
 
Table A1.1.  Effect of tunicamycin treatment for 48 hours on cell number 
 302 
Cell line Conc. Cell viability (%)   Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 90.0 94.6 90.2 91.6 2.6 
HL-60 10nM 82.1 84.7 89.4 85.4 3.7 
HL-60 100nM 84.2 83.1 88.1 85.1 2.6 
HL-60 1!M 52.6 68.6 70.0 63.7 9.7 
HL-60 10!M 53.1 60.9 67.4 60.5 7.1 
HL-60 100!M 83.0 81.7 95.2 86.6 7.4 
       
THP-1 0 96.0 96.2 95.4 95.9 0.5 
THP-1 10nM 92.2 95.5 94.2 94.0 1.7 
THP-1 100nM 75.0 86.9 76.1 79.3 6.6 
THP-1 1!M 74.3 76.5 63.0 71.2 7.2 
THP-1 10!M 58.3 66.1 58.9 61.1 4.4 
THP-1 100!M 47.3 60.6 79.1 62.3 16.0 
       
RPMI-8226 0 91.1 90.7 85.5 89.1 3.1 
RPMI-8226 10nM 84.4 90.2 86.6 87.1 2.9 
RPMI-8226 100nM 78.3 89.3 85.7 84.5 5.6 
RPMI-8226 1!M 51.4 59.3 57.5 56.1 4.2 
RPMI-8226 10!M 40.2 35.9 25.2 33.8 7.7 
RPMI-8226 100!M 8.2 28.7 15.6 17.5 10.4 
       
U266 0 90.1 94.6 92.6 92.4 2.3 
U266 10nM 89.2 94.2 93.2 92.2 2.6 
U266 100nM 86.1 90.5 88.3 88.3 2.2 
U266 1!M 80.9 83.7 92.1 85.6 5.8 
U266 10!M 69.8 89.7 87.2 82.2 10.8 
U266 100!M 35.3 40.4 54.2 43.3 9.8 
       
DOHH2 0 83.6 88.5 80.1 84.1 4.2 
DOHH2 10nM 74.9 88.8 84.4 82.7 7.1 
DOHH2 100nM 57.5 64.1 67.9 63.2 5.3 
DOHH2 1!M 21.2 22.7 21.7 21.9 0.8 
DOHH2 10!M 24.0 23.5 22.4 23.3 0.9 
DOHH2 100!M 25.8 23.4 24.9 24.7 1.2 
       
SUD4 0 89.4 90.4 94.3 91.4 2.6 
SUD4 10nM 90.8 95.0 93.9 93.3 2.2 
SUD4 100nM 74.1 76.7 84.3 78.4 5.3 
SUD4 1!M 51.4 54.5 58.4 54.8 3.5 
SUD4 10!M 58.8 40.9 54.0 51.2 9.2 
SUD4 100!M 5.9 0.0 31.5 12.5 16.8 
 
Table A1.2.  Effect of tunicamycin treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 1nM 67.0 69.4 82.0 72.8 8.1 
HL-60 10nM 51.5 50.2 39.5 47.1 6.6 
HL-60 100nM 53.7 49.8 37.6 47.0 8.4 
HL-60 1!M 59.6 43.3 37.6 46.8 11.4 
HL-60 3!M 31.7 50.4 39.4 40.5 9.4 
HL-60 10!M 64.5 64.4 38.8 55.9 14.8 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 1nM 94.7 96.9 103.5 98.4 4.6 
THP-1 10nM 47.8 49.9 60.5 52.7 6.8 
THP-1 100nM 46.1 36.4 39.4 40.6 5.0 
THP-1 1!M 40.0 52.0 34.4 42.1 9.0 
THP-1 3!M 38.6 44.1 35.4 39.4 4.4 
THP-1 10!M 29.6 37.2 33.9 33.6 3.8 
       
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 1nM 89.8 83.3 92.9 88.7 4.9 
RPMI-8226 10nM 48.0 46.3 54.2 49.5 4.2 
RPMI-8226 100nM 52.4 46.1 60.1 52.9 7.0 
RPMI-8226 1!M 70.3 60.3 58.8 63.1 6.3 
RPMI-8226 3!M 82.4 54.8 40.9 59.4 21.1 
RPMI-8226 10!M 49.6 40.6 41.9 44.0 4.9 
       
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 1nM 96.3 86.8 97.7 93.6 5.9 
U266 10nM 64.6 68.2 70.7 67.8 3.1 
U266 100nM 59.5 61.5 58.2 59.7 1.7 
U266 1!M 57.9 61.1 57.2 58.7 2.1 
U266 3!M 55.9 57.4 53.2 55.5 2.1 
U266 10!M 53.2 56.6 55.8 55.2 1.8 
       
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 1nM 75.4 74.1 83.2 77.6 4.9 
DOHH2 10nM 40.6 41.0 54.0 45.2 7.6 
DOHH2 100nM 25.4 37.2 51.4 38.0 13.0 
DOHH2 1!M 31.8 39.4 54.4 41.9 11.5 
DOHH2 3!M 37.3 40.6 51.3 43.1 7.3 
DOHH2 10!M 39.6 40.5 43.8 41.3 2.2 
       
SUD4 0 100.0 100.0 100.0 100.0 0.0 
SUD4 1nM 91.4 90.4 98.0 93.3 4.1 
SUD4 10nM 66.3 50.9 53.7 57.0 8.2 
SUD4 100nM 52.2 39.3 41.5 44.3 6.9 
SUD4 1!M 57.4 35.2 39.9 44.2 11.7 
SUD4 3!M 45.2 34.3 37.3 38.9 5.6 
SUD4 10!M 45.2 33.2 31.8 32.5 1.0 
 
Table A1.3.  Effect of thapsigargin treatment for 48 hours on cell number 
 304 
 
Cell line Conc. Cell viability (%)   Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 90.0 90.2 89.5 89.9 0.4 
HL-60 1nM 58.3 74.0 53.2 61.8 10.9 
HL-60 10nM 65.2 50.2 28.9 48.1 18.3 
HL-60 100nM 53.1 49.8 14.7 39.2 21.3 
HL-60 1!M 51.1 42.2 18.7 37.3 16.8 
HL-60 3!M 38.4 43.2 26.0 35.9 8.9 
HL-60 10!M 27.9 34.0 35.1 32.3 3.9 
       
THP-1 0 95.4 96.9 97.5 96.6 1.1 
THP-1 1nM 95.2 97.8 97.6 96.9 1.4 
THP-1 10nM 84.0 88.4 91.6 88.0 3.8 
THP-1 100nM 63.0 61.8 71.4 65.4 5.2 
THP-1 1!M 41.8 50.4 63.5 51.9 10.9 
THP-1 3!M 28.0 49.9 47.9 41.9 12.1 
THP-1 10!M 7.5 15.4 19.6 14.1 6.2 
       
RPMI-8226 0 90.6 92.2 90.9 91.2 0.8 
RPMI-8226 1nM 76.1 93.3 88.8 86.1 8.9 
RPMI-8226 10nM 65.8 68.7 56.3 63.6 6.5 
RPMI-8226 100nM 28.3 30.5 38.7 32.5 5.5 
RPMI-8226 1!M 16.7 19.7 32.1 22.8 8.1 
RPMI-8226 3!M 26.0 13.6 27.5 22.4 7.6 
RPMI-8226 10!M 3.5 44.8 13.5 20.6 21.5 
       
U266 0 94.3 94.2 94.6 94.4 0.2 
U266 1nM 83.4 95.0 96.2 91.5 7.1 
U266 10nM 78.7 91.2 94.6 88.2 8.4 
U266 100nM 78.2 81.4 92.6 84.1 7.5 
U266 1!M 61.4 85.7 89.7 78.9 15.3 
U266 3!M 73.3 83.9 78.7 78.6 5.3 
U266 10!M 45.0 32.2 56.0 44.4 11.9 
       
DOHH2 0 86.6 88.5 78.5 84.5 5.3 
DOHH2 1nM 84.9 73.9 70.1 76.3 7.7 
DOHH2 10nM 26.3 11.5 15.2 17.7 7.7 
DOHH2 100nM 9.5 12.3 10.6 10.8 1.4 
DOHH2 1!M 9.5 19.1 9.6 12.7 5.5 
DOHH2 3!M 9.8 15.4 17.9 14.4 4.1 
DOHH2 10!M 16.4 13.2 12.4 14.0 2.1 
       
SUD4 0 94.4 93.4 94.3 94.1 0.6 
SUD4 1nM 91.8 92.2 94.2 92.7 1.3 
SUD4 10nM 79.9 87.7 86.2 84.6 4.1 
SUD4 100nM 70.0 81.4 69.4 73.6 6.7 
SUD4 1!M 63.4 59.5 67.1 63.3 3.8 
SUD4 3!M 28.0 30.1 51.1 36.4 12.8 
SUD4 10!M 9.4 18.0 20.5 15.9 5.8 
 
Table A1.4.  Effect of thapsigargin treatment for 48 hours on cell viability 
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Cell no. (% of control) Cell line Conc. 
Set 1 Set 2 Set 3 
Average SD 
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 1nM 83.7 88.3 85.8 85.9 2.3 
HL-60 10nM 79.5 81.4 76.5 79.1 2.5 
HL-60 100nM 47.2 34.7 41.2 41.0 6.3 
HL-60 300nM 45.2 37.0 38.8 40.3 4.3 
HL-60 1!M 42.7 34.1 33.7 36.8 5.1 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 1nM 98.2 92.5 91.6 94.1 3.6 
THP-1 10nM 96.1 82.7 80.9 86.6 8.3 
THP-1 100nM 41.3 32.8 31.8 35.3 5.2 
THP-1 300nM 41.2 31.0 37.1 36.4 5.1 
THP-1 1!M 40.8 30.6 33.2 34.9 5.3 
       
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 1nM 89.5 86.3 87.7 87.8 1.6 
RPMI-8226 10nM 62.7 62.5 76.2 67.1 7.9 
RPMI-8226 100nM 30.7 27.4 27.1 28.4 2.0 
RPMI-8226 300nM 28.3 28.9 28.8 28.7 0.3 
RPMI-8226 1!M 43.2 42.4 45.9 43.8 1.8 
       
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 1nM 88.5 89.9 83.6 87.3 3.3 
U266 10nM 65.2 86.6 80.6 77.5 11.0 
U266 100nM 42.7 56.5 62.9 54.0 10.3 
U266 300nM 52.2 48.7 58.5 53.1 5.0 
U266 1!M 56.6 47.8 54.7 53.0 4.6 
U266 3!M 67.3 60.3 59.3 62.3 4.4 
       
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 1nM 82.7 84.5 85.7 84.3 1.5 
DOHH2 10nM 63.8 62.1 54.0 60.0 5.2 
DOHH2 100nM 36.4 35.1 43.2 38.2 4.4 
DOHH2 300nM 35.0 30.3 30.8 32.0 2.6 
DOHH2 1!M 37.6 26.9 29.7 31.4 5.5 
       
SUD4 0 100.0 100.0 100.0 100.0 0.0 
SUD4 1nM 80.7 71.9 66.5 73.0 7.2 
SUD4 10nM 53.8 42.0 42.1 46.0 6.8 
SUD4 100nM 33.7 21.3 27.7 27.6 6.2 
SUD4 300nM 36.6 22.6 30.8 30.0 7.0 
SUD4 1!M 31.5 24.9 31.0 29.1 3.7 
 
Table A1.5.  Effect of doxorubicin treatment for 48 hours on cell number 
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Cell viability (%) Cell line Conc. 
Set 1 Set 2 Set 3 
Average SD 
HL-60 0 94.0 90.2 85.6 89.9 4.2 
HL-60 1nM 80.1 86.3 89.9 85.4 5.0 
HL-60 10nM 86.4 85.0 91.2 87.5 3.3 
HL-60 100nM 77.0 72.1 67.6 72.2 4.7 
HL-60 300nM 11.1 24.6 32.7 22.8 10.9 
HL-60 1!M 0.0 8.6 0.0 2.9 5.0 
       
THP-1 0 95.0 95.5 97.5 96.0 1.3 
THP-1 1nM 96.6 96.8 95.9 96.4 0.5 
THP-1 10nM 97.6 96.5 94.6 96.2 1.5 
THP-1 100nM 89.5 92.4 93.1 91.7 1.9 
THP-1 300nM 0.0 5.1 0.0 1.7 2.9 
THP-1 1!M 0.0 0.0 0.0 0.0 0.0 
       
RPMI-8226 0 89.0 92.2 91.3 90.8 1.6 
RPMI-8226 1nM 84.3 89.4 91.8 88.5 3.8 
RPMI-8226 10nM 81.7 86.6 86.5 84.9 2.8 
RPMI-8226 100nM 81.6 82.1 63.7 75.8 10.5 
RPMI-8226 300nM 0.0 0.0 0.0 0.0 0.0 
RPMI-8226 1!M 0.0 0.0 5.3 1.8 3.0 
       
U266 0 96.8 94.6 93.2 94.9 1.8 
U266 1nM 90.8 93.3 95.4 93.2 2.3 
U266 10nM 93.3 93.2 93.7 93.4 0.3 
U266 100nM 95.5 96.0 88.0 93.2 4.5 
U266 300nM 95.1 76.3 89.6 87.0 9.7 
U266 1!M 56.1 51.6 48.5 52.1 3.9 
U266 3!M 0.0 0.0 0.0 0.0 0.0 
       
DOHH2 0 85.5 85.1 88.5 86.4 1.8 
DOHH2 1nM 71.9 91.5 87.3 83.6 10.3 
DOHH2 10nM 76.7 71.3 70.6 72.9 3.3 
DOHH2 100nM 29.0 27.3 27.7 28.0 0.9 
DOHH2 300nM 17.0 21.9 35.7 24.9 9.7 
DOHH2 1!M 16.5 16.5 20.1 17.7 2.1 
       
SUD4 0 91.2 94.3 90.9 92.1 1.9 
SUD4 1nM 94.6 90.8 92.6 92.7 1.9 
SUD4 10nM 90.6 88.7 84.0 87.7 3.4 
SUD4 100nM 74.2 73.5 71.4 73.0 1.4 
SUD4 300nM 79.8 52.8 67.8 66.8 13.5 
SUD4 1!M 0.0 0.0 11.7 3.9 6.7 
 
Table A1.6.  Effect of doxorubicin treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 1nM 95.5 80.9 82.9 86.4 7.9 
HL-60 3nM 46.8 57.0 56.2 53.3 5.7 
HL-60 10nM 49.2 37.1 36.8 41.0 7.1 
HL-60 30nM 49.0 37.8 28.8 38.5 10.1 
HL-60 100nM 45.0 35.0 29.1 36.4 8.0 
HL-60 300nM 42.7 40.7 35.8 39.7 3.6 
HL-60 1!M 45.7 40.4 34.3 40.1 5.7 
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 1nM 97.6 79.0 89.1 88.6 9.3 
THP-1 3nM 74.6 72.2 67.1 71.3 3.8 
THP-1 10nM 45.2 32.4 30.8 36.1 7.9 
THP-1 30nM 40.4 34.2 33.9 36.2 3.7 
THP-1 100nM 42.2 29.9 34.4 35.5 6.2 
THP-1 300nM 45.7 47.7 31.8 41.7 8.7 
THP-1 1!M 49.7 35.3 32.0 39.0 9.4 
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 1nM 98.8 89.7 86.8 91.8 6.3 
RPMI-8226 3nM 66.9 57.8 51.5 58.7 7.7 
RPMI-8226 10nM 55.7 48.0 45.5 49.7 5.3 
RPMI-8226 30nM 51.3 46.8 50.8 49.6 2.5 
RPMI-8226 100nM 57.8 56.4 55.7 56.6 1.1 
RPMI-8226 300nM 70.1 76.1 72.2 72.8 3.0 
RPMI-8226 1!M 73.3 79.8 58.2 70.4 11.1 
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 1nM 79.1 84.9 82.2 82.1 2.9 
U266 3nM 49.6 55.7 52.4 52.6 3.1 
U266 10nM 42.6 50.6 45.1 46.1 4.1 
U266 30nM 37.4 50.5 47.8 45.2 6.9 
U266 100nM 44.4 55.0 49.9 49.8 5.3 
U266 300nM 48.8 55.4 62.1 55.4 6.7 
U266 1!M 54.2 61.1 53.8 56.4 4.1 
U266 3!M 42.2 55.8 57.9 52.0 8.5 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 1nM 92.1 90.2 100.3 94.2 5.4 
DOHH2 3nM 88.9 78.5 82.6 83.3 5.2 
DOHH2 10nM 42.6 41.0 36.4 40.0 3.2 
DOHH2 30nM 42.9 42.8 33.7 39.8 5.3 
DOHH2 100nM 35.5 32.7 33.8 34.0 1.4 
DOHH2 300nM 37.0 33.3 38.0 36.1 2.5 
DOHH2 1!M 42.9 32.7 42.2 39.3 5.7 
SUD4 0 100.0 100.0 100.0 100.0 0.0 
SUD4 1nM 107.6 93.5 80.5 93.9 13.6 
SUD4 3nM 99.1 90.5 75.7 88.4 11.8 
SUD4 10nM 38.7 38.1 28.9 35.2 5.5 
SUD4 30nM 38.0 35.7 28.3 34.0 5.1 
SUD4 100nM 35.1 26.6 44.5 35.4 9.0 
SUD4 300nM 33.0 46.6 44.3 41.3 7.3 
SUD4 1!M 42.1 51.7 30.9 41.6 10.4 
Table A1.7.  Effect of bortezomib treatment for 48 hours on cell number 
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Cell line Conc. Cell viability (%)   Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 90.0 90.2 90.2 90.1 0.1 
HL-60 1nM 85.7 91.7 89.4 88.9 3.0 
HL-60 3nM 66.1 75.8 80.1 74.0 7.1 
HL-60 10nM 34.7 25.2 44.5 34.8 9.6 
HL-60 30nM 15.5 25.7 30.5 23.9 7.7 
HL-60 100nM 10.7 17.6 29.5 19.3 9.5 
HL-60 300nM 8.3 16.8 35.1 20.1 13.7 
HL-60 1!M 10.5 16.0 35.6 20.7 13.2 
THP-1 0 97.9 97.3 97.5 97.6 0.3 
THP-1 1nM 97.3 97.5 95.2 96.6 1.3 
THP-1 3nM 90.6 85.6 78.6 84.9 6.0 
THP-1 10nM 21.5 29.0 49.1 33.2 14.3 
THP-1 30nM 8.7 17.4 7.7 13.0 6.1 
THP-1 100nM 0.0 0.0 45.2 15.1 26.1 
THP-1 300nM 3.5 2.8 37.1 14.5 19.6 
THP-1 1!M 0.0 4.5 13.9 6.1 7.1 
RPMI-8226 0 90.0 92.2 88.6 90.3 1.8 
RPMI-8226 1nM 88.6 91.0 88.2 89.3 1.5 
RPMI-8226 3nM 71.2 74.2 67.8 71.0 3.2 
RPMI-8226 10nM 42.5 39.2 33.3 38.3 4.7 
RPMI-8226 30nM 35.9 17.2 23.8 25.6 9.5 
RPMI-8226 100nM 30.0 6.8 20.8 19.2 11.7 
RPMI-8226 300nM 18.3 12.2 29.6 20.0 8.8 
RPMI-8226 1!M 16.0 15.6 13.7 15.1 1.2 
U266 0 92.8 94.6 93.9 93.7 0.9 
U266 1nM 91.7 92.5 92.6 92.3 0.5 
U266 3nM 78.8 82.7 79.9 80.5 2.0 
U266 10nM 65.4 72.6 77.7 71.9 6.2 
U266 30nM 62.7 77.8 75.7 72.1 8.2 
U266 100nM 57.2 69.4 76.1 67.6 9.6 
U266 300nM 60.5 63.8 65.3 63.2 2.5 
U266 1!M 64.8 73.1 45.9 61.3 13.9 
U266 3!M 58.0 71.9 30.6 53.5 21.0 
DOHH2 0 82.2 88.5 80.8 83.8 4.1 
DOHH2 1nM 73.6 85.1 83.7 80.8 6.3 
DOHH2 3nM 74.3 81.1 82.7 79.3 4.5 
DOHH2 10nM 18.0 16.4 18.6 17.6 1.1 
DOHH2 30nM 12.4 13.2 16.1 13.9 1.9 
DOHH2 100nM 22.8 7.6 10.4 13.6 8.1 
DOHH2 300nM 38.6 25.5 14.8 26.3 11.9 
DOHH2 1!M 13.8 10.0 12.2 12.0 1.9 
SUD4 0 96.6 94.3 90.6 93.8 3.0 
SUD4 1nM 91.2 92.8 91.3 91.8 0.9 
SUD4 3nM 89.2 90.8 90.3 90.1 0.8 
SUD4 10nM 31.0 28.9 29.5 29.8 1.1 
SUD4 30nM 33.7 22.5 27.4 27.8 5.6 
SUD4 100nM 26.6 23.6 17.9 22.7 4.4 
SUD4 300nM 31.7 19.5 16.4 22.5 8.1 
SUD4 1!M 22.8 17.8 6.9 15.8 8.1 
 
Table A1.8.  Effect of bortezomib treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 1nM 100.0 71.7 83.3 85.0 14.2 
HL-60 10nM 112.4 78.2 70.1 86.9 22.5 
HL-60 100nM 117.3 81.2 66.1 88.2 26.3 
HL-60 1!M 77.7 76.0 58.1 70.6 10.9 
HL-60 10!M 48.7 35.8 27.7 37.4 10.6 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 1nM 93.8 92.4 70.8 85.7 12.9 
THP-1 10nM 93.5 91.5 85.6 90.2 4.1 
THP-1 100nM 101.9 88.4 82.2 90.8 10.1 
THP-1 1!M 83.4 77.9 71.2 77.5 6.1 
THP-1 10!M 39.4 31.6 35.3 35.4 3.9 
       
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 1nM 87.5 74.8 94.6 85.6 10.0 
RPMI-8226 10nM 94.6 81.6 92.8 89.7 7.0 
RPMI-8226 100nM 89.6 83.2 88.5 87.1 3.4 
RPMI-8226 1!M 63.6 63.5 64.6 63.9 0.6 
RPMI-8226 10!M 49.9 40.9 39.6 43.5 5.6 
RPMI-8226 100!M 65.1 54.6 45.1 54.9 10.0 
       
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 1nM 90.5 95.3 75.4 87.1 10.4 
U266 10nM 97.3 87.6 84.9 89.9 6.5 
U266 100nM 98.5 96.5 85.7 93.6 6.9 
U266 1!M 76.1 74.9 73.5 74.8 1.3 
U266 10!M 61.2 60.4 60.6 60.7 0.4 
U266 100!M 63.2 50.9 53.4 55.8 6.5 
       
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 1nM 100.0 100.0 88.4 96.1 6.7 
DOHH2 10nM 92.4 71.7 69.7 77.9 12.6 
DOHH2 100nM 88.6 75.0 67.5 77.0 10.7 
DOHH2 1!M 40.2 34.7 40.6 38.5 3.3 
DOHH2 10!M 41.7 27.6 23.1 30.8 9.7 
       
SUD4 0 100.0 100.0 100.0 100.0 0.0 
SUD4 1nM 100.0 100.0 74.9 91.6 14.5 
SUD4 10nM 98.5 95.1 91.1 94.9 3.7 
SUD4 100nM 99.8 95.1 90.0 95.0 4.9 
SUD4 1!M 82.6 75.2 59.1 72.3 12.0 
SUD4 10!M 36.1 29.4 40.1 35.2 5.4 
 
Table A1.9.  Effect of 4-HC treatment for 48 hours on cell number 
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Cell line Conc. Cell viability (%) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 94.0 88.4 94.2 92.2 3.3 
HL-60 1nM 85.0 75.7 93.7 84.8 9.0 
HL-60 10nM 73.4 86.1 86.6 82.0 7.5 
HL-60 100nM 79.3 83.7 81.9 81.6 2.2 
HL-60 1!M 69.5 87.2 74.6 77.1 9.1 
HL-60 10!M 16.6 16.8 10.3 14.6 3.7 
       
THP-1 0 95.3 97.1 97.0 96.5 1.0 
THP-1 1nM 96.5 97.7 95.7 96.6 1.0 
THP-1 10nM 94.0 96.8 98.3 96.4 2.2 
THP-1 100nM 97.2 96.3 96.8 96.8 0.4 
THP-1 1!M 96.2 97.4 96.5 96.7 0.6 
THP-1 10!M 28.4 19.5 38.2 28.7 9.3 
       
RPMI-8226 0 89.0 92.2 91.3 90.8 1.6 
RPMI-8226 1nM 87.1 84.8 86.5 86.1 1.2 
RPMI-8226 10nM 80.7 89.2 82.2 84.0 4.5 
RPMI-8226 100nM 87.2 91.7 81.6 86.8 5.1 
RPMI-8226 1!M 67.7 87.5 76.8 77.3 9.9 
RPMI-8226 10!M 45.2 51.8 40.2 45.7 5.8 
RPMI-8226 100!M 3.0 0.0 0.0 1.0 1.8 
       
U266 0 96.8 94.6 93.2 94.9 1.8 
U266 1nM 86.4 88.9 83.7 86.3 2.6 
U266 10nM 91.6 94.1 79.2 88.3 8.0 
U266 100nM 85.3 91.1 76.1 84.2 7.6 
U266 1!M 94.2 85.4 75.2 85.0 9.5 
U266 10!M 64.2 62.2 63.0 63.1 1.0 
U266 100!M 8.7 11.3 0.0 6.7 5.9 
       
DOHH2 0 85.5 85.1 88.5 86.4 1.8 
DOHH2 1nM 86.2 88.6 61.9 78.9 14.8 
DOHH2 10nM 81.7 91.1 76.9 83.2 7.2 
DOHH2 100nM 74.4 84.0 81.2 79.9 4.9 
DOHH2 1!M 42.2 31.2 19.7 31.1 11.2 
DOHH2 10!M 11.1 14.1 23.7 16.3 6.6 
       
SUD4 0 91.2 93.2 90.9 91.8 1.3 
SUD4 1nM 84.0 93.1 71.2 82.7 11.0 
SUD4 10nM 81.7 93.5 92.6 89.3 6.6 
SUD4 100nM 95.5 94.8 90.7 93.7 2.6 
SUD4 1!M 94.5 86.4 93.7 91.5 4.4 
SUD4 10!M 13.2 17.3 32.8 21.1 10.3 
 
Table A1.10.  Effect of 4-HC treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 10nM 69.4 75.9 76.5 73.9 3.9 
HL-60 100nM 42.5 41.8 51.7 45.3 5.5 
HL-60 1!M 36.5 34.3 31.1 34.0 2.7 
HL-60 10!M 39.0 31.5 32.2 34.2 4.1 
HL-60 100!M 41.8 31.9 31.5 35.1 5.8 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 10nM 90.3 82.9 85.2 86.1 3.8 
THP-1 100nM 67.0 56.8 60.5 61.4 5.2 
THP-1 1!M 35.3 34.5 33.5 34.4 0.9 
THP-1 10!M 36.6 33.8 29.0 33.1 3.8 
THP-1 100!M 35.7 35.7 30.6 34.0 2.9 
 
Table A1.11.  Effect of cytarabine treatment for 48 hours on cell number 
 
 
 
Cell line Conc. Cell viability (%) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 89.1 96.7 94.1 93.3 3.9 
HL-60 10nM 87.8 96.1 94.3 92.7 4.4 
HL-60 100nM 73.4 89.0 90.4 84.3 9.5 
HL-60 1!M 38.7 51.5 34.7 41.6 8.8 
HL-60 10!M 35.4 39.6 17.4 30.8 11.8 
HL-60 100!M 26.7 32.9 13.1 24.2 10.2 
       
THP-1 0 96.6 97.2 97.9 97.2 0.7 
THP-1 10nM 96.9 96.8 97.6 97.1 0.4 
THP-1 100nM 96.4 96.5 97.4 96.8 0.6 
THP-1 1!M 93.2 91.9 95.5 93.5 1.8 
THP-1 10!M 66.0 52.4 59.3 59.2 6.8 
THP-1 100!M 60.6 43.9 27.5 44.0 16.5 
 
Table A1.12.  Effect of cytarabine treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 10nM 95.2 97.8 87.8 93.6 5.2 
HL-60 100nM 69.4 61.9 64.1 65.1 3.9 
HL-60 1!M 42.9 37.0 30.5 36.8 6.2 
HL-60 10!M 42.5 31.7 28.1 34.1 7.5 
HL-60 30!M 41.1 33.7 29.3 34.7 6.0 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 10nM 93.1 96.7 94.4 94.7 1.8 
THP-1 100nM 56.7 56.5 55.9 56.4 0.4 
THP-1 1!M 34.5 30.8 30.4 31.9 2.3 
THP-1 10!M 36.8 30.9 26.1 31.3 5.4 
THP-1 30!M 38.6 29.9 27.8 32.1 5.7 
 
Table A1.13.  Effect of etoposide treatment for 48 hours on cell number 
 
 
 
Cell line Conc. Cell viability (%) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 87.0 93.5 93.3 91.3 3.7 
HL-60 10nM 88.0 95.2 92.2 91.8 3.7 
HL-60 100nM 81.9 94.4 88.1 88.1 6.2 
HL-60 1!M 43.8 67.6 37.9 49.8 15.8 
HL-60 10!M 36.1 52.6 23.5 37.4 14.6 
HL-60 30!M 17.0 43.1 26.6 28.9 13.2 
       
THP-1 0 95.3 95.9 97.2 96.1 1.0 
THP-1 10nM 96.2 96.8 97.2 96.7 0.5 
THP-1 100nM 92.9 96.6 97.6 95.7 2.5 
THP-1 1!M 72.7 56.1 53.2 60.6 10.5 
THP-1 10!M 29.1 38.4 23.2 30.2 7.7 
THP-1 30!M 17.2 25.1 32.3 24.9 7.6 
 
Table A1.14.  Effect of etoposide treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 100.0 100.0 100.0 100.0 0.0 
HL-60 10nM 97.3 91.9 91.1 93.4 3.4 
HL-60 100nM 94.2 94.6 85.1 91.3 5.4 
HL-60 300nM 88.9 90.2 80.2 86.4 5.4 
HL-60 1!M 52.0 50.9 41.1 48.0 6.0 
HL-60 10!M 37.6 29.7 27.7 31.7 5.2 
       
THP-1 0 100.0 100.0 100.0 100.0 0.0 
THP-1 10nM 94.4 89.0 89.1 90.8 3.1 
THP-1 100nM 89.8 87.3 80.5 85.9 4.8 
THP-1 300nM 75.3 74.9 66.7 72.3 4.9 
THP-1 1!M 37.1 32.9 28.9 33.0 4.1 
THP-1 10!M 32.7 29.4 25.5 29.2 3.6 
 
Table A1.15.  Effect of KW-2478 treatment for 48 hours on cell number 
 
 
 
Cell line Conc. Cell viability (%)   Average SD 
    Set 1 Set 2 Set 3     
HL-60 0 96.4 91.8 93.8 94.0 2.3 
HL-60 10nM 96.0 91.7 93.6 93.8 2.2 
HL-60 100nM 95.7 92.6 92.5 93.6 1.8 
HL-60 300nM 96.4 92.7 93.1 94.1 2.0 
HL-60 1!M 88.7 82.8 79.6 83.7 4.6 
HL-60 10!M 35.3 26.3 45.6 35.7 9.6 
       
THP-1 0 97.5 98.2 97.3 97.7 0.5 
THP-1 10nM 96.9 98.0 97.8 97.6 0.6 
THP-1 100nM 96.9 98.4 97.9 97.7 0.8 
THP-1 300nM 97.6 97.8 96.7 97.4 0.6 
THP-1 1!M 89.2 91.3 86.7 89.1 2.3 
THP-1 10!M 80.1 75.0 72.8 76.0 3.7 
 
Table A1.16.  Effect of KW-2478 treatment for 48 hours on cell viability 
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Cell line Conc. Cell no. (% of control) Average SD 
    Set 1 Set 2 Set 3     
RPMI-8226 0 100.0 100.0 100.0 100.0 0.0 
RPMI-8226 10nM 93.7 95.9 90.1 93.2 2.9 
RPMI-8226 100nM 89.5 95.4 83.2 89.4 6.1 
RPMI-8226 1!M 67.8 74.8 64.2 68.9 5.4 
RPMI-8226 10!M 51.3 45.3 35.3 44.0 8.1 
RPMI-8226 100!M 50.2 53.7 54.7 52.9 2.4 
       
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 10nM 94.8 99.4 86.2 93.5 6.7 
U266 100nM 97.2 93.1 79.2 89.8 9.4 
U266 1!M 88.7 80.4 68.9 79.3 9.9 
U266 10!M 84.2 58.0 55.4 65.9 15.9 
U266 100!M 67.9 57.6 54.4 60.0 7.1 
 
Table A1.17.  Effect of melphalan treatment for 48 hours on cell number 
 
 
 
Cell line Conc. Cell viability (%)   Average SD 
    Set 1 Set 2 Set 3     
RPMI-8226 0 83.1 87.8 83.2 84.7 2.7 
RPMI-8226 10nM 72.0 92.8 83.6 82.8 10.4 
RPMI-8226 100nM 69.4 88.7 83.2 80.4 10.0 
RPMI-8226 1!M 82.6 85.7 83.4 83.9 1.6 
RPMI-8226 10!M 60.6 85.6 68.5 71.6 12.8 
RPMI-8226 100!M 34.2 27.3 18.4 26.7 7.9 
       
U266 0 93.3 94.6 93.2 93.7 0.8 
U266 10nM 77.4 93.4 83.5 84.8 8.1 
U266 100nM 76.7 93.9 81.0 83.9 9.0 
U266 1!M 81.6 93.2 79.3 84.7 7.4 
U266 10!M 80.6 88.5 75.0 81.4 6.8 
U266 100!M 55.5 44.2 39.0 46.2 8.4 
 
Table A1.18.  Effect of melphalan treatment for 48 hours on cell viability 
 
 
 315 
 
Drug Cell line EC50 cell 
number 
95% CI EC50 cell 
viability 
95% CI 
Doxorubicin HL-60 18.16nM 6.87nM to 47.96nM 191.60nM 163.60nM to 224.50nM 
  THP-1 16.04nM 2.53nM to 101.70nM 161.10nM 147.10nM to 176.30nM 
  RPMI-8226 8.49 nM 4.46nM to 16.17nM 115.4nM 1.5950e-026 to 8.3400e+011 
  U266 9.62nM 2.00nM to 46.33nM 1.06!M 973.60nM to 1.16!M 
  DOHH2 6.92nM 4.27nM to 11.21nM 64.13nM 39.75nM to 103.4nM 
  SUD4 2.13nM 1.19nM to 3.80nM 420.50nM 324.30nM to 545.10nM 
Bortezomib HL-60 1.82nM 1.41nM to 2.36nM 5.45nM 4.02nM to 7.40nM 
  THP-1 3.08nM 2.31nM to 4.10nM 6.24nM 4.28nM to 9.08nM 
  RPMI-8226 1.17nM 1.7840e-021 to 763.1 5.85nM 4.54nM to 7.54nM 
  U266 1.17nM 0.89nM to 1.55nM 5.95nM 1.81nM to 19.54nM 
  DOHH2 4.29nM 3.56nM to 5.18nM 4.88nM 2.70nM to 8.83nM 
  SUD4 3.79nM 7.1650e-013 to 2.0080e-005 6.11nM 4.81nM to 7.75nM 
Tunicamycin HL-60 1.23!M 61.70nM to 24.36!M 251.80nM 59.43nM to 1.07!M 
  THP-1 22.58nM 8.96nM to 56.93nM 220.90nM 271.90nM to 1.79!M 
  RPMI-8226 3.86!M 113.60nM to 131.00!M 1.68!M 702.60nM to 4.00!M 
  U266 84.08!M 38.10!M to 185.50!M 85.78!M 52.81!M to 139.30!M 
  DOHH2 198.40nM 138.60nM to 284.10nM 116.4nM 1.2400e-010 to 0.0001093 
  SUD4 122.60nM 25.12nM to 598.10nM 4.87!M 2.05!M to 11.59!M 
Thapsigargin HL-60 0.99nM   1.00nM 0.085nM to 11.92nM 
  THP-1 5.51nM 3.04nM to 9.99nM 922.90nM 534.80nM to 1.59!M 
  RPMI-8226 1.26nM   16.22nM 7.29nM to 36.09nM 
  U266 4.18nM 2.93nM to 5.96nM 10.6!M 5.59!M to 20.09!M 
  DOHH2 1.43nM 0.80nM to 2.55nM 2.67nM 1.78nM to 3.99nM 
  SUD4 4.80nM 2.70nM to 8.53nM 1.58!M 1.02!M to 2.44!M 
      
     Table A1.19.  EC50 values, with 95% confidence intervals for doxorubicin, bortezomib, tunicamycin and thapsigargin  
     on cell number and viability  
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Drug Cell line EC50 cell 
number 
95% CI EC50 cell 
viability 
95% CI 
4-HC HL-60 4.62!M 913.2nM to 23.33!M 3.18!M 2.02!M to 4.99!M 
  THP-1 4.65!M 2.34!M to 9.26!M 7.30!M 4.02!M to 13.25!M 
  RPMI-8226 5.61!M 2.32!M to 13.55!M 9.13!M 6.22!M to 13.41!M 
  U266 61.36!M 7.81!M to 482.20!M 18.35!M 10.62!M to 31.70!M 
  DOHH2 726.60nM 311.20nM to1.70!M 642.90nM 329.60nM to 1.25!M 
  SUD4 4.13!M 2.39!M to 7.16!M 5.55!M 3.01!M to 10.23!M 
Cytarabine HL-60 16.29nM 11.24nM to 23.60nM 396.90nM 203.70nM to 773.30nM 
  THP-1 61.96nM 43.10nM to 89.06nM 5.63!M 2.84!M to 11.14!M 
Etoposide HL-60 88.23nM 59.68nM to 130.40nM 555.80nM 233.10nM to 1.33!M 
  THP-1 66.05nM 53.05nM to 82.24nM 982.20nM 684.30nM to 1.41!M 
KW-2478 HL-60 588.90nM 436.80nM to 794.10nM 2.01!M 353.60nM to 11.45!M 
  THP-1 361.1nM 253.40nM to 514.60nM 1.16!M 897.30nM to 1.52!M 
Melphalan RPMI-8226 515.10nM 212.40nM to 1.25!M 46.19!M 28.64!M to 74.49!M 
  U266 1.53!M 11.71nM to 199.7!M 107.4!M 52.43!M to 220.1!M 
 
     Table A1.20.  EC50 values, with 95% confidence intervals for 4-HC, cytarabine, etoposide, KW-2478, and melphalan  
     on cell number and viability 
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Appendix 2 
 
Additional data for chapter 5: 
 
TG Simultaneous treatment 
 
% of control HL-60 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 0.05nM 92.2 89.0 85.0 88.7 3.6 
Dox 5nM 95.1 75.6 88.6 86.5 9.9 
Dox 75nM 66.2 59.2 36.7 54.0 15.4 
TG 0.05nM + Dox 5nM 89.2 77.9 92.8 86.6 7.8 
TG 0.05nM + Dox 75nM 47.1 55.0 48.0 50.0 4.3 
Bort 1nM 94.0 88.6 87.8 90.1 3.4 
Bort 3nM 93.9 83.5 84.2 87.2 5.9 
TG 0.05nM + Bort 1nM 80.8 89.7 74.0 81.5 7.8 
TG 0.05nM + Bort 3nM 83.0 88.3 73.9 81.7 7.2 
17-AAG 50nM 62.9 57.2 80.4 66.8 12.1 
17-AAG 250nM 46.8 42.7 53.6 47.7 5.5 
TG 0.05nM + 17-AAG 50nM 74.3 66.1 76.4 72.3 5.5 
TG 0.05nM + 17-AAG 250nM 48.5 40.4 50.9 46.6 5.5 
SAHA 100nM 77.2 74.6 89.1 80.3 7.7 
SAHA 500nM 46.1 50.2 58.7 51.7 6.4 
TG 0.05nM + SAHA 100nM 72.3 58.7 77.3 69.5 9.6 
TG 0.05nM + SAHA 500nM 66.8 42.2 63.4 57.5 13.4 
  Table A2.1.  TG 0.05nM combined with drug treatment for 48 hours in the HL60  
  cell line  
 
% of control HL-60 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 0.5nM 81.5 85.4 80.8 82.6 2.5 
Dox 5nM 80.4 84.6 76.9 80.6 3.9 
Dox 75nM 53.4 53.6 39.3 48.8 8.2 
TG 0.5nM + Dox 5nM 75.0 88.9 78.4 80.8 7.2 
TG 0.5nM + Dox 75nM 65.3 54.4 39.0 52.9 13.2 
Bort 1nM 76.6 89.2 87.8 84.5 6.9 
Bort 3nM 77.6 85.1 84.2 82.3 4.1 
TG 0.5nM + Bort 1nM 68.3 70.4 69.6 69.4 1.0 
TG 0.5nM + Bort 3nM 67.5 72.3 66.5 68.8 3.1 
17-AAG 50nM 86.3 75.1 76.4 79.2 6.1 
17-AAG 250nM 52.1 43.0 58.6 51.2 7.8 
TG 0.5nM + 17-AAG 50nM 72.0 73.6 65.0 70.2 4.5 
TG 0.5nM + 17-AAG 250nM 48.7 38.7 44.9 44.1 5.0 
SAHA 100nM 63.1 73.6 79.6 72.1 8.3 
SAHA 500nM 51.4 52.1 59.8 54.4 4.7 
TG 0.5nM + SAHA 100nM 78.4 65.5 67.8 70.6 6.9 
TG 0.5nM + SAHA 500nM 57.7 37.0 60.4 51.7 12.8 
  Table A2.2.  TG 0. 5nM combined with drug treatment for 48 hours in the HL60  
  cell line 
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% of control THP1  
Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 1nM 91.0 87.6 87.2 88.6 2.1 
Dox 10nM 89.2 86.4 99.0 91.5 6.6 
Dox 75nM 54.0 36.3 30.5 40.3 12.3 
TG 1nM + Dox 10nM 85.1 87.7 98.6 90.5 7.1 
TG 1nM + Dox 75nM 56.1 35.1 32.6 41.3 12.9 
Bort 1nM 89.4 87.7 96.2 91.1 4.5 
Bort 3nM 88.6 82.6 91.0 87.4 4.3 
TG 1nM + Bort 1nM 83.5 90.7 82.9 85.7 4.3 
TG 1nM + Bort 3nM 83.9 74.9 77.6 78.8 4.6 
17-AAG 50nM 54.8 63.2 54.3 57.4 5.0 
17-AAG 250nM 17.4 18.6 21.0 19.0 1.8 
TG 1nM + 17-AAG 50nM 55.7 53.8 58.5 56.0 2.4 
TG 1nM + 17-AAG 250nM 17.2 17.3 27.4 20.7 5.9 
SAHA 100nM 90.2 89.3 92.7 90.7 1.8 
SAHA 500nM 63.1 65.6 62.2 63.6 1.8 
TG 1nM + SAHA 100nM 83.7 91.0 90.4 88.4 4.1 
TG 1nM + SAHA 500nM 61.0 64.6 79.5 68.3 9.8 
  Table A2.3.  TG 1nM combined with drug treatment for 48 hours in the THP1  
  cell line  
 
 
% of control THP1 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 5nM 84.8 75.1 79.5 79.8 4.9 
Dox 10nM 89.1 89.1 89.0 89.1 0.1 
Dox 75nM 52.4 36.1 33.2 40.6 10.4 
TG 5nM + Dox 10nM 86.2 77.7 76.7 80.2 5.2 
TG 5nM + Dox 75nM 60.1 37.3 30.8 42.7 15.4 
Bort 1nM 84.7 91.0 87.4 87.7 3.1 
Bort 3nM 84.8 89.8 81.8 85.5 4.0 
TG 5nM + Bort 1nM 74.5 80.0 77.5 77.3 2.8 
TG 5nM + Bort 3nM 74.9 69.2 60.1 68.1 7.4 
17-AAG 50nM 52.8 61.0 57.8 57.2 4.1 
17-AAG 250nM 17.2 19.3 25.9 20.8 4.5 
TG 5nM + 17-AAG 50nM 58.2 61.1 65.6 61.6 3.7 
TG 5nM + 17-AAG 250nM 11.9 13.4 21.8 15.7 5.3 
SAHA 100nM 84.5 83.4 79.1 82.3 2.9 
SAHA 500nM 63.8 71.2 65.5 66.8 3.9 
TG 5nM + SAHA 100nM 76.9 80.2 87.6 81.6 5.5 
TG 5nM + SAHA 500nM 53.5 47.7 57.3 52.8 4.8 
  Table A2.4.  TG 5nM combined with drug treatment for 48 hours in the THP1  
  cell line  
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% of control RPMI-8226 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 0.5nM 88.3 92.2 89.1 89.8 2.0 
Dox 5nM 88.9 94.0 85.7 89.5 4.2 
Dox 75nM 78.1 91.6 76.5 82.0 8.3 
TG 0.5nM + Dox 5nM 84.1 87.1 86.6 85.9 1.6 
TG 0.5nM + Dox 75nM 79.0 86.7 80.1 81.9 4.2 
Bort 1nM 86.6 92.3 94.9 91.2 4.2 
Bort 3nM 87.5 91.8 86.3 88.5 2.9 
TG 0.5nM + Bort 1nM 80.2 88.3 86.0 84.9 4.2 
TG 0.5nM + Bort 3nM 83.6 87.5 83.6 84.9 2.2 
17-AAG 100nM 62.5 94.7 66.7 74.6 17.5 
17-AAG 500nM 44.3 51.3 36.9 44.2 7.2 
TG 0.5nM + 17-AAG 100nM 58.6 92.3 58.8 69.9 19.4 
TG 0.5nM + 17-AAG 500nM 39.0 49.8 35.5 41.4 7.5 
SAHA 100nM 84.3 73.8 74.9 77.7 5.8 
SAHA 500nM 52.5 24.0 54.7 43.7 17.1 
TG 0.5nM + SAHA 100nM 73.3 71.8 79.4 74.8 4.1 
TG 0.5nM + SAHA 500nM 48.4 22.7 53.8 41.6 16.6 
  Table A2.5.  TG 0.5nM combined with drug treatment for 48 hours in the  
  RPMI8226 cell line  
 
 
% of control RPMI-8226 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 5nM 65.4 40.0 46.5 50.6 13.2 
Dox 5nM 89.4 85.2 93.0 89.2 3.9 
Dox 75nM 88.6 76.6 90.8 85.3 7.6 
TG 5nM + Dox 5nM 47.3 43.9 49.4 46.9 2.8 
TG 5nM + Dox 75nM 63.3 53.7 48.9 55.3 7.3 
Bort 1nM 86.8 90.6 91.3 89.6 2.4 
Bort 3nM 88.2 88.4 85.9 87.5 1.4 
TG 5nM + Bort 1nM 60.6 41.2 41.2 47.6 11.2 
TG 5nM + Bort 3nM 64.9 38.0 35.7 46.2 16.2 
17-AAG 100nM 98.8 61.8 62.0 74.2 21.3 
17-AAG 500nM 48.2 38.0 50.2 45.5 6.6 
TG 5nM + 17-AAG 100nM 71.5 35.9 44.0 50.5 18.7 
TG 5nM + 17-AAG 500nM 49.6 23.4 33.0 35.4 13.3 
SAHA 100nM 73.4 83.9 91.3 82.9 9.0 
SAHA 500nM 20.7 55.0 57.8 44.5 20.6 
TG 5nM + SAHA 100nM 42.7 39.9 42.9 41.8 1.7 
TG 5nM + SAHA 500nM 14.0 24.4 26.4 21.6 6.7 
  Table A2.6.  TG 5nM combined with drug treatment for 48 hours in the  
  RPMI8226 cell line  
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% of control U266 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 1nM 87.8 87.9 90.8 88.8 1.7 
Dox 10nM 90.9 85.9 87.7 88.2 2.5 
Dox 75nM 88.8 84.9 82.2 85.3 3.3 
TG 1nM + Dox 10nM 81.6 85.3 81.2 82.7 2.2 
TG 1nM + Dox 75nM 79.7 80.5 83.0 81.1 1.7 
Bort 1nM 89.2 84.8 86.9 86.9 2.2 
Bort 3nM 85.6 80.8 66.8 77.7 9.7 
TG 1nM + Bort 1nM 77.4 81.4 87.0 81.9 4.8 
TG 1nM + Bort 3nM 73.6 77.8 64.3 71.9 6.9 
17-AAG 100nM 67.5 82.0 69.9 73.1 7.8 
17-AAG 500nM 22.1 36.4 26.4 28.3 7.3 
TG 1nM + 17-AAG 100nM 64.6 80.3 78.7 74.5 8.6 
TG 1nM + 17-AAG 500nM 22.3 41.7 26.4 30.2 10.2 
SAHA 100nM 78.0 89.5 80.4 82.6 6.0 
SAHA 500nM 63.1 70.1 66.6 66.6 3.5 
TG 1nM + SAHA100nM 77.8 88.6 88.1 84.8 6.1 
TG 1nM + SAHA 500nM 68.8 69.2 78.2 72.1 5.3 
  Table A2.7.  TG 1nM combined with drug treatment for 48 hours in the U266 
  cell line  
 
% of control U266 
  Set 1 Set 2 Set 3 Set 4 Average SD 
Control 100.0 100.0 100.0 100.0 100.0 0.0 
TG 5nM 77.0 80.0 62.2 79.0 74.6 8.3 
Dox 10nM 90.0 82.6 90.7 88.2 87.9 3.6 
Dox 75nM 83.3 73.5 87.7 77.7 80.6 6.2 
TG 5nM + Dox 10nM 67.4 68.9 65.1 85.4 71.7 9.3 
TG 5nM + Dox 75nM 75.9 68.0 65.0 72.2 70.3 4.8 
Bort 1nM 96.3 77.3 91.1 87.2 87.9 8.0 
Bort 3nM 78.4 73.9 69.3 79.1 75.2 4.6 
TG 5nM + Bort 1nM 65.7 79.8 64.4 80.5 72.6 8.8 
TG 5nM + Bort 3nM 65.4 75.6 42.3 72.9 64.1 15.1 
17-AAG 100nM 64.8 82.8 84.0 81.3 78.2 9.0 
17-AAG 500nM 23.4 31.7 26.8 24.8 26.6 3.6 
TG 5nM + 17-AAG 100nM 57.2 70.6 56.4 67.7 63.0 7.2 
TG 5nM + 17-AAG 500nM 21.2 28.6 14.9 15.4 20.0 6.4 
SAHA 100nM 83.3 74.4 86.0 90.3 83.5 6.7 
SAHA 500nM 66.1 57.5 72.0 69.4 66.2 6.3 
TG 5nM + SAHA100nM 70.4 70.3 69.3 86.2 74.0 8.1 
TG 5nM + SAHA 500nM 59.6 37.6 58.5 73.4 57.3 14.8 
  Table A2.8.  TG 5nM combined with drug treatment for 48 hours in the U266 cell line  
 
 321 
 
% of control DOHH2 
  Set 1 Set 2 Average SD 
Control 100.0 100.0 100.0 0.0 
TG 0.05nM 84.4 84.4 84.4 0.1 
Dox 5nM 46.5 44.2 45.4 1.6 
Dox 50nM 2.3 2.1 2.2 0.2 
TG 0.05nM + Dox 5nM 48.7 45.3 47.0 2.4 
TG 0.05nM + Dox 50nM 1.0 1.1 1.0 0.0 
Bort 1nM 95.0 80.0 87.5 10.6 
Bort 3nM 91.4 78.2 84.8 9.3 
TG 0.05nM + Bort 1nM 85.3 83.0 84.1 1.6 
TG 0.05nM + Bort 3nM 91.3 76.6 84.0 10.4 
17-AAG 50nM 76.1 80.2 78.2 2.9 
17-AAG 250nM 58.8 54.8 56.8 2.8 
TG 0.05nM + 17-AAG 50nM 72.9 70.2 71.6 1.9 
TG 0.05nM + 17-AAG 250nM 62.9 53.2 58.0 6.9 
SAHA 100nM 89.6 86.5 88.1 2.2 
SAHA 500nM 63.5 66.2 64.8 1.8 
TG 0.05nM + SAHA 100nM 88.6 80.1 84.3 6.0 
TG 0.05nM + SAHA 500nM 69.7 62.2 65.9 5.3 
  Table A2.9.  TG 0.05nM combined with drug treatment for 48 hours in  
  the DOHH2 cell line  
 
% of control DOHH2 
  Set 1 Set 2 Average SD 
Control 100.0 100.0 100.0 0.0 
TG 0.5nM 81.5 79.8 80.6 1.2 
Dox 5nM 44.0 40.5 42.3 2.5 
Dox 50nM 2.3 2.3 2.3 0.1 
TG 0.5nM + Dox 5nM 41.2 42.8 42.0 1.1 
TG 0.5nM + Dox 50nM 0.9 0.9 0.9 0.0 
Bort 1nM 80.2 77.8 79.0 1.7 
Bort 3nM 79.5 77.3 78.4 1.5 
TG 0.5nM + Bort 1nM 84.6 89.3 87.0 3.3 
TG 0.5nM + Bort 3nM 81.1 99.2 90.1 12.8 
17-AAG 50nM 77.0 91.8 84.4 10.5 
17-AAG 250nM 61.6 65.7 63.6 2.9 
TG 0.5nM + 17-AAG 50nM 76.0 88.8 82.4 9.1 
TG 0.5nM + 17-AAG 250nM 56.3 63.9 60.1 5.4 
SAHA 100nM 86.4 91.7 89.1 3.8 
SAHA 500nM 63.9 60.7 62.3 2.3 
TG 0.5nM + SAHA 100nM 78.6 91.7 85.1 9.3 
TG 0.5nM + SAHA 500nM 55.3 69.5 62.4 10.0 
  Table A2.10.  TG 0.5nM combined with drug treatment for 48 hours in  
  the DOHH2 cell line  
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% of control SUD4 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 2nM 82.4 92.1 84.2 86.2 5.1 
Dox 10nM 64.4 84.4 77.9 75.6 10.2 
Dox 75nM 65.5 61.3 45.7 57.5 10.4 
TG 2nM + Dox 10nM 64.5 62.5 58.9 62.0 2.9 
TG 2nM + Dox 75nM 77.3 48.2 69.5 65.0 15.1 
Bort 1nM 73.0 75.5 89.8 79.4 9.0 
Bort 5nM 63.2 70.7 59.2 64.4 5.9 
TG 2nM + Bort 1nM 92.5 77.8 80.4 83.6 7.9 
TG 2nM + Bort 5nM 83.5 82.7 65.3 77.2 10.3 
17-AAG 500nM 24.0 13.0 8.6 15.2 7.9 
17-AAG 1!M 11.5 5.8 6.3 7.9 3.2 
TG 2nM + 17-AAG 500nM 16.0 12.9 10.9 13.3 2.6 
TG 2nM + 17-AAG 1!M 5.4 6.6 5.6 5.9 0.6 
SAHA 100nM 65.9 62.8 70.8 66.5 4.0 
SAHA 500nM 38.3 27.2 28.2 31.2 6.1 
TG 2nM + SAHA100nM 71.3 73.3 62.4 69.0 5.8 
TG 2nM + SAHA 500nM 44.1 25.9 33.1 34.3 9.2 
  Table A2.11.  TG 2nM combined with drug treatment for 48 hours in the SUD4 
  cell line  
 
% of control SUD4 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 10nM 53.1 50.4 49.6 51.1 1.8 
Dox 10nM 81.6 86.1 66.9 78.2 10.0 
Dox 75nM 65.0 56.7 57.4 59.7 4.6 
TG 10nM + Dox 10nM 48.1 47.1 59.7 51.6 7.0 
TG 10nM + Dox 75nM 56.2 50.7 58.4 55.1 4.0 
Bort 1nM 89.3 86.4 95.2 90.3 4.5 
Bort 5nM 69.2 75.8 70.8 71.9 3.5 
TG 10nM + Bort 1nM 70.9 60.0 75.1 68.7 7.8 
TG 10nM + Bort 5nM 56.3 57.3 65.3 59.6 4.9 
17-AAG 500nM 16.2 20.9 30.7 22.6 7.4 
17-AAG 1!M 8.4 8.5 23.2 13.4 8.5 
TG 10nM + 17-AAG 500nM 7.7 10.8 30.1 16.2 12.1 
TG 10nM + 17-AAG 1!M 5.2 4.5 16.7 8.8 6.8 
SAHA 100nM 65.8 91.9 58.9 72.2 17.4 
SAHA 500nM 33.1 30.8 26.1 30.0 3.6 
TG 10nM + SAHA100nM 39.8 50.2 40.3 43.5 5.8 
TG 10nM + SAHA 500nM 17.0 14.4 4.3 11.9 6.7 
  Table A2.12.  TG 10nM combined with drug treatment for 48 hours in the SUD4 
  cell line  
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Combination Effect HL60 
Set 1 Set 2 Set 3 
TG 0.05nM + Dox 5nM 1.02 1.16 1.23 
TG 0.05nM + Dox 75nM 0.77 1.04 1.54 
TG 0.05nM + Bort 1nM 0.93 1.14 0.99 
TG 0.05nM + Bort 3nM 0.96 1.19 1.03 
TG 0.05nM + 17-AAG 50nM 1.28 1.30 1.12 
TG 0.05nM + 17-AAG 250nM 1.12 1.06 1.12 
TG 0.05nM + SAHA 100nM 1.02 0.88 1.02 
TG 0.05nM + SAHA 500nM 1.57 0.94 1.27 
    
TG 0.5nM + Dox 5nM 1.15 1.23 1.26 
TG 0.5nM + Dox 75nM 1.50 1.19 1.23 
TG 0.5nM + Bort 1nM 1.10 0.92 0.98 
TG 0.5nM + Bort 3nM 1.07 0.99 0.98 
TG 0.5nM + 17-AAG 50nM 1.02 1.15 1.05 
TG 0.5nM + 17-AAG 250nM 1.15 1.05 0.95 
TG 0.5nM + SAHA 100nM 1.52 1.04 1.05 
TG 0.5nM + SAHA 500nM 1.38 0.83 1.25 
  Table A2.13.  Combination effect of TG combined with drug  
  treatment for 48 hours in the HL60 cell line (calculated using  
  the fractional product method). 
 
 
Combination Effect THP1 
Set 1 Set 2 Set 3 
TG 1nM + Dox 10nM 1.05 1.16 1.14 
TG 1nM + Dox 75nM 1.14 1.10 1.22 
TG 1nM + Bort 1nM 1.03 1.18 0.99 
TG 1nM + Bort 3nM 1.04 1.03 0.98 
TG 1nM + 17-AAG 50nM 1.12 0.97 1.24 
TG 1nM + 17-AAG 250nM 1.09 1.06 1.50 
TG 1nM + SAHA 100nM 1.02 1.16 1.12 
TG 1nM + SAHA 500nM 1.06 1.12 1.47 
    
TG 5nM + Dox 10nM 1.14 1.16 1.08 
TG 5nM + Dox 75nM 1.35 1.37 1.17 
TG 5nM + Bort 1nM 1.04 1.17 1.11 
TG 5nM + Bort 3nM 1.04 1.03 0.92 
TG 5nM + 17-AAG 50nM 1.30 1.33 1.43 
TG 5nM + 17-AAG 250nM 0.82 0.92 1.06 
TG 5nM + SAHA 100nM 1.07 1.28 1.39 
TG 5nM + SAHA 500nM 0.99 0.89 1.10 
  Table A2.14.  Combination effect of TG combined with drug  
  treatment for 48 hours in the THP1 cell line (calculated using  
  the fractional product method). 
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Combination Effect RPMI8226 
Set 1 Set 2 Set 3 
TG 0.5nM + Dox 5nM 1.07 1.01 1.13 
TG 0.5nM + Dox 75nM 1.15 1.03 1.18 
TG 0.5nM + Bort 1nM 1.05 1.04 1.02 
TG 0.5nM + Bort 3nM 1.08 1.03 1.09 
TG 0.5nM + 17-AAG 100nM 1.06 1.06 0.99 
TG 0.5nM + 17-AAG 500nM 1.00 1.05 1.08 
TG 0.5nM + SAHA 100nM 0.98 1.06 1.19 
TG 0.5nM + SAHA 500nM 1.04 1.03 1.11 
    
TG 5nM + Dox 5nM 0.81 1.29 1.14 
TG 5nM + Dox 75nM 1.09 1.75 1.16 
TG 5nM + Bort 1nM 1.07 1.14 0.97 
TG 5nM + Bort 3nM 1.12 1.07 0.89 
TG 5nM + 17-AAG 100nM 1.11 1.45 1.52 
TG 5nM + 17-AAG 500nM 1.58 1.54 1.41 
TG 5nM + SAHA 100nM 0.89 1.19 1.01 
TG 5nM + SAHA 500nM 1.03 1.11 0.98 
  Table A2.15.  Combination effect of TG combined with drug  
  treatment for 48 hours in the RPMI8226 cell line (calculated  
  using the fractional product method). 
 
 
Combination Effect U266 
Set 1 Set 2 Set 3 Set 4 
TG 1nM + Dox 10nM 1.02 1.13 1.02  
TG 1nM + Dox 75nM 1.02 1.08 1.11  
TG 1nM + Bort 1nM 0.99 1.09 1.10  
TG 1nM + Bort 3nM 0.98 1.10 1.06  
TG 1nM + 17-AAG 100nM 1.09 1.11 1.24  
TG 1nM + 17-AAG 500nM 1.15 1.30 1.10  
TG 1nM + SAHA100nM 1.13 1.13 1.21  
TG 1nM + SAHA 500nM 1.24 1.12 1.29  
     
TG 5nM + Dox 10nM 0.97 1.04 1.15 1.23 
TG 5nM + Dox 75nM 1.18 1.16 1.19 1.18 
TG 5nM + Bort 1nM 0.89 1.29 1.14 1.17 
TG 5nM + Bort 3nM 1.08 1.28 0.98 1.17 
TG 5nM + 17-AAG 100nM 1.15 1.07 1.08 1.05 
TG 5nM + 17-AAG 500nM 1.18 1.13 0.90 0.79 
TG 5nM + SAHA100nM 1.10 1.18 1.30 1.21 
TG 5nM + SAHA 500nM 1.17 0.82 1.31 1.34 
  Table A2.16.  Combination effect of TG combined with drug treatment  
  for 48 hours in the U266 cell line (calculated using the fractional  
  product method). 
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Combination 
Effect 
DOHH2 
Set 1 Set 2 
TG 0.05nM + Dox 5nM 1.24 1.21 
TG 0.05nM + Dox 50nM 0.53 0.60 
TG 0.05nM + Bort 1nM 1.06 1.23 
TG 0.05nM + Bort 3nM 1.18 1.16 
TG 0.05nM + 17-AAG 50nM 1.13 1.04 
TG 0.05nM + 17-AAG 250nM 1.27 1.15 
TG 0.05nM + SAHA 100nM 1.17 1.10 
TG 0.05nM + SAHA 500nM 1.30 1.11 
   
TG 0.5nM + Dox 5nM 1.15 1.32 
TG 0.5nM + Dox 50nM 0.48 0.49 
TG 0.5nM + Bort 1nM 1.29 1.44 
TG 0.5nM + Bort 3nM 1.25 1.61 
TG 0.5nM + 17-AAG 50nM 1.21 1.21 
TG 0.5nM + 17-AAG 250nM 1.12 1.22 
TG 0.5nM + SAHA 100nM 1.12 1.25 
TG 0.5nM + SAHA 500nM 1.06 1.44 
  Table A2.17.  Combination effect of TG combined  
  with drug treatment for 48 hours in the DOHH2 cell  
  line (calculated using the fractional product method). 
 
 
Combination Effect SUD4 
Set 1 Set 2 Set 3 
TG 2nM + Dox 10nM 1.22 0.80 0.90 
TG 2nM + Dox 75nM 1.43 0.85 1.81 
TG 2nM + Bort 1nM 1.54 1.12 1.06 
TG 2nM + Bort 5nM 1.60 1.27 1.31 
TG 2nM + 17-AAG 500nM 0.81 1.08 1.51 
TG 2nM + 17-AAG 1!M 0.56 1.23 1.06 
TG 2nM + SAHA100nM 1.31 1.27 1.05 
TG 2nM + SAHA 500nM 1.40 1.03 1.39 
    
TG 10nM + Dox 10nM 1.11 1.09 1.80 
TG 10nM + Dox 75nM 1.63 1.77 2.05 
TG 10nM + Bort 1nM 1.49 1.38 1.59 
TG 10nM + Bort 5nM 1.53 1.50 1.86 
TG 10nM + 17-AAG 500nM 0.90 1.02 1.98 
TG 10nM + 17-AAG 1!M 1.17 1.04 1.45 
TG 10nM + SAHA100nM 1.14 1.08 1.38 
TG 10nM + SAHA 500nM 0.97 0.93 0.34 
  Table A2.18.  Combination effect of TG combined with drug  
  treatment for 48 hours in the SUD4 cell line (calculated using  
  the fractional product method). 
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TG Pre-treatment 
 
% of control THP1 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 1nM 86.7 85.4 82.7 84.9 2.0 
Dox 10nM 81.8 86.5 80.6 83.0 3.1 
Dox 75nM 20.9 14.2 14.2 16.4 3.8 
TG 1nM + Dox 10nM 88.4 94.9 83.6 88.9 5.7 
TG 1nM + Dox 75nM 28.3 13.6 14.9 18.9 8.2 
Bort 1nM 88.5 84.3 76.4 83.1 6.1 
Bort 5nM 45.2 33.5 30.9 36.5 7.6 
TG 1nM + Bort 1nM 79.9 81.9 66.1 76.0 8.6 
TG 1nM + Bort 5nM 40.7 31.2 29.2 33.7 6.2 
17-AAG 50nM 46.2 72.2 70.8 63.1 14.6 
17-AAG 250nM 21.8 37.6 35.4 31.6 8.6 
TG 1nM + 17-AAG 50nM 52.5 64.1 59.8 58.8 5.9 
TG 1nM + 17-AAG 250nM 21.5 39.2 37.2 32.6 9.7 
SAHA 100nM 82.9 79.3 73.8 78.7 4.6 
SAHA 500nM 72.6 72.4 71.0 72.0 0.9 
TG 1nM + SAHA 100nM 98.6 83.4 78.4 86.8 10.5 
TG 1nM + SAHA 500nM 75.0 71.8 73.7 73.5 1.6 
  Table A2.19.  TG 1nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the THP1 cell line. 
 
% of control THP1 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 5nM 80.2 83.1 81.1 81.5 1.5 
Dox 10nM 79.9 81.3 80.0 80.4 0.8 
Dox 75nM 24.0 14.5 13.0 17.2 5.9 
TG 5nM + Dox 10nM 80.7 81.6 77.7 80.0 2.1 
TG 5nM + Dox 75nM 23.0 12.1 15.5 16.9 5.6 
Bort 1nM 76.1 82.8 80.0 79.6 3.4 
Bort 5nM 38.1 30.2 33.2 33.8 4.0 
TG 5nM + Bort 1nM 77.0 72.9 58.1 69.3 10.0 
TG 5nM + Bort 5nM 34.2 29.2 29.6 31.0 2.8 
17-AAG 50nM 52.8 57.5 67.5 59.3 7.5 
17-AAG 250nM 19.6 31.9 37.3 29.6 9.0 
TG 5nM + 17-AAG 50nM 45.9 70.6 65.6 60.7 13.1 
TG 5nM + 17-AAG 250nM 18.1 40.5 36.5 31.7 12.0 
SAHA 100nM 76.2 78.1 72.3 75.5 2.9 
SAHA 500nM 61.8 66.7 64.1 64.2 2.4 
TG 5nM + SAHA 100nM 72.2 81.5 70.3 74.7 6.0 
TG 5nM + SAHA 500nM 64.1 73.6 63.4 67.0 5.7 
  Table A2.20.  TG 5nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the THP1 cell line. 
 
 327 
 
 
% of control U266 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 1nM 72.3 79.3 83.8 78.5 5.8 
Dox 10nM 73.1 80.4 82.7 78.7 5.0 
Dox 75nM 70.4 75.4 79.5 75.1 4.6 
TG 1nM + Dox 10nM 77.8 68.8 77.8 74.8 5.2 
TG 1nM + Dox 75nM 64.7 63.8 75.4 68.0 6.5 
Bort 1nM 74.3 75.5 84.7 78.2 5.7 
Bort 5nM 5.1 5.7 6.3 5.7 0.6 
TG 1nM + Bort 1nM 70.1 65.9 68.3 68.1 2.1 
TG 1nM + Bort 5nM 4.6 4.2 5.3 4.7 0.5 
17-AAG 50nM 71.1 66.0 76.6 71.2 5.3 
17-AAG 250nM 44.8 61.0 73.9 59.9 14.6 
TG 1nM + 17-AAG 50nM 69.0 65.9 64.6 66.5 2.3 
TG 1nM + 17-AAG 250nM 47.8 68.9 75.3 64.0 14.3 
SAHA 100nM 66.9 71.0 80.3 72.7 6.9 
SAHA 500nM 59.8 58.9 76.1 65.0 9.7 
TG 1nM + SAHA 100nM 73.1 73.3 71.4 72.6 1.0 
TG 1nM + SAHA 500nM 61.9 68.7 64.0 64.9 3.5 
  Table A2.21.  TG 1nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the U266 cell line. 
 
 
% of control U266 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 5nM 65.8 73.9 77.6 72.4 6.0 
Dox 10nM 67.8 74.4 82.3 74.8 7.2 
Dox 75nM 60.3 69.1 63.6 64.3 4.5 
TG 5nM + Dox 10nM 67.1 67.6 70.0 68.3 1.5 
TG 5nM + Dox 75nM 65.7 52.3 70.3 62.8 9.3 
Bort 1nM 64.4 70.6 63.4 66.1 3.9 
Bort 5nM 4.6 5.0 4.7 4.8 0.2 
TG 5nM + Bort 1nM 68.5 59.3 71.9 66.5 6.5 
TG 5nM + Bort 5nM 3.6 3.5 5.5 4.2 1.2 
17-AAG 50nM 68.0 61.4 81.0 70.2 10.0 
17-AAG 250nM 42.4 59.7 67.9 56.6 13.0 
TG 5nM + 17-AAG 50nM 60.0 54.4 69.9 61.4 7.8 
TG 5nM + 17-AAG 250nM 43.9 68.4 61.9 58.1 12.7 
SAHA 100nM 62.5 67.0 72.1 67.2 4.8 
SAHA 500nM 54.4 62.8 67.4 61.5 6.6 
TG 5nM + SAHA 100nM 58.9 59.6 56.7 58.4 1.5 
TG 5nM + SAHA 500nM 55.2 40.0 64.9 53.4 12.6 
  Table A2.22.  TG 5nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the U266 cell line. 
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% of control SUD4 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 1nM 74.0 78.7 75.2 76.0 2.5 
Dox 10nM 56.7 47.2 41.1 48.4 7.9 
Dox 75nM 30.0 30.7 23.0 27.9 4.2 
TG 1nM + Dox 10nM 67.9 49.0 42.1 53.0 13.3 
TG 1nM + Dox 75nM 45.5 33.1 30.2 36.3 8.1 
Bort 1nM 70.9 76.6 63.3 70.3 6.7 
Bort 5nM 73.4 83.0 65.5 74.0 8.7 
TG 1nM + Bort 1nM 75.8 64.0 73.0 70.9 6.2 
TG 1nM + Bort 5nM 68.8 57.4 64.3 63.5 5.8 
17-AAG 50nM 67.8 70.8 70.4 69.7 1.6 
17-AAG 250nM 44.6 57.9 55.2 52.5 7.0 
TG 1nM + 17-AAG 50nM 61.6 63.7 64.8 63.3 1.7 
TG 1nM + 17-AAG 250nM 55.0 67.1 63.1 61.7 6.2 
SAHA 100nM 58.2 63.3 49.5 57.0 7.0 
SAHA 500nM 36.2 47.7 27.8 37.3 10.0 
TG 1nM + SAHA 100nM 85.4 65.6 71.6 74.2 10.2 
TG 1nM + SAHA 500nM 64.7 53.5 60.1 59.4 5.6 
  Table A2.23.  TG 1nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the SUD4 cell line. 
 
 
% of control SUD4 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
TG 10nM 59.0 60.3 61.9 60.4 1.4 
Dox 10nM 47.3 55.2 38.4 46.9 8.4 
Dox 75nM 28.2 24.3 22.7 25.1 2.8 
TG 10nM + Dox 10nM 49.4 48.2 42.5 46.7 3.7 
TG 10nM + Dox 75nM 41.5 24.8 31.2 32.5 8.4 
Bort 1nM 69.8 57.5 57.6 61.6 7.1 
Bort 5nM 53.6 51.8 65.3 56.9 7.3 
TG 10nM + Bort 1nM 87.5 82.7 69.4 79.9 9.4 
TG 10nM + Bort 5nM 62.3 63.7 54.3 60.1 5.0 
17-AAG 50nM 72.5 53.2 68.7 64.8 10.3 
17-AAG 250nM 37.9 14.9 43.6 32.2 15.2 
TG 10nM + 17-AAG 50nM 34.6 50.3 54.3 46.4 10.4 
TG 10nM + 17-AAG 250nM 42.4 21.3 50.9 38.2 15.3 
SAHA 100nM 47.1 52.3 39.5 46.3 6.4 
SAHA 500nM 27.9 22.0 30.6 26.8 4.4 
TG 10nM + SAHA 100nM 73.0 52.0 56.3 60.4 11.1 
TG 10nM + SAHA 500nM 49.7 18.0 50.9 39.5 18.6 
  Table A2.24.  TG 10nM pretreatment for 6 hours combined with drug treatment for  
  a further 48 hours in the SUD4 cell line. 
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Combination Effect THP1 
Set 1 Set 2 Set 3 
TG 1nM + Dox 10nM 1.25 1.28 1.25 
TG 1nM + Dox 75nM 1.57 1.12 1.26 
TG 1nM + Bort 1nM 1.04 1.14 1.05 
TG 1nM + Bort 5nM 1.04 1.09 1.14 
TG 1nM + 17-AAG 50nM 1.31 1.04 1.02 
TG 1nM + 17-AAG 250nM 1.14 1.22 1.27 
TG 1nM + SAHA 100nM 1.37 1.23 1.28 
TG 1nM + SAHA 500nM 1.19 1.16 1.26 
    
TG 5nM + Dox 10nM 1.26 1.21 1.20 
TG 5nM + Dox 75nM 1.20 1.00 1.47 
TG 5nM + Bort 1nM 1.26 1.06 0.90 
TG 5nM + Bort 5nM 1.12 1.16 1.10 
TG 5nM + 17-AAG 50nM 1.08 1.48 1.20 
TG 5nM + 17-AAG 250nM 1.15 1.53 1.21 
TG 5nM + SAHA 100nM 1.18 1.26 1.20 
TG 5nM + SAHA 500nM 1.29 1.33 1.22 
  Table A2.25.  Combination effect of TG pretreatment for  
  6 hours combined with drug treatment for a further 48 hours  
  in the THP1 cell line (calculated using the fractional product  
  method). 
 
 
Combination Effect U266 
Set 1 Set 2 Set 3 
TG 1nM + Dox 10nM 1.47 1.08 1.12 
TG 1nM + Dox 75nM 1.27 1.07 1.13 
TG 1nM + Bort 1nM 1.31 1.10 0.96 
TG 1nM + Bort 5nM 1.24 0.95 1.01 
TG 1nM + 17-AAG 50nM 1.34 1.26 1.01 
TG 1nM + 17-AAG 250nM 1.48 1.42 1.21 
TG 1nM + SAHA 100nM 1.51 1.30 1.06 
TG 1nM + SAHA 500nM 1.43 1.47 1.00 
    
TG 5nM + Dox 10nM 1.50 1.23 1.10 
TG 5nM + Dox 75nM 1.66 1.02 1.42 
TG 5nM + Bort 1nM 1.61 1.14 1.46 
TG 5nM + Bort 5nM 1.18 0.95 1.52 
TG 5nM + 17-AAG 50nM 1.34 1.20 1.11 
TG 5nM + 17-AAG 250nM 1.57 1.55 1.18 
TG 5nM + SAHA 100nM 1.43 1.20 1.01 
TG 5nM + SAHA 500nM 1.54 0.86 1.24 
  Table A2.26.  Combination effect of TG pretreatment for  
  6 hours combined with drug treatment for a further 48 hours  
  in the U266 cell line (calculated using the fractional product  
  method). 
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Combination Index SUD4 
Set 1 Set 2 Set 3 
TG 1nM + Dox 10nM 1.62 1.32 1.36 
TG 1nM + Dox 75nM 2.05 1.37 1.75 
TG 1nM + Bort 1nM 1.45 1.06 1.53 
TG 1nM + Bort 5nM 1.27 0.88 1.31 
TG 1nM + 17-AAG 50nM 1.23 1.14 1.23 
TG 1nM + 17-AAG 250nM 1.67 1.47 1.52 
TG 1nM + SAHA 100nM 1.99 1.31 1.92 
TG 1nM + SAHA 500nM 2.41 1.42 2.88 
    
TG 10nM + Dox 10nM 1.77 1.45 1.79 
TG 10nM + Dox 75nM 2.49 1.69 2.22 
TG 10nM + Bort 1nM 2.12 2.38 1.95 
TG 10nM + Bort 5nM 1.97 2.04 1.35 
TG 10nM + 17-AAG 50nM 0.81 1.57 1.28 
TG 10nM + 17-AAG 250nM 1.89 2.36 1.89 
TG 10nM + SAHA 100nM 2.62 1.65 2.30 
TG 10nM + SAHA 500nM 3.02 1.36 2.69 
  Table A2.27.  Combination effect of TG pretreatment for  
  6 hours combined with drug treatment for a further 48 hours  
  in the SUD4 cell line (calculated using the fractional product  
  method). 
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THP1 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 0.5 0.4 0.5 0.5 0.1 
  late apoptosis/dead cells 1.6 2.0 1.7 1.8 0.2 
  viable cells 91.1 90.1 90.0 90.4 0.6 
  early apoptosis 6.8 7.5 7.8 7.4 0.5 
TG 5nM nuclear debris 0.3 0.5 0.4 0.4 0.1 
  late apoptosis/dead cells 1.3 1.4 1.4 1.4 0.1 
  viable cells 91.2 90.3 90.0 90.5 0.6 
  early apoptosis 7.2 7.8 8.1 7.7 0.5 
Dox 1!M nuclear debris 0.1 0.1 0.0 0.1 0.1 
(positive control) late apoptosis/dead cells 62.2 59.9 62.4 61.5 1.4 
  viable cells 13.5 13.7 13.3 13.5 0.2 
  early apoptosis 24.2 26.3 24.3 24.9 1.2 
Dox 75nM nuclear debris 0.3 0.4 0.4 0.4 0.1 
  late apoptosis/dead cells 4.3 4.2 4.5 4.3 0.2 
  viable cells 51.4 47.7 45.1 48.1 3.2 
  early apoptosis 44.0 47.6 50.0 47.2 3.0 
TG + Dox nuclear debris 0.4 0.3 0.2 0.3 0.1 
  late apoptosis/dead cells 4.9 4.7 4.3 4.6 0.3 
  viable cells 39.2 44.0 44.7 42.6 3.0 
  early apoptosis 55.5 51.0 50.8 52.4 2.7 
Bort 5nM nuclear debris 0.8 0.9 0.7 0.8 0.1 
  late apoptosis/dead cells 4.3 4.3 3.6 4.1 0.4 
  viable cells 84.1 81.7 81.8 82.5 1.4 
  early apoptosis 10.8 13.2 13.9 12.6 1.6 
TG + Bort nuclear debris 0.6 0.7 0.4 0.6 0.2 
  late apoptosis/dead cells 4.6 4.9 4.6 4.7 0.2 
  viable cells 77.7 77.9 76.2 77.3 0.9 
  early apoptosis 17.1 16.5 18.7 17.4 1.1 
17-AAG 250nM nuclear debris 0.6 0.3 0.5 0.5 0.2 
  late apoptosis/dead cells 1.8 1.7 1.6 1.7 0.1 
  viable cells 90.4 87.9 90.0 89.4 1.3 
  early apoptosis 7.2 10.1 7.9 8.4 1.5 
TG + 17-AAG  nuclear debris 0.4 0.6 0.3 0.4 0.2 
  late apoptosis/dead cells 2.1 2.6 1.7 2.1 0.5 
  viable cells 86.1 86.4 89.4 87.3 1.8 
  early apoptosis 11.4 10.4 8.6 10.1 1.4 
SAHA 500nM nuclear debris 0.6 0.6 0.7 0.6 0.1 
  late apoptosis/dead cells 2.6 2.1 2.5 2.4 0.3 
  viable cells 88.0 87.0 86.0 87.0 1.0 
  early apoptosis 8.8 10.3 10.7 9.9 1.0 
TG + SAHA nuclear debris 0.2 0.4 0.6 0.4 0.2 
  late apoptosis/dead cells 3.1 2.4 2.4 2.6 0.4 
  viable cells 86.0 87.2 85.9 86.4 0.7 
  early apoptosis 10.7 9.9 11.1 10.6 0.6 
 
Table A2.28.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment in the THP1 cell line 
 
 332 
 
 
THP1 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 2671 2510 2533 2571 87 
  late apoptosis/dead cells 8546 11391 8779 9572 1579 
  viable cells 486576 522047 455680 488101 33210 
  early apoptosis 36320 43247 39507 39691 3467 
TG 5nM nuclear debris 1453 2206 1839 1832 377 
  late apoptosis/dead cells 6295 6775 6590 6553 242 
  viable cells 441604 426643 413958 427402 13839 
  early apoptosis 34864 37024 37396 36428 1367 
Dox 1!M nuclear debris 271 142 0 138 136 
(positive control) late apoptosis/dead cells 126380 127753 137800 130644 6235 
  viable cells 27512 29219 29386 28706 1037 
  early apoptosis 49129 56163 53765 53019 3576 
Dox 75nM nuclear debris 629 1121 1112 954 282 
  late apoptosis/dead cells 10215 10863 11635 10904 711 
  viable cells 121166 123455 115664 120095 4005 
  early apoptosis 103722 123196 128239 118386 12947 
TG + Dox nuclear debris 952 820 579 784 189 
  late apoptosis/dead cells 11586 11484 10753 11274 455 
  viable cells 93324 108280 110838 104148 9460 
  early apoptosis 132209 125507 125975 127897 3742 
Bort 5nM nuclear debris 3122 3342 2731 3065 310 
  late apoptosis/dead cells 16911 16453 14882 16082 1064 
  viable cells 328212 314921 334914 326016 10176 
  early apoptosis 42018 50901 57071 49997 7567 
TG + Bort nuclear debris 2447 2677 1448 2191 653 
  late apoptosis/dead cells 17642 17886 15485 17004 1321 
  viable cells 300171 284352 254672 279731 23099 
  early apoptosis 66061 60107 62610 62926 2990 
17-AAG 250nM nuclear debris 3009 1222 2325 2185 902 
  late apoptosis/dead cells 8551 6925 7596 7691 817 
  viable cells 429311 357939 418574 401941 38483 
  early apoptosis 34206 41280 36586 37357 3600 
TG + 17-AAG  nuclear debris 1568 2298 1292 1719 520 
  late apoptosis/dead cells 8981 10546 8234 9254 1180 
  viable cells 368206 350448 433174 383943 43550 
  early apoptosis 48895 42319 41654 44289 4002 
SAHA 500nM nuclear debris 2165 2403 2536 2368 188 
  late apoptosis/dead cells 8772 7840 8761 8458 535 
  viable cells 300637 330030 297414 309361 17973 
  early apoptosis 30189 39073 37119 35460 4668 
TG + SAHA nuclear debris 741 1551 2075 1456 672 
  late apoptosis/dead cells 11604 8591 8912 9702 1655 
  viable cells 318368 312256 314714 315112 3075 
  early apoptosis 39626 35557 40530 38571 2649 
 
Table A2.29.  Apoptosis assay results for cells number by region following 48 hours of drug 
treatment in the THP1 cell line. 
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Apoptotic cells (%) THP1 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 48.3 51.8 54.5 60.4 55.7 55.1 0.24843 
Bort 5nM 15.1 17.5 17.6 21.7 21.4 23.4 0.02071 
17-AAG 250nM 9.0 11.8 9.5 13.5 13.0 10.3 0.20709 
SAHA 500nM 11.4 12.4 13.3 13.8 12.3 13.5 0.37811 
         Table 2.30.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 6 hours of thapsigargin pretreatment, in  
         the THP1 cell line. 
 
Total cell number (%) THP1 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 44.1 44.7 50.7 49.2 52.1 54.0 0.04796 
Bort 5nM 73.1 66.6 80.9 79.8 77.2 72.7 0.64672 
17-AAG 250nM 88.9 70.3 91.8 88.3 85.8 105.3 0.20341 
SAHA 500nM 64.0 65.5 68.3 76.5 75.7 79.7 0.00327 
         Table 2.31.  Total cell number (%) after 48 hours treatment with drug, with or  
         without 6 hours of thapsigargin pretreatment, in the THP1 cell line (each  
         normalised to its own control). 
 
Viable cell number (%) THP1 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 24.9 23.6 25.4 21.1 25.4 26.8 0.91491 
Bort 5nM 67.5 60.3 73.5 68.0 66.6 61.5 0.78136 
17-AAG 250nM 88.2 68.6 91.9 83.4 82.1 104.6 0.35554 
SAHA 500nM 61.8 63.2 65.3 72.1 73.2 76.0 0.00049 
         Table 2.32.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the THP1 cell line (each  
         normalised to its own control). 
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U266 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 0.2 0.4 0.2 0.3 0.1 
  late apoptosis/dead cells 3.1 2.9 2.9 3.0 0.1 
  viable cells 83.8 85.2 83.4 84.1 0.9 
  early apoptosis 12.9 11.5 13.5 12.6 1.0 
TG 5nM nuclear debris 0.5 0.5 0.7 0.6 0.1 
  late apoptosis/dead cells 3.4 1.7 2.1 2.4 0.9 
  viable cells 81.9 85.8 85.8 84.5 2.3 
  early apoptosis 14.2 12.0 11.3 12.5 1.5 
Dox 1!M nuclear debris 0.0 0.0 0.0 0.0 0.0 
(positive control) late apoptosis/dead cells 34.8 41.2 46.2 40.7 5.7 
  viable cells 5.7 4.1 3.1 4.3 1.3 
  early apoptosis 59.5 54.8 50.7 55.0 4.4 
Dox 75nM nuclear debris 0.6 0.1 0.2 0.3 0.3 
  late apoptosis/dead cells 7.3 7.1 6.6 7.0 0.4 
  viable cells 47.1 33.4 39.8 40.1 6.9 
  early apoptosis 45.0 59.4 53.5 52.6 7.2 
TG + Dox nuclear debris 0.3 0.1 0.1 0.2 0.1 
  late apoptosis/dead cells 7.6 6.0 6.2 6.6 0.9 
  viable cells 33.2 31.6 33.0 32.6 0.9 
  early apoptosis 58.9 62.3 60.7 60.6 1.7 
Bort 5nM nuclear debris 0.5 0.3 0.3 0.4 0.1 
  late apoptosis/dead cells 4.3 4.1 4.1 4.2 0.1 
  viable cells 64.3 61.9 63.1 63.1 1.2 
  early apoptosis 30.9 33.6 32.5 32.3 1.4 
TG + Bort nuclear debris 0.3 0.3 0.4 0.3 0.1 
  late apoptosis/dead cells 4.8 4.3 4.5 4.5 0.3 
  viable cells 59.3 72.0 72.5 67.9 7.5 
  early apoptosis 35.6 23.5 22.6 27.2 7.3 
17-AAG 250nM nuclear debris 0.6 0.2 0.6 0.5 0.2 
  late apoptosis/dead cells 3.5 2.8 3.2 3.2 0.4 
  viable cells 75.2 76.1 75.2 75.5 0.5 
  early apoptosis 20.7 21.0 20.9 20.9 0.2 
TG + 17-AAG  nuclear debris 0.3 0.3 0.7 0.4 0.2 
  late apoptosis/dead cells 4.6 4.5 5.9 5.0 0.8 
  viable cells 66.9 72.6 69.2 69.6 2.9 
  early apoptosis 28.3 22.6 24.2 25.0 2.9 
SAHA 500nM nuclear debris 0.7 0.5 0.2 0.5 0.3 
  late apoptosis/dead cells 4.7 3.4 3.3 3.8 0.8 
  viable cells 71.5 73.4 75.9 73.6 2.2 
  early apoptosis 23.2 22.8 20.6 22.2 1.4 
TG + SAHA nuclear debris 0.2 0.4 0.3 0.3 0.1 
  late apoptosis/dead cells 5.0 3.7 4.2 4.3 0.7 
  viable cells 67.7 71.7 68.6 69.3 2.1 
  early apoptosis 27.2 24.2 26.9 26.1 1.7 
 
Table A2.33.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment in the U266 cell line. 
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U266 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 577 1008 446 677 294 
  late apoptosis/dead cells 7337 7059 7496 7297 221 
  viable cells 199746 206990 215066 207267 7664 
  early apoptosis 30832 27901 34892 31208 3511 
TG 5nM nuclear debris 1271 992 1620 1294 315 
  late apoptosis/dead cells 8897 3739 4705 5780 2742 
  viable cells 216619 188553 189515 198229 15934 
  early apoptosis 37677 26402 24914 29664 6979 
Dox 1!M nuclear debris 0 0 0 0 0 
(positive control) late apoptosis/dead cells 43836 51235 61712 52261 8982 
  viable cells 7235 5044 4177 5486 1576 
  early apoptosis 75063 68118 67640 70274 4154 
Dox 75nM nuclear debris 699 183 267 383 277 
  late apoptosis/dead cells 8926 9659 8720 9101 493 
  viable cells 57833 45592 52809 52078 6153 
  early apoptosis 55200 81205 71005 69137 13103 
TG + Dox nuclear debris 489 160 121 257 202 
  late apoptosis/dead cells 12219 7129 7484 8944 2842 
  viable cells 53762 37607 39713 43694 8782 
  early apoptosis 95305 74052 72948 80769 12601 
Bort 5nM nuclear debris 952 688 663 767 160 
  late apoptosis/dead cells 8058 8460 7953 8157 268 
  viable cells 121315 126907 123802 124008 2802 
  early apoptosis 58246 68991 63889 63709 5374 
TG + Bort nuclear debris 597 525 795 639 140 
  late apoptosis/dead cells 10592 8275 8876 9248 1202 
  viable cells 131428 140022 142750 138067 5909 
  early apoptosis 78991 45777 44382 56383 19592 
17-AAG 250nM nuclear debris 1210 316 1071 865 481 
  late apoptosis/dead cells 6923 5240 5354 5839 940 
  viable cells 150356 143000 126351 139902 12299 
  early apoptosis 41471 39459 35166 38699 3220 
TG + 17-AAG  nuclear debris 613 481 1118 737 337 
  late apoptosis/dead cells 10414 8053 8896 9121 1196 
  viable cells 152301 130110 104566 128992 23887 
  early apoptosis 64320 40565 36550 47145 15009 
SAHA 500nM nuclear debris 1022 880 425 776 312 
  late apoptosis/dead cells 7101 5869 5893 6288 705 
  viable cells 108867 128464 137613 124981 14686 
  early apoptosis 35250 39907 37304 37487 2334 
TG + SAHA nuclear debris 368 706 524 533 169 
  late apoptosis/dead cells 10975 6474 7219 8223 2413 
  viable cells 148498 125942 119231 131224 15332 
  early apoptosis 59591 42491 46749 49610 8902 
 
Table A2.34.  Apoptosis assay results for cell number by region following 48 hours of drug 
treatment in the U266 cell line. 
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Apoptotic cells (%) U266 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 52.0 66.2 59.7 66.0 67.6 66.6 0.17874 
Bort 5nM 34.8 37.5 36.1 40.0 27.4 26.8 0.44107 
17-AAG 250nM 24.0 23.6 24.0 32.5 27.0 29.8 0.05820 
SAHA 500nM 27.6 26.0 23.7 31.9 27.7 30.9 0.10782 
         Table A2.35.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 6 hours of thapsigargin pretreatment, in  
         the U266 cell line. 
 
Total cell number (%) U266 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 49.9 54.5 49.9 59.8 52.5 52.2 0.42980 
Bort 5nM 77.0 81.8 74.3 82.2 86.1 85.9 0.09422 
17-AAG 250nM 81.5 75.1 63.2 84.3 78.8 65.9 0.00850 
SAHA 500nM 62.0 69.8 68.1 81.1 77.1 75.5 0.10334 
         Table A2.36.  Total cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the U266 cell line (each  
         normalised to its own control). 
 
Viable cell number (%) U266 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 29.0 22.0 24.6 24.8 19.9 21.0 0.03356 
Bort 5nM 60.7 61.3 57.6 60.7 74.3 75.3 0.19496 
17-AAG 250nM 75.3 69.1 58.7 70.3 69.0 55.2 0.18655 
SAHA 500nM 54.5 62.1 64.0 68.6 66.8 62.9 0.31215 
         Table A2.37.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the U266 cell line (each  
         normalised to its own control). 
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 SUD4 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 2.9 2.2 2.7 2.6 0.4 
  late apoptosis/dead cells 3.3 2.7 2.8 2.9 0.3 
  viable cells 90.3 91.3 90.2 90.6 0.6 
  early apoptosis 3.4 3.8 4.4 3.9 0.5 
TG 10nM nuclear debris 1.8 1.5 2.1 1.8 0.3 
  late apoptosis/dead cells 2.5 2.2 2.4 2.4 0.2 
  viable cells 89.8 91.5 89.8 90.4 1.0 
  early apoptosis 5.9 4.8 5.7 5.5 0.6 
Dox 1!M nuclear debris 0.3 0.5 0.5 0.4 0.1 
(positive control) late apoptosis/dead cells 40.6 39.3 42.6 40.8 1.7 
  viable cells 18.5 18.3 15.5 17.4 1.7 
  early apoptosis 40.5 41.9 41.4 41.3 0.7 
Dox 75nM nuclear debris 2.2 2.2 2.0 2.1 0.1 
  late apoptosis/dead cells 14.2 12.7 12.6 13.2 0.9 
  viable cells 57.0 57.4 57.1 57.2 0.2 
  early apoptosis 26.6 27.7 28.3 27.5 0.9 
TG + Dox nuclear debris 2.0 2.2 2.3 2.2 0.2 
  late apoptosis/dead cells 13.1 13.1 14.3 13.5 0.7 
  viable cells 54.8 54.7 52.6 54.0 1.2 
  early apoptosis 30.1 30.0 30.8 30.3 0.4 
Bort 5nM nuclear debris 2.6 2.6 2.0 2.4 0.3 
  late apoptosis/dead cells 3.7 3.9 4.7 4.1 0.5 
  viable cells 87.4 87.7 87.0 87.4 0.4 
  early apoptosis 6.3 5.8 6.3 6.1 0.3 
TG + Bort nuclear debris 1.8 2.3 2.6 2.2 0.4 
  late apoptosis/dead cells 4.2 5.3 4.7 4.7 0.6 
  viable cells 86.5 84.5 85.9 85.6 1.0 
  early apoptosis 7.5 7.9 6.8 7.4 0.6 
17-AAG 250nM nuclear debris 2.2 1.8 2.0 2.0 0.2 
  late apoptosis/dead cells 2.8 3.1 2.9 2.9 0.2 
  viable cells 88.7 90.0 89.0 89.2 0.7 
  early apoptosis 6.3 5.2 6.1 5.9 0.6 
TG + 17-AAG  nuclear debris 2.5 1.8 2.2 2.2 0.4 
  late apoptosis/dead cells 2.8 3.9 3.2 3.3 0.6 
  viable cells 88.2 86.3 86.7 87.1 1.0 
  early apoptosis 6.6 8.0 7.9 7.5 0.8 
SAHA 500nM nuclear debris 2.6 2.4 2.5 2.5 0.1 
  late apoptosis/dead cells 3.7 3.9 3.3 3.6 0.3 
  viable cells 88.0 87.2 88.5 87.9 0.7 
  early apoptosis 5.7 6.5 5.7 6.0 0.5 
TG + SAHA nuclear debris 2.8 1.9 2.8 2.5 0.5 
  late apoptosis/dead cells 3.7 4.2 3.5 3.8 0.4 
  viable cells 86.0 85.7 86.1 85.9 0.2 
  early apoptosis 7.6 8.2 7.6 7.8 0.3 
 
Table A2.38.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment in the SUD4 cell line. 
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 SUD4 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 24034 16918 19754 20235 3582 
  late apoptosis/dead cells 27311 20507 20495 22771 3932 
  viable cells 740126 702370 667941 703479 36105 
  early apoptosis 27857 29223 32595 29891 2438 
TG 10nM nuclear debris 12555 10573 14213 12447 1822 
  late apoptosis/dead cells 18003 14940 16243 16396 1537 
  viable cells 637932 630939 607760 625544 15793 
  early apoptosis 42166 33098 38577 37947 4566 
Dox 1!M nuclear debris 783 1253 1036 1024 235 
(positive control) late apoptosis/dead cells 95423 92265 94610 94099 1640 
  viable cells 43445 43078 34471 40331 5079 
  early apoptosis 95188 98374 91799 95120 3288 
Dox 75nM nuclear debris 4439 4522 4239 4400 146 
  late apoptosis/dead cells 29090 26507 26267 27288 1565 
  viable cells 116768 119803 119035 118536 1578 
  early apoptosis 54560 57884 58927 57124 2281 
TG + Dox nuclear debris 4450 4689 4685 4608 137 
  late apoptosis/dead cells 28598 27434 29623 28552 1095 
  viable cells 119935 114777 108778 114496 5583 
  early apoptosis 65876 63057 63586 64173 1499 
Bort 5nM nuclear debris 15219 15241 11827 14095 1965 
  late apoptosis/dead cells 21657 23356 27337 24117 2915 
  viable cells 511772 520766 505838 512792 7516 
  early apoptosis 36681 34441 36644 35922 1283 
TG + Bort nuclear debris 10633 11781 14639 12351 2063 
  late apoptosis/dead cells 25480 27547 26650 26559 1037 
  viable cells 520833 439191 483645 481223 40875 
  early apoptosis 44941 41234 38099 41424 3425 
17-AAG 250nM nuclear debris 14630 11764 13826 13407 1478 
  late apoptosis/dead cells 18399 20043 19492 19311 837 
  viable cells 590095 587992 605392 594493 9497 
  early apoptosis 41896 33768 41251 38972 4518 
TG + 17-AAG  nuclear debris 16213 11627 15017 14286 2379 
  late apoptosis/dead cells 18404 25667 21616 21896 3640 
  viable cells 579505 568189 591821 579838 11819 
  early apoptosis 43162 52651 54154 49989 5960 
SAHA 500nM nuclear debris 15632 15189 15181 15334 258 
  late apoptosis/dead cells 22447 24344 19776 22189 2295 
  viable cells 529097 544096 530348 534514 8322 
  early apoptosis 34071 40573 33958 36201 3787 
TG + SAHA nuclear debris 15957 10525 16609 14364 3340 
  late apoptosis/dead cells 21148 23081 21011 21747 1158 
  viable cells 496016 474923 517079 496006 21078 
  early apoptosis 43642 45424 45625 44897 1092 
 
Table A2.39.  Apoptosis assay results for cell number by region following 48 hours of drug 
treatment in the SUD4 cell line. 
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Apoptotic cells (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 40.8 40.4 40.9 43.2 43.1 45.1 0.03436 
Bort 5nM 10.0 9.7 11.0 11.7 13.2 11.5 0.15934 
17-AAG 250nM 9.1 8.2 8.9 9.4 11.9 11.1 0.17062 
SAHA 500nM 9.4 10.4 9.0 11.2 12.4 11.1 0.00192 
         Table A2.40.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 6 hours of thapsigargin pretreatment, in  
         the SUD4 cell line. 
 
Total cell number (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 25.0 27.1 28.1 30.8 30.4 30.5 0.06359 
Bort 5nM 71.4 77.2 78.5 84.7 75.4 83.2 0.34470 
17-AAG 250nM 81.2 85.0 91.8 92.5 95.4 100.9 0.00405 
SAHA 500nM 73.4 81.2 80.9 81.2 80.3 88.7 0.22936 
         Table A2.41.  Total cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the SUD4 cell line (each  
         normalised to its own control). 
 
Viable cell number (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 75nM 15.8 17.1 17.8 18.8 18.2 17.9 0.24308 
Bort 5nM 69.1 74.1 75.7 81.6 69.6 79.6 0.50735 
17-AAG 250nM 79.7 83.7 90.6 90.8 90.1 97.4 0.03408 
SAHA 500nM 71.5 77.5 79.4 77.8 75.3 85.1 0.35553 
         Table A2.42.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the SUD4 cell line (each  
         normalised to its own control). 
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 SUD4 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 3.0 3.7 2.7 3.1 0.5 
  late apoptosis/dead cells 10.3 12.2 10.8 11.1 1.0 
  viable cells 80.4 77.2 80.1 79.2 1.8 
  early apoptosis 6.3 6.9 6.4 6.5 0.3 
TG 100nM nuclear debris 2.5 2.6 3.1 2.7 0.3 
  late apoptosis/dead cells 11.5 11.3 18.0 13.6 3.8 
  viable cells 78.9 79.5 70.7 76.4 4.9 
  early apoptosis 7.0 6.6 8.1 7.2 0.8 
Dox 1!M nuclear debris 0.3 0.3 0.2 0.3 0.1 
(positive control) late apoptosis/dead cells 50.3 52.5 55.0 52.6 2.4 
  viable cells 16.2 14.0 11.8 14.0 2.2 
  early apoptosis 33.2 33.2 32.9 33.1 0.2 
Dox 100nM nuclear debris 1.4 1.2 1.1 1.2 0.2 
  late apoptosis/dead cells 32.3 33.8 32.3 32.8 0.9 
  viable cells 42.3 41.2 42.8 42.1 0.8 
  early apoptosis 24.0 23.8 23.7 23.8 0.2 
TG + Dox  nuclear debris 1.5 1.2 1.0 1.2 0.3 
  late apoptosis/dead cells 34.3 34.8 33.4 34.2 0.7 
  viable cells 40.3 38.0 39.3 39.2 1.2 
  early apoptosis 23.9 26.0 26.2 25.4 1.3 
Bort 10nM nuclear debris 6.0 5.8 4.8 5.5 0.6 
  late apoptosis/dead cells 32.5 33.8 33.9 33.4 0.8 
  viable cells 46.9 43.1 46.2 45.4 2.0 
  early apoptosis 14.6 17.3 15.1 15.7 1.4 
TG + Bort nuclear debris 4.3 4.6 3.8 4.2 0.4 
  late apoptosis/dead cells 36.9 39.6 38.3 38.3 1.4 
  viable cells 40.7 39.5 41.2 40.5 0.9 
  early apoptosis 18.0 16.3 16.7 17.0 0.9 
17-AAG 1!M nuclear debris 3.6 2.6 4.2 3.5 0.8 
  late apoptosis/dead cells 23.8 21.2 27.0 24.0 2.9 
  viable cells 56.3 60.5 51.6 56.1 4.5 
  early apoptosis 16.2 15.7 17.2 16.4 0.8 
TG + 17-AAG  nuclear debris 2.6 2.3 2.6 2.5 0.2 
  late apoptosis/dead cells 28.7 26.4 35.3 30.1 4.6 
  viable cells 47.3 53.2 38.8 46.4 7.2 
  early apoptosis 21.5 18.1 23.3 21.0 2.6 
SAHA 1!M nuclear debris 2.5 2.0 2.1 2.2 0.3 
  late apoptosis/dead cells 13.7 17.4 16.1 15.7 1.9 
  viable cells 69.7 63.6 67.9 67.1 3.1 
  early apoptosis 14.1 17.1 14.0 15.1 1.8 
TG + SAHA nuclear debris 2.4 5.3 6.3 4.7 2.0 
  late apoptosis/dead cells 14.9 25.9 34.5 25.1 9.8 
  viable cells 67.9 52.8 42.8 54.5 12.6 
  early apoptosis 14.7 15.9 16.4 15.7 0.9 
 
Table A2.43.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment with higher drug concentrations in the SUD4 cell line. 
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 SUD4 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 10933 11732 10280 10982 727 
  late apoptosis/dead cells 37005 38233 41119 38786 2112 
  viable cells 289911 242598 304839 279116 32495 
  early apoptosis 22587 21683 24494 22921 1435 
TG 100nM nuclear debris 8624 8207 7827 8219 399 
  late apoptosis/dead cells 39263 36131 45048 40147 4524 
  viable cells 268710 254306 176696 233237 49493 
  early apoptosis 23830 21103 20234 21722 1876 
Dox 1!M nuclear debris 455 416 272 381 96 
(positive control) late apoptosis/dead cells 76232 81995 74875 77700 3780 
  viable cells 24568 21903 16100 20857 4330 
  early apoptosis 50400 51767 44807 48991 3688 
Dox 100nM nuclear debris 2101 1681 1895 1892 210 
  late apoptosis/dead cells 48414 48699 54061 50391 3181 
  viable cells 63519 59409 71617 64848 6212 
  early apoptosis 36011 34291 39626 36643 2723 
TG + Dox nuclear debris 2589 2015 1565 2056 513 
  late apoptosis/dead cells 57916 58428 50632 55659 4361 
  viable cells 68047 63856 59567 63824 4240 
  early apoptosis 40299 43597 39678 41191 2106 
Bort 10nM nuclear debris 11768 10673 9602 10681 1083 
  late apoptosis/dead cells 63741 62134 67817 64564 2930 
  viable cells 92048 79309 92357 87905 7446 
  early apoptosis 28569 31895 30274 30246 1663 
TG + Bort nuclear debris 7872 8167 6912 7650 656 
  late apoptosis/dead cells 67093 69860 69123 68692 1433 
  viable cells 73936 69566 74232 72578 2613 
  early apoptosis 32759 28672 30053 30495 2079 
17-AAG 1!M nuclear debris 6405 5047 6694 6049 879 
  late apoptosis/dead cells 42015 40567 43430 42004 1431 
  viable cells 99308 115889 82897 99365 16496 
  early apoptosis 28558 30154 27632 28782 1276 
TG + 17-AAG  nuclear debris 4722 4081 4193 4332 343 
  late apoptosis/dead cells 63299 47588 46226 52371 9488 
  viable cells 69575 95717 76220 80504 13587 
  early apoptosis 41721 32646 34616 36328 4774 
SAHA 1!M nuclear debris 5969 4949 4992 5303 577 
  late apoptosis/dead cells 33231 42973 38807 38337 4888 
  viable cells 168575 157294 164004 163291 5674 
  early apoptosis 34199 42231 33735 36722 4777 
TG + SAHA nuclear debris 5825 10911 12198 9644 3370 
  late apoptosis/dead cells 35668 53386 66733 51929 15584 
  viable cells 162620 108763 82932 118105 40657 
  early apoptosis 35269 32800 31753 33274 1805 
 
Table A2.44.  Apoptosis assay results for cell number by region following 48 hours of drug 
treatment with higher drug concentrations in the SUD4 cell line. 
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Apoptotic cells (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 100nM 56.3 57.6 56.0 58.2 60.8 59.6 0.02978 
Bort 10nM 47.1 51.1 49.0 55.0 55.9 55.0 0.02046 
17-AAG 1µM 40.0 36.9 44.2 50.1 44.6 58.6 0.03157 
SAHA 1µM 27.9 34.4 30.0 29.6 41.9 50.9 0.21858 
         Table A2.45.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 6 hours of thapsigargin pretreatment, in  
         the SUD4 cell line. 
 
 
Total cell number (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 100nM 41.6 45.8 43.9 49.6 52.5 60.6 0.08031 
Bort 10nM 49.6 52.5 60.6 54.4 58.6 52.5 0.56162 
17-AAG 1µM 54.4 58.6 52.5 53.4 55.1 72.2 0.46539 
SAHA 1µM 53.4 55.1 72.2 48.9 61.0 42.2 0.91803 
         Table A2.46.  Total cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the SUD4 cell line (each  
         normalised to its own control). 
 
 
Viable cell number (%) SUD4 
Drug alone Drug with TG 
pretreatment 
p value 
Dox 100nM 21.9 24.5 23.5 25.3 25.1 33.7 0.23741 
Bort 10nM 25.3 25.1 33.7 31.8 32.7 30.3 0.90872 
17-AAG 1µM 31.8 32.7 30.3 27.5 27.4 42.0 0.92869 
SAHA 1µM 27.5 27.4 42.0 34.3 47.8 27.2 0.33991 
         Table A2.47.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 6 hours of thapsigargin pretreatment, in the SUD4 cell line (each  
         normalised to its own control). 
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Appendix 3 
 
ADDITIONAL DATA FOR CHAPTER 6 
 
ATP ASSAY: 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
THP1 0 100.0 100.0 100.0 100.0 0.0 
THP1 100!M 100.8 96.5 98.8 98.7 2.2 
THP1 300!M 95.6 92.7 97.3 95.2 2.3 
THP1 1mM 78.0 67.6 67.3 71.0 6.1 
THP1 3mM 37.9 36.6 31.1 35.2 3.6 
THP1 10mM 0.5 2.5 0.0 1.0 1.3 
Table A3.1.  Effect of 4-PBA treatment for 48 hours on cell viability (ATP content) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 100!M 97.4 92.8 99.1 96.4 3.3 
U266 300!M 96.2 92.6 96.9 95.2 2.4 
U266 1mM 71.2 65.7 76.5 71.1 5.4 
U266 3mM 26.3 25.8 25.7 25.9 0.3 
U266 10mM 1.4 8.1 0.0 3.2 4.3 
Table A3.2.  Effect of 4-PBA treatment for 48 hours on cell viability (ATP content) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 100!M 86.6 89.8 93.3 89.9 3.3 
DOHH2 300!M 83.8 84.4 89.5 85.9 3.2 
DOHH2 1mM 36.5 46.0 38.6 40.3 5.0 
DOHH2 3mM 4.1 10.8 2.1 5.7 4.6 
DOHH2 10mM 0.0 4.6 0.0 1.5 2.7 
Table A3.3.  Effect of 4-PBA treatment for 48 hours on cell viability (ATP content) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
HT29 0 100.0 100.0 100.0 100.0 0.0 
HT29 100!M 95.0 94.7 87.5 92.4 4.2 
HT29 300!M 86.5 90.2 90.7 89.1 2.3 
HT29 1mM 87.5 72.8 76.5 78.9 7.7 
HT29 3mM 68.2 50.0 46.4 54.9 11.7 
HT29 10mM 1.3 0.9 1.0 1.1 0.2 
Table A3.4.  Effect of 4-PBA treatment for 48 hours on cell viability (ATP content) 
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GUAVA VIACOUNT ASSAY: 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
THP1 0 100.0 100.0 100.0 100.0 0.0 
THP1 100!M 83.7 90.6 93.9 89.4 5.2 
THP1 300!M 81.1 83.0 88.8 84.3 4.0 
THP1 1mM 54.1 48.1 57.2 53.1 4.6 
THP1 3mM 35.5 28.1 35.1 32.9 4.2 
THP1 10mM 16.8 17.7 18.2 17.6 0.7 
Table A3.5.  Effect of 4-PBA treatment for 48 hours on cell number (% of control) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
THP1 0 100.0 100.0 100.0 100.0 0.0 
THP1 100!M 98.7 100.2 99.8 99.6 0.8 
THP1 300!M 97.6 100.1 100.2 99.3 1.4 
THP1 1mM 94.3 98.8 97.3 96.8 2.3 
THP1 3mM 91.5 87.8 93.6 90.9 2.9 
THP1 10mM 0.0 42.1 35.8 26.0 22.7 
Table A3.6.  Effect of 4-PBA treatment for 48 hours on cell viability (% of control) 
 
 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
U266 0 100.0 100.0 100.0 100.0 100.0 
U266 100!M 95.0 97.0 98.8 102.3 97.0 
U266 300!M 88.3 83.2 92.4 95.0 88.0 
U266 1mM 71.9 71.2 65.6 65.8 69.6 
U266 3mM 61.4 45.7 40.5 38.4 49.2 
U266 10mM 54.0 42.5 35.9 29.2 44.1 
Table A3.7.  Effect of 4-PBA treatment for 48 hours on cell number (% of control) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 100!M 99.3 98.4 99.7 99.1 0.7 
U266 300!M 99.3 97.5 99.3 98.7 1.0 
U266 1mM 93.7 92.0 93.6 93.1 0.9 
U266 3mM 79.0 64.3 76.4 73.3 7.8 
U266 10mM 26.5 28.3 29.3 28.0 1.4 
Table A3.8.  Effect of 4-PBA treatment for 48 hours on cell viability (% of control) 
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Cell line Conc. Set 1 Set 2 Set 3 Average SD 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 100!M 93.6 103.4 100.0 99.0 5.0 
DOHH2 300!M 86.6 102.1 94.0 94.2 7.8 
DOHH2 1mM 79.6 75.9 78.5 78.0 1.9 
DOHH2 3mM 71.5 48.3 72.5 64.1 13.7 
DOHH2 10mM 57.3 34.5 24.6 38.8 16.8 
Table A3.9.  Effect of 4-PBA treatment for 48 hours on cell number (% of control) 
 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 100!M 58.7 90.1 88.3 79.0 17.7 
DOHH2 300!M 61.2 69.7 82.4 71.1 10.6 
DOHH2 1mM 58.9 64.3 62.3 61.8 2.7 
DOHH2 3mM 46.1 25.1 42.9 38.0 11.3 
DOHH2 10mM 37.3 0.0 34.1 23.8 20.7 
Table A3.10.  Effect of 4-PBA treatment for 48 hours on cell number (% of control) 
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4-PBA Simultaneous treatment 
 
% of control THP1 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 93.1 81.0 89.3 87.8 6.2 
TM 100nM 26.1 55.1 17.4 32.9 19.8 
TM 1!M 7.5 10.1 10.2 9.3 1.5 
PBA 0.5mM + TM 100nM 21.6 55.4 14.2 30.4 22.0 
PBA 0.5mM + TM 1!M 5.7 6.2 6.1 6.0 0.3 
TG 1nM 60.5 55.8 97.7 71.3 23.0 
TG 10nM 32.0 33.2 44.3 36.5 6.8 
PBA 0.5mM + TG 1nM 55.8 49.4 86.5 63.9 19.9 
PBA 0.5mM + TG 10nM 27.4 27.2 44.3 33.0 9.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 91.2 80.6 83.2 85.0 5.5 
Dox 10nM 92.3 91.3 66.6 83.4 14.6 
Dox 75nM 85.5 83.5 68.1 79.0 9.5 
PBA 0.5mM + Dox 10nM 87.1 78.2 61.6 75.6 12.9 
PBA 0.5mM + Dox 75nM 78.6 70.5 64.9 71.3 6.9 
Bort 1nM 92.9 87.0 70.5 83.5 11.6 
Bort 5nM 92.4 89.4 69.7 83.8 12.3 
PBA 0.5mM + Bort 1nM 90.9 77.5 65.1 77.8 12.9 
PBA 0.5mM + Bort 5nM 81.4 78.4 64.2 74.7 9.2 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 89.2 80.2 90.1 86.5 5.5 
17-AAG 50nM 87.6 89.9 98.0 91.8 5.5 
17-AAG 250nM 70.1 61.2 77.5 69.6 8.2 
PBA 0.5mM + 17-AAG 50nM 83.4 75.7 90.1 83.0 7.2 
PBA 0.5mM + 17-AAG 250nM 70.6 68.5 64.6 67.9 3.0 
SAHA 100nM 77.9 81.0 99.4 86.1 11.7 
SAHA 500nM 73.5 72.8 91.6 79.3 10.7 
PBA 0.5mM + SAHA 100nM 74.1 76.7 89.3 80.0 8.1 
PBA 0.5mM + SAHA 500nM 68.1 65.2 82.3 71.9 9.2 
 
   Table A3.11.  4-PBA 0.5mM combined with drug treatment for 48 hours in the THP1  
   cell line  
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% of control U266 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 94.4 84.7 89.9 89.7 4.9 
TM 100nM 24.0 55.7 22.5 34.1 18.8 
TM 10!M 10.6 11.2 13.1 11.6 1.3 
PBA 0.5mM + TM 100nM 23.9 54.2 19.6 32.5 18.8 
PBA 0.5mM + TM 10!M 8.8 8.2 8.5 8.5 0.3 
TG 1nM 98.4 57.3 97.3 84.3 23.4 
TG 10nM 46.0 39.6 46.0 43.9 3.7 
PBA 0.5mM + TG 1nM 97.2 66.9 74.6 79.6 15.8 
PBA 0.5mM + TG 10nM 41.0 37.3 42.7 40.3 2.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 94.2 82.2 85.9 87.4 6.1 
Dox 10nM 95.7 92.4 94.7 94.3 1.7 
Dox 75nM 98.5 82.2 92.3 91.0 8.2 
PBA 0.5mM + Dox 10nM 91.0 88.1 92.7 90.6 2.3 
PBA 0.5mM + Dox 75nM 92.8 74.3 81.1 82.7 9.3 
Bort 1nM 100.8 83.8 99.6 94.7 9.5 
Bort 5nM 74.4 82.5 93.2 83.4 9.4 
PBA 0.5mM + Bort 1nM 89.0 81.1 88.7 86.3 4.4 
PBA 0.5mM + Bort 5nM 82.2 80.3 89.0 83.8 4.6 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 93.6 85.0 88.2 88.9 4.3 
17-AAG 50nM 98.5 97.7 96.1 97.4 1.3 
17-AAG 250nM 87.6 77.0 75.2 79.9 6.7 
PBA 0.5mM + 17-AAG 50nM 95.2 88.9 86.1 90.1 4.6 
PBA 0.5mM + 17-AAG 250nM 98.1 80.9 78.8 85.9 10.6 
SAHA 100nM 95.7 97.0 95.7 96.1 0.8 
SAHA 500nM 80.0 84.1 84.8 83.0 2.6 
PBA 0.5mM + SAHA 100nM 90.1 87.2 84.7 87.3 2.7 
PBA 0.5mM + SAHA 500nM 91.5 72.5 76.9 80.3 9.9 
 
   Table A3.12.  4-PBA 0.5mM combined with drug treatment for 48 hours in the U266  
   cell line  
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% of control DOHH2 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 72.4 81.5 82.5 78.8 5.6 
TM 100nM 97.6 96.4 96.6 96.9 0.7 
TM 1!M 60.6 46.3 37.8 48.2 11.5 
PBA 0.5mM + TM 100nM 72.2 66.1 64.6 67.6 4.0 
PBA 0.5mM + TM 1!M 48.2 35.0 36.8 40.0 7.2 
TG 1nM 91.2 90.8 84.0 88.7 4.1 
TG 10nM 80.8 82.7 91.2 84.9 5.5 
PBA 0.5mM + TG 1nM 67.4 67.2 76.9 70.5 5.6 
PBA 0.5mM + TG 10nM 65.3 55.9 60.8 60.7 4.7 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 73.8 72.2 76.3 74.1 2.1 
Dox 5nM 96.1 79.6 86.4 87.4 8.3 
Dox 50nM 71.5 70.7 67.3 69.8 2.2 
PBA 0.5mM + Dox 5nM 85.1 64.9 68.2 72.7 10.8 
PBA 0.5mM + Dox 50nM 64.9 48.3 59.6 57.6 8.5 
Bort 1nM 83.1 78.3 83.2 81.5 2.8 
Bort 5nM 74.1 70.3 75.5 73.3 2.7 
PBA 0.5mM + Bort 1nM 69.4 67.7 70.1 69.1 1.2 
PBA 0.5mM + Bort 5nM 70.0 60.7 63.1 64.6 4.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 75.0 66.8 69.2 70.3 4.2 
17-AAG 50nM 72.4 70.5 64.5 69.2 4.1 
17-AAG 250nM 52.7 15.2 31.8 33.3 18.8 
PBA 0.5mM + 17-AAG 50nM 63.1 51.1 62.0 58.7 6.6 
PBA 0.5mM + 17-AAG 250nM 47.0 21.1 20.8 29.6 15.0 
SAHA 100nM 73.5 74.5 73.7 73.9 0.5 
SAHA 500nM 46.2 45.2 62.7 51.4 9.8 
PBA 0.5mM + SAHA 100nM 59.5 58.3 71.5 63.1 7.3 
PBA 0.5mM + SAHA 500nM 36.9 36.4 33.0 35.4 2.1 
 
   Table A3.13.  4-PBA 0.5mM combined with drug treatment for 48 hours in the DOHH2  
   cell line  
 
 349 
 
 
% of control HT29 
 Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 87.1 93.7 89.5 90.1 3.4 
TM 100nM 87.2 82.9 87.8 85.9 2.6 
TM 1!M 75.4 44.8 46.3 55.5 17.2 
PBA 0.5mM + TM 100nM 92.2 82.2 86.7 87.0 5.0 
PBA 0.5mM + TM 1!M 70.7 43.8 43.8 52.8 15.5 
TG 1nM 80.7 93.8 91.0 88.5 6.9 
TG 10nM 28.7 70.2 84.1 61.0 28.8 
PBA 0.5mM + TG 1nM 72.1 89.8 88.7 83.5 9.9 
PBA 0.5mM + TG 10nM 30.9 72.5 67.6 57.0 22.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 88.9 88.3 92.4 89.8 2.2 
Dox 10nM 89.1 93.5 97.5 93.3 4.2 
Dox 75nM 88.8 94.2 96.3 93.1 3.9 
PBA 0.5mM + Dox 10nM 88.3 97.1 96.0 93.8 4.8 
PBA 0.5mM + Dox 75nM 90.2 91.8 93.4 91.8 1.6 
Bort 1nM 93.7 93.6 96.8 94.7 1.8 
Bort 5nM 92.3 90.5 92.0 91.6 1.0 
PBA 0.5mM + Bort 1nM 98.3 89.7 89.8 92.6 4.9 
PBA 0.5mM + Bort 5nM 100.5 91.3 93.3 95.0 4.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 90.5 92.7 94.3 92.5 1.9 
17-AAG 50nM 81.9 96.4 93.0 90.4 7.6 
17-AAG 250nM 32.4 57.2 56.6 48.7 14.2 
PBA 0.5mM + 17-AAG 50nM 91.6 91.0 95.0 92.5 2.1 
PBA 0.5mM + 17-AAG 250nM 33.8 55.0 56.4 48.4 12.7 
SAHA 100nM 87.7 95.5 96.4 93.2 4.8 
SAHA 500nM 78.7 91.1 90.1 86.6 6.9 
PBA 0.5mM + SAHA 100nM 98.8 96.7 99.8 98.5 1.6 
PBA 0.5mM + SAHA 500nM 82.7 86.6 89.0 86.1 3.2 
 
   Table A3.14.  4-PBA 0.5mM combined with drug treatment for 48 hours in the HT29  
   cell line  
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Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
THP1 PBA 0.5mM + TM 100nM 0.89 1.24 0.92 
THP1 PBA 0.5mM + TM 1!M 0.82 0.76 0.67 
THP1 PBA 0.5mM + TG 1nM 0.99 1.09 0.99 
THP1 PBA 0.5mM + TG 10nM 0.92 1.01 1.12 
THP1 PBA 0.5mM + Dox 10nM 1.03 1.06 1.11 
THP1 PBA 0.5mM + Dox 75nM 1.01 1.05 1.14 
THP1 PBA 0.5mM + Bort 1nM 1.07 1.11 1.11 
THP1 PBA 0.5mM + Bort 5nM 0.97 1.09 1.11 
THP1 PBA 0.5mM + 17-AAG 50nM 1.07 1.05 1.02 
THP1 PBA 0.5mM + 17-AAG 250nM 1.13 1.39 0.93 
THP1 PBA 0.5mM + SAHA 100nM 1.07 1.18 1.00 
THP1 PBA 0.5mM + SAHA 500nM 1.04 1.12 1.00 
   Table A3.15.  Combination effect of 4-PBA combined with drug treatment  
   for 48 hours in the THP1 cell line (calculated using the fractional product  
   method). 
 
 
 
 
Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
U266 PBA 0.5mM + TM 100nM 1.06 1.15 0.97 
U266 PBA 0.5mM + TM 10!M 0.88 0.87 0.73 
U266 PBA 0.5mM + TG 1nM 1.05 1.38 0.85 
U266 PBA 0.5mM + TG 10nM 0.94 1.11 1.03 
U266 PBA 0.5mM + Dox 10nM 1.01 1.16 1.14 
U266 PBA 0.5mM + Dox 75nM 1.00 1.10 1.02 
U266 PBA 0.5mM + Bort 1nM 0.94 1.18 1.04 
U266 PBA 0.5mM + Bort 5nM 1.17 1.18 1.11 
U266 PBA 0.5mM + 17-AAG 50nM 1.03 1.07 1.02 
U266 PBA 0.5mM + 17-AAG 250nM 1.20 1.24 1.19 
U266 PBA 0.5mM + SAHA 100nM 1.01 1.06 1.00 
U266 PBA 0.5mM + SAHA 500nM 1.22 1.01 1.03 
   Table A3.16.  Combination effect of 4-PBA combined with drug treatment  
   for 48 hours in the U266 cell line (calculated using the fractional product  
   method). 
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Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
DOHH2 PBA 0.5mM + TM 100nM 1.02 0.84 0.81 
DOHH2 PBA 0.5mM + TM 1!M 1.10 0.93 1.18 
DOHH2 PBA 0.5mM + TG 1nM 1.02 0.91 1.11 
DOHH2 PBA 0.5mM + TG 10nM 1.12 0.83 0.81 
DOHH2 PBA 0.5mM + Dox 5nM 1.20 1.13 1.03 
DOHH2 PBA 0.5mM + Dox 50nM 1.23 0.95 1.16 
DOHH2 PBA 0.5mM + Bort 1nM 1.13 1.20 1.10 
DOHH2 PBA 0.5mM + Bort 5nM 1.28 1.20 1.10 
DOHH2 PBA 0.5mM + 17-AAG 50nM 1.16 1.09 1.39 
DOHH2 PBA 0.5mM + 17-AAG 250nM 1.19 2.07 0.95 
DOHH2 PBA 0.5mM + SAHA 100nM 1.08 1.17 1.40 
DOHH2 PBA 0.5mM + SAHA 500nM 1.07 1.20 0.76 
   Table A3.17.  Combination effect of 4-PBA combined with drug treatment  
   for 48 hours in the DOHH2 cell line (calculated using the fractional product  
   method). 
 
 
 
 
 
Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
HT29 PBA 0.5mM + TM 100nM 1.21 1.06 1.10 
HT29 PBA 0.5mM + TM 1!M 1.08 1.04 1.06 
HT29 PBA 0.5mM + TG 1nM 1.03 1.02 1.09 
HT29 PBA 0.5mM + TG 10nM 1.23 1.10 0.90 
HT29 PBA 0.5mM + Dox 10nM 1.12 1.18 1.07 
HT29 PBA 0.5mM + Dox 75nM 1.14 1.10 1.05 
HT29 PBA 0.5mM + Bort 1nM 1.18 1.08 1.01 
HT29 PBA 0.5mM + Bort 5nM 1.23 1.14 1.10 
HT29 PBA 0.5mM + 17-AAG 50nM 1.24 1.02 1.08 
HT29 PBA 0.5mM + 17-AAG 250nM 1.16 1.04 1.06 
HT29 PBA 0.5mM + SAHA 100nM 1.25 1.09 1.10 
HT29 PBA 0.5mM + SAHA 500nM 1.16 1.03 1.05 
   Table A3.18.  Combination effect of 4-PBA combined with drug treatment  
   for 48 hours in the HT29 cell line (calculated using the fractional product  
   method). 
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4-PBA Pre-treatment 
 
% of control THP1 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 82.6 88.2 88.0 86.2 3.2 
TM 100nM 26.8 33.6 47.8 36.1 10.7 
TM 1!M 15.2 21.5 24.9 20.5 4.9 
PBA 0.5mM + TM 100nM 24.3 29.5 44.4 32.7 10.4 
PBA 0.5mM + TM 1!M 12.1 17.0 23.5 17.5 5.7 
TG 1nM 99.1 98.8 88.8 95.6 5.9 
TG 10nM 54.0 56.3 38.8 49.7 9.5 
PBA 0.5mM + TG 1nM 90.8 93.5 88.0 90.8 2.8 
PBA 0.5mM + TG 10nM 44.8 43.5 33.7 40.7 6.1 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 77.9 87.5 87.3 84.2 5.5 
Dox 10nM 99.7 98.3 92.2 96.7 4.0 
Dox 75nM 86.8 78.4 48.8 71.3 20.0 
PBA 0.5mM + Dox 10nM 78.4 88.2 82.9 83.2 4.9 
PBA 0.5mM + Dox 75nM 64.0 68.8 52.8 61.9 8.2 
Bort 1nM 97.7 99.4 91.9 96.3 3.9 
Bort 5nM 90.2 98.7 87.7 92.2 5.8 
PBA 0.5mM + Bort 1nM 82.2 88.1 86.7 85.7 3.1 
PBA 0.5mM + Bort 5nM 84.7 91.0 88.8 88.2 3.2 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 73.4 89.2 88.5 83.7 9.0 
17-AAG 50nM 89.2 91.2 87.1 89.2 2.0 
17-AAG 250nM 70.1 75.2 68.5 71.2 3.5 
PBA 0.5mM + 17-AAG 50nM 72.1 82.3 88.2 80.9 8.2 
PBA 0.5mM + 17-AAG 250nM 51.1 62.4 62.8 58.7 6.7 
SAHA 100nM 88.5 89.4 90.8 89.6 1.1 
SAHA 500nM 85.8 86.1 84.1 85.3 1.0 
PBA 0.5mM + SAHA 100nM 75.5 83.7 88.3 82.5 6.5 
PBA 0.5mM + SAHA 500nM 66.5 73.7 75.3 71.9 4.7 
 
   Table A3.19.  4-PBA 0.5mM pretreatment for 24 hours combined with drug treatment  
   for a further 48 hours in the THP1 cell line. 
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% of control U266 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 80.5 88.4 83.5 84.1 4.0 
TM 100nM 30.3 40.9 50.7 40.6 10.2 
TM 10!M 14.5 18.9 25.8 19.7 5.7 
PBA 0.5mM + TM 100nM 30.7 39.9 51.5 40.7 10.4 
PBA 0.5mM + TM 10!M 12.9 18.8 24.6 18.8 5.9 
TG 1nM 99.1 99.3 85.8 94.7 7.7 
TG 10nM 59.5 68.8 50.6 59.6 9.1 
PBA 0.5mM + TG 1nM 82.7 80.5 87.1 83.4 3.3 
PBA 0.5mM + TG 10nM 49.9 45.0 45.1 46.7 2.8 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 80.2 87.0 86.3 84.5 3.8 
Dox 10nM 97.5 92.3 94.2 94.7 2.6 
Dox 75nM 81.1 69.4 47.9 66.1 16.8 
PBA 0.5mM + Dox 10nM 78.1 83.9 92.6 84.9 7.3 
PBA 0.5mM + Dox 75nM 67.9 63.4 48.5 60.0 10.2 
Bort 1nM 94.6 93.5 87.6 91.9 3.8 
Bort 5nM 90.8 94.7 89.7 91.7 2.6 
PBA 0.5mM + Bort 1nM 78.1 85.6 93.0 85.6 7.5 
PBA 0.5mM + Bort 5nM 78.8 85.0 87.1 83.6 4.3 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 79.3 83.3 84.0 82.2 2.5 
17-AAG 50nM 93.7 98.5 92.5 94.9 3.2 
17-AAG 250nM 74.6 82.6 68.6 75.3 7.0 
PBA 0.5mM + 17-AAG 50nM 73.5 87.7 80.3 80.5 7.1 
PBA 0.5mM + 17-AAG 250nM 53.7 65.4 54.1 57.8 6.7 
SAHA 100nM 92.8 98.2 87.4 92.8 5.4 
SAHA 500nM 81.6 93.6 78.2 84.4 8.1 
PBA 0.5mM + SAHA 100nM 73.5 89.3 70.3 77.7 10.2 
PBA 0.5mM + SAHA 500nM 62.6 76.5 66.3 68.5 7.2 
 
   Table A3.20.  4-PBA 0.5mM pretreatment for 24 hours combined with drug treatment  
   for a further 48 hours in the U266 cell line. 
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% of control DOHH2 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 71.5 75.8 83.1 76.8 5.8 
TM 100nM 94.2 79.7 90.1 88.0 7.5 
TM 1!M 54.6 35.2 34.8 41.5 11.3 
PBA 0.5mM + TM 100nM 62.0 66.7 87.6 72.1 13.7 
PBA 0.5mM + TM 1!M 47.6 28.3 35.8 37.2 9.7 
TG 1nM 81.1 76.6 52.5 70.1 15.4 
TG 5nM 63.9 60.1 49.6 57.9 7.4 
PBA 0.5mM + TG 1nM 58.6 62.3 61.3 60.7 1.9 
PBA 0.5mM + TG 5nM 48.0 52.2 48.9 49.7 2.2 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 71.1 71.5 86.4 76.3 8.7 
Dox 10nM 86.5 79.2 70.4 78.7 8.0 
Dox 75nM 42.8 42.2 19.4 34.8 13.4 
PBA 0.5mM + Dox 5nM 52.8 59.3 74.8 62.3 11.3 
PBA 0.5mM + Dox 50nM 31.3 35.2 24.6 30.4 5.4 
Bort 1nM 96.0 95.7 95.4 95.7 0.3 
Bort 5nM 78.3 90.8 87.0 85.4 6.4 
PBA 0.5mM + Bort 1nM 61.8 70.7 91.7 74.7 15.3 
PBA 0.5mM + Bort 5nM 60.7 67.7 92.3 73.6 16.6 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 69.7 76.1 81.0 75.6 5.6 
17-AAG 50nM 54.7 89.5 93.8 79.3 21.5 
17-AAG 250nM 29.8 54.8 69.2 51.3 20.0 
PBA 0.5mM + 17-AAG 50nM 46.3 69.8 86.5 67.5 20.2 
PBA 0.5mM + 17-AAG 250nM 22.3 40.4 54.3 39.0 16.0 
SAHA 100nM 91.5 75.7 91.1 86.1 9.0 
SAHA 500nM 59.8 41.7 47.7 49.7 9.2 
PBA 0.5mM + SAHA 100nM 56.3 59.3 72.7 62.8 8.7 
PBA 0.5mM + SAHA 500nM 42.3 34.4 46.2 41.0 6.0 
 
   Table A3.21.  4-PBA 0.5mM pretreatment for 24 hours combined with drug treatment  
   for a further 48 hours in the DOHH2 cell line. 
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% of control HT29 
  Set 1 Set 2 Set 3 Average SD 
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 81.3 91.8 88.3 87.2 5.3 
TM 100nM 92.8 88.7 92.2 91.2 2.2 
TM 1!M 57.8 60.9 65.4 61.3 3.8 
PBA 0.5mM + TM 100nM 80.2 81.0 80.3 80.5 0.5 
PBA 0.5mM + TM 1!M 44.5 61.3 56.1 54.0 8.6 
TG 1nM 92.0 83.1 91.6 88.9 5.0 
TG 10nM 69.5 47.6 37.7 51.6 16.3 
PBA 0.5mM + TG 1nM 88.5 79.6 82.1 83.4 4.6 
PBA 0.5mM + TG 10nM 55.8 42.3 40.0 46.0 8.5 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 85.3 93.2 92.6 90.4 4.4 
Dox 10nM 98.1 98.8 93.8 96.9 2.7 
Dox 75nM 92.4 97.0 91.9 93.7 2.8 
PBA 0.5mM + Dox 10nM 83.3 85.9 91.3 86.8 4.1 
PBA 0.5mM + Dox 75nM 89.9 94.3 87.1 90.4 3.6 
Bort 1nM 98.2 97.3 95.3 96.9 1.5 
Bort 5nM 93.7 97.8 87.5 93.0 5.2 
PBA 0.5mM + Bort 1nM 87.3 88.3 83.5 86.4 2.5 
PBA 0.5mM + Bort 5nM 86.0 87.6 86.2 86.6 0.9 
       
Control 100.0 100.0 100.0 100.0 0.0 
PBA 0.5mM 86.1 91.4 91.3 89.6 3.0 
17-AAG 50nM 90.9 92.3 94.9 92.7 2.0 
17-AAG 250nM 66.7 72.2 69.8 69.6 2.7 
PBA 0.5mM + 17-AAG 50nM 76.7 85.3 89.5 83.8 6.5 
PBA 0.5mM + 17-AAG 250nM 64.6 73.7 66.6 68.3 4.8 
SAHA 100nM 87.8 99.4 92.4 93.2 5.8 
SAHA 500nM 83.1 92.6 82.3 86.0 5.7 
PBA 0.5mM + SAHA 100nM 84.1 84.0 84.1 84.0 0.1 
PBA 0.5mM + SAHA 500nM 73.2 80.4 76.9 76.9 3.6 
 
   Table A3.22.  4-PBA 0.5mM pretreatment for 24 hours combined with drug treatment  
   for a further 48 hours in the HT29 cell line. 
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Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
THP1 PBA 0.5mM + TM 100nM 1.10 1.00 1.06 
THP1 PBA 0.5mM + TM 1!M 0.96 0.90 1.08 
THP1 PBA 0.5mM + TG 1nM 1.11 1.07 1.13 
THP1 PBA 0.5mM + TG 10nM 1.00 0.88 0.99 
THP1 PBA 0.5mM + Dox 10nM 1.01 1.02 1.03 
THP1 PBA 0.5mM + Dox 75nM 0.95 1.00 1.24 
THP1 PBA 0.5mM + Bort 1nM 1.08 1.01 1.08 
THP1 PBA 0.5mM + Bort 5nM 1.21 1.05 1.16 
THP1 PBA 0.5mM + 17-AAG 50nM 1.10 1.01 1.14 
THP1 PBA 0.5mM + 17-AAG 250nM 0.99 0.93 1.04 
THP1 PBA 0.5mM + SAHA 100nM 1.16 1.05 1.10 
THP1 PBA 0.5mM + SAHA 500nM 1.06 0.96 1.01 
    Table A3.23.  Combination effect of 4-PBA pretreatment for 24 hours  
    combined with drug treatment for a further 48 hours in the THP1 cell line  
    (calculated using the fractional product method). 
 
 
 
 
 
Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
U266 PBA 0.5mM + TM 100nM 1.26 1.10 1.22 
U266 PBA 0.5mM + TM 10!M 1.11 1.13 1.14 
U266 PBA 0.5mM + TG 1nM 1.04 0.92 1.22 
U266 PBA 0.5mM + TG 10nM 1.04 0.74 1.07 
U266 PBA 0.5mM + Dox 10nM 1.00 1.04 1.14 
U266 PBA 0.5mM + Dox 75nM 1.04 1.05 1.17 
U266 PBA 0.5mM + Bort 1nM 1.03 1.05 1.23 
U266 PBA 0.5mM + Bort 5nM 1.08 1.03 1.12 
U266 PBA 0.5mM + 17-AAG 50nM 0.99 1.07 1.03 
U266 PBA 0.5mM + 17-AAG 250nM 0.91 0.95 0.94 
U266 PBA 0.5mM + SAHA 100nM 1.00 1.09 0.96 
U266 PBA 0.5mM + SAHA 500nM 0.97 0.98 1.01 
    Table A3.24.  Combination effect of 4-PBA pretreatment for 24 hours  
    combined with drug treatment for a further 48 hours in the U266 cell line  
    (calculated using the fractional product method). 
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Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
DOHH2 PBA 0.5mM + TM 100nM 0.92 1.11 1.17 
DOHH2 PBA 0.5mM + TM 1!M 1.22 1.06 1.24 
DOHH2 PBA 0.5mM + TG 1nM 1.01 1.07 1.41 
DOHH2 PBA 0.5mM + TG 10nM 1.05 1.15 1.19 
DOHH2 PBA 0.5mM + Dox 5nM 0.86 1.05 1.23 
DOHH2 PBA 0.5mM + Dox 50nM 1.03 1.17 1.47 
DOHH2 PBA 0.5mM + Bort 1nM 0.91 1.03 1.11 
DOHH2 PBA 0.5mM + Bort 5nM 1.09 1.04 1.23 
DOHH2 PBA 0.5mM + 17-AAG 50nM 1.21 1.02 1.14 
DOHH2 PBA 0.5mM + 17-AAG 250nM 1.07 0.97 0.97 
DOHH2 PBA 0.5mM + SAHA 100nM 0.88 1.03 0.98 
DOHH2 PBA 0.5mM + SAHA 500nM 1.02 1.08 1.20 
    Table A3.25.  Combination effect of 4-PBA pretreatment for 24 hours  
    combined with drug treatment for a further 48 hours in the DOHH2 cell line  
    (calculated using the fractional product method). 
 
 
 
Combination Effect Cell line Drug concentrations 
Set 1 Set 2 Set 3 
HT29 PBA 0.5mM + TM 100nM 1.06 1.00 0.99 
HT29 PBA 0.5mM + TM 1!M 0.95 1.10 0.97 
HT29 PBA 0.5mM + TG 1nM 1.18 1.04 1.01 
HT29 PBA 0.5mM + TG 10nM 0.99 0.97 1.20 
HT29 PBA 0.5mM + Dox 10nM 0.99 0.93 1.05 
HT29 PBA 0.5mM + Dox 75nM 1.14 1.04 1.02 
HT29 PBA 0.5mM + Bort 1nM 1.04 0.97 0.95 
HT29 PBA 0.5mM + Bort 5nM 1.07 0.96 1.06 
HT29 PBA 0.5mM + 17-AAG 50nM 0.98 1.01 1.03 
HT29 PBA 0.5mM + 17-AAG 250nM 1.12 1.12 1.05 
HT29 PBA 0.5mM + SAHA 100nM 1.11 0.92 1.00 
HT29 PBA 0.5mM + SAHA 500nM 1.02 0.95 1.02 
    Table A3.26.  Combination effect of 4-PBA pretreatment for 24 hours  
    combined with drug treatment for a further 48 hours in the HT29 cell line  
    (calculated using the fractional product method). 
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THP1 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 0.1 0.3 0.3 0.2 0.1 
  late apoptosis/dead cells 2.2 2.2 2.6 2.3 0.2 
  viable cells 91.4 91.5 91.2 91.4 0.2 
  early apoptosis 6.3 6.1 5.9 6.1 0.2 
              
PBA 0.5mM nuclear debris 0.2 0.3 0.3 0.3 0.1 
  late apoptosis/dead cells 2.8 2.4 2.4 2.5 0.2 
  viable cells 91.3 92.2 91.2 91.6 0.6 
  early apoptosis 5.7 5.1 6.1 5.6 0.5 
              
TM 100nM nuclear debris 0.2 0.2 0.2 0.2 0.0 
  late apoptosis/dead cells 4.5 4.6 5.1 4.7 0.3 
  viable cells 79.3 78.2 77.0 78.2 1.2 
  early apoptosis 16.1 16.9 17.7 16.9 0.8 
              
PBA + TM 100nM nuclear debris 0.2 0.3 0.3 0.3 0.1 
  late apoptosis/dead cells 5.8 5.3 5.4 5.5 0.3 
  viable cells 77.9 79.7 78.6 78.7 0.9 
  early apoptosis 16.1 14.6 15.7 15.5 0.8 
              
TM 1!M nuclear debris 0.2 0.3 0.9 0.5 0.4 
  late apoptosis/dead cells 10.3 12.8 12.9 12.0 1.5 
  viable cells 57.6 57.4 56.0 57.0 0.9 
  early apoptosis 31.8 29.5 30.2 30.5 1.2 
              
PBA + TM 1!M nuclear debris 0.9 0.6 0.6 0.7 0.2 
  late apoptosis/dead cells 18.5 19.6 17.7 18.6 1.0 
  viable cells 52.5 54.4 53.4 53.4 1.0 
  early apoptosis 28.1 25.4 28.3 27.3 1.6 
              
TG 10nM nuclear debris 0.3 0.3 0.4 0.3 0.1 
  late apoptosis/dead cells 10.7 9.7 10.9 10.4 0.6 
  viable cells 76.2 77.7 75.9 76.6 1.0 
  early apoptosis 12.8 12.3 12.8 12.6 0.3 
              
PBA + TG 10nM nuclear debris 0.5 0.6 0.4 0.5 0.1 
  late apoptosis/dead cells 15.8 14.5 14.3 14.9 0.8 
  viable cells 68.5 70.2 70.1 69.6 1.0 
  early apoptosis 15.2 14.7 15.2 15.0 0.3 
              
TG 100nM nuclear debris 1.0 0.6 1.1 0.9 0.3 
  late apoptosis/dead cells 13.0 12.3 11.9 12.4 0.6 
  viable cells 63.1 59.4 65.6 62.7 3.1 
  early apoptosis 22.9 27.7 21.4 24.0 3.3 
              
PBA + TG 100nM nuclear debris 0.9 1.2 0.8 1.0 0.2 
  late apoptosis/dead cells 21.0 22.7 20.3 21.3 1.2 
  viable cells 53.1 49.8 59.4 54.1 4.9 
  early apoptosis 25.0 26.3 19.5 23.6 3.6 
Table A3.27.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment in the THP1 cell line. 
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THP1 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 1148 2255 2284 1896 648 
  late apoptosis/dead cells 19231 18322 21986 19846 1908 
  viable cells 786751 773465 781500 780572 6691 
  early apoptosis 53962 51583 50825 52123 1637 
              
PBA 0.5mM nuclear debris 3142 1943 1935 2340 694 
  late apoptosis/dead cells 20159 19983 19628 19923 270 
  viable cells 716032 765723 766043 749266 28782 
  early apoptosis 46077 44961 41744 44261 2250 
              
TM 100nM nuclear debris 926 1297 1201 1141 193 
  late apoptosis/dead cells 24805 25574 30613 26997 3155 
  viable cells 440204 434941 462395 445847 14571 
  early apoptosis 89411 94141 106045 96532 8571 
              
PBA + TM 100nM nuclear debris 1212 1753 1580 1515 276 
  late apoptosis/dead cells 29957 27880 28611 28816 1053 
  viable cells 404854 419433 413899 412729 7359 
  early apoptosis 83464 76978 82499 80980 3500 
              
TM 1!M nuclear debris 1155 1407 4283 2282 1738 
  late apoptosis/dead cells 51156 59885 63916 58319 6522 
  viable cells 285154 269248 276748 277050 7957 
  early apoptosis 157594 138533 149246 148457 9555 
              
PBA + TM 1!M nuclear debris 3808 2985 2664 3152 590 
  late apoptosis/dead cells 81150 92224 78582 83985 7250 
  viable cells 230852 256248 237226 241442 13213 
  early apoptosis 123629 119876 125494 123000 2862 
              
TG 10nM nuclear debris 1905 2126 2816 2282 475 
  late apoptosis/dead cells 76663 68742 76978 74127 4667 
  viable cells 544020 550877 534149 543016 8409 
  early apoptosis 91662 86931 90120 89571 2413 
              
PBA + TG 10nM nuclear debris 3056 3843 2155 3018 845 
  late apoptosis/dead cells 96584 93083 84050 91239 6467 
  viable cells 418737 449401 412218 426785 19855 
  early apoptosis 92917 94150 89340 92136 2498 
              
TG 100nM nuclear debris 2862 3333 3113 3103 236 
  late apoptosis/dead cells 104934 94890 116156 105327 10638 
  viable cells 469816 440896 469173 459962 16515 
  early apoptosis 137845 127558 130046 131816 5367 
              
PBA + TG 100nM nuclear debris 2829 3501 2822 3051 390 
  late apoptosis/dead cells 109323 101984 95016 102107 7154 
  viable cells 275053 241565 251180 255933 17243 
  early apoptosis 111985 109595 121357 114312 6217 
Table A3.28.  Apoptosis assay results for cell number by region following 48 hours of drug 
treatment in the THP1 cell line. 
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Apoptotic cells (%) THP1 
Drug alone Drug with 4-PBA 
pretreatment 
p value 
TM 100nM 20.6 21.5 22.8 21.8 19.9 21.1 0.53810 
TM 1!M 42.2 42.3 43.1 46.6 45.0 46.0 0.02494 
TG 10nM 23.6 22.0 23.7 31.0 29.2 29.5 0.00543 
TG 100nM 33.9 33.4 34.3 44.3 46.3 46.0 0.00381 
         Table A3.29.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 24 hours of 4-PBA pretreatment, in  
         the THP1 cell line. 
 
Total cell number (%) THP1 
Drug alone Drug with TG 
pretreatment 
p value 
TM 100nM 64.5 65.7 70.1 66.1 63.2 63.5 0.40327 
TM 1!M 57.5 55.5 57.7 56.0 56.6 53.5 0.42482 
TG 10nM 82.9 83.8 82.2 77.8 76.9 70.9 0.05206 
TG 100nM 83.1 78.8 83.9 63.6 54.8 56.7 0.00871 
         Table A3.30.  Total cell number (%) after 48 hours treatment with drug, with  
         or without 24 hours of 4-PBA pretreatment, in the THP1 cell line (each  
         normalised to its own control). 
 
Viable cell number (%) THP1 
Drug alone Drug with TG 
pretreatment 
p value 
TM 100nM 56.0 56.2 59.2 56.5 54.8 54.0 0.35466 
TM 1!M 36.2 34.8 35.4 32.2 33.5 31.0 0.07778 
TG 10nM 69.1 71.2 68.3 58.5 58.7 53.8 0.00780 
TG 100nM 59.7 57.0 60.0 38.4 31.5 32.8 0.00505 
         Table A3.31.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 24 hours of 4-PBA pretreatment, in the THP1 cell line (each  
         normalised to its own control). 
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U266 
 
  Cells In Each Region (%) Average SD 
Control nuclear debris 0.9 0.7 0.9 0.8 0.1 
  late apoptosis/dead cells 3.0 3.0 3.7 3.2 0.4 
  viable cells 89.1 89.5 87.4 88.7 1.1 
  early apoptosis 6.9 6.8 8.0 7.2 0.7 
              
PBA 0.5mM nuclear debris 0.9 0.7 0.9 0.8 0.1 
  late apoptosis/dead cells 3.1 2.7 2.6 2.8 0.3 
  viable cells 90.3 90.0 90.0 90.1 0.2 
  early apoptosis 5.8 6.5 6.6 6.3 0.4 
              
TM 100nM nuclear debris 0.6 0.4 1.1 0.7 0.4 
  late apoptosis/dead cells 6.4 6.3 7.3 6.7 0.6 
  viable cells 76.0 79.1 74.7 76.6 2.3 
  early apoptosis 17.0 14.2 16.8 16.0 1.6 
              
PBA + TM 100nM nuclear debris 1.3 0.8 0.7 0.9 0.3 
  late apoptosis/dead cells 8.8 8.0 9.2 8.7 0.6 
  viable cells 77.0 78.7 76.9 77.5 1.0 
  early apoptosis 12.9 12.5 13.3 12.9 0.4 
              
TM 10!M nuclear debris 1.0 1.2 1.0 1.1 0.1 
  late apoptosis/dead cells 21.4 19.0 19.9 20.1 1.2 
  viable cells 53.5 56.9 57.2 55.9 2.1 
  early apoptosis 24.1 22.8 21.9 22.9 1.1 
              
PBA + TM 10!M nuclear debris 2.0 1.6 1.8 1.8 0.2 
  late apoptosis/dead cells 24.0 24.5 25.4 24.6 0.7 
  viable cells 58.4 55.3 53.5 55.7 2.5 
  early apoptosis 15.6 18.7 19.4 17.9 2.0 
              
TG 10nM nuclear debris 0.5 0.8 0.8 0.7 0.2 
  late apoptosis/dead cells 7.7 8.0 7.9 7.9 0.2 
  viable cells 75.7 76.1 78.3 76.7 1.4 
  early apoptosis 16.0 15.1 13.1 14.7 1.5 
              
PBA + TG 10nM nuclear debris 1.1 0.9 0.5 0.8 0.3 
  late apoptosis/dead cells 14.3 12.7 12.8 13.3 0.9 
  viable cells 69.5 70.0 71.6 70.4 1.1 
  early apoptosis 15.1 16.4 15.1 15.5 0.8 
              
TG 100nM nuclear debris 1.1 1.0 0.6 0.9 0.3 
  late apoptosis/dead cells 11.9 13.0 12.3 12.4 0.6 
  viable cells 65.6 63.1 59.4 62.7 3.1 
  early apoptosis 21.4 22.9 27.7 24.0 3.3 
              
PBA + TG 100nM nuclear debris 0.8 0.9 1.2 1.0 0.2 
  late apoptosis/dead cells 20.3 21.0 22.7 21.3 1.2 
  viable cells 59.4 53.1 49.8 54.1 4.9 
  early apoptosis 19.5 25.0 26.3 23.6 3.6 
Table A3.32.  Apoptosis assay results for cells in each region (%) following 48 hours of 
drug treatment in the U266 cell line. 
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U266 
 
   Cell No. By Region 
(cells/mL) 
Average SD 
Control nuclear debris 5705 4318 5247 5090 706 
  late apoptosis/dead cells 18337 19648 21765 19916 1730 
  viable cells 544801 579942 509330 544691 35306 
  early apoptosis 42378 43830 46638 44282 2166 
              
PBA 0.5mM nuclear debris 5674 4362 4984 5007 656 
  late apoptosis/dead cells 20079 17034 14762 17292 2668 
  viable cells 591016 561094 517619 556576 36906 
  early apoptosis 37975 40716 37767 38819 1646 
              
TM 100nM nuclear debris 2278 1828 4343 2816 1341 
  late apoptosis/dead cells 24170 26580 28950 26567 2390 
  viable cells 288518 333723 295031 305757 24437 
  early apoptosis 64663 59769 66454 63629 3461 
              
PBA + TM 100nM nuclear debris 5299 3165 2525 3663 1452 
  late apoptosis/dead cells 35732 30386 34722 33613 2840 
  viable cells 313848 298924 291156 301309 11533 
  early apoptosis 52716 47352 50378 50148 2689 
              
TM 10!M nuclear debris 3587 4581 3613 3927 566 
  late apoptosis/dead cells 74401 70565 71891 72286 1949 
  viable cells 185598 211447 206641 201229 13748 
  early apoptosis 83542 84801 79116 82487 2986 
              
PBA + TM 10!M nuclear debris 7129 5556 6236 6307 789 
  late apoptosis/dead cells 87120 86891 89652 87888 1532 
  viable cells 211698 196008 188716 198808 11744 
  early apoptosis 56550 66203 68357 63703 6288 
              
TG 10nM nuclear debris 2720 4150 4133 3668 821 
  late apoptosis/dead cells 39270 39675 40642 39863 705 
  viable cells 386243 378824 404355 389808 13133 
  early apoptosis 81771 75366 67507 74881 7144 
              
PBA + TG 10nM nuclear debris 4867 4050 2467 3795 1220 
  late apoptosis/dead cells 65248 55253 59051 59851 5045 
  viable cells 317264 303604 331181 317350 13789 
  early apoptosis 68898 71019 69844 69920 1063 
              
TG 100nM nuclear debris 2291 4223 4751 3755 1295 
  late apoptosis/dead cells 49854 55033 51396 52095 2659 
  viable cells 240110 266300 283182 263197 21703 
  early apoptosis 111970 96695 92570 100412 10220 
              
PBA + TG 100nM nuclear debris 2340 3326 4136 3267 899 
  late apoptosis/dead cells 62059 74839 78117 71672 8485 
  viable cells 181395 189235 171628 180752 8821 
  early apoptosis 59414 88975 90754 79714 17603 
Table A3.33.  Apoptosis assay results for cell number by region following 48 hours of drug 
treatment in the U266 cell line. 
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Apoptotic cells (%) U266 
Drug alone Drug with 4-PBA 
pretreatment 
p value 
TM 100nM 23.4 20.5 24.2 21.7 20.5 22.5 0.18350 
TM 10!M 45.5 41.8 41.8 39.6 43.2 44.8 0.87199 
TG 10nM 23.7 23.1 20.9 29.4 29.1 27.9 0.00395 
TG 100nM 33.3 35.9 40.0 39.8 46.0 49.0 0.01522 
         Table A3.34.  Apoptotic cells (as a percentage of total cells) after 48 hours  
         treatment with drug, with or without 24 hours of 4-PBA pretreatment, in  
         the U266 cell line. 
 
Total cell number (%) U266 
Drug alone Drug with TG 
pretreatment 
p value 
TM 100nM 62.1 65.1 67.7 74.5 60.4 61.0 0.96215 
TM 10!M 56.8 57.3 62.0 66.2 56.4 56.9 0.81610 
TG 10nM 83.4 76.9 88.6 83.4 69.0 74.5 0.21233 
TG 100nM 66.1 65.2 74.1 55.8 56.7 55.5 0.05634 
         Table A3.35.  Total cell number (%) after 48 hours treatment with drug, with  
         or without 24 hours of 4-PBA pretreatment, in the U266 cell line (each  
         normalised to its own control). 
 
 
Viable cell number (%) U266 
Drug alone Drug with TG 
pretreatment 
p value 
TM 100nM 53.0 57.5 57.9 53.1 53.3 56.2 0.27017 
TM 10!M 34.1 36.5 40.6 35.8 34.9 36.5 0.52491 
TG 10nM 70.9 65.3 79.4 53.7 54.1 64.0 0.01449 
TG 100nM 44.1 45.9 55.6 30.7 33.7 33.2 0.03855 
         Table A3.36.  Viable cell number (%) after 48 hours treatment with drug, with  
         or without 24 hours of 4-PBA pretreatment, in the U266 cell line (each  
         normalised to its own control). 
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Drug Conc. Set 1 Set 2 Set 3 Average SD p value 
Trichostatin A 0 100.0 100.0 100.0 100.0 0.0  
  0.5nM 91.1 99.7 84.9 91.9 7.4 0.19969 
  5nM 51.9 53.0 47.0 50.6 3.2 0.00438 
  50nM 5.0 8.3 5.4 6.2 1.8 0.00161 
               
4-PBA 0 100.0 100.0 100.0 100.0 0.0  
  0.1mM 91.7 97.9 85.2 91.6 6.3 0.14906 
  0.5mM 75.8 85.2 69.6 76.9 7.8 0.03634 
  1mM 63.6 72.0 64.0 66.5 4.7 0.00661 
  5mM 31.6 39.9 27.3 32.9 6.4 0.00302 
               
SAHA 0 100.0 100.0 100.0 100.0 0.0  
  0.5!M 24.0 34.8 23.4 27.4 6.4 0.00259 
  1!M 11.2 21.0 7.2 13.1 7.1 0.00222 
  5!M 3.0 8.5 0.0 3.8 4.3 0.00066 
 
Table A3.37.   Results of HDAC activity assay for 4-PBA expressed as percentage of  
control.  Trichostatin A is used as the positive control for HDAC inhibition in this  
assay.  SAHA, a known HDAC inhibitor used in this project, is included for  
comparison purposes.  P value from paired t-test comparing drug treated sample to  
control sample is shown (p<0.05 considered statistically significant). 
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Appendix 4 
 
ADDITIONAL DATA FOR CHAPTER 7 
 
ATP ASSAY: 
 
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
THP1 0 100.0 100.0 100.0 100.0 0.0 
THP1 0.3!M 92.6 98.6 93.5 94.9 3.3 
THP1 1!M 65.8 67.1 82.9 72.0 9.5 
THP1 3!M 44.3 43.6 47.0 45.0 1.8 
THP1 10!M 28.8 25.1 31.1 28.3 3.1 
THP1 30!M 7.4 6.2 5.4 6.3 1.0 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 0.3!M 92.0 94.0 99.1 95.0 3.7 
U266 1!M 80.1 76.8 89.5 82.1 6.6 
U266 3!M 58.8 49.4 82.1 63.4 16.9 
U266 10!M 47.0 29.6 59.8 45.5 15.1 
U266 30!M 40.7 13.6 22.2 25.5 13.9 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 0.3!M 94.9 87.0 89.4 90.4 4.0 
DOHH2 1!M 78.5 80.4 70.9 76.6 5.1 
DOHH2 3!M 29.4 54.3 38.0 40.6 12.6 
DOHH2 10!M 5.3 26.1 22.0 17.8 11.0 
DOHH2 30!M 0.3 4.3 7.2 3.9 3.5 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
HT29 0 100.0 100.0 100.0 100.0 0.0 
HT29 0.3!M 85.4 98.0 94.7 92.7 6.5 
HT29 1!M 94.3 94.6 71.8 86.9 13.1 
HT29 3!M 86.9 89.8 61.4 79.4 15.6 
HT29 10!M 72.8 66.0 55.9 64.9 8.5 
HT29 30!M 44.0 34.2 36.5 38.3 5.1 
 
Table A4.1.  Effect of versipelostatin treatment for 48 hours on cell viability (ATP  
content) 
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Cell line Conc. Set 1 Set 2 Set 3 Average SD 
THP1 0 100.0 100.0 100.0 100.0 0.0 
THP1 10!M 80.0 98.0 94.1 90.7 9.5 
THP1 100!M 88.0 101.2 89.2 92.8 7.3 
THP1 1mM 67.6 78.6 63.3 69.9 7.9 
THP1 10mM 20.2 21.2 13.6 18.3 4.1 
THP1 100mM 2.9 2.4 1.2 2.2 0.9 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
U266 0 100.0 100.0 100.0 100.0 0.0 
U266 10!M 77.4 95.8 95.6 89.6 10.6 
U266 100!M 87.6 101.4 94.3 94.4 6.9 
U266 1mM 78.1 71.4 54.0 67.9 12.4 
U266 10mM 46.3 24.6 15.3 28.7 15.9 
U266 100mM 22.1 7.6 2.5 10.8 10.1 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
DOHH2 0 100.0 100.0 100.0 100.0 0.0 
DOHH2 10!M 80.5 95.2 85.7 87.1 7.5 
DOHH2 100!M 72.9 87.6 90.7 83.7 9.5 
DOHH2 1mM 16.1 61.0 39.2 38.8 22.4 
DOHH2 10mM 0.3 13.5 8.1 7.3 6.6 
DOHH2 100mM 0.0 0.3 0.2 0.2 0.2 
       
Cell line Conc. Set 1 Set 2 Set 3 Average SD 
HT29 0 100.0 100.0 100.0 100.0 0.0 
HT29 10!M 96.9 96.7 95.0 96.2 1.0 
HT29 100!M 92.4 89.2 91.2 90.9 1.6 
HT29 1mM 76.7 72.0 78.1 75.6 3.2 
HT29 10mM 31.9 24.6 30.0 28.8 3.8 
HT29 100mM 8.6 10.0 12.4 10.4 1.9 
 
Table A4.2.  Effect of 2-DG treatment for 48 hours on cell viability (ATP content) 
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GUAVA VIACOUNT: 
 
THP1 Cell viability (% of control) Cell no (% of control) 
VST Set 1 Set 2 Average  SD Set 1 Set 2 Average SD 
0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 0.0 
0.3!M 97.8 99.1 98.4 0.9 85.3 90.2 87.7 3.5 
1!M 95.5 97.2 96.3 1.2 64.5 59.6 62.0 3.5 
3!M 93.5 92.9 93.2 0.4 43.9 38.3 41.1 4.0 
10!M 75.0 71.2 73.1 2.7 35.2 28.4 31.8 4.8 
30!M 22.4 22.8 22.6 0.3 27.7 19.1 23.4 6.1 
Table A4.3.  Effect of versipelostatin treatment for 48 hours on cell viability and  
cell number (% of control) in the THP1 cell line. 
 
 
U266 Cell viability (% of control) Cell no (% of control) 
VST Set 1 Set 2 Average  SD Set 1 Set 2 Average SD 
0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 0.0 
0.3!M 100.1 98.9 99.5 0.8 82.7 96.1 89.4 9.5 
1!M 96.8 96.2 96.5 0.5 57.8 78.2 68.0 14.4 
3!M 83.3 82.7 83.0 0.4 39.5 49.5 44.5 7.1 
10!M 58.6 65.8 62.2 5.0 29.0 41.7 35.3 8.9 
30!M 28.4 42.7 35.5 10.1 24.0 35.1 29.6 7.9 
Table A4.4.  Effect of versipelostatin treatment for 48 hours on cell viability and  
cell number (% of control) in the U266 cell line. 
 
 
THP1 Cell viability (% of control) Cell no (% of control) 
2DG Set 1 Set 2 Average  SD Set 1 Set 2 Average SD 
0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 0.0 
10!M 96.7 99.2 98.0 1.7 81.2 98.1 89.6 11.9 
100!M 101.3 99.4 100.3 1.4 82.2 96.6 89.4 10.2 
1mM 99.1 98.3 98.7 0.6 73.5 81.1 77.3 5.4 
10mM 75.9 67.9 71.9 5.7 41.3 29.0 35.2 8.7 
100mM 22.9 12.5 17.7 7.3 25.6 18.1 21.9 5.3 
Table A4.5.  Effect of 2-DG treatment for 48 hours on cell viability and cell number  
(% of control) in the THP1 cell line. 
 
U266 Cell viability (% of control) Cell no (% of control) 
2DG Set 1 Set 2 Average  SD Set 1 Set 2 Average SD 
0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 0.0 
10!M 99.6 100.8 100.2 0.9 97.0 100.2 98.6 2.2 
100!M 99.8 99.3 99.5 0.3 100.7 100.5 100.6 0.1 
1mM 96.1 98.7 97.4 1.9 72.9 82.0 77.4 6.5 
10mM 57.6 68.8 63.2 7.9 35.2 45.4 40.3 7.2 
100mM 17.0 33.5 25.3 11.7 26.2 37.2 31.7 7.8 
Table A4.6.  Effect of 2-DG treatment for 48 hours on cell viability and cell number  
(% of control) in the U266 cell line. 
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VST 2DG Cell viability Average SD 
 -  - 97.1 92.0 94.5 3.6 
0.3!M  - 93.5 92.9 93.2 0.4 
1!M  - 90.3 87.4 88.8 2.0 
3!M  - 90.8 87.8 89.3 2.1 
10!M  - 85.4 82.2 83.8 2.3 
 - 10mM 90.1 92.5 91.3 1.7 
0.3!M 10mM 86.2 88.3 87.2 1.5 
1!M 10mM 70.3 71.1 70.7 0.5 
3!M 10mM 57.1 59.5 58.3 1.7 
10!M 10mM 26.8 30.7 28.7 2.8 
Table A4.7.  Effect of versipelostatin treatment alone, or in combination  
with 2-DG, for 24 hours on cell viability in the THP1 cell line. 
 
 
 
VST 2DG Cell no (cells/ml) Average SD % of 
control 
 -  - 889689 707392 798540 128903 100.0 
0.3!M  - 806851 762872 784862 31098 98.3 
1!M  - 760234 619425 689830 99567 86.4 
3!M  - 644482 588766 616624 39397 77.2 
10!M  - 656243 633392 644818 16158 80.7 
 - 10mM 688069 712145 700107 17024 87.7 
0.3!M 10mM 590664 571170 580917 13784 72.7 
1!M 10mM 540449 498328 519389 29785 65.0 
3!M 10mM 502605 574478 538541 50822 67.4 
10!M 10mM 640289 623932 632111 11566 79.2 
Table A4.8.  Effect of versipelostatin treatment alone, or in combination with 2-DG,  
for 24 hours on cell number in the THP1 cell line. 
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VST 2DG Cell viability Average SD 
 -  - 67.3 78.4 72.9 7.9 
0.3!M  - 68.2 55.0 61.6 9.3 
1!M  - 65.6 64.5 65.1 0.8 
3!M  - 61.3 65.8 63.6 3.2 
10!M  - 60.1 58.5 59.3 1.1 
 - 10mM 63.7 63.9 63.8 0.1 
0.3!M 10mM 45.2 63.7 54.4 13.1 
1!M 10mM 43.8 48.3 46.0 3.2 
3!M 10mM 23.7 20.0 21.8 2.6 
10!M 10mM 28.3 24.3 26.3 2.8 
Table A4.9.  Effect of versipelostatin treatment alone, or in combination  
with 2-DG, for 24 hours on cell viability in the U266 cell line. 
 
 
 
VST 2DG Cell no (cells/ml) Average SD % of 
control 
 -  - 325256 374052 349654 34504 100.0 
0.3!M  - 343343 336693 340018 4702 97.2 
1!M  - 312498 333890 323194 15127 92.4 
3!M  - 298541 302682 300611 2928 86.0 
10!M  - 278002 294754 286378 11845 81.9 
 - 10mM 268610 297413 283011 20367 80.9 
0.3!M 10mM 253603 338982 296293 60372 84.7 
1!M 10mM 240202 287366 263784 33350 75.4 
3!M 10mM 285477 276225 280851 6542 80.3 
10!M 10mM 374155 399623 386889 18008 110.6 
Table A4.10.  Effect of versipelostatin treatment alone, or in combination with 2-DG,  
for 24 hours on cell number in the U266 cell line. 
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Appendix 5 
 
ADDITIONAL DATA FOR CHAPTER 8 
 
 
Cell line Transfection efficiency (%) 
 Set 1 Set 2 Set 3 
THP1 93.1 93.2 92.8 
U266 86.1 91.4 90.3 
DOHH2 80.0 75.0 77.0 
        Table A5.1.  Transfection efficiency (percentage of  
        transfected cells from the total cell population) for each  
        cell line as determined by flow cytometry.  Values shown  
        are results from three separate experiments 
 
 
 
 
Figure A5.1.  Flow cytometry histogram plot of the second transfection efficiency 
experiment in the THP1 cell line. 
KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
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Figure A5.2.  Flow cytometry histogram plot of the third transfection efficiency experiment 
in the THP1 cell line. 
KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
 
 
 
 
 
Figure A5.3.  Flow cytometry histogram plot of the second transfection efficiency 
experiment in the U266 cell line. 
KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
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Figure A5.4.  Flow cytometry histogram plot of the third transfection efficiency experiment 
in the U266 cell line. 
KEY:  Red = Untransfected control 
 Black = Mock transfected  
 Green = siRNA only 
 Blue = siRNA transfected 
 
 
 
 
 
 
 
      Table A5.2.  Cell viability and cell number of transfected cells at 24 hours post  
      transfection in each cell line.  Values shown are mean and standard deviation of 
      three separate experiments 
 
 
 
Cell line Sample Cell viability SD Cell number 
(% of control) 
SD 
THP1 Control 95.2 1.0 100.0 0.0 
THP1 Mock transfected 94.0 3.1 95.1 3.8 
THP1 siRNA only 95.2 1.2 94.8 5.2 
THP1 siRNA transfected 95.7 0.8 88.6 7.6 
      
U266 Control 95.6 0.3 100.0 0.0 
U266 Mock transfected 92.3 2.0 99.2 3.9 
U266 siRNA only 93.6 1.3 96.4 1.1 
U266 siRNA transfected 91.4 3.3 93.2 6.1 
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   GRP78  
 
   GRP94  
 
 
Figure A5.5.  Western blot to show GRP78 and GRP94 protein expression in  
untransfected cells, mock transfected cells, and cells transfected with siRNA  
targeting GRP78, GRP94 or GFP at 72 hours post transfection. 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
Table A5.3.  Cell viability and cell number of transfected cells at 48 hours post  
transfection in each cell line.  Values shown are mean and standard deviation of 
three separate experiments. 
 
 
 
 
Cell line Sample Cell viability SD Cell number 
(% of control) 
SD 
THP1 Control 90.9 5.6 100.0 0.0 
THP1 Mock transfected 94.1 3.0 90.9 4.9 
THP1 siRNA only 94.3 0.8 90.3 9.6 
THP1 siRNA transfected 93.9 0.7 90.0 6.8 
      
U266 Control 93.5 4.2 100.0 0.0 
U266 Mock transfected 93.5 2.4 77.5 10.6 
U266 siRNA only 91.3 2.2 80.9 8.0 
U266 siRNA transfected 88.7 0.3 76.5 6.5 
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THP1 GRP78 GRP94 GFP 
 Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM 
Control 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 
TM 100nM 52.3 44.2 40.4 45.6 3.5 52.6 33.3 27.5 37.8 7.6 60.4 47.2 52.8 53.5 3.8 
TM 1!M 46.8 39.6 32.3 39.6 4.2 39.3 24.9 26.7 30.3 4.5 57.5 45.0 46.1 49.5 4.0 
TM 10!M 49.1 41.5 30.2 40.3 5.5 41.6 26.3 28.4 32.1 4.8 54.2 42.5 50.8 49.2 3.5 
TG 10nM 39.1 33.0 24.1 32.1 4.4 39.2 24.8 23.5 29.1 5.0 44.7 35.0 34.1 37.9 3.4 
TG 100nM 46.9 39.6 28.0 38.1 5.5 39.7 25.2 25.6 30.2 4.8 49.0 38.3 43.0 43.4 3.1 
TG 3!M 49.2 41.5 24.2 38.3 7.4 59.4 37.6 31.4 42.8 8.5 61.5 48.2 42.6 50.8 5.6 
Dox 10nM 79.0 114.7 54.2 82.6 17.6 82.4 89.0 51.8 74.4 11.5 83.2 103.2 88.6 91.7 6.0 
Dox 100nM 47.6 57.5 27.5 44.2 8.8 44.6 43.0 22.8 36.8 7.0 52.6 50.6 40.6 47.9 3.7 
Dox 250nM 41.7 49.0 25.7 38.8 6.9 39.2 37.4 21.9 32.8 5.5 43.7 45.7 40.1 43.2 1.7 
Bort 1nM 79.0 118.7 60.2 86.0 17.2 90.8 95.0 51.1 79.0 14.0 94.2 105.7 85.7 95.2 5.8 
Bort 5nM 82.2 121.6 63.0 88.9 17.2 93.7 95.9 54.2 81.3 13.5 99.0 105.1 91.2 98.4 4.0 
Bort 10nM 99.4 115.3 57.2 90.6 17.3 91.1 90.2 53.2 78.1 12.5 91.7 97.9 86.9 92.2 3.2 
17-AAG 250nM 72.0 71.4 56.9 66.8 4.9 62.8 57.9 40.2 53.7 6.9 77.8 57.3 79.2 71.5 7.1 
17-AAG 1!M 43.1 50.7 30.7 41.5 5.8 49.2 44.4 28.7 40.7 6.2 43.7 38.9 44.9 42.5 1.8 
17-AAG 3!M 38.7 50.4 29.1 39.4 6.2 40.0 40.5 26.4 35.6 4.6 40.7 40.5 42.7 41.3 0.7 
SAHA 500nM 61.9 95.5 56.5 71.3 12.2 75.7 83.1 47.2 68.7 10.9 69.2 78.7 88.3 78.8 5.5 
SAHA 1!M 53.2 69.8 60.3 61.1 4.8 81.5 63.2 38.3 61.0 12.5 63.5 68.7 72.4 68.2 2.6 
SAHA 3!M 50.2 43.8 35.7 43.3 4.2 74.5 40.3 27.8 47.5 13.9 63.4 47.7 52.9 54.7 4.6 
 
   Table A5.4.  Effect of drug treatment for 48 hours on cell number (% of control) in THP1 cells transfected with siRNA targeting GRP78, GRP94 and the 
   control siRNA targeting GFP. 
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THP1 GRP78 GRP94 GFP 
 Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM 
Control 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 
TM 100nM 60.7 74.7 61.3 65.6 4.6 71.4 68.3 61.4 67.1 3.0 83.9 79.5 71.2 78.2 3.7 
TM 1!M 63.0 69.1 63.9 65.3 1.9 61.3 62.0 64.0 62.4 0.8 67.0 71.7 67.7 68.8 1.5 
TM 10!M 57.7 62.5 63.4 61.2 1.8 57.9 69.6 62.5 63.4 3.4 55.9 67.2 66.9 63.3 3.7 
TG 10nM 60.5 56.4 55.3 57.4 1.6 57.3 51.6 50.4 53.1 2.1 63.1 55.3 59.1 59.2 2.3 
TG 100nM 52.4 59.2 60.4 57.3 2.5 51.0 47.7 52.0 50.3 1.3 57.6 45.8 54.1 52.5 3.5 
TG 3!M 67.1 65.3 61.1 64.5 1.8 58.6 61.8 59.6 60.0 1.0 71.6 64.3 63.1 66.3 2.6 
Dox 10nM 92.5 98.0 95.6 95.4 1.6 93.6 97.3 98.0 96.3 1.4 94.6 98.5 95.7 96.3 1.2 
Dox 100nM 87.1 97.6 62.1 82.2 10.5 97.7 97.4 91.8 95.6 1.9 99.7 94.9 87.5 94.0 3.5 
Dox 250nM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 3.0 3.0 
Bort 1nM 95.0 99.5 98.7 97.7 1.4 99.3 100.5 97.6 99.2 0.8 97.3 102.6 100.5 100.1 1.5 
Bort 5nM 92.8 100.9 99.3 97.7 2.5 95.5 101.2 97.2 97.9 1.7 99.1 104.2 97.6 100.3 2.0 
Bort 10nM 97.3 100.1 95.9 97.8 1.2 96.1 100.1 93.9 96.7 1.8 99.8 99.5 97.0 98.7 0.9 
17-AAG 250nM 97.4 99.0 101.8 99.4 1.3 93.0 98.2 95.0 95.4 1.5 96.4 92.8 95.8 95.0 1.1 
17-AAG 1!M 86.3 96.8 93.3 92.1 3.1 78.6 78.7 81.4 79.6 0.9 80.9 84.5 87.2 84.2 1.8 
17-AAG 3!M 81.0 84.4 83.3 82.9 1.0 79.7 83.1 75.6 79.5 2.1 81.1 84.7 84.8 83.5 1.2 
SAHA 500nM 87.5 96.8 93.2 92.5 2.7 89.2 97.0 91.9 92.7 2.3 90.3 94.7 96.4 93.8 1.8 
SAHA 1!M 74.7 81.1 92.1 82.6 5.1 80.6 86.3 84.8 83.9 1.7 85.5 87.9 83.9 85.8 1.2 
SAHA 3!M 49.8 41.6 48.2 46.5 2.5 47.7 45.3 47.3 46.8 0.7 55.5 45.5 64.5 55.2 5.5 
 
   Table A5.5.  Effect of drug treatment for 48 hours on cell viability (% of control) in THP1 cells transfected with siRNA targeting GRP78, GRP94 and the 
   control siRNA targeting GFP. 
 
 
 
 376 
 
 
U266 GRP78 GRP94 GFP 
 Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM 
Control 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 
TM 100nM 91.2 85.3 59.4 78.7 9.8 104.1 67.2 62.7 78.0 13.1 120.8 86.7 63.6 90.3 16.6 
TM 1!M 87.1 72.3 52.8 70.7 9.9 85.0 59.2 63.8 69.3 8.0 98.6 79.9 51.4 76.6 13.7 
TM 100!M 103.8 88.3 48.2 80.1 16.6 85.9 50.5 48.4 61.6 12.1 97.4 72.7 50.1 73.4 13.7 
TG 10nM 74.5 89.1 63.2 75.6 7.5 79.4 57.4 61.0 65.9 6.8 84.8 67.7 57.8 70.1 7.9 
TG 100nM 65.4 73.3 51.4 63.4 6.4 70.8 51.2 50.5 57.5 6.6 74.0 65.3 52.5 63.9 6.2 
TG 3!M 74.3 78.4 53.6 68.8 7.7 85.5 55.5 48.6 63.2 11.3 94.5 63.9 58.8 72.4 11.1 
Dox 10nM 182.5 126.8 73.7 127.7 31.4 166.8 90.1 90.2 115.7 25.5 186.5 107.1 74.3 122.6 33.3 
Dox 100nM 64.6 65.9 47.5 59.4 5.9 76.8 47.9 47.5 57.4 9.7 71.8 54.2 45.3 57.1 7.8 
Dox 500nM 66.5 68.7 54.9 63.4 4.3 80.6 49.4 50.3 60.1 10.2 79.2 60.7 54.4 64.8 7.5 
Bort 1nM 123.1 131.1 88.8 114.3 13.0 161.0 101.3 93.8 118.7 21.3 122.1 118.8 97.9 112.9 7.6 
Bort 5nM 129.5 124.1 86.1 113.2 13.6 158.3 107.5 98.7 121.5 18.6 136.5 120.0 101.5 119.3 10.1 
Bort 10nM 162.6 123.3 81.8 122.6 23.3 173.0 99.4 92.1 121.5 25.8 249.8 123.8 90.8 154.8 48.4 
17-AAG 250nM 151.8 74.9 72.5 99.7 26.1 94.5 64.7 52.8 70.7 12.4 108.9 64.1 87.5 86.8 12.9 
17-AAG 1!M 71.6 55.9 42.9 56.8 8.3 75.1 43.8 44.1 54.3 10.4 62.4 51.9 59.1 57.8 3.1 
17-AAG 3!M 71.1 57.3 44.8 57.7 7.6 76.7 45.4 44.9 55.6 10.5 58.1 49.5 59.9 55.8 3.2 
SAHA 500nM 117.0 94.0 70.5 93.8 13.4 127.8 74.9 70.0 90.9 18.5 90.8 94.2 101.3 95.4 3.1 
SAHA 1!M 115.7 77.5 66.4 86.6 14.9 101.9 60.4 66.1 76.1 13.0 100.2 77.2 95.1 90.8 7.0 
SAHA 3!M 153.6 67.1 68.2 96.3 28.7 105.3 51.9 65.6 74.3 16.0 158.7 71.0 87.9 105.8 26.9 
 
   Table A5.6.  Effect of drug treatment for 48 hours on cell number (% of control) in U266 cells transfected with siRNA targeting GRP78, GRP94 and the 
   control siRNA targeting GFP. 
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U266 GRP78 GRP94 GFP 
 Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM Set 1 Set 2 Set 3 Average  SEM 
Control 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 100.0 0.0 
TM 100nM 59.6 80.7 53.9 64.7 8.2 66.4 71.1 58.7 65.4 3.6 70.2 87.9 70.3 76.1 5.9 
TM 1!M 46.5 67.0 60.0 57.8 6.0 66.3 57.4 58.8 60.8 2.7 78.5 83.3 60.7 74.2 6.9 
TM 100!M 31.6 40.7 16.4 29.6 7.1 45.6 21.8 15.1 27.5 9.2 52.2 16.8 12.0 27.0 12.7 
TG 10nM 65.3 79.0 74.9 73.1 4.1 80.0 73.1 66.3 73.1 4.0 85.3 72.9 49.9 69.3 10.4 
TG 100nM 74.6 65.9 71.2 70.6 2.6 64.3 60.5 52.7 59.2 3.4 68.4 64.6 69.0 67.3 1.4 
TG 3!M 81.5 74.0 79.8 78.4 2.3 83.4 62.2 53.2 66.3 8.9 71.4 69.3 52.4 64.4 6.0 
Dox 10nM 98.7 99.5 100.9 99.7 0.7 101.4 100.7 99.3 100.5 0.6 105.3 99.4 93.4 99.4 3.4 
Dox 100nM 94.6 99.7 81.4 91.9 5.4 101.4 97.2 82.0 93.5 5.9 96.3 97.6 83.7 92.5 4.4 
Dox 500nM 0.0 0.0 0.0 0.0 0.0 20.7 0.0 0.0 6.9 6.9 40.2 0.0 0.0 13.4 13.4 
Bort 1nM 88.2 101.7 96.5 95.5 3.9 100.7 103.2 101.6 101.8 0.7 98.7 102.5 97.3 99.5 1.6 
Bort 5nM 93.9 103.5 100.3 99.2 2.8 100.9 101.8 100.8 101.2 0.3 94.9 102.1 97.9 98.3 2.1 
Bort 10nM 93.5 103.5 96.0 97.7 3.0 100.1 100.3 93.7 98.0 2.2 99.1 102.8 92.7 98.2 2.9 
17-AAG 250nM 96.0 95.5 100.3 97.2 1.5 101.4 94.3 92.8 96.2 2.7 98.0 84.0 90.1 90.7 4.1 
17-AAG 1!M 89.4 78.3 89.9 85.9 3.8 85.1 74.5 68.9 76.2 4.7 96.4 82.1 83.6 87.3 4.6 
17-AAG 3!M 75.5 78.9 77.0 77.1 1.0 73.1 60.9 63.6 65.9 3.7 82.9 83.7 86.8 84.5 1.2 
SAHA 500nM 89.8 97.3 95.6 94.2 2.3 94.6 95.9 88.2 92.9 2.4 94.8 93.4 95.6 94.6 0.6 
SAHA 1!M 86.6 92.0 84.5 87.7 2.2 86.0 83.6 77.1 82.2 2.7 93.0 71.9 79.5 81.5 6.2 
SAHA 3!M 57.5 53.8 60.0 57.1 1.8 65.3 42.8 44.1 50.8 7.3 72.4 32.3 51.3 52.0 11.6 
 
   Table A5.7.  Effect of drug treatment for 48 hours on cell viability (% of control) in U266 cells transfected with siRNA targeting GRP78, GRP94 and the 
   control siRNA targeting GFP. 
 
 
 378 
 
 THP1 U266 
 GRP78 GRP94 GRP78 GRP94 
 p value p value p value p value 
TM 100nM 0.10067 0.09281 0.32186 0.16662 
TM 1!M 0.05540 0.00087 0.26258 0.54469 
TM 10!M 0.27611 0.02683 0.31551 0.18466 
TG 10nM 0.12733 0.03236 0.60970 0.39946 
TG 100nM 0.39786 0.03018 0.91694 0.23855 
TG 3!M 0.06707 0.11147 0.75224 0.00301 
Dox 10nM 0.57142 0.24219 0.56450 0.60464 
Dox 100nM 0.58472 0.07898 0.71902 0.93983 
Dox 250nM 0.48943 0.12597 0.83846 0.32963 
Bort 1nM 0.50668 0.22615 0.84099 0.76674 
Bort 5nM 0.55186 0.22783 0.39438 0.84965 
Bort 10nM 0.92494 0.29859 0.36309 0.28425 
17-AAG 250nM 0.70154 0.26197 0.52215 0.25438 
17-AAG 1!M 0.90502 0.82781 0.90803 0.71644 
17-AAG 3!M 0.80705 0.39843 0.84891 0.98535 
SAHA 500nM 0.64922 0.58273 0.93118 0.84963 
SAHA 1!M 0.22771 0.67857 0.77313 0.24106 
SAHA 3!M 0.10156 0.56590 0.20036 0.10196 
 
   Table A5.8.  P value from paired t-test comparing cell number following drug  
   treatment in cells transfected with target siRNA (GRP78 or GRP94) and  
   control siRNA (GFP) (p<0.05 considered statistically significant). 
 
 
 
 THP1 U266 
 GRP78 GRP94 GRP78 GRP94 
 p value p value p value p value 
TM 100nM 0.14661 0.00486 0.05220 0.10346 
TM 1!M 0.01399 0.06914 0.21365 0.19411 
TM 10!M 0.40246 0.98980 0.86113 0.90557 
TG 10nM 0.35035 0.05318 0.80087 0.61901 
TG 100nM 0.46346 0.46198 0.16334 0.18304 
TG 3!M 0.35821 0.20033 0.17672 0.76650 
Dox 10nM 0.27077 0.98755 0.93670 0.73529 
Dox 100nM 0.28492 0.47762 0.69190 0.68184 
Dox 250nM 0.42265 0.42265 0.42265 0.42265 
Bort 1nM 0.02534 0.58775 0.34070 0.15265 
Bort 5nM 0.37066 0.13337 0.45923 0.25360 
Bort 10nM 0.40682 0.27255 0.85698 0.89523 
17-AAG 250nM 0.12182 0.89247 0.26929 0.15395 
17-AAG 1!M 0.06768 0.05694 0.74528 0.03237 
17-AAG 3!M 0.30095 0.25292 0.03530 0.05128 
SAHA 500nM 0.52625 0.64221 0.90306 0.62368 
SAHA 1!M 0.64326 0.38706 0.50504 0.91161 
SAHA 3!M 0.15485 0.22891 0.67944 0.84997 
 
   Table A5.9.  P value from paired t-test comparing cell viability following drug  
   treatment in cells transfected with target siRNA (GRP78 or GRP94) and  
   control siRNA (GFP) (p<0.05 considered statistically significant). 
 
 
 
